Characterisation of the cross-linking and calcification associated with glutaraldehyde-treated cardic bioprostheses. by Delogne, Christophe.
Characterisation of the cross-linking and calcification 
associated with glutaraldehyde-treated cardic 
bioprostheses.
DELOGNE, Christophe.
Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/19550/
This document is the author deposited version.  You are advised to consult the 
publisher's version if you wish to cite from it.
Published version
DELOGNE, Christophe. (2002). Characterisation of the cross-linking and calcification 
associated with glutaraldehyde-treated cardic bioprostheses. Doctoral, Sheffield 
Hallam University (United Kingdom).. 
Copyright and re-use policy
See http://shura.shu.ac.uk/information.html
Sheffield Hallam University Research Archive
http://shura.shu.ac.uk
CITY CW*m, HOWARD STREETj
1 0 1  7 1 5  9 0 0  9
REFERENCE
ProQuest Number: 10694431
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com ple te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10694431
Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
C h a r a c t e r is a t io n  o f  t h e  c r o s s -l in k in g
AND CALCIFICATION ASSOCIATED WITH 
GLUTARALDEHYDE-TREATED CARDIAC 
BIOPROSTHESES
M r  C h r i s t o p h e  D e l o g n e
A thesis submitted in partial fulfilment of the requirements of 
Sheffield Hallam University 
for the degree of Doctor of Philosophy
October 2002

Abstract
Around 170000 patients worldwide receive cardiac valve substitutes each year. Valve 
replacement with mechanical or bioprosthetic devices enhances patient survival and quality of life. 
Bioprosthetic valves have a significant advantage over mechanical valves: they do not necessarily 
require long-term anticoagulant therapy however, dystrophic calcification can lead to early failure. 
The actual mechanism of calcification is still poorly understood despite several established possible 
factors associated with it. Amongst these is the glutaraldehyde pre-treatment of the valves during their 
manufacture. Glutaraldehyde has been used for the treatment o f bioprosthetic valves for the last thirty 
years, as a cross-linking agent and a sterilant. Whilst it is assumed to introduce stable inter- and intra- 
fibrillar collagen cross-links, which contribute to the durability of these valves, the specific chemistry 
of the fixation process is not fully understood. Additionally, glutaraldehyde is thought to be involved 
somehow in the process of dystrophic calcification of these same bioprosthetic valves.
The primary aim of this study was to gain a greater understanding of the chemistry involved 
in the treatment of collagenous valve tissue with glutaraldehyde. Amino acids, peptides and proteins 
were thus used to mimic the effect o f the glutaraldehyde treatment and to model potential reactions 
involved in such treatment. Techniques such as MALDI-TOF MS, ESI MS, NMR, FTIR-ATR and 
Raman spectroscopy were utilised to study the products of the glutaraldehyde reaction and their 
relationship with the calcification process. Data obtained from the products of the reactions between 
glutaraldehyde and model compounds showed the presence of: aldol and aldol/Michael condensation 
products of glutaraldehyde, Schiff base moieties (including cross-links) and various cyclisation 
products incorporating pyridinium and dihydropyridine ring structures. Some of these structures are in 
agreement with the literature, whilst others are essentially new structures that have never been 
proposed.
Glutaric acid, used to mimic the oxidation of glutaraldehyde that can occur in-vivo, was shown to 
have the ability to form complexes with cations such as calcium in-vitro. A similar result was found 
with aqueous dilute solutions of glutaraldehyde (similar concentrations to the ones used in valve 
manufacture), thus leading to the hypothesis o f its strong role in the initiation of calcification in-vivo. 
However, an extrapolation of these results to the role of the nucleophilic groups of amino acids or 
peptides, that could behave as the collagen macromolecule, was difficult to assess using FTIR because 
of the complex infrared spectra. However some findings corroborated the hypothesis that amino acids 
of the collagen tissue may also play a role in the initiation of calcification.
Secondly, methodology was developed to allow successful analysis o f tissue calcification 
using environmental scanning electron microscopy (ESEM). This is thought to be an important step in 
the analysis o f tissues in their native state. Investigation of the calcification process with samples from 
clinical investigations (explanted human calcified valves), in-vivo screening (rat subcutaneous 
implantation model) and in-vitro screening (pericardial tissue incubated in metastable calcification 
solution) was thus undertaken using ESEM, along with other techniques such as FTIR-ATR, Raman, 
XRD spectroscopy and ICP-OES. The data revealed both similarities and differences between in-vivo 
and in-vitro calcification, although the process is unequivocally different. Late calcific deposits were 
assigned to poorly crystalline hydroxyapatite with high Ca/P ratios due to the probable presence of 
carbonate and possibly cations such as silicon and magnesium. A picture of the onset o f 
mineralisation was hypothesised involving precursors, containing various amounts o f calcium and 
phosphate, along with the incorporation of magnesium and silicon. These precursors phases evolved 
with time o f implantation to the poorly crystalline form of hydroxyapatite found in the late stage o f 
calcification.
This work has provided an insight into how glutaraldehyde reacts with valve tissue and a 
possible explanation as to why valves fail by non-calcific or calcific mechanisms. A new approach to 
the study of calcified valve tissue has also been developed using ESEM methodology.
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Chapter 1
i
1 Bioprosthetic heart valves and their pathological 
calcification.
1.1 Introduction
On Monday 2 July 2001, the first artificial self-sufficient heart (called the AbioCor) 
was successfully implanted by Drs Laman Gray and Robert Dowling1 in an 
American patient at the Jewish Hospital of Louisville in Kentucky. Without doubt, 
this represents a gigantic achievement in prosthetic replacement advances and 
showed how much both science and technology have accomplished since the first 
total artificial heart replacement implanted in Dr Barney Clark two decades ago in 
1982. Nevertheless, many aspects of cardiovascular research require further 
understanding and improvements. Such is the case for cardiac valve replacement. In 
the past four decades, countless models of valve substitutes have been designed and 
improved. However, an ideal valve replacement device has not yet been achieved.
Approximately 200,000 artificial heart valves are implanted annually worldwide2, 
from which it is estimated that 60% are mechanical and 40% are tissue 
(bioprosthetic), with an increasing interest towards the use of tissue valves over the 
last 10 years . This represents a worldwide market of $600,000,000.
The UK Heart Valve Registry (UKHVR) was established in 19864 to provide data 
and information for professionals in cardiology and legitimate patients’ interests. 
From the UK Heart Valve Registry 2000 report5, around 7000 patients received heart 
valve replacements in the UK, 37% of these being bioprosthetic valves. The number 
of bioprosthetic heart valves used has risen steadily over the last decade from 24% to 
36%5, in comparison to the use of mechanical valves. This clinical popularity is the
1
result of many improvements and factors that will be discussed in the following 
sections of this chapter.
Cardiac valve replacement with mechanical or bioprosthetic devices enhances 
greatly patient survival and quality of life. However, even the latest designs have a 
finite life-span. Furthermore, prosthesis associated complications are frequent. 
Bioprosthetic heart valves have better hemodynamic efficiency and 
thromboresistance than mechanical valves; trileaflet tissue valves have a central 
orifice analogous to natural human valves.
For patients with mechanical valves, the most common and important problems are 
thrombus and thromboembolic complications, necessitating chronic anticoagulation6 
treatment. In contrast, patients with a bioprosthetic valve, composed essentially of 
chemically-treated animal tissue (bovine or porcine), in general, do not require long­
term anticoagulant therapy.
Bioprothetic valves tend to fail by progressive tissue deterioration, especially that 
involving cusp calcification. Thus, tissue valves are superior to mechanical valves 
with respect to lack of thromboembolic complications and better hemodynamic 
characteristics, however, their long-term durability is questionable7.
1.2 Replacement heart valves
1.2.1 Introduction
The human heart has four cardiac valves (see figure 1.1). These respond passively to 
pressure and flow changes within the heart and function as loose flaps that seal the 
valvular orifices against regurgitation of blood when closed but fold out of the way 
when the valve is open, to provide an obstruction-free orifice. They open and close 
around 38 million times a year and are capable of withstanding pressure differences 
in excess of 100 mmHg (greater than this in hypertension). The left side of the heart 
must impart more energy to the blood to overcome the higher resistance of the 
systemic circulation. This is reflected in higher pressures and higher stresses on the 
valves. This in turn results in a higher incidence of valve disease in the left than in 
the right side of the heart.
2
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Figure 1.1. Schematic diagram of the human heart showing the four valves.
For the detailed anatomy of the heart, readers are invited to refer to publications such 
as those by Schoen and Marks and Marks9.
There are numerous different replacement valves available. The principal types of 
cardiac prostheses include mechanical, polymeric, bioprosthetic, and tissue- 
engineered valves, although the latter are still in their infancy. The following 
sections give an overview of the type of bioprosthetic valves available over the past 
25 years.
Bioprostheses are intended for use in patients whose aortic or mitral valve disease is 
sufficiently advanced to warrant replacement of their natural valve with a prosthetic 
one. They may also be used to replace a failing aortic or mitral valve prosthesis.
In the presence of conditions affecting calcium metabolism or when calcium- 
containing chronic drug therapies are used, the use of mechanical prostheses is 
preferred. This is also true for patients under 20 years of age, those on a high calcium 
diet and for patients who are on maintenance hemodialysis. This is due to high risk 
of calcification of bioprosthetic valves in these patient groups10"12.
1.2.2 The ideal valve replacement
The ideal valve replacement would meet the following criteria:
-Be easy to implant
-Be quickly and permanently incorporated into the heart by host tissues 
-Present minimal resistance to forward flow and allow insignificant regurgitation 
-Not damage cellular and molecular blood components
-Undergo minimal wear or other degradative change following long-term 
implantation
-Not be excessively noisy or cause other discomfort to the patient13
Despite almost 50 years of this type of surgery, there are many questions that remain 
to be answered. The search for the optimal replacement device continues.
1.2.3 Bioprosthetic valves
1.2.3.1 Introduction:
Tissue valves, with low intrinsic thrombogenicity, are an attractive alternative to 
mechanical prosthetic valves when anticoagulation is contraindicated or undesirable. 
However, despite their superficial resemblance to natural valves, contemporary 
bioprostheses are non-viable and hence non-self renewing. (Re-endothelialisation of 
porcine bioprosthetic valve cusps has been reported. However this is only focal and 
far from complete14. Re-endothelialisation has not been demonstrated with 
pericardial bioprosthetic valves). They undergo structural degenerative changes 
during function, leading to progressive tissue deterioration with time (this includes 
both calcific and non-calcific damage). Whilst the rate of progression of 
degeneration varies from patient to patient, bioprostheses are generally reported to 
have a functional life span of 10-15 years. Glutaraldehyde-treated xenografts are an 
excellent choice for the elderly patient (greater than 70 years of age) or patients with 
an expected life span of less than 10 years15' 19. Beyond this time, mineralisation and 
calcification are major disadvantages of the devitalised valve tissue, being
• • 90particularly a problem in younger patients . Consequently, limitations of durability 
have been the major impediment to the wider use of bioprostheses, undermining 
their attractiveness as valve substitutes of choice for many patient groups 21'27. This 
has resulted in a swing back to the use of mechanical valves28 until very recently. 
The statistics quoted earlier indeed suggest that the use of bioprosthesis is increasing.
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Certain patient groups necessitate special considerations when choosing suitable 
valve treatment. For children, a durable valve substitute with a low valve-related 
mortality is essential. The frequent need for prosthesis of small size demands 
maximum hemodynamic efficiency to minimise the need for replacement as the 
child continues to grow. Elimination of a requirement for systemic anticoagulants 
would avoid the risk of hemorrhage due to normal childhood activities. 
Bioprostheses were initially believed to be ideal for children, but accelerated calcific 
degeneration has made these valves an undesirable selection for young patients. 
Many clinicians favour bioprosthetic heart valves for women of child-bearing age. 
There are a number of reasons for this; warfarin anticoagulation has been shown to 
be teratogenic and is associated with increased spontaneous abortion also, 
anticoagulation is difficult to manage during pregnancy29. Unfortunately, there is 
evidence to suggest that pregnancy might potentiate calcification of porcine
onbioprostheses so the appropriate choice in this situation is by no means clear.
1.2.3.2 Stented porcine aortic valves:
1.2.3.2.1 The various valve generations:
For the last 25 years, stented porcine valves (stented bioprosthetic valves are 
mounted on a supporting frame or stent) have been the most widely used biological 
valves and as such represent a standard for measuring the performance of newer 
biological valve designs.
In the mid-sixties, hearts from a number of different animals (calves, pigs and sheep) 
were studied and it was found that the size of the pig heart was the closest to that of 
the human . This was where the interest in using porcine aortic valves as stented 
xenograft prostheses emerged32. First-generation porcine aortic valves33,34, such as 
the Hancock I bioprosthesis and the Carpentier-Edwards Standard bioprosthesis35 
were introduced in the early 1980s. Second-generation porcine valves incorporated 
improvements namely a better configuration to reduce transvalvular gradients and an 
optimised stent flexibility to reduce tissue stress36'38. Data on second-generation 
porcine valves such as the porcine SJM Biocor (see figure 1.2 below), the Intact39, 
the Hancock H40,41 and the Carpentier Edwards Supra-Annular bioprosthesis42 
suggest that the mechanical properties of cusps are improved when fixation occurs in 
an isotonic glutaraldehyde solution. These second-generation valves are
5
manufactured using quality control measures such as muscle bar-devoided leaflets 
thus eliminating potential calcification sites and the possible obstruction of the 
orifice.
Figure 1.2: An unimplanted trileaflet porcine SJM bioprosthetic heart valve from St. 
Jude Medical.
1.2.3.2.2 Failure o f  porcine aortic valve bioprostheses:
Cuspal tears and calcification43,44 of the cusps are the most common causes of valve 
dysfunction45,46 and failure in stented porcine valves47. The most frequent 
clinicopathological failure mode of porcine valves is regurgitation caused by a 
combination of calcification and leaflet tearing43. Pure stenosis occurs less 
frequently. In contrast the primary mode of failure of pericardial valves, is
AOcalcification . Stenosis is often due to stiffening because of dystrophic calcification. 
Cuspal tears or perforations of tissue unrelated to either calcification or endocarditis 
can also lead to valve failure. Non-calcific tissue tears probably reflect mechanical 
failure of collagen architecture during function; the incidence of such structural 
valve deterioration may occur virtually anytime post-operatively and is more 
frequently seen with valves implanted in the mitral position rather than in the aortic 
position49,50.
Calcific deposits are found predominantly at the cuspal commissures and basal 
attachments and are visible by the naked eye as nodular grey/white masses 
(predominantly found in the spongiosa in porcine valves51), which frequently 
ulcerate through the cuspal tissue. Calcification of the aortic wall is less frequent
COthan that of the corresponding cusps .
6
In spite of these problems, the durability of porcine valves appears to be improving. 
This is due in part to patient selection, especially with regard to age, but is also due 
to improved valve design .
1.2.3.3 Stentless porcine aortic valves:
The replacement of diseased heart valves with non-stented xenografts is a relatively 
recent development54. Non-stented porcine aortic valve bioprostheses comprise 
glutaraldehyde-pretreated pig aortic root and valve cusps, and have no supporting 
stent55,56. They are thus very similar to homograft valves (homografts are cadaveric 
human valves transplanted to unrelated recipients) in appearance and method of 
insertion. Compared to their stented counterparts, they differ slightly in overall 
configuration: the glutaraldehyde pretreatments conditions used, in design (they do 
not contain a true sewing ring) and, particularly, in the amount of aortic wall 
included. Stentless porcine valves were first designed essentially to improve the 
hemodynamic performance of porcine aortic valves and to enhance their 
durability57,58.
The main advantage of the stentless design is that a larger bioprosthesis can be 
implanted for a given size of aortic root. This results in enhanced hemodynamics58 
and patient survival59 when compared to stented porcine valves. In the latter, the 
stent and sewing ring take up space within the recipient aortic root, lowering the 
orifice area.
The disadvantage of using a stentless valve is the surgical skill required to implant 
such a device. Predilation of the valve root during the fixation at manufacture helps 
to produce valves with improved hydrodynamic performance. This is because the 
glutaraldehyde-treatment reduces the extensibility of the root, resulting in a lowering 
of biomechanical function compared to the fresh root60. Several types of stentless 
valves are clinically available: they differ considerably in terms of design, tissue 
preservation and anticalcification treatment. Morphologically, this type of valve is 
similar to the native aortic valve61. Their longevity is expected to be similar to or 
better than the stented bioprosthetic valves (greater than 10-15 years life span)62.
1.2.3.4 Bovine pericardial valves:
Recently, there has been a renewed interest in bovine pericardial valves .
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1.2.3.4.1 The various valve generations:
The first commercially available pericardial bioprosthesis, the Ionescu-Shiley 
pericardial valve, was developed by Marion Ionescu64. This first-generation valve 
type was used from 1976 to 1987. As these valves were fashioned from sheets of 
pericardial tissue, they could be made in a wide range of sizes. Despite early 
favourable reports and excellent hemodynamic performance, they were withdrawn 
from clinical use because of a high potential for structural valve dysfunction and 
failure65,66. This was later found to be due to design-related tissue 
preparation/mounting techniques67: a suture which secured the leaflets to the stent 
post was associated with leaflet tears causing regurgitation68,69 and wearing against 
the fabric stent cover caused leaflet abrasion70,71.
In consequence, second-generation pericardial valves, such as the Carpentier-
79Edwards Perimount valve, were developed with substantial design modifications 
(especially the improved tissue preservation without pressure in glutaraldehyde, the 
computer-aided design for optimal leaflet-to-stent matching, and no stent-post 
sutures as used with first-generation valves). These were introduced into clinical use
7Tin the early 1980s . Many types of second-generation pericardial bioprostheses are 
on the market. Such valves show excellent results, especially in patients over 60 
years of age74, and provide satisfactory hemodynamic results with low 
thrombogenicity and structural deterioration63,75. However, leaflet degeneration is 
still a problem in patients under the age of 60 years. Recent data, from a study of 
many bioprostheses, show that stented bovine valves seem to be as good as stentless 
porcine valves, whilst being superior to conventional stented porcine bioprostheses 
with regard to leaflet calcification76. Other obvious advantages of stented types of 
valves are their relative ease of insertion and the predictable hemodynamic 
performance77.
1.2.3.4.2 Failure o f  bovine pericardial bioprostheses:
Calcific and non-calcific degeneration failures of pericardial bioprostheses have been
z t q  no  o nfrequently reported for both adults and children ’ ' . Contemporary valves appear 
to have superior performance and durability to those of previous pericardial
OO O 1valves ’ ’ , but their ultimate mode of failure is mainly because of primary 
dystrophic calcification. In general, the performance of pericardial bioprostheses is
superior to that of porcine bioprostheses at 10 years in terms of freedom from 
structural valve deterioration , but they suffer from calcification.
1.2.3.5 Autologous tissue/Auto grafts/Homografts:
Historically, allografts (valves from different human individuals) were obtained from 
cadavers, but now they are also harvested from hearts removed from cardiac 
transplant recipients. However, as with all organ-donor situations, the availability of 
such grafts is severely limited, restricting the number of procedures that can be 
carried out.
The use of an aortic homograft valve in the subcoronary position was reported as
ft9 ft9 —early as 1962 ’ , and the technique is still in use today. It involves a normal human 
aortic valve removed at post-mortem examination and treated with appropriate 
antibiotics so that it can be transplanted into a suitable host. The first pulmonary
ft4autograft was described in 1967 . This type of surgery involves replacement of the 
aortic valve or root by the patient’s own pulmonary valve and is a common
85 86procedure ’ . The removed pulmonary valve is usually replaced by a human 
pulmonic valve allograft.
Over the same period, other types of autologous tissues and allografts were 
investigated to try to eliminate some of the possible valve-related factors that were 
thought to be responsible for tissue calcification (inflammatory response and foreign 
tissue components). Valves were made of pericardium87, dura mater88 and fascia 
lata89,9 (fascia lata valve was developed in 196691 and constructed at the time of 
operation using the patient’s own living tissue, but its use was discontinued by 1978, 
whilst dura mater is also no longer used these days). Unfortunately, in practice, none 
of these grafts have been very successful. Failure rates have been high due to cuspal 
thickening, fibrosis with shrinkage, endocarditis and loss of graft pliability90,92' . 
Autologous materials were used fresh. Failure was due to the behaviour of the 
untreated tissue and the time-consuming, non-standardised methods used to 
construct such a valve. This led to problems after implantation.
A new approach was developed to rapidly construct intra-operatively a stent- 
mounted glutaraldehyde-fixed autologous pericardial valve in a standardised 
fashion95. After successful in-vitro and in-vivo testing, the first clinical trials were 
described in the early 1990s96. Autologous pericardium was excised, fixed in
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glutaraldehyde for a short period of time (5 to 15 min) during surgery, cut into leaflet 
shapes by means of a special die and subsequently mounted on a stent97. The brief 
glutaraldehyde treatment enhances the mechanical properties of the tissue. But 
following glutaraldehyde treatment, the tissue has been shown to calcifiy, showing a 
glutaraldehyde-dependent calcification pattern in the implants98,99. However, if the 
treatment is too short (less than 10 minutes), elongation of the tissue after 
implantation and reduction in strength have been observed100. Since the initial 
studies, almost five hundred autologous briefly-glutaraldehyde-treated bovine 
pericardium valves have been used throughout Europe101. Unfortunately, the 
selection and preparation of the autologous pericardium can make this type of valve 
graft problematic. Mechanical properties of the tissue can vary from patient to
patient and brief glutaraldehyde treatment is sometimes insufficient for mechanical
1 0?stability . However, the low level of calcification generally observed by either X- 
ray analysis or by macroscopical or histological examination, and the possibility of 
nearly complete re-endothelialisation of the smooth outflow surface and rare 
endothelial in-growth on the rough inflow sides are encouraging for these types of 
valvular grafts101.
The advantage of using stent-mounted allografts made of autologous tissue is that 
they can be used to replace the mitral valve, while unmounted allografts (homograft) 
can only be used as aortic valve replacements (mechanical and stented bioprosthetic 
valves can be used in either site). It is also well accepted that the time course of 
failure of allografts is slower than that for other tissue valves, especially in a young
1 03population . Thus, the potential benefit of this difficult surgical technique is to 
provide a hemodynamically superior and potentially viable valve that might grow 
with somatic growth of children or adolescents for whom there is unfortunately no 
real satisfactory alternative.
1.3 Pathological considerations after cardiac valve replacement
1.3.1 Introduction
Re-operation and replacement of a prosthesis is to be avoided as it is associated with 
significant risk of mortality, hence anything which extends the life of a prosthesis is
10
of benefit. Early mortality of patients (within a few weeks of operation) for a first 
valve replacement is low (less than 10%). Early deaths are due mainly to 
complications associated with pre-existing pathological conditions, such as 
pulmonary hypertension, coronary artery disease and left ventricular myocardial 
degenerative changes. As late survival is enhanced and as an increasing number of 
younger patients undergo valve replacement, the frequency of re-operation for valve 
related problems is likely to increase. Late mortality (one month or more post- 
operatively) results from residual or associated cardiac defects or prosthesis- 
associated complications. These latter cause approximately half of late 
deaths26,104,105. Leaflet deterioration106 may be due to infection, calcification, tissue 
overgrowth, tissue degeneration, suture abrasion or trauma caused by the placement 
during surgery. The most common complications associated with replacement valves 
are thromboembolic complications, endocarditis, paravalvular leak, non-calcific 
valvular deterioration and calcification. As the current work is involved with 
calcification of bioprostheses, this is discussed further.
1.3.2 Calcification
The major cause of bioprosthetic valve dysfunction is primary tissue failure,
10 1 n -7 1 AOespecially related to cuspal calcification ’ ’ . Regurgitation through tears forming
adjacent to calcific nodules is the most frequent failure mode. The amount of 
calcification seen after long-term implantation is very variable. Although 
mineralisation is observed in almost all porcine aortic valve bioprostheses after 4 
years of implantation, valves with minimal or, in some cases, no calcification are 
found occasionally after 10 years of implantation. Pericardial prostheses also suffer 
from this problem, however non-calcific cuspal perforations and tears frequently 
cause failure of these valves, depending on the valve generation109,110.
As stated before, patient age is certain to affect mineralisation, with the process 
being accelerated in children, adolescents and young adults79,111,112. This increase in 
incidence of failure is reported up to the age of 35 years11 .
Calcific deposits are composed of calcium phosphates, closely related to physiologic 
bone mineral (hydroxyapatite). These form predominantly at the cuspal commissures 
and basal attachments of the leaflets. In the initial stages, calcific deposits are often
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found in association with connective tissue cells as well as collagen51,114. Details of 
calcification can be found in section 1.6.
1.4 Type of tissue used in valve manufacture
1.4.1 The porcine valve
The porcine valve shows most resemblance to the human valve with regard to its 
dimensions and anatomical features115. In porcine bioprosthetic valves, the natural 
cuspal attachment to the aortic wall is retained. Since in pigs (not humans) the 
interventricular wall extends to the base of the right coronary cusp116, the base of the 
cusp is supported by strip of septal myocardium “the muscle shelf’ (see figure 1.4 
below). The muscular part of this cusp can be weakened by trimming, leading to 
stretching and subsequent prolapse of the valve. A slight asymmetry of the stent with 
a flattened part corresponding to the right coronary cusp makes it possible to cover 
and so to incorporate the muscular part of the right coronary cusp into the stent.
Figure 1.4: Comparative configuration of the human (left) and the porcine (right) 
aortic valves showing the difference of extension of the inter-ventricular wall along 
with the difference of support brought by the septal muscle myocardium. Adapted 
from Carpentier116.
Porcine aortic valve cusps are structurally non-homogeneous, having three well- 
defined structural layers (see figure 1.5 below) very much like the natural human 
cardiac valves: the ventricularis, near the inflow surface, is predominantly 
collagenous with some small amounts of elastin; the central spongiosa is a viscous
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gelatinous layer made of loosely arranged collagen and contains abundant
117mucopolysaccharides such as proteoglycans; and the fibrosa has densely packed 
collagen and faces the outflow surface118. Blood vessels are absent except at the base 
of the leaflet. The collagen of porcine aortic valves is heterogeneous, being largely 
type I but a significant amount of type III is present, probably in a ratio of 
approximately 70% to 30%119. The elastin component of the ventricularis expands 
when the cusps stretch under backpressure. This increases the coaptation area and 
this improves competence. The elastin recoils to make the cusp smaller in the open
190 191phase ’ . Shear stresses caused by the differential movement of the layers and the
shock of valve closure are dissipated by the spongiosa. Hydrophilic 
glycosaminoglycans (GAGs) in this layer readily absorb water, swell to form a gel 
and resist compression forces.
Cusp Free 
Edge \
Aorta
Fibrosa
Spongiosa
Ventricularis
Figure 1.5: Schematic drawing of the leaflet and its aortic wall showing the three 
distinctive layers where the fibrosa appear as a folded sheet which can unfold when 
the leaflet stretches (adapted from Vesely121).
1.4.2 Pericardium
The cusps of pericardial valves are formed from glutaraldehyde-treated pericardium. 
The pericardium is attached to a frame. The various designs differ in the way the 
tissue is mounted on the frame.
The major structural protein of pericardium is type I collagen122, a small amount of 
low-molecular-weight dermatan proteoglycan123,124 and elastin has been
1 9 Sdemonstrated microscopically . Native porcine pericardium is thinner than bovine 
and thicker than human pericardium, and is used sometimes for heart valve
1 /Tbioprostheses , although bovine pericardium is more common. The thickness of
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bovine pericardium used for valve manufacture is approximately 0.4 mm. The tissue 
is heterogeneous and has been commonly selected for uniformity of thickness, 
absence of blood vessels, etc, rather than for its mechanical characteristics. Recently, 
it has been acknowledged that collagen fibre architecture is an important parameter 
for both the characterisation of mechanical behaviour and the material selection for
1 9 7  1 9Qfabrication of bioprostheses. The intrinsic structural and mechanical variability 
of pericardium is now recognised as a drawback. However, whilst the pericardial sac
198 190has regions which are “highly variable” ’ areas have been identified which have 
the prerequiste properties for bioprosthetic heart valve fabrication or for other 
biomaterial applications.
Pericardium has been described as a pliant biological composite with three or more 
layers of laminated or interwoven collagen fibres embedded in an amorphous
1 97  191matrix ’ . Unstressed, the collagen fibres are arranged in wavy bundles with small
numbers of elastin fibres that are usually arranged at right angles to the collagen. In 
contrast to porcine tissue, pericardium tissue is as a relatively homogenous sheet of
199 *laminated collagen , with frequent blood vessels in the plane of the tissue. 
However, in addition to the lamellar structure, the bovine pericardial collagen 
consists of three layers that can be identified in cross section; i) a smooth serosal 
surface, covered by mesothelial cells ii) fibrosa (which constitutes almost the entire 
thickness) which contains collagen, elastic fibres such as elastin, nerves and blood 
vessels and iii) rough epipericardial connective tissue consisting of loosely arranged
199199collagen and elastin ’ and containing fat and numerous blood vessels. The rough 
epipericardial layer of the pericardium is removed during tissue preparation132,133. 
The smooth side of the pericardium (formerly the serosal surface, facing the 
pericardial space) is usually used as the cuspal outflow aspect; the rough surface 
forms the inflow side of the cusp. This rougher surface will be well-washed with 
blood flow following implantation. This is thought to reduce the possibility of 
thrombosis2.
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1.5 Tissue treatment
1.5.1 Introduction
As discussed in section 1.4, many tissue components contribute to the function of the 
valve. The major structural component is collagen, with elastin representing a small 
but relatively important contribution to tissue properties. Further consideration of the 
components (collagen and elastin) of valve tissue is required before the treatments 
and chemistry of the valve tissue can be considered further.
1.5.2 Elastin
Elastin, a structural protein of the extracellular matrix is a major component of 
elastic fibres in connective tissue with a unique elasticity and tensile strength. Heart 
valve cusps contain approximately 50% collagen, but also 13% elastin by dry 
weight134 (as measured by hydroxyproline assay).
In common with most elastomers, elastin consists of randomly coiled polymer 
chains, joined together by cross-links into an extensible, three-dimensional 
network135. Historically, it was thought that elastin consisted of an amorphous 
system of peptides chains covalently cross-linked at intervals136, to account for its 
elastic properties and insolubility. These unknown probable cross-links were 
investigated and thus it led to the isolation (from bovine ligamentum nuchae 
elastin137 and later from elastin of different tissues and species138) of the amino acids 
named desmosine and isodesmosine. Desmosine is 4-(4-amino-4-carboxybutyl)-l- 
(5 -amino-5 -carboxypentyl)-3,5 -bis(3 -amino-3 -carboxypropyl)pyridinium and
isodesmosine is 2-(4-amino-4-carboxybutyl)-l-(5-amino-5-carboxypentyl)-3,5-bis(3- 
amino-3-carboxypropyl)pyridinium. It is worth noting that these two cross-linking 
structures are not found in naturally cross-linked collagen. As each compound has a 
strongly basic quaternary pyridinium nucleus and four a-amino and a-carboxylic 
groups, they are capable of cross-linking four lysine residues in different polypeptide 
chains, resulting in the tridimensional polymerisation of tropoelastin and the 
formation of the characteristic cross-links of mature elastin. It has been reported that 
each isodesmosine and desmosine molecule can cross-link two polypeptide chains139. 
Several other lysine-derived amino acids have since been isolated, most of them 
being intermediates in the formation of desmosine and isodesmosine. These are
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lysinonorleucine140, dehydrolysinonorleucine (imine from allysine and lysine)141, 
mero- and dehydromerodesmosine (a,/3-unsaturated imine)142, allysine (also known 
as ce-aminoadipic acid 5-semialdehyde)143, and a dehydrated aldol condensation 
product of allysine144. Although lysinonorleucine and merodesmosine are other 
possible cross-links, desmosine and isodesmosine are thought to be the primary 
inter-molecular cross-links responsible for the elastomeric properties of elastin145. 
The other cross-links require only two lysine residues (not four) and are thus 
hypothesised to be involved in intra-molecular (bridges) cross-links while desmosine 
and isodesmosine-like cross-links are considered as “knots” rather than bridges. A 
mechanism for the formation of desmosine and isodesmosine was postulated and 
proposed146,147. The process of cross-linking starts with the alignment of lysine pairs
1 i rin the tropoelastin precursor , which are turned into allysine residues by the action 
of lysyl oxidase action (oxidative deamination of the 6-amino group of the lysine 
residue) and then go through the appropriate aldol and Schiff base condensation 
reactions (see figure 1.6). It has also been reported148 that elastin, in addition to 
desmosine and isodesmosine, contains high levels of intermediates of higher 
reduction state: their respective cyclic dehydrodesmopiperidine precursors
(dihydrodesmosines and dihydroisodesmosine that can be oxidised spontaneously to 
the respective (iso)-desmosines). The cross-links render elastin a highly 
hydrophobic, insoluble and elastic protein149. The elastin in heart valves is not 
confined primarily to the ventricularis, as suggested in the past150,151, but is widely
distributed throughout the aortic valve in what appears to be a highly functional
120fashion . The mechanical role of elastin in heart valves has been largely ignored 
due to its low content and its limited stiffness. But the importance of elastin (even 
when present as a minor component) in proper mechanical function indicates that 
any disruption of elastin through disease or other means could be the reason for 
mechanical failure of a valve152.
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Figure 1.6: Proposed reactions for the formation of cross-links in elastin (AASA is
148a-amino adipic acid). Adapted from Paz et al .
1.5.3 Collagen
There are 16 distinct types of collagen15 ,154. Amongst these, type I collagen is the 
most abundant and the most important with respect to biomaterials. Three types of 
collagen have been isolated and identified from bovine heart valves. These are; type 
I (the predominant component of heart valve tissue), type III and V. Type I collagen 
consists of three left-handed, helical a-chains (each chain contains 1050 amino 
acids) aggregated to form a right-handed triple helix. Every third residue in the chain
is the amino acid glycine. Other major amino acids are proline, lysine and 
hydroxylysine. The primary structure of collagen is a repeating amino acid triplet of 
the form (Gly-Pro-X)n, where X can be any amino acid. Several amino acids present 
in the sequence contain potentially reactive groups. For examples the oxygen- 
containing groups would tend towards nucleophilicity, whereas the basic nitrogen- 
containing groups would tend towards electrophilicity. The triple helix is stabilised 
by hydrogen bonding. Non-helical terminal regions are thought to contain 
hydroxylysine residues. These are involved in natural inter-molecular cross-linking 
and further stabilise the structure. Such triple helices are assembled into ordered 
polymers called fibrils (100-300 nm in diameter) or fibres o f several microns in 
diameter. When viewed by electron microscopy, collagen fibrils exhibit a 
characteristic banding pattern due to the staggered arrangement of the component 
tropocollagen molecules. For a more detailed review of collagen, the reader is 
invited to refer to some excellent publications in this area154' 156.
1.5.3.1 Collagen for medical applications:
Collagen-based biomaterials are employed in numerous medical applications. Whilst 
a detailed description of the full range of applications is outside the scope of this 
thesis, however it is worth mentioning a few such as channels for nerve 
regeneration157, tissue reconstruction158,159, tissue augmentation160,161, bum and 
wound dressings162' 164, drug delivery systems165' 167, soft contact lenses and ocular 
surfaces168, urinary tract surgery169,170 and urinary incontinence in the
171exstrophy/epispadias complex , closure of the pericardial sac after open-heart 
surgery172, vascular grafts173,174, valved conduits99 and ligament replacement175. The 
materials most widely used are those derived from bovine, porcine and equine 
pericardium, all of which are or have been employed in the construction of cardiac 
prostheses.
1.5.3.2 Natural cross-linking of collagen:
In normal biological tissues, the collagen fibrils are stabilised and strengthened by 
covalent inter- and intra-molecular cross-links. Cross-linking also provides fibres 
with an adequate degree of tensile strength and visco-elasticity176,177. Native cross­
links, within the tropocollagen molecule (intra-molecular cross-links) and between 
different molecules (inter-molecular cross-links), are formed predominantly between
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lysine and hydroxylysine residues. Intra-molecular cross-links in tropocollagen are 
formed between lysine residues located in the non-helical region near the amino 
terminal. Inter-molecular cross-links are formed by the joining of two hydroxylysine 
residues and one lysine residue. These cross-links are formed between residues near 
the amino terminal of one tropocollagen molecule and the carboxyl terminal of 
another. Three natural cross-linking reaction pathways occurring in type I collagen 
can be found in the literature. The allysine-derived pathway178 (with two 
alternatives); the hydroxyallysine-derived pathway178; and the formation of pyrrolic
1 7Q 1 ROcross-links ’ . A common feature in these natural cross-linking mechanisms is a
requirement for the enzyme lysyl monoamine oxidase (a copper metalloenzyme). 
This initiates the cross-linking by specifically oxidatively deaminating some 6-amino 
groups of lysine and hydroxylysine into aldehydes. Thus lysine and hydroxylysine 
residues are turned into allysine and hydroxyallysine respectively. These can then 
undergo a series of condensation and imine formation reactions to form the intra- 
and inter-molecular cross-links involving mainly lysine, hydroxylysine and histidine 
residues. It has been proposed that aldehyde formation occurs by the enzyme binding 
to the carboxy-terminal telopeptide region of fibrillar collagen181, although there are 
reports that suggest the enzyme can act on lysine and hydroxylysine residues located 
in the helical regions182.
1.5.3.2.1 The allysine-derived cross-links (a)
Two allysines undergo an aldol condensation forming an intra-molecular cross-link 
between two chains in the N-terminal non-helical region of the same collagen 
molecule. A histidine residue reacts with this aldol condensation product by a 
Michael-type addition to form a dehydro-aldolhistidine. This, in turn, reacts with 
hydroxylysine to form a reducible dehydro-histidinohydroxymerodesmosine (deH-
i noHHMD) cross-link . The histidinohydroxymerodesmosine is shown in figure 1.7 
below.
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Figure 1.7: The structure of histidinohydroxymerodesmosine 
1.5.3.2.2 The allysine-derived cross-links (b)
Allysines in the C- and N-terminal regions condense with 6-amino groups of specific 
helical peptidyl residues of lysine or hydroxylysine to form a reducible Schiff base 
inter-molecular cross-link (dehydro-hydroxylysinonorleucine). A histidine residue 
subsequently reacts to form a stable non-reducible histidinohydroxylysinonorleucine 
(HHL) inter-molecular cross-link178. The histidinohydroxylysinonorleucine is shown 
in figure 1.8 below.
O H
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Figure 1.8: The structure of histidinohydroxylysinonorleucine 
1.5.3.2.3 The hydroxy ally sine-derived cross-links
Hydroxyallysine in the non-helical regions condenses with hydroxylysine to form 
reducible Schiff base cross-links (dehydro-dihydroxylysinonorleucine). The Schiff 
base undergoes an Amadori rearrangement forming stable ketoamine cross-links. 
The ketoamine undergoes a series of reactions with a further ketoamine or a 
hydroxyallysine to form a non-reducible pyridinoline inter-molecular cross-link178. 
There are reports, however, which suggest that some of the cross-links remain in the
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1 O ’)unstable Schiff base form . The pyrodinoline cross-link can be seen in figure 1.9 
below.
H O
H N
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Figure 1.9: The pyrodinoline cross-link
1.5.3.2.4 The pyrrolic cross-links
1 7 QKemp and Scott proposed the presence of pyrrolic cross-links, involving Ehrlich 
chromogens (EC) in collagen. In 1992, Kuypers et al180 provided strong evidence 
that the collagen-associated EC is a major cross-link involving primarily the C- 
terminal helical cross-link region of the a 2 (l)  chain in bovine type I collagen. They 
proposed that the EC is a trisubstituted pyrrole formed from allysine reacting with 
hydroxylysino-5-oxonorleucine to form a Schiff base, which leads to a trisubstituted 
pyrrole. Such a trisubstituted pyrrole can be seen in figure 1.10 below.
:n h
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Figure 1.10: The structure of a trisubstituted pyrrole
To further stabilise collagen fibres in biological tissue, exogenous cross-links may be 
added to a tropocollagen molecule within its individual helical strands (intra­
molecular cross-links), between adjacent tropocollagen molecules (inter-molecular
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cross-links) or between tropocollagen and other molecular species, using cross- 
linking agents, as will be discussed in the following section.
1.5.4 Induced cross-linking by chemical and physical methods
1.5.4.1 Introduction:
As already mentioned, collagenous tissue degrades quite quickly once harvested. For 
clinical devices, this deterioration must be delayed or prevented and hence there is a 
need for stabilising by chemical or physical cross-linking techniques. To allow the 
exploitation of tissue, its structural and mechanical integrity has to be enhanced and 
maintained. In addition, the tissue’s antigenic properties have to be neutralised while 
maintaining sterility and cross-linking indeed helps to abolish or minimise
• • • 184antigenicity . Additionally, there is a decrease in the concentration of naturally 
occurring cross-linking in explanted tissue compared with non-implanted tissue185. 
This means that naturally occurring cross-links break down during implantation. 
Preparatory methods for collagen tissue are thus mainly concerned with the 
enhancement of mechanical stability by creating additional bonds. Thereby 
increasing the numbers of intra-molecular and inter-molecular cross-links186 
increases the mechanical strength of the tissue and its stability during implantation78. 
Currently there are two different approaches to improving the properties of 
biological biomaterials: chemical and physical procedures, although some have their 
limitations.
1.5.4.2 Physical procedures:
Methods such as dehydrothermal treatment, photo-oxidation and UV irradiation, are 
primarily designed to avoid introducing potentially toxic chemical agents (there is no 
use of foreign substance). However the physical methods of cross-linking generally
• 1 7provide a low density of cross-links and are out of the scope of this thesis.
1.5.4.3 Chemical procedures:
1 0*7  1 OO 1 OQChemical cross-linkers include hexamethylene diisocyanate , epoxy resins ’ ,
carbodiimides176, acyl azide190 and genipin191 192. Although some of these cross- 
linking agents seem to be preferable in terms of the reduced cytotoxicity, they cannot 
equal glutaraldehyde in terms of its ability to stabilise collagen193. All current valve 
manufacturers employ glutaraldehyde at some stage of their tissue treatment
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processes. Glutaraldehyde also has many other applications in various fields. A 
major hurdle to the introduction of a new cross-linking agent for valve stabilisation 
is the requirement for approval of the resulting product by the US Food and Drug 
Administration (FDA) and/or the EU Regulatory Agencies for implantation in 
humans. Due to the time associated with such a process and hence its cost, valve 
manufacturers have placed their research investments in the development of a more 
robust valve whilst retaining glutaraldehyde as the fixative, rather than adopting the 
radical approach of employing another agent.
Due to its importance in the manufacturing process in the valve industry and also 
because of its importance regarding the theme of this thesis, chapter 2 is dedicated to 
glutaraldehyde including its applications (particularly its use in the valve fixation 
process), toxicity and complex chemistry in solution and with proteins.
1.6 Calcification: pathology and prevention
1.6.1 Introduction
Calcification remains a major cause of clinical failure of glutaraldehyde-treated heart 
valves. Approximately 30% of bioprosthetic valves fail within 10 years of 
implantation194. Almost half of these, display mineralisation that can lead to 
irreversible damage to the valve, such as leaflet rupture. Such a calcified valve can 
be seen in figure 1.11. Unfortunately, an incomplete understanding of the factors 
leading to mineralisation hampers the development of a prosthesis that is resistant to 
calcific failure.
In the following section, an insight into the process of non-pathological calcification 
will be given. This is followed by a discussion of the factors influencing the 
pathological calcification and the mechanism of calcification found in bioprosthetic 
heart valves.
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Figure 1.11: Explanted tissue valve exhibiting significant calcification.
1.6.2 Non-pathological calcification
Deposition of calcium in tissues can be part of a normal process, for example 
mineralisation of osteoid during endochondral bone formation, or formation of 
dentin and tooth enamel195. In general, normal calcification essentially equates with 
bone formation. The mineral deposited initially in normal calcification is 
predominantly a poorly crystalline form of hydroxyapatite [Caio(P0 4 )6(OH)2], often 
substituted in carbonate196,197. This is insoluble in body fluids. Once formed, the 
calcific deposits tend to proliferate at the levels of calcium and phosphate found in 
serum, with initial crystals serving as nuclei or templates for the precipitation of new 
crystals. Under normal conditions, the concentrations of calcium and phosphate ions 
present in biological fluids are in a metastable state (their concentrations are too low 
for the spontaneous precipitation of hydroxyapatite to occur), however, physiological 
levels of these ions are sufficient to support the growth of crystals once precipitation
• 1QRis initiated . In early studies, it was suggested that collagen was capable of 
nucleating hydroxyapatite from a metastable solution because of a specific molecular 
stereoconformation that would have high affinity for cations199. More recently, 
collagen has been hypothesised to play a role in mineralisation in bone200,201 and to
909orientate the newly formed crystals . Although many hypotheses have been 
postulated regarding the initiation of calcification, there is support for the hypothesis 
that the normal mineralisation process is initiated by extracellular matrix vesicles,
9 09  90^which are rich in lipids and phospholipids ' . The earliest hydroxyapatite crystals
detected were reported to occur in association with extracellular matrix
90£ 907vesicles ’ . The matrix vesicles are reported to form templates where salt
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precipitation can take place in an ordered manner208. In the early phase of 
calcification, crystals are formed inside the matrix vesicle. Acidic phospholipids 
(phosphatidyl serine), present in matrix vesicles209, are known to possess a high
91 0affinity for calcium and could act by trapping calcium ions, hence acting as 
initiator sites. Moreover, proteolipids have been reported to be able to nucleate both
911 919normal and pathological calcification " . Furthermore, due to the action of energy-
requiring transmembrane enzymes such as ATPase or phosphatases concentrated in 
the matrix vesicles, concentrations of calcium and phosphate are elevated to the 
point of spontaneous nucleation of calcium phosphate mineral214. Additionally, 
pyrophosphate, a natural inhibitor of hydroxyapatite, can be hydrolysed by inorganic
91 Spyrophosphatase and alkaline phosphatase , which are both found in abundance at 
calcification sites, thus also providing phosphate for the nascent mineral formation. 
At the earliest stage, a mixture of calcium complexes may lead to the formation of 
calcified deposit mineral precursors. The complexes could then interact with 
phosphate ions to form calcium phosphate precursor nuclei, although the product 
could still be co-ordinately bound to the organic fraction216. Once formed, apatite 
crystals are insoluble and tend to be self-propagating.
1.6.3 Pathological calcification
Calcium deposition can lead to functional anomalies (such as atherosclerotic 
plaques, tendon and joint dysfunction and failure of implantable prostheses including 
heart valve prostheses) when it takes place at ectopic sites, that is, sites other than 
within normal mineralised tissue such as bone or dental mineral195. It is also worth 
mentioning that calcification in natural human aortic valves is found in about 2.9% 
of the elderly population, giving rise to calcific aortic stenosis. The risk increases
217218 219with age ’ . This is the most common form of valvular heart disease . In 
addition, such calcification is enhanced in damaged valves, such as those with 
congenital anomalies or those affected by rheumatic valvulitis.
Pathological calcification in-vivo has been classified in three categories:
Heterotopic calcification: This formation of true bone is quite commonly found after 
hip replacement and in association with the deposition of cartilage and generation of 
new osteoblasts, but the initial stimulus for this mineralisation remains unknown.
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Metastatic calcification: This occurs when the plasma concentrations of calcium 
and/or phosphate ions rise above critical levels leading to deposits of apatite crystals, 
usually in association with a local rise in pH. It is often associated with renal disease 
and can be prevented by reducing plasma phosphate with ingested aluminium 
hydroxide.
Dystrophic calcification: It is defined as mineralisation that occurs in tissues other 
than teeth or bones in the absence of a systemic mineral imbalance220. Dystrophic 
calcification is a common response to injury in soft tissues and can have devastating 
effects when it occurs in soft tissues such as artificial heart valves and arteries. It is 
also a common detrimental consequence of implantation of many biomaterials, 
prostheses and other medical devices. Dystrophic calcification can be either intrinsic 
(i.e. directly associated with the biomaterial, for example in valves it is found with 
collagen bundles or connective tissue cells as well as at the commissures of the valve 
cusps); or extrinsic (i.e. superficial to the biomaterial and in association with debris 
attached to the surface of the material, for example with valves it can be found in 
association with thrombus, cell debris or vegetations221.
Although the process of mineralisation of hard tissues has been extensively
9 0 7  9 9 9  9 9 Ainvestigated throughout the last four decades ’ ' , it is not yet fully understood.
Pathologic calcification in calcific disease203 (e.g. degenerative calcific aortic
99c O 0Astenosis of aged aortic valves , atherosclerotic plaque , arthritis, dental calculus 
and calcification of implanted medical devices) and the normal calcification of 
skeletal and dental tissues share important features. Deposits of calcium phosphate 
salts in bioprosthetic valves are chemically and crystallographically very similar to
9 9 7  99Qbone mineral ' , resembling hydroxyapatite crystals [Caio(P0 4 )6(OH)2] in
composition and structure. The initial mineral deposits are poorly crystalline apatic 
mineral, highly insoluble in body fluids at physiological pH but able to proliferate in 
serum concentrations of calcium and phosphate. Cell and collagen crystal deposits 
are present ultimately, and initial crystal formation is believed to occur on cell 
membranes, usually in the form of extracellular vesicles202,203,225,226,230. Similarly, 
mineral initiation in developing bones, in the dentin of teeth and in the epiphyseal 
growth plate cartilage of long bones results from the deposition of apatite crystals 
within and upon extracellular matrix vesicles. These structures have a high 
concentration of calcium-binding acidic phospholipids within their membranes and
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exhibit high phosphatase activity, especially alkaline phosphatase202,203,230. Alkaline 
phosphatase, an enzyme critical to bone mineral nucleation, is present in both fresh 
and fixed bioprosthetic tissue and has been identified at sites where early 
mineralisation occurs231,232. In normal bone calcification, the growth of apatite 
crystals is regulated by several non-collagenous matrix proteins, including 
osteopontin (an acidic calcium-binding phosphoprotein with high affinity to
9qq 'J'lAhydroxyapatite that is abundant in the foci of cardiovascular calcification * ),
osteonectin (known as secreted protein acidic rich in cysteine (SPARC)), and 
osteocalcin proteins, such as matrix glycosaminoglycan protein (MGP) ’ .
Osteopontin has been shown to inhibit calcification237 it has also been identified in
99Qcalcified bioprosthetic and native heart valves removed from patients ’ . Recent
studies suggest that both physiologic and pathologic calcification are genetically
907 9 4 a  949controlled by inhibitory molecules ’ ' and that calcification occurs passively
when inhibitors are absent.
1.6.3.1 Calcification of valves:
Both experimental243,244 and clinical studies245 of valve bioprostheses have 
demonstrated that mineralisation occurs by deposition of crystalline calcium 
phosphate, namely hydroxyapatite, predominantly deep in the valve tissue. 
Calcification has been demonstrated to proceed in two major phases, the nucleation 
and then propagation of crystals246.
1.6.3.1.1 Nucleation phase:
This first phase of calcification is very critical because in normal biological fluids, 
calcium and phosphate levels are found in insufficient concentrations to allow 
spontaneous precipitation of hydroxyapatite from their possible preliminary 
compounds, namely amorphous calcium phosphate and octacalcium phosphate. Once 
hydroxyapatite is formed however, the reaction is irreversible as the product is 
insoluble. At the site of calcification, a localised micro-environment occurs in which 
concentrations of calcium and phosphate are elevated to the point of apatite 
precipitation. The initiation site has never been established conclusively. In a normal 
environment, calcium exists in metastable equilibrium with dissolved phosphate
947species . This equilibrium is dependent on the pH, temperature or serum 
concentrations of the dissolved chemical species and can easily be changed in the
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presence of foreign substances such as trace impurities or surface changes248. The 
subsequent shift of equilibrium may result in the spontaneous precipitation of 
calcium phosphate crystals at lower levels of super-saturation than those encountered
94 7physiologically . Furthermore, it has been demonstrated that the presence of other 
ions can also promote the precipitation of calcium phosphate249. This may explain 
why calcification seems to result from the formation of calcium phosphate crystals 
with substantial incorporation of sodium, magnesium and carbonate that, by 
subsequent crystal aggregation, grow to form the calcified nodules that result in 
valve dysfunction and failure250. In contrast to bone formation, a non-energy-
2_j_requiring Ca trap has been postulated to occur in dystrophic mineralisation as a 
result of the presence of phospholipid complexes (e.g. phosphatidyl-serine), which 
can nucleate mineral phases from metastable calcium and phosphate198,210. It has also 
been demonstrated that the initial calcium-forming event in bioprosthetic valve 
involves calcium diffusion into the phosphorus-rich ultrastructure of glutaraldehyde-
999 9S1devitalised cells ’ . In viable cells there is a 10000 fold gradient of calcium across
the plasma membrane. Low intra-cellular calcium concentrations are maintained by 
energy-dependent pumps in the cell membranes. In cells rendered non-viable by 
glutaraldehyde fixation, the mechanisms for calcium exclusion are no longer 
functional (the calcium pumps are impaired) and calcium passively diffuses into the 
cytoplasm where it can react with phospholipids of the plasma membrane and
199 9 ^9membrane bound organelles such as mitochondria ’ . Cell debris, consisting of
nuclear membrane and organelle fragments, is known to be a potential primary site
199 9S9for calcification ’ . Recent studies in cultured cells suggest that calcification does
not occur in dead cells, but in chemically-injured cells. This suggests that the 
calcium influx into the injured/dead cells is not passive but may be regulated at a 
cellular level in-vitro and at an organic level in-vivo254. More recently, results from a 
study of porcine valve fibroblasts agreed with the fact that mineralisation is initiated 
in cells but suggested that glutaraldehyde fixation causes a massive cytosolic
255calcium increase along with a concomitant increase in phosphorus concentration . 
It was also recently reported that cells initiate calcification and extracellular matrix 
serves as a substrate for the subsequent growth of apatite in glutaraldehyde-treated
9  r z rvascular tissue . Findings by others support the concept that valve calcification is 
not a random passive, degenerative process, but an active regulated process
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involving either a transformation of the human valve fibroblast cell to an osteoblast­
like phenotype or the recruitment of osteoblast precursor cell in the inflamed area257.
The presence of endogenous or host proteins, the host’s immune response, the 
fixative used and other parameters may be other possible factors in the explanation 
of consistent intrinsic calcification and these will be discussed later in this chapter.
1.6.3.1.2 Propagation phase:
Once nucleation has occurred, the concentration of calcium and phosphate in 
metastable fluids is sufficient to allow for crystal propagation. Precipitation may then 
proceed through the formation of unstable precursor phases since the various 
calcium phosphates have thermodynamically different solubilities. This is followed 
by the accumulation of calcium phosphate crystals. These are usually associated with 
the collagen fibrils of glutaraldehyde-treated valve tissues. The deposits increase in 
terms of size and number with time of implantation, finally obliterating implant 
architecture (cells, collagen) with subsequent nodule eruption through the tissue 
surface122'243.
1.6.3.2 The calcification of elastin and collagen:
9SQCalcification of collagen and elastin occurs by independent yet poorly understood 
mechanisms. Elastin-associated calcification was first reported in the calcification of
Iff) 1ft 1aortic wall in the early 1970s and was later observed in aortic wall allografts
9 9 0and glutaraldehyde-treated heterologous vascular grafts implanted subcutaneously 
in rats. Mineralisation within elastin fibres has been reported to occur independently 
of cross-linking whilst in collagen some alteration to the collagen molecule such as
9^ 9aldehyde cross-linking is required . Moreover, vascular elastin fibres have a 
tendency to calcify but cuspal elastin fibres do not . This would suggest that the 
mineralisation capability (and also possibly the cross-linking capability) of elastin 
fibers of one tissue differs from that of others. It has been demonstrated that elastin 
fibres might be the principal site of calcification of biological vascular grafts when
9 9 0  n)f.\implanted in animals ’ . A decrease in the degree of natural cross-linkage was
found in the elastin in calcified atherosclerotic plaques within the aortic wall264. It
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has been suggested that space within the macromolecular cross-linking of elastin
'y zrrmay provide a nucleation site for mineralisation .
1.6.3.3 The mineralisation of valves of different origin:
Data from a recent study shows that pericardial valves appear less prone to 
calcification than porcine valves, although further tests with a greater number of 
samples are required to prove this finding since many factors, such as tissue or 
manufacturing differences, or even the tissue source, must be taken into account266. 
Nevertheless, as already discussed earlier in this chapter, several reports support the 
finding that the performance of pericardial valves currently in clinical use is equal or 
superior to that of porcine valves53,81.
Bovine pericardium has, however, been shown to calcify with pathological features
and mechanisms of mineralisation identical to those of porcine aortic valves, despite
122differences in infrastructure . Calcific deposits in either porcine valves or bovine 
pericardial tissue can be seen morphologically in residual connective-tissue cells of 
the bioprosthetic tissue (intrinsic calcification) within 48 h following subcutaneous
122 243implantation ’ . Calcification can also occur within adherent thrombi or infective
vegetations (extrinsic calcification)51,202’267, but this is not relevant to this present 
work.
1.6.4 The formation of hydroxyapatite (HAP) and its derivatives
It has already been mentioned that the deposits of calcium phosphate salts found in 
bioprosthetic valves are chemically and crystallographically very similar to bone
99 7  99Qmineral ' and resemble apatite crystallites in composition and structure. The term 
“apatite” refers to a structural type that can be represented by the formula 
[A4B6(M0 4 )6X2]. In bone, A and B are mostly calcium ions in two kinds of site, 
MO4 is a PO4 group (possibly with some substitutions) and X2 are mostly OH' ions. 
Hard vertebrate tissues are composites primarily composed of impure, calcium 
deficient hydroxyapatite (HAP) and collagen. The main product of calcification in
91 /z 'yr obone is usually considered to be a variant o f HAP ’ . The formula for
stoichiometric HAP is [Caio(P0 4 )6(OH)2], the unit cell of the crystal containing all 
eighteen ions of the formula. A detailed account of its structure can be found in the
9/rQliterature . Stoichiometric HAP contains constitutional water, in the form of OH" 
ions; this water can be driven off by high temperature treatment (e.g. ashing), first
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producing a partially dehydrated HAP and then disproportionating according to the 
following reaction269:
Ca10(PO4)6(OH)2^  Ca40 (P 0 4) 2 + 2Ca3(P 0 4) 2 + H20
Additionally, various proposals for non-stoichiometric apatites have been reported 
and include H20  in place of hydroxide ions270, H20  or H30 + in place of Ca+ 21 \  
water as (C 0 3+H20 )2' substituting for P 0 42" 269, interstitial H+ as hydrogen bonds 
between oxygens of the phosphate ions272 or even water hydration in octacalcium 
phosphate (OCP) (Ca8H2(P 0 4)6.5H20 ) interlaid with HAP273. Indeed, HAP 
compound has a range of composition that may be characterised in terms of Ca/P 
ratios. The Ca/P ratio of stoichiometric HAP is generally reported as being 1.670, 
but stable compositions (assuming that no ionic substitution has taken place in the 
apatic structure) may have ratios extending down to approximately 1.500. This 
corresponds to a defective structure [Ca9(HP0 4)(P0 4)5 0 H] created by the removal of 
a mole of CaO from the stoichiometric HAP274. It is widely known that low Ca/P 
ratios result from the presence of calcium vacancies, with charge compensation 
achieved by incorporation of protons interstitially, as H P042' or H30 + ions, or by 
protonating OH' ions to form H20  272,275. Furthermore, the apparent presence of 
octacalcium phosphate (OCP CasH2(P 0 4)6.5H20), brushite (dicalcium phosphate 
dihydrate DCPD CaHP04 .2H20 ) and possibly monetite (dicalcium phosphate 
anhydrous DCPA CaHP04) and “amorphous” calcium phosphate (ACP) as phases 
which are separate from the apatic mineral in bone has been cited as a possible cause
9 AQfor the observed variations in the Ca/P ratios , associated with the maturation and
9 7 9 7 7aging of biological apatites ’ . In fact the most commonly proposed precursors to
9 7 8  9 8 0HAP have been these same compounds, amorphous calcium phosphate (ACP) ’ ,
brushite (DCPD)281, and octacalcium phosphate (OCP)282. However, other 
researchers have stated that there is no evidence for the presence of a precursor phase
98Twith only the presence of apatite as the single mineral component being observed
98S . Thus, it is thought that a few of the compounds are worthy of further 
consideration.
Amorphous calcium phosphate (ACP): It has been reported that as much as half of
98the mineral in bone is in the form of ACP, although the same group later stated 
that fully developed bone mineral could not contain more than 10% ACP287. ACP
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has been reported as the precursor to the formation of apatite269. ACP has been 
observed to represent the major solid CaP phase in the very earliest mineral
987 98Qdeposits " . The Ca/P of ACP does not vary as much as the one of crystalline
hydroxyapatite: it varies only from 1.200 to 1.500 where the structural unit is 
thought to be Ca^POz^290.
Octacalcium phosphate (OCP): The possible role of OCP as a precursor was 
reported as early as 1957291. The structural composition of OCP (CagTCCPO^ATCO) 
has been reported269 to be closely related to the one of HAP, with similar unit cell 
lengths b and c and also the enclosed angle alpha. The OCP structure thus consists of 
an apatitic layer almost identical in structure to HAP but also a hydrated layer that 
differs totally in its composition and structure from that of HAP. In-vitro at ambient 
temperatures, OCP crystals grow more rapidly than do HAP crystals (even in the 
presence of serum, where crystal growth poisons are reported to greatly hinder the
9Q9formation of HAP but not that of OCP ), additionally it was reported that this 
process of fast crystal growth was probably taking place too in-vivo during bone
9Q3growth . It was reported that the initial bone crystallites appeared to be mostly thin 
plates, several Angstroms long, nearly as wide and about 50 A thick, with a lack of 
hexagonal symmetry but a pronounced platy crystal morphology typical of
9^Qoctacalcium phosphate . Because of the similarity in the structures o f OCP and 
HAP, which can lead to the formation of epitaxial overgrowths of one on the
273other , OCP is also thought to be the basis for the formation of non-stoichiometric 
apatites, by the presence of OCP as a separate phase293, by an incomplete hydrolysis
97T —of OCP to HAP or by the presence of half an OCP unit cell transition layer on 
crystallites resulting in lowering of the Ca/P ratio down to about 1.550 or even 
1.400294. It has also been suggested that microdomains with an atomic arrangement 
different from that of apatite may exist273 and a plausible model involving the 
interlayering of OCP and HAP was evocated for the nucleating entity of bone and
9QSenamel , and is refered to as octacalcium phosphate hydrolysate (OCPH). Such 
mixed crystals were reported to generate a slightly distorted but nevertheless apatite­
like XRD pattern, explaining the failure to detect a phase other than apatite. Their 
composition would also account for the nonstoichiometry of biological apatite. 
Moreover, it is thought that apatitic biominerals are formed through a precursor 
mechanism in which OCP precipitates first and then hydrolyses irreversibly to a
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transition product intermediate to OCP and HAP, which is OCPH197. The hydrolysis 
of OCP has been studied in-vitro and was showed to yield a calcium-deficient 
apatite, providing good evidence also that OCP may be a precursor phase in the 
formation of pathological calcified deposits and normal biomineral which appear to 
be a complex hydrolysate of OCP296. The characterisation of biominerals in 
cardiovascular deposits showed that OCPH was the most likely compound according 
to many characteristics such as the presence of water and the incorporation of CO3 2",
-f* 9+ 292Na and Mg . The same study showed the presence of carbonate in these 
biominerals and it is known that when OCP hydrolyses in the presence of carbonate 
ions it incorporates them, while a similar situation does not exist for hydroxyapatite 
prepared under the same conditions297.
Whitlockites: Whitlockite is /5-tricalcium phosphate (/5-TCP Ca3(P0 4 )2). Whitlockites
9QRhave been identified in-vitro , but also in-vivo, associated with apatites and/or 
other calcium phosphates in pathological calcifications e.g.. soft tissue 
calcification299’300, in human dental calculus301' 303 occasionally in human urinary 
calculi304, and also in synthetic systems305. It has been reported that biological 
whitlockites show a partial substitution of magnesium for calcium ions305 and such 
biological whitlockite is referred to as magnesium-substituted TCP or /5-TCMP. /5-
•J Ajf O AHTCMP was reported to be present when some species of bone ’ or amorphous
1 A Ocalcium phosphate were calcinied at temperatures around 700-800°C. Such 
transformations from calcium-deficient apatite to /5-tricalcium phosphate have been 
extensively studied because of their importance in calcium phosphate ceramics309 
and problems with their differentiation310. For example, the expected Ca/P ratio for 
/5-TCP is 1.500, while that for amorphous calcium phosphate can approach a similar 
value of 1.520. However, a comparative study of the Raman spectra of both HAP 
and /5-TCP reported recently allowed their differentiation311.
Now, regarding the process of calcification, it has been observed that the first 
crystals to form are the least stable but most rapidly growing (CaHP0 4 .2 H2 0 ). This 
salt then hydrolyses, first to C a g ^ P C ^ A ^ O  and then to Ca5(P0 4 )3 0 H273, 
sometimes also forming monetite CaHPCU as an intermediate. All these products 
may account for some of the observed variations from the amorphous calcium
33
phosphate Ca/P ratio of 1.500269. Afterwards, the CasCPO^OH converts slowly to 
crystalline apatite by an autocatalytic mechanism313 associated with an increased in 
the Ca/P ratio reaching the ideal pure crystalline HAP phase with a ratio o f 1.670. 
This amorphous calcium phosphate was hypothesised to be able to change somehow 
to a tricalcium phosphate, while according to others314, HPO42' ions are deposited 
and then quickly lose H+ at the crystal surface. In either case, the overall reaction can 
be described by the following equation:
10Ca2+ + 6 HPO42' + 2H20  Caio(P04)6(OH) 2 + 8 H+
If the ions equivalent to the formation of a single HAP unit cell are to form a mineral 
nucleus, the eight corresponding protons must somehow be removed from the 
reaction sites. Unless the pH is raised or if no protons acceptors are made available, 
then the reaction tends to reverse and the crystal nuclei desintegrates instead of 
growing. The protons scavengers are thought to be organic compounds, possibly 
some combination of proteins and polysaccharides, possibly with some lipids216 (as 
in the case o f atherosclerotic plaques, where natural proton acceptors are made 
available). The inability of the environmental fluid (containing proteins, 
polysaccharides, lipids etc.) to remove from the calcifying tissue all the protons 
released by the formation of hydroxyapatite may explain the several-stage formation 
of some bone216.
The understanding of naturally occurring calcification, leading to the formation of  
hydroxyapatite, was investigated mostly with the help of in-vitro experimentations. 
Collagenous matrices were first found to induce apatite formation from a soluble 
phase comparable to serum with respect to pH, ionic strength, calcium and phosphate 
concentration ’ . It was hypothesised that matrix-induced calcification occurs by a
31 f\ 317multistep process ’ , similar qualitatively to the spontaneous precipitation system
318leading to hydroxyapatite formation . The majority of information on CaP crystal 
phases comes from studies of calcium phosphate ceramics used in tissue/bone
-J1Qengineering ’ . However, although in the majority o f the cases no CaP mineral 
phase other than apatite is detected in the crystals, it is not possible to rule out the 
possibility that a very transient non-apatic CaP solid phase is the initial CaP species 
formed, which very rapidly undergoes phase transformation to purely crystalline 
apatite. For instance, the hypothesis involving octacalcium phosphate as a precursor
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phase, either as a solution aggregate or as a distinct solid crystalline phase, formed as 
a precursor of the subsequent formation of poorly crystalline apatite crystals285,321,322 
is supported by a research group in many of their studies; although as they 
postulated, the transition may be so rapid that no significant concentration o f a solid 
crystalline phase allow its detection by XRD, or FTIR323,324. Thus, the formation of 
hydroxyapatite-like structures in calcified tissue, is hypothesised to involve 
precursors such like OCP (octacalcium phosphate CagH^PO^.SH^O), DCPD 
(dicalcium phosphate dihydrate or brushite CaHP0 4 .2 H2 0 ), DCPA (dicalcium 
phosphate anhydrous CaHP0 4 ), a - or /3-TCP (tricalcium phosphate Ca3(P0 4 )2), 
TTCP (tetracalcium phosphate Ca4(P0 4 )2 0 ), CaO (calcium oxide), Ca(OH)2  
(calcium hydroxide).
It is thought that the various hydroxyapatite structures formed may incorporate 
cations such as carbonate, magnesium, sodium etc, which may come from the 
surrounding blood plasma. Plasma contains approximately the following: Na+ 142 
mM, K+ 5 mM, Ca2+ 2.5 mM, Mg2+ 1.5 mM, HC03‘ 4.2 mM, Cl' 148 mM, HP042' 1 
mM, and SO42' 0.5 mM325. Magnesium is the fourth most abundant cation in the 
body and, after potassium, the most abundant intra-cellular metal. A 70 kg man 
contains 1.18 kg calcium, 146 g potassium, 104 g sodium and 24 g magnesium326. 
Approximately 60% of total body magnesium is in the skeleton, either as an integral 
component of the hydroxyapatite (bone mineral) lattice (40%) or in an exchangeable 
fraction (20%) adsorbed to apatite and in equilibrium with the extracellular fluid. In 
contrast, only 1 % of total bone calcium is considered to be readily exchangeable327. 
Plasma magnesium like plasma calcium exists either bound to serum proteins such 
as albumin , complexed to organic anions such as citrate or as a free ion , 
which has the greatest biological activity330. Biological apatites (inorganic phases o f  
enamel, dentin, cementum, bone and some pathological calcifications) are reported 
to be associated with magnesium ' . Bioapatites are generally known to contain 
relatively high levels of ions, (CO32', Na+, Mg2+, H+, Cl' and others334), and lattice 
defects compared to the synthetic analogue hydroxyapatite. In relation to this, data 
have shown that during the hydrolysis of OCP, impurities and defects were 
incorporated into the structure of the non-stoichiometric apatitic product335. 
Furthermore, it is well known for example that Ca2+ can be replaced by different 
cations in the hydroxyapatite structure336,337. It has been reported that sodium but not
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potassium was able to interchange with calcium on the surface of the crystals338 and 
that other ions such as Mg2+, CO 32', HCO 3 ', or pyrophosphate could be strongly 
adsorbed and affect the surface charge of apatites339. For instance hydroxyapatite can 
incorporate carbonate: the type-B carbonated HAP is an HAP with some 
replacement of P 0 43" by CO 32" in its structure340,341. Only about one half of the 
carbonate associated with carbonate-containing apatite is exchangeable, the 
remainder is presumed to be in the lattice .
1.6.5 Use of in-vivo and in-vitro models
Preclinical evaluation in a variety of animal models is used to evaluate the 
functionality of a valve design and assess its resistance to calcification. Models are 
useful to screen putative anticalcification therapies, study graft calcification and test 
new treatments. Clinical data in comparison to in-vivo and in-vitro models take 
many years to amass and are cost effective.
Calcification studies are commonly conducted in two types of animal model: the 
subcutaneous (static in-vivo) and the circulatory model (dynamic in-vivo). In both 
models, the biochemistry, morphology, host and implant determinants of 
bioprosthetic valve calcification are similar to those observed clinically but with 
accelerated kinetics . In-vivo models (subdermal implantation under rat skin and 
orthotopic implantation in sheep), although used routinely, show variability in 
calcification due to individual host factors343. It is often difficult to extrapolate such 
data to the long-term results that could be experienced in humans or to determine the 
primary factors involved in mineralisation. A lengthy period of implantation is often 
necessary to assess calcification rate.
1.6.5.1 Subcutaneous models (static in-vivoj:
Subcutaneous implant models have been developed using small animals of young 
age such as rabbits122,344, mice or rats243,345,346 (the latter being the most commonly 
used animal). They provide convenient, inexpensive and relatively well-controlled 
models, with accelerated rates of calcification. Results obtained in the rat model are
9H 9 'XA'lcomparable to those obtained in the sheep circulatory model ’ and display 
histological and chemical features consistent with failed clinical implants348,349.
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Although the samples are not in contact with circulating blood (proteins, lipids and 
cells can all potentially affect the mineralisation2) and do not experience the 
mechanical stresses imposed by implantation into the heart, the rat subcutaneous 
model is used as routine tool to screen candidate materials190,350 before continuing to 
the expense of larger animal studies. The validity of this test has been questioned as 
some anticalcification strategies have been found to be effective in the subcutaneous 
model, but later proved ineffective in a circulatory model351. Reasons for this are 
numerous as, within the subcutaneous model itself, there are many variations in how 
the implanted tissues are fixed, along with the age, sex and species o f animal in 
which tissue is implanted. If one takes the rat model as an example, there are 
potentially large variations o f age, strain and sex of the animals from one study to 
another. Animal age is critical since tissue implanted into juvenile animals calcifies 
more rapidly than tissue implanted into older animals346. This behaviour is known to 
be analogous to the clinically-observed accelerated calcification o f bioprosthetic 
valves in children/adolescents relative to adults. The use of different sexes and 
strains of rats352 can also result in differences in the rate o f calcification, although the 
reason for this is unclear. If the mineralisation process is considered as 
exponentional with time, then a small difference in the number o f nucleation sites 
could produce a large difference in mineralisation after a few weeks. The appropriate 
control of other factors, such as pH and temperature, must also be carefully
3 C'Smonitored , as these may affect the degree of calcification. Any comparison made 
between individual studies has to be carried out with caution.
1.6.5.2 Circulatory models fdynamic in-vivo):
In large animal circulatory models253,259,354 the valve or tissue is implanted into the 
aortic or mitral position of sheep355,356 or calves93,357. Occasionally dogs358 or 
goats359 are used. Bioprosthetic valve implantation in juvenile sheep360 are most 
frequently used to test the in-vivo durability and calcification characteristics of  
bioprosthetic valves. Such models can display an accelerated mineralisation within a 
few months that would take several years to develop in patients361. For example, 
calcification can occur within a few months in valves implanted in young, growing 
sheep. However, such experiments are technically difficult because the animals need 
to be maintained for a relatively long period o f time (i.e. 2 0 0  days) and are very
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expensive because of the extracorporeal circulation, the long-term housing of the 
animal and the high mortality rate (over 50%)362,363.
The overall predictive capacity of these models suffers from the differences between 
lipoprotein blood content and accelerated calcium metabolism when compared to 
humans. They do not take into account the different human coagulation pathways, or 
the effects of cardiovascular disease. Furthermore, since some of the reported results 
show differences between the subcutaneous and the circulatory models, different 
mechanisms may apply. Despite these concerns, implantation in an animal is an 
essential step in the evaluation of any prosthetic valve prior to initial clinical 
evaluation and represents the only way of studying the effect of biological processes 
such as calcification, thrombosis and tissue ingrowth.
1.6.5.3 In-vitro model:
Several in-vitro methods have been developed for studying the calcification of 
isolated molecules such as proteins, as well as bioprosthetic valve materials. As in- 
vivo calcification occurs relatively rapidly, it is difficult to produce controlled, low 
levels of calcification for investigation of the early stages of the process. However 
in-vitro systems can theoretically achieve this. In the in-vitro system calcium 
phosphate is randomly deposited (in the biomaterial and the environment) in contrast 
to specific pathological calcification364, thus this method can only be used as first 
line screening for rapid evaluation of mechanisms of calcification or testing 
anticalcification strategies. Also, the amount of calcium phosphate available for 
precipitation is limited as it depends on concentrations of the initial working 
solution. For example, an early report of an in-vitro system described the 
mineralisation (formation of hydroxyapatite) of many gels, including type I collagen, 
using a cross-product of Ca and P of over 32 mM to ensure spontaneous
i / r rmineralisation . A smaller cross-product of 2.4 mM was used by Bemacca et
'l/Z/Z 'XfJlal ’ , which still allowed tissue to calcify. Earlier studies showed that calcium
phosphate formation within 2 0  h was achieved with a calcium concentration of 2  
mM and a phosphate concentration of 1.14 mM368. Mineral deposition also occurred 
within 24 h from a balanced salt solution369 containing 1.71 mM calcium and 1.18 
mM phosphate at pH 7.4, with these concentrations being close to the values found 
in serum and rat dorsal interstitial fluid . In contrast to in-vitro tests, body
38
homeostasis generates relatively unlimited amounts of calcium phosphate. Thus, the 
crystalline mineral phase in the in-vitro system is almost completely unpredictable 
and may not bear any resemblance to that occurring in-vivo.
< 371In-vitro models of calcification may be static or dynamic. Calcium-rich solutions 
can be applied to bioprosthetic valves placed into a fatigue system which opens and 
closes the valve at a variety of frequencies372*374 (dynamic in-vitro test); or placed in 
(shaken or not) tubes (static in-vitro test). Bemacca et al, using both static and 
dynamic375,376 in-vitro systems, investigated several calcium/phosphate media 
including bovine plasma and succeeded in producing calcification patterns in 
pericardial tissue similar to the ones seen in clinical explants by histological 
examination. The retained solution consisted of 135 mM NaCl, 2 mM CaCl2 2 H2 0 ,
1.2 mM KH2PO4 in a 0.05 mM MOPS buffer, and was based on previously reported 
work318. This solution produced calcification of 14.22 mg/g with a standard 
deviation of 21.78 mg/g after 21 days375. Many other metastable solutions were 
investigated377, all with varying concentrations of salts to mimic factors343 such as 
ion concentration, pH, temperature and condition of the calcium solution can be
070critical when studying in-vitro calcification . Other groups performed extensive 
studies of in-vitro calcification of various bioprostheses374,379 and demonstrated, with 
the help of soft X-ray analysis and holographic interferometry, that mineralisation 
was initially minimal and then increased exponentially.
Although some authors reported patterns similar to those seen in clinical explants, 
the limitation o f this technique is not the ability to produce calcification but 
difficulties in correlating the histologic and ultrastructural manifestation o f this 
calcification to that seen in animal models and in human explants. In-vitro, at the 
earliest stage o f the calcification process, a mixture o f calcium complexes may lead 
to the formation o f calcified deposit mineral precursors. These complexes may then 
interact with inorganic phosphate ions to form the calcium phosphate precursor 
nucleus, however, the product could still be coordinately bound to the organic 
fraction . At first, the atomic molar ratio of calcium and phosphorus is high, due to 
the incorporation of sodium, magnesium and carbonate in the crystal formation. It 
then decreases with time, finally approaching a value between those of OCP and 
HAP (e.g. 1.83 in 14 days380 and 2.16 at 14 days381). Unfortunately, no in-vitro test 
system has yet been developed which reproduces the calcification rates seen in-vivo,
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or the morphological characteristics of in-vivo models and clinical explants380. 
Although in-vitro models give reproducible data with respect to the end products of 
mineral deposition, their contribution to the understanding o f the mechanisms of 
calcification and the role of different factors in each step of the process is quite 
limited. In fact, some studies report a poor correlation between the results o f in-vitro
TOOand in-vivo methods . On the contrary a recent study found that in-vitro results 
compared relatively well with rat subcutaneous implant data, whilst the dynamic in- 
vitro model, studying valve mineralisation, showed promise in accelerating the 
screening of valves (which may ultimately reduce the cost and need for animal 
model experiments).
Histological staining is widely used as a qualitative technique to assess calcification, 
for example Von Kossa staining enables the calcification to be identified within the 
tissue, whereas Ca-analysis techniques, such as inductively-coupled plasma optical 
emission spectrometry (ICP-OES), may give quantitative data. However, Von Kossa 
staining is not very sensitive to early deposition and it only stains the phosphate of 
the calcium phosphate mineral to brown-black, cell nuclei in red, and cytoplasm in 
pink384.
In summary, no single model is able to determine the propensity of a bioprosthetic 
heart valve to calcify. However, the different test methods complement each other 
and the use of multiple models, along with an understanding of their differences and 
limitations, can help to build a fuller picture of the process of calcium deposition and 
the factors important to its promotion.
1.7 Factors influencing mineralisation
Several factors have been identified which promote calcification. These include 
glutaraldehyde treatment, tissue devitalisation, the quality o f the biological material, 
mechanical stress and the presence of phospholipids. The extent and progression of  
calcification also depend on host factors such as age, the presence o f renal disease, or 
pregnancy. Although many factors have been identified, the mechanism of 
calcification remains incompletely understood and other factors are under 
investigation. The often conflicting data and studies, previously discussed, serve to
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underline the complexity of the calcification process and emphasise the multiplicity 
of pathways by which calcification can be initiated385. The following sections are 
designed to give a succinct overview of the separate “host” and “tissue” factors 
involved. These are, in reality, closely correlated.
1.7.1 Host factors:
1.7.1.1 Age:
Bioprosthetic tissue calcification is dependent on metabolic factors in the recipient,
OO/T TOO _the most important host factor being age " . The clinically observed accelerated
calcification in the young is simulated in the rat subcutaneous model as discussed 
previously. Calcification was reported as being associated with both346 high serum
TOQ # TQOphosphate and osteocalcin levels , as well as the enhanced parathyroid hormone
• • TQ1and vitamin D metabolism seen in the young. However, no direct correlation was 
found between individual serum phosphate or osteocalcin levels and calcium, 
phosphate or osteocalcin content in the valves346. Some recent in-vitro calcification 
results have shown that calcium accumulation is also dependent on the initial
T Q 'Tcalcium concentration in the medium , thus explaining the extensive calcification 
of bioprostheses in children who have a high metabolic turnover of calcium with 
high peak serum concentrations. Another hypothesis lies with the role of alkaline 
phosphatase (see later) because children (and young rats), have higher serum levels 
of alkaline phosphatase than adults393,394.
1.7.1.2 Renal failure linked to phosphate and calcium metabolism:
Patients with renal failure are reported to suffer from early degeneration of their 
biological implants . A recent study showed the prognostic implication of cardiac
T Q /Tvalve calcification in long-term dialysis patients . It has been suggested that the 
availability of phosphate ions could determine the rate of calcification, since 
calcification develops earlier in patients undergoing hemodialysis who have 
increased levels of serum phosphates . Indeed, patients with chronic renal disease
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also have a high rate of calcium turnover with rapid changes in their serum calcium 
concentrations398.
1.7.1.3 Deposition of proteins and circulating cells:
The deposition of extrinsic proteins399 from the host (adsorption of calcium-binding 
proteins) and circulating cells after implantation is thought to be a factor in valve 
mineralisation400,401. It is hypothesised that proteins which normally contribute to 
bone matrix calcification may be involved, since serum proteins are known to be 
taken up in mineralised tissue402. It was reported that calcification was associated 
with increased content of calcium-binding non-collagenous proteins containing 7 - 
carboxyglutamic acid (Gla) residues403 within the tissue. These may serve as an 
initiator of calcification in the rat model345 and also in clinical studies in 
humans388,404. It has been proposed that pre-adsorbed proteins and cells on 
biomaterial surfaces could induce local redistribution of the calcium fraction on the 
material surface and subsequently might act as the initial nuclei of calcification405. 
Others, however, refuted these findings195,346. In particular, one study reports no 
correlation between Gla and calcium deposition, suggesting that although Gla may 
be adsorbed onto the forming calcium deposits it does not contribute to the 
calcification process406.
1.7.1.4 Anticoagulation treatment/Antiplatelet treatment:
Anticoagulants may be able to retard bioprosthetic valve calcification but this is a 
controversial subject. Vitamin K-dependent blood coagulation factors were the first 
proteins discovered to contain the 7 -carboxyglutamic acid (Gla)-containing calcium- 
binding proteins407. Anticoagulant drugs, such as warfarin, inhibit Gla synthesis, 
resulting in a loss of calcium binding and anticoagulation408. An inhibitory effect of 
sodium warfarin on mineralisation was thus suggested409 because a number of Gla- 
containing proteins have been demonstrated to be associated with normal410 and 
pathological calcification345,411,412. However, the inhibition of Gla protein 
synthesis400, with the vitamin K antagonist warfarin, reduced the level of Gla but 
calcification was not significantly reduced. Other studies have also failed to 
demonstrate an effect of warfarin on calcification413. They concluded that the Gla- 
containing protein was probably adsorbed onto the mineral from the blood and so did
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not play an active role. This was later confirmed406 as they found no correlation 
between calcium and Gla concentration in explanted valves.
Calcium is required for most forms of platelet aggregation, and it is believed that 
cyclic adenosine monophosphate functions in platelets by directing the uptake of 
calcium414. It is thus possible that the calcium influx (mineralisation) is due to 
cellular components such as the platelets or involves plasma proteins such as 
fibrinogen molecules. It was recently strongly hypothesised that cellular components 
(platelet activation and adhesion) and plasma proteins (fibrinogen) on biomaterial 
surfaces can affect salt precipitation, determining somehow the propensity o f the 
implant to calcify415.
Antiplatelet agents inhibit platelet activation and adhesion to biomaterials and reduce 
calcium deposition415. Since human platelets possess membrane receptors for, for 
example, fibrinogen and collagen, it seems conceivable that these may modify, mask 
or prevent the expression of binding sites for adhesive proteins and cause reduction 
of platelet densities on the surfaces. Studies show that the deposition of calcium on 
glutaraldehyde-treated bovine pericardium416 can be inhibited by very low levels of 
antiplatelet drugs, possibly by modifying the pericardial surface. Nevertheless, 
further studies are required to assess the definite involvement of cellular components 
and plasma proteins in tissue-associated mineralisation415.
1.7.1.5 Host immune reaction:
The immunological reaction has been considered by some to be responsible for the 
calcific degeneration of cross-linked bioprosthetic heart valves417,418. It has been 
suggested that rejection of the graft may play a significant role in calcium 
accumulation419. However, some studies showed a positive correlation between an 
active immune response and bioprosthetic tissue degeneration420 despite the fact that 
they found no obvious relationship between immunogeneity (T-cell activation) and 
bioprosthetic calcification421,422. Also, it was reported that neither non-specific 
inflammation nor specific immunologic responses appeared to mediate bioprosthetic 
tissue calcification and that no mineral deposition nor resorption were associated
A')'}with inflammation . However, recently, there has been a renewed interest in the 
contribution of immune response to the inflammation o f tissue valves424 and their 
calcific degeneration425.
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It was also demonstrated that the inflammatory reaction is inversely related to the 
extent of glutaraldehyde cross-linking of tissue426,427, and a theory developed to link 
valve degeneration with immune response was that of sub-optimally masked 
antigenicity. Additionally, a number o f studies have provided evidence that 
contemporary heart valve prostheses are insufficiently cross-linked428-430. It was 
shown possible to decrease calcification by 90% by increasing the density o f these 
cross-links424. It is thought by some that glutaraldehyde cross-linking, provides some 
protection against calcification, although it is agreed that short-fixation has a 
tendency to produce a greater calcification than longer fixation treatments, even 
though low fixation is sufficient to alter the immunogenicity o f bioprostheses431. In 
addition, it is hypothesised that the diffusion of plasma between the collagen 
meshwork is favoured after long-term implantation when the cross-links may be 
lost406. These low-density cross-linked valves can therefore allow protein insudation 
and elicit an immune reaction432 that may contribute largely to degeneration.
Thus, the contribution of immune responses to tissue mineralisation could probably 
be more important than initially thought, although the role of cross-links must be 
taken into account too.
1.7.2 Tissue factors:
1.7.2.1 Tissue as a potential initiation site/factor for calcification:
Collagen and bovine pericardium can bind calcium and phosphate in-vitro in the 
absence o f host factors198,318,375. It has been reported that collagen has potential 
calcium-binding sites (e.g. amino, carbonyl, carboxylic groups) and therefore may 
have a natural tendency to calcify51; these sites may normally be protected by 
glycosaminoglycans and proteoglycans that are subsequently lost during the 
glutaraldehyde treatment process. In addition, elastin has been reported as a 
predominant site o f calcification in aortic tissue261; the concept o f “neutral binding 
site/charge neutralisation” has been proposed to explain the calcification o f aortic 
elastin, suggesting that the binding sites for calcium are carbonyl oxygens o f the 
peptide backbone433. In addition, glutaraldehyde cross-linking is reported to enhance 
the affinity of collagen tissue for calcium binding434. Thus, a likely candidate for a 
general calcification mechanism is cation chelation by groups present in the material 
containing lone pairs of electrons susceptible to interactions with electron-deficient
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species (e.g. carbonyl oxygens from the collagen backbone or glutaraldehyde 
species). It is hypothesised that phosphate would be carried along in this process as 
the accompanying anion to maintain charge neutrality. Such a mechanism could 
explain both intrinsic and extrinsic calcification, since cellular debris could 
potentially provide similar binding sites.
1.7.2.2 Matrix and associated proteins:
Early mineral deposits have been reported in transplanted connective tissue cells but 
also involve extracellular collagen fibres114. Cells and their remnants can be found in 
the collagen/elastin matrix. Decellularisation of the tissue has been employed as a 
calcification mitigation strategy435. Matrix vesicles and proteolipids are thought to be 
involved in the initiation of hydroxyapatite deposition436. A recent study stated that 
the presence of matrix metalloproteinases may contribute to the in-vivo degradability 
of pericardium-based cardiac valves437. Acidic phospholipids are recognised as being 
involved in the initiation of both calcification in bone and dystrophic calcification 
44°. Intrinsic phospholipids (and also proteolipids212) have been considered to be an 
initial source of phosphorus in the initial stages of heart valve mineralisation due to 
phospho-ester hydrolysis202,349, possibly due to electrostatic attraction between 
phospholipids in the connective tissue and calcium introduced into the system441,442. 
The role of these phospholipids has recently been reconsidered as a potential 
nucleation source443 and a relatively recent dynamic in-vitro study also found a 
positive correlation of calcification with lipid deposits374. Infrared spectroscopy has 
helped to show that lipids may play a significant role in the first steps of the 
mineralisation process in the subcutaneous implant model, the lipid (phospholipids 
or triglycerides) content of the samples being directly correlated with the duration of 
implantation and preceeding the appearance of phosphate444. Cholesterol (inherent or 
adsorbed during implantation) is also thought to be involved in intra-cellular 
pathologic calcification of bioprosthetic heart valves although the exact mechanism 
of this is not understood445. Furthermore, membrane-bound phospholipids have also 
been associated with calcification nucleation due to alkaline phosphatase
909hydrolysis . Alkaline phosphatase activity was found in both fresh and
99 1glutaraldehyde-treated bioprosthetic tissue .
1.7.2.3 Enzymatic activity:
45
It is believed that tissues treated with glutaraldehyde are rendered “non viable”446,447. 
However, some enzymatic activity has been shown to be retained in various cellular 
fractions446,448. In particular, it has been demonstrated that most hydrolases177, in 
particular, proteases449,450, are not inhibited by glutaraldehyde. It was suggested that 
tissue failure might be due to proteolytic enzymes originating from intrinsic 
(immobilised tissue proteases derived from devitalised cells) or extrinsic (infiltrating 
plasma and phagocytes) sources451.
Early studies failed to find any correlation between enzyme activity (particularly 
alkaline phosphatase) and the mineralisation process in bioprosthetic valves452'454. 
However, it was subsequently reported that alkaline phosphatase was still active in 
cells within bioprosthetic bovine pericardial heart valves despite glutaraldehyde
911treatment and that its distribution was correlated with the sites of early calcific 
deposits. In addition, the presence of alkaline phosphatase together with calcium- 
binding phosphoproteins was later shown to be associated with crystal formation in 
mineralising tissues455'457. Alkaline phosphatase can hydrolyse ATP and lead to the 
possible deposition of calcium and phosphate by matrix vesicles.
1.7.2.4 Mechanical stress factors:
Calcification in bioprosthetic valve tissue in association with mechnical stress is a 
controversial matter.
In-vivo bioprostheses are subjected to high levels of mechanical stress during each 
cardiac cycle, their leaflets undergoing cyclic loading and unloading with reversal of 
leaflet curvature and an extreme degree of flexion in the narrow zone of leaflet 
attachment . This causes fatigue and flexion failure of the tissue resulting in loss of 
function459. In porcine valves, calcification initially occurs in the commissural 
regions where the stress is the highest and then later in the basal region (the middle 
of the leaflet, where a significant amount of flexion is observed).
Mechanical stress plays a role in the breakdown of collagen118 and it has been 
suggested that damaged collagen could be associated with focal calcification in-
' i f / i  1 7 c  ' X l f svitro ’ ’ . The calcification patterns, obtained from valves placed in a metastable
calcium solution under dynamic loading, appear to be correlated with areas of sharp 
leaflet flexure where the mechanical stress is the greatest. It has been proposed that a 
likely mechanism of initiation of calcification is the breakdown of collagen resulting
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from high local mechanical stress, which exposes calcium-binding sites previously 
protected by the intact surface, or the products of breakdown that can initiate 
calcification460.
Several other groups also postulated a close connection between the mechanical 
stress applied to a bioprosthetic heart valve and the process of calcification, although 
there was some uncertainty as to whether mechanical stress initiated calcification or 
vice versa461. In another study, it was reported that dynamic stress may promote 
calcification but it is not essential, as subcutaneous implants, which are not subjected 
to mechanical deformation, also calcify343.
1.7.2.5 Cross-linking:
Glutaraldehyde remains the reagent of choice for bioprosthetic valve fabrication, 
because it improves biostability and structural integrity of treated-tissue346 and 
allows the treated-tissue to exhibit useful properties such as superior stability and 
tissue thromboresistance208. However, there is evidence to suggest that 
glutaraldehyde pre-treatment plays a critical role in calcification259,462 and 
subsequent mechanical degeneration of bioprosthetic heart valves in-vivo98. The 
specific mechanisms by which glutaraldehyde fixation facilitates calcification are not
1 99fully understood . It is ironic that the glutaraldehyde treatment itself, presently used 
in commercial valve processing, might be a calcification initiator. Glutaraldehyde 
cross-linking is thought to potentiate mineral deposition423,463,464, possibly due to 
other structural deterioration of collagen, or by affecting the mechanical behaviour of 
the valves, with the tissue becoming stiffer and less flexible over time due to the 
extent of the glutaraldehyde process. Such findings suggest that the fundamental 
mechanisms of tissue mineralisation may depend on specific chemical modifications 
to the microstructural components of the tissue induced by the cross-linking agent. 
Untreated, type I collagen is resorbed within 3 weeks after implantation in the rat 
model without any sign of calcification346. Such implants are associated with a 
classic foreign body reaction, primarily composed of macrophages45,346. Implanted 
aldehyde-treated purified type I collagen sponges, calcify in the absence o f a foreign 
body reaction or cell-mediated mineral deposition259,465, revealing the role of 
glutaraldehyde in decreasing the antigenicity of xenogeneic tissue as well as in 
calcification.
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The glutaraldehyde process is also thought to alter the tissue by extracting some 
extracellular proteins (e.g. glycosaminoglycans (GAGs))466'468. It has been suggested 
that phosphate can form covalent bonds connecting inorganic and organic 
components via the 6-amino groups of lysine and hydroxylysine in collagen and that 
glycoproteins and proteoglycans (GAGs on protein back-bone), which would 
normally block these sites, are lost during processing of the tissue by 
glutaraldehyde51. This could initiate the mineralisation process. Additionally, this 
extraction mechanism may also creates voids and cavities that form physical niches 
for calcification190 and the morphologic equivalent of this loss is an abundance of 
water spaces in the tissue, which is associated with a high propensity for 
calcification170,466. It has also been postulated that mineralisation is nucleated in the
94Tcells because of their devitalisation and the inactivation of their ion pumps by the 
glutaraldehyde process469. This would allow calcium to passively diffuse into the 
phosphate rich cells and accumulate leading to hydroxyapatite formation122. This 
mode of action would be analogous to the matrix vesicle theory of normal 
calcification (see section 1.6.2). Normal intra-cellular phosphorus levels are 
relatively high. Phosphate is incorporated in many proteins, lipids and the nucleus is 
especially prevalent within plasma and organellar membranes in the form of
1 ophospholipids. Schoen , using electron energy loss spectrometry (EELS), 
demonstrated high concentrations of intra-cellular phosphorus in unimplanted, 
glutaraldehyde-preserved porcine aortic valves and bovine pericardium. He also 
showed the early entry of calcium ions at these sites following implantation.
In contrast, certain findings do not support the involvement of glutaraldehyde. Tissue 
stored in glutaraldehyde for more than 1 year are resistant to calcification470. In 
addition, valves treated with high concentrations of glutaraldehyde show diminished 
calcification . Furthermore, contrary to the Schoen’s hypothesis, glutaraldehyde 
cross-linking of an intact cell membrane may “freeze” the membrane-bound ion 
pumps rather than causing membrane breakdown, rendering it impermeable to 
sodium, potassium and calcium471,472.
Another aspect of the effect of the cross-linking process is the loss of endothelial 
coverage. The aldehyde treatment also inhibits endothelial regrowth following 
implantation473. This is due to the toxicity of glutaraldehyde. This has been 
demonstrated in cell culture, where concentrations as low as 3 ppm427,474 or even 1
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ppm475 were found to be toxic. The natural heart valve is totally covered by a 
confluent layer of endothelial cells150, this prevents plasma insudation and fibrin and 
platelet aggregation476 and must in part be responsible for the absence of thrombosis 
on the surface of normal heart valves. The lack of cell growth on the bioprosthesis 
surface may decrease biocompatibility. Loss of endothelial cells are implicated in 
calcification, inflammation, an increase in surface thrombogenicity and degeneration 
of bioprosthetic heart valves473.
Glutaraldehyde-treated bioprostheses are known to slowly release glutaraldehyde 
over time, possibly by the partial hydrolytic degradation and reversibility of some 
cross-links163,477,478 (for example, Schiff bases possess a N=CH group which 
represents the hydrolysis-sensitive site479). It is also possible that unreacted 
glutaraldehyde is released from tissue or from the decomposition of its derivatives 
such as large molecular weight polymers (a,/3-unsaturated polymers and acetal 
polymers-see chapter 2-) that can serve as a reservoir for the ongoing cytotoxic 
release of glutaraldehyde474,478. It has been postulated that the glutaraldehyde 
measured might represent the degradation of only a fraction of all cross-links, most 
of which are thought to be stable475. It has also been postulated that this slow release 
of residual glutaraldehyde or free aldehyde moieties on the surface o f the 
bioprosthesis tissue may play a role in calcification480,481. It is also believed that 
unreacted glutaraldehyde can leach out into the body causing side effects, with its 
reaction products being cytotoxic427,482 and resulting in the deposition o f cellular 
debris344. It was reported that hydrolysis is the main mechanism for glutaraldehyde 
being released at cytotoxic levels from glutaraldehyde cross-linked tendons for up to 
6 months, even after extensive rinsing of the tendons483. It has also been speculated 
that it is polymerised hemi-acetals rather than the actual stable cross-links that cause 
calcification428.
The slow release of glutaraldehyde within tissue being a potential initiator for 
calcification, is supported by the fact that mineralisation is prevented by the use of 
binding agents that react with residual or free glutaraldehyde moieties482. This basic 
idea o f removing the unreacted glutaraldehyde residues by various methods, such as 
blocking with amino compounds has the potential to decrease calcification. Not all 
amino compounds are equally effective in preventing calcification480. This was 
suggested to be possibly related to the different “bridging effect” o f the various
49
amino compounds (for example how many amino termini are available to react with 
the free aldehyde groups)480, although other reasons behind these discrepancies in the 
results remain unknown.
Tissue valve calcification has been hypothesised to correlate with the calcium- 
binding ability of glutaraldehyde polymers that are present on the surface of treated 
tissue484. That is, the final form of the cross-linked tissue tends to contain
A O t r  A O ZTnucleophilic residues such as carbonyl oxygens ’ . The reaction of glutaraldehyde
with lysine side chains (lysyl and hydroxylysyl residues of collagenous tissue) may 
lead to an impaired balance between positively and negatively charged functional 
groups in the collagenous tissue, thus favouring calcium ion deposition487'490. Many 
reports have suggested a role for aldehyde-induced intra- and inter-molecular 
collagen cross-links in initiating tissue mineralisation190,491'493. Quaternary 
pyridinium-type cross-links found in both elastin and collagen are also thought to 
serve as a nucleation point for calcification494. Moreover, a dipyridine structure was 
suggested to account for the high stability of the cross-links as well as being 
involved in calcification of glutaraldehyde-cross-linked collagen170. This hypothesis 
was also confirmed by others495, who showed the possible involvement of cyclic 
cross-links. Additionally, it has been postulated that glutaraldehyde may cause 
calcification directly by the oxidation of free unreacted aldehyde groups (formyl), 
which might result in some carboxylic residues on the surface of the implant to 
attract and trap the host plasma calcium and contribute toward initiating calcification 
during implantation427,480,483. It is easy to hypothesise that glutaraldehyde may 
oxidise to formylbutanoic acid since the air oxidation of aldehydes to carboxylic 
acids has been reported496,497. Others agreed with this theory and proposed that 
blockage of the formyl groups should be effective in reducing calcification190,208,498. 
However, this hypothesis has also been partially refuted495 in a report stating that 
neither NH2 nor COOH groups seem to be involved in calcification in-vitro. They 
showed that cross-linking with hexamethylene diisocyanate, which only links with 
amino groups, did not induced calcification of the collagen. Furthermore all dermal 
sheep collagen were sterilised by ethylene oxide, which should block the remaining 
amino groups. In addition, cross-linking by acyl azide, which should block carboxyl 
residues, clearly reduced calcification of collagen, however, they believed that this is
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not due to blockage of the carboxylic residues and that COOH groups are not 
involved in calcification.
In conclusion, in the production of commercial bioprosthetic heart valves, although 
cross-linking is necessary to minimise antigenicity and increase mechanical stability, 
the cross-linking process fails to prevent autolytic tissue degradation and 
extracellular component deprivation, and may, in fact, induce calcification.
1.7.3 Conclusion:
It is suggested that host metabolic and implant factors are responsible for the 
inherent propensity of bioprosthetic tissue to calcify499. The dynamic environment 
and exposure to blood promote but are not required for nucleation and growth of 
calcific deposits. Many factors potentially influencing mineralisation are still under 
active investigation. This thesis focuses on tissue and cross-linking factors.
1.8 Prevention of calcification with anticalcification treatments
The preclinical determination of the efficacy and safety of an anticalcification agent 
includes four stages: i) initial qualification using heterotopic implantation (rat 
model...), ii) hydrodynamic/durability testing (pulse simulator), iii) morphologic 
studies of unimplanted material to assess treatment-induced degradation and iv) 
valve replacement (orthotopic implantation) in an animal model (sheep). The 
durability of valves treated with such agents can only be assessed with certainty by 
long-term clinical follow-up (>10years).
Until now, the predominant chemical treatment for biological tissues has been cross- 
linking with glutaraldehyde. To date there has been no clinically proven effective 
strategy for preventing the calcification of bioprosthetic heart valves, or a successful 
replacement for glutaraldehyde. One reason for this is that the exact mechanism of 
induction and propagation of calcification is not well defined and thus a method to 
prevent it remains unclear. Various strategies for prevention of bioprosthetic valve 
mineralisation involve modification of either the implant or its local environment. 
These include (i) blocking the free aldehyde groups left after the glutaraldehyde 
treatment to avoid subsequent reactions; (ii) removal of potentially calcifiable 
materials from the tissue; (iii) inhibiting the mineral growth; (iv) altering the overall
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surface charge; or (v) using alternative cross-linking agents in tandem with 
glutaraldehyde fixation.
The fundamental mechanisms of tissue mineralisation depend on specific 
biochemical modifications (such as glutaraldehyde fixation) to implant 
microstructural components induced by aldehyde or other pre-treatment. It was 
suggested in the early 1980s that reduced-calcification would possibly be attained 
using alternative cross-linking agents17 . Therefore, many alternative cross-linking 
methods208,500,501 were sought. Multifactorial approaches have been suggested502. 
These approaches include careful removal of non-covalently bound glutaraldehyde 
or labile-associated non-bifunctionally unreacted residues of glutaraldehyde by 
thorough rinsing or neutralisation before implantation, removal of lipids and non- 
collagenous proteins (ideally including the antigenic nonhelical collagen 
telopeptides), along with a treatment which would interfere with potential crystal 
growth (such as a biphosphonate) in order to prevent the accumulation of any 
mineral in the tissue. This approach is valid, although a definitive treatment is 
difficult to achieve. More research is needed in order to understand the process of 
mineralisation and its co-factors.
1.9 Outline of the project
The reactions of glutaraldehyde with collagen remain incompletely understood. A 
number of studies have investigated the reactions of glutaraldehyde with a range of 
model compounds, from the simplest amino acids to complex collagenous tissue. A 
number of structures have been proposed for reactions products (see chapter 2) but at 
present there is no definitive understanding of the processes that take place. An 
understanding of the interactions between glutaraldehyde and tissue is essential in 
order if we are to comprehend why bioprostheses calcify and ultimately fail. 
Furthermore, the exact mechanism of calcification is unknown. Previous work 
approached this issue in an empirical fashion, due to the lack of specific knowledge 
regarding the mechanism of calcification. It is likely that the mechanism involves, 
amongst other factors, a contribution from both the tissue and the aldehyde fixative 
(glutaraldehyde) used routinely in the manufacturing process.
The aims of the present study are as follows:
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• To study the behaviour of glutaraldehyde in solution to further our understanding 
of the nature of this compound in aqueous solution.
• To study the reactions between glutaraldehyde and amines, peptides and proteins, 
to determine the structures o f the likely reaction products, and to extrapolate 
these to those occuring during the glutaraldehyde pre-treatment o f bioprosthetic 
valves.
• To investigate the possible involvement of glutaraldehyde and the collagenous 
tissue itself in the calcification mechanism, by mimicking the effect of the 
glutaraldehyde treatment using various amino acids, peptides and protein models, 
in order to investigate the relationship between the products and the calcification 
process.
• To develop a methodology to investigate the calcification o f bioprosthetic heart 
valves using an environmental scanning electron microscope (ESEM).
• To apply this methodology to allow the study of the dystrophic calcification 
process using calcified clinical explants, in-vivo screening (rat subcutaneous 
implantation model) and in-vitro screening (pericardial tissue incubated in 
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Chapter 2
2 Glutaraldehyde.
2.1 Introduction
Glutaraldehyde (1,5-pentanedialdehyde CAS111-30-8) is a bifunctional reagent 
containing two aldehyde groups. It has been the most extensively used cross-linking 
agent for the treatment of bioprosthetic devices for over thirty years1'3. It is readily 
available, inexpensive and its aqueous solutions can effectively cross-link 
collagenous tissues in a relatively short period4. The first isolation and 
characterisation of glutaraldehyde, from the ozonolysis of cyclopentene, was 
reported in 19085. The traditional process for the preparation of glutaraldehyde (a 
two-step process, converting acrolein via an ethoxy dihydro pyran to glutaraldehyde 
by acid hydrolysis)6 involved relatively expensive raw materials and drastic reaction 
conditions7. Thus, an improved method is now used in industry, giving a better yield 
and employing moderate reaction conditions8. The process involves hydrogenation 
of the raw material cyclopentadiene to cyclopentene, which is then oxidised to 
glutaraldehyde by hydrogen peroxide with tungstic acid as catalyst and t-butanal as 
solvent, whilst stirring at room temperature for 24 hours.
2.1.1 History
Glutaraldehyde was reported to be an excellent tanning agent for the leather industry 
in the early 1950s9, producing fairly good leather of a light tan colour over a very 
wide pH range. It was also more stable to washing processes and alkaline solutions 
than other tanning agents such as formaldehyde10. In 1963, glutaraldehyde was first 
introduced as a fixative for electron microscopy and electron histochemistry11. Due 
to the instability and subsequent failure of formaldehyde-treated valve 
bioprostheses12' 14, other aldehydes, including glutaraldehyde, were investigated for
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their cross-linking properties. It was found that glutaraldehyde introduced more 
stable cross-links into collagen15 compared to other aldehydes investigated. 
Glutaraldehyde treatment resulted in enhanced mechanical properties o f treated 
tissue-derived materials and also seemed to introduce chemically stable cross-links 
that are resistant to biologic degradation. Furthermore, it appeared to be the most 
effective agent for decreasing the antigenicity and increasing the stability o f the 
tissue. Glutaraldehyde pre-treatment of bioprosthetic tissue was thus adopted in 1968 
as the method of choice in preparation of tissue valves1. Current commercial 
bioprosthetic valves are treated exclusively with glutaraldehyde; its concentrations 
are kept low and vary between 0.2% v/v (Hancock valve) and 0.625% v/v 
(Carpentier-Edwards valve). These low concentrations are considered to be 
insufficient for efficient sterilisation but higher concentrations lead to unwanted 
stiffening of the valve leaflets16. After primary fixation by glutaraldehyde, the valves 
are normally stored in either glutaraldehyde or formaldehyde to ensure a better 
sterilisation. The successful use of thousands of glutaraldehyde-treated bioprosthetic 
implants over the last decades, indicates its effectiveness and clinical acceptability 
despite its cytotoxicity3’17,18.
2.1.2 The fixation process
The glutaraldehyde treatment used in the industrial production o f valves is intended 
to reduce the immunogenicity of the material, increase its resistance to degradation 
by both the host and bacterial enzymes and sterilise the tissue19. In the valve 
industry, cross-linking is presently carried out in large containers, which 
unfortunately introduces impurities that can have a detrimental effect on the fixation 
procedure . Delay in the fixation, due to the distance between abattoirs and 
fixation/production plants, may also have an effect on the resulting bioprostheses. 
Other factors such as temperature, reagent concentration, pH etc. can also be 
important as will be discussed below. Additionally, before implantation in a patient, 
valves are stored in buffered aldehydes (formaldehyde or glutaraldehyde depending 
on the valve manufacture) for varying lengths o f time. Manufactures also advise 
storage between 5 and 25° C, avoidance of exposure to sun or UV light and storage 
for less than 36 months. An optimal fixation procedure, to preserve the 
ultrastructural integrity and stability of contemporary manufactured bioprosthetic 
heart valves, has been investigated21,22 and the conditions are discussed below.
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2.1.2.1 Temperature:
On raising the cross-linking temperature, two events occur: faster glutaraldehyde 
penetration and tissue reaction, as well as an accelerated autolytic process. At 37°C, 
it was found that there is faster penetration of glutaraldehyde into the tissue and that 
the tissue damage caused by autolysis is less severe than found at room temperature 
(the relationship between autolysis and cross-linking is not linear). The best 
ultrastructural tissue preservation is found at 4°C, whilst the worst results are found 
at room temperature (22°C), although room temperature cross-linking of commercial 
tissue has been used experimentally in many cases and the fact that the industrial 
fixation of valves is carried out at room temperature.
Glutaraldehyde commercial solutions and valves stored in buffered glutaraldehyde
solutions tend to become darker and more yellow in colour especially after 23-32
months21; although no apparent changes are seen when stored at refrigerated
temperature. It is assumed that the colour formation may be due to polymerisation of
glutaraldehyde mechanism, forming oligomeric and polymeric products that might
react with the valve tissue to produce this yellower colour (analogous to a Schiff 
21base colour) . It is known that glutaraldehyde polymerisation increases
9Texponentially with temperature and that the rate of glutaraldehyde polymerisation 
is influenced by many factors including concentration, pH, and temperature24. The 
storage temperature, but not the length of storage, was shown to have a significant 
effect on some mechanical properties of the valves21 that may influence their long­
term in-vivo performance.
2.1.2.2 pH/solvents:
The pH of the glutaraldehyde solution remains constant at refrigerator (4°C) 
temperature, but at room temperature the pH tends to drop significantly with
91 9Stime ’ . The pH of stored valves is usually kept as similar as possible to the pH of 
blood (7.4), by the use of phosphate-buffered glutaraldehyde solutions, without any 
control of the temperature. Some studies have indicated that the higher the pH and 
the lower the temperature of the glutaraldehyde incubation solution, the greater the 
amount of glutaraldehyde bound to bovine pericardial valve tissue26, thus 
glutaraldehyde uptake was enhanced at a temperature of 4°C and pH of 10. The 
glutaraldehyde fixation always takes place in water-based phosphate buffered
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solutions in the valve industry, as it has been found that the use of other solvents can
onyield materials with mechanical properties not useful for heart valve leaflets .
2.1.2.3 Delayed fixation:
There is conflicting evidence in the literature relating to the effect of delayed 
fixation. Whilst some report no major effect of a delay28, other studies report that 
immediately after slaughter signs o f cell damage appear, and that immediate fixation 
rather than after two days of storage on ice, decreased aortic wall calcification in rats 
by 25%29.
2.1.2.4 Concentration of glutaraldehyde:
For fear of stiffness and tissue toxicity, “sub-optimal” concentrations o f cross- 
linking agents (glutaraldehyde) were chosen, and thus the resultant low 
immunogenicity30, alkaline phosphatase activity31 and protease activity32 had to be 
accepted along with a known risk of calcification. Calcification has been related to 
the amount of glutaraldehyde introduced into the collagen33,34, hence the use of a low 
concentration of glutaraldehyde in the manufacture of bioprostheses. Initially, 
residual antigenicity was not considered to be a major contributing factor to 
bioprosthetic tissue degeneration, however more recent studies have shown a 
correlation between antigenicity and calcification35,36.
The actual concentrations o f glutaraldehyde used commercially range from 0.2% to 
0.65% v/v. Collagen cross-linked with a glutaraldehyde concentration as low as 
0.0075% demonstrated a significantly better resistance to proteolytic degradation
onthan non-cross-linked material . However, glutaraldehyde-treated tissue was shown 
to retain significant antigenicity when a 0 .2 % concentration was used38, but it has 
also been shown that short-term exposure to such low concentrations of  
glutaraldehyde optimally preserved the natural structure of pericardial valves39. 
Cross-linking can also be undertaken at slightly higher concentrations. For example,
it was shown that a significant improvement in structural preservation occurred at a
• 00concentration of 1 % compared to lower concentrations and that no inflammatory 
reactions to implants were seen when a concentration o f 2.5% was used40. However, 
at a concentration of 4%, a tissue-hardening phenomenon was observed41. Increased 
exposure to glutaraldehyde42 has been shown to reduce calcification (see later in this 
section) and it has also been shown that higher glutaraldehyde concentrations
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(increasing concentration from 0.2% to 3%) can reduce (by almost one third) rather 
than increase tissue calcification in both the rat29,43 and sheep model44. This finding 
is valid for porcine valve leaflets, pericardial tissue and also for aortic wall tissue. A 
further benefit of higher glutaraldehyde concentrations has been stated to be 
improvement in the ultra structural tissue preservation22, a reduction in the 
macrophage activation45 and suppression of the immune response36. However, the 
fact that the calcification sites remained the same after fixation at higher 
concentrations of glutaraldehyde, whereas overall calcification diminished, suggests 
that improved cross-linking only mitigates rather than alters the calcification 
mechanism .
2.1.2.5 Physical state of the glutaraldehyde cross-linker:
Glutaraldehyde is used as a solution buffered with phosphate at pH 7.4, in the valve 
industry and in the majority of studies reported in the literature. However, it has been 
reported that the use of glutaraldehyde vapour would improve the resistance of the 
treated tissue to degradation (collagenase tested in-vitro), increase the uniformity of 
the treatment and minimise the homopolymerisation of the cross-linking agent46. The 
cross-linking could also be better controlled, as it would not be influenced by the 
ionic strength of the reaction medium, pH or concentration. The glutaraldehyde 
vapour, obtained from an 8 % aqueous solution, was at a very low concentration in 
the gaseous phase owing to its small vapour pressure, however it was demonstrated 
to efficiently cross-link soluble collagen films47.
2.1.2 .6  Duration of fixation:
The variation in fixation methods used by different valve manufacturers lies mainly 
in the duration of fixation: valve tissues have been reported as having been fixed for 
periods of time ranging from a few hours to several months. Whilst some authors 
have reported complete glutaraldehyde uptake by bioprosthetic tissue within 24 
hours of incubation , others have observed that complete glutaraldehyde uptake did 
not occur even one month after the onset of treatment when the bioprosthesis was 
preserved in glutaraldehyde solution of a particular concentration49. Long-term 
storage of collagen or collagenous tissues in glutaraldehyde has been reported as 
being essential for optimal cross-linking to occur50 because the polymerisation 
reaction of glutaraldehyde and lysine is found to be fast initially but continues to
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proceed slowly with time. It has also been mentioned that long-term fixation (bovine 
and porcine pericardial tissue stored in glutaraldehyde for 15 months) might decrease 
susceptibility to calcification51. The authors reported inverse linear-relationships 
between the time in glutaraldehyde and the amount of extractable calcium in both 
types of tissue and also between duration of storage and shrinkage temperature. They 
concluded that the decrease in calcification was related to a decline in the number of 
glutaraldehyde cross-links within the tissue. Others presume that, whether prolonged 
or short-term, fixation probably does not change the features o f calcification o f the 
bioprosthesis when only glutaraldehyde treatment is used52. Such a discrepancy in 
the literature shows that, although various duration of fixation are used in valves 
industry for over 40 years, the important factor that represents the duration of 
fixation still requires further research, which is impeded by the lack of 
communication between the valve manufacturers.
2.1.2.7 Storage of valves in aldehydes:
After the initial glutaraldehyde fixation and before implantation in a patient, valves 
are stored in buffered aldehydes (formaldehyde or glutaraldehyde) for varying 
lengths of time. This is because the concentration of glutaraldehyde used routinely 
for fixation is not considered sufficient to ensure valve sterility. Formaldehyde was 
mainly used in the 1980s as a storage solutionI6,53,54, while nowadays both 
glutaraldehyde and formaldehyde are used, depending mainly on the valve 
manufacturing protocol. It has been shown that tissue samples taken from valves 
stored for prolonged periods of time in formaldehyde failed to calcify in the rat 
subcutaneous implant model55. Schryer et al have also demonstrated the benefit of 
long-term storage in glutaraldehyde on resistance against calcification51. 
Additionally, it has been shown that prolonged storage (>5 years) in glutaraldehyde 
can reduce the levels of calcification occurring in porcine aortic valves in the rat 
subcutaneous model56. Also, valves stored in a glutaraldehyde solution for an 
extended period of time were shown by Girardot et al to resist calcification better 
than those that had been fixed for a short term57. They found that cuspal calcification 
decreased significantly in the rat subcutaneous model after 1 2  months storage in 
glutaraldehyde. However, if  prior to implantation, the valves were re-exposed to a 
similar glutaraldehyde solution at the end of the 1 2  months storage period, the cusps 
displayed high levels o f calcification. It was thus proposed that re-exposure to
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glutaraldehyde forms new Schiff bases and re-introduces free aldehydes that may 
have been converted during storage and so may have a key function in cuspal 
calcification. A more recent dynamic in-vitro study showed variation in calcification 
between similarly glutaraldehyde-stored valves (two months and four years): the
r  ovalves with the shorter storage period calcified to the highest degree . In fact, 
fixation/storage time has been an uncontrolled variable in many studies and has thus 
made comparison of calcification rates between studies difficult.
Another matter arises when treated-valves are stored in aldehydes. Although many 
authors seem to assume that the formaldehyde incubation step (storage/sterilisation) 
does not alter the glutaraldehyde incorporated into the tissue during cross- 
linking3,54,59 and that formaldehyde is not retained within the tissue, it appears that 
formaldehyde, due to its smaller molecular size, can be incorporated into the 
glutaraldehyde-fixed tissue and may replace Schiff base bonded glutaraldehyde55. 
Formaldehyde is thus displacing some of the glutaraldehyde from the treated-porcine 
or bovine tissue, and is also reacting with further free 6 -amino lysyl groups that were 
stereochemically inaccessible to the larger glutaraldehyde molecules60. This 
displacement of glutaraldehyde by formaldehyde is ruled out theoretically by organic 
chemistry principles that dictate that if a second aldehyde is added to the 
glutaraldehyde-treated tissue, substitution of the original aldehyde in the Schiff base 
may occur, depending on the concentration of this second aldehyde61,62. It is 
hypothesised that formaldehyde condensation and crossed-Cannizzaro reactions can 
occur in the presence of an excess of formaldehyde, reducing the formyl groups and
ATforming methylol groups . The authors also suggested that long-term storage in 
formaldehyde may be significantly better than glutaraldehyde, since at neutral pH 
(pH 7.4) formaldehyde is more reactive than glutaraldehyde and physically smaller, 
thus the formaldehyde aldol/crossed-Cannizzaro reactions might proceed at a much 
higher rate.
2.1.2.8 Washing:
Generally, prior to implantation, valves are washed with phosphate-buffered saline 
solutions to remove any unbound cytotoxic glutaraldehyde moieties. Tissues fixed in 
glutaraldehyde exhibit ranging degrees of toxicity due to the presence of 
glutaraldehyde (while untreated collagen is compatible with cell growth64), the level
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of which depends upon the storage solution and method of washing65. The toxic 
effects of glutaraldehyde are apparent at very low concentrations (>10-25ppm)66. It 
has been reported that glutaraldehyde-treated tissues washed in a glycine buffer 
showed less toxicity than simply glutaraldehyde-treated tissues, with the amino 
groups reacting with the excess free aldehydes that are responsible for the 
cytotoxicity65. The effectiveness of the usual rinse with phosphate-buffered buffer 
was reported limited, because the glutaraldehyde reactivity could persist for a long 
period of time in the interstices of the tissues50.
2.2 Chemistry of glutaraldehyde
2.2.1 Glutaraldehyde in solution
2.2.1.1 Introduction:
The chemical composition of glutaraldehyde solutions is not simple and is still in the 
process of being clearly defined (one aim of this thesis). A simple formula of five 
carbons with two carbonyl groups (monomeric glutaraldehyde) was first attributed to 
glutaraldehyde in solution and is still accepted these days by some authors. However, 
if such a formula was true, reaction of the aldehyde with the amino groups of 
proteins would lead to the formation of a Schiff base. This reaction would be 
reversible (pure principle of organic chemistry) and the product would not withstand 
reported treatments with acids, urea, semicarbazide and heat67'69. In fact, it appears 
that glutaraldehyde is actually a mixture of monomeric dialdehydes with varying 
amounts of “impurities” 24,66 (including glutaric acid, acrolein, glutaraldoxime and 
polymers of glutaraldehyde)20,70, along with mono- and di-hydrated monomeric 
glutaraldehyde, oligomers, monomeric and polymeric cyclic hemiacetals, various 
aldol condensation products (such as the a;j3-unsaturated polymers) 71 and probably 
other kinds of impurities not yet reported. The oxidation of aldehyde in solution to 
form carboxylic acids (glutaric acid being the dicarboxylic acid of glutaraldehyde)
79 79has been reported in the literature ’ . A relatively recent analysis of the 
glutaraldehyde vapour by GC-FTIR revealed six main components, which three has 
been characterised as being methanol, butyraldehyde and likely what they refer to as 
monomeric glutaraldehyde74. The presence of methanol being explained by the fact 
that the addition of methanol in glutaraldehyde solutions has been recommended to
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enable them to be kept for longer periods through the formation o f a hemi-acetal75. 
In aqueous solution, it is believed that all these chemical species are in equilibrium 
but if  a change in conditions occurs (e.g. pH or temperature) then the equilibrium 
will be displaced and the concentrations of the various species will be altered. 
However, the actual content of the “impurities” of glutaraldehyde is quite 
controversial. For example, it has been reported that the impurities of glutaraldehyde 
are not likely to be due to the accumulation of glutaric acid, because of the absence 
of the UV absorbance of glutaric acid in the absorbance o f glutaraldehyde
nrsolutions . Also, while extensive polymerisation is often reported to be present, 
there is no consensus on the mechanism and nature of the polymerisation 
process23,24. However, most of these “impurities” are thought to have a major impact 
on the phenomenon of cross-linking proteins with glutaraldehyde24. Because of the 
many contradictory statements found in the literature over the last 40 years, and also 
because of the importance of the composition of glutaraldehyde solution for this 
thesis, a more complete assessment of all the molecular structures of glutaraldehyde 
in solution will be reviewed in section 2 .2 .2 .
2.2.1.2 Purification methods:
Glutaraldehyde used in electron microscopy and for fixation in the valve industry is 
referred to as EM grade, distillation purified. This grade is supposed to provide a 
highly pure glutaraldehyde solution, free from polymers and other contaminants, 
sealed under dry nitrogen. However, it is known that repeated defrosting and 
recapping of a solution will promote the polymerisation of glutaraldehyde, shown by 
the production of an ultraviolet absorption peak at 235nm rather than at 280nm, as 
seen with pure EM grade glutaraldehyde. (The carbonyl peak at 280nm is due to 
monomeric glutaraldehyde, whereas the peak at 235nm is attributed to the presence 
of polymeric products77). Indeed, purified glutaraldehyde was reported78 to be 
unstable over time in aqueous solution at pH 7.4, since a freshly purified solution 
( 1 %) after lh of equilibrium at room temperature showed limited polymerisation 
measured at 235nm, while after 24h extensive polymerisation was observed. The 
glutaraldehyde solution used in our work (25% glutaraldehyde solution EM grade 
Merck, UK) was reported to be stable for at least three days when refrigerated at 
4°C79. Various methods have been suggested to remove the polymeric impurities. 
For example, a method of vacuum distillation has been proposed80, as has
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purification by fractionation on Sephadex G-1081 or by the use of activated
90charcoal . However, even after five purifications with activated charcoal, some 
impurities were still observed. The two main UV peaks found in commercial 
glutaraldehyde solutions (the carbonyl peak at 280nm and the peak at 235nm) are 
commercially used to assess the purity of the solution.
2.2.1.3 Effects of temperature, pH and concentration:
Generally, pH is considered to be an important factor that fundamentally controls the 
molecular state of glutaraldehyde82, although sometimes contradicted83. 
Polymerisation of glutaraldehyde is known to be enhanced at high concentration 
(>0.5%) and at alkaline pH. Temperature is also a factor, which can affect the 
molecular structure of glutaraldehyde in solution24. For example, increasing 
monomer concentration and decreasing hemiacetal concentration is seen when the 
temperature is raised . Polymerisation has also been reported to be independent of 
light and oxygen, and almost independent of temperature in the range 1-25°C84. 
However, in contrast, although no polymerisation was reported to occur when a 
solution of glutaraldehyde was stored for 5 months at -14°C, there was a slight 
increase with storage at 4°C and a rapid increase with storage around 20°C which
99continued with increasing temperature . Other workers have shown that 
glutaraldehyde solutions equilibrated at various increasing temperatures (25-40°C) 
did not induced new components when compared to a room temperature solution but 
the concentration of the components was reported to increase74. Yokota et al have 
reported the structure of glutaraldehyde in solution be temperature dependent 
between -60°C and 40°C85: between -60°C and 0°C up to 80% of glutaraldehyde is 
in form A (see figure 2.1 below), while at temperatures above 0°C form B 
predominates, along with traces of form A.
FORM A: (Temperatures between -60 and 0 degrees C) FORM B: (Temperatures above 0 degrees C)
Figure 2.1: Two forms of glutaraldehyde oligomers present in solution in function of 
the temperature factor as reported by Yokota et al85.
84
The formation of glutaraldehyde monomers from polymeric forms was reported to 
be enhanced by heating for a short time (less than 1 hour) below 90°C, although 
heating for longer periods or heating at temperatures higher than 90°C could also 
enhance the formation of glutaraldehyde polymers86. It has been reported also that 
the concentration of free glutaraldehyde will rise from 4 %  at room temperature to 
35% at 50°C . Ruijgrok et al have reported that high temperature promoted the 
cross-linking of collagen by glutaraldehyde, allowing the use of lower
R7glutaraldehyde concentrations . In the same study, microwave irradiation was 
showed to be more effective in enhancing the cross-linking process compared with 
conventional heating. An even distribution of cross-links was thought to have been 
achieved by pre-soaking the tissue in glutaraldehyde at low temperature with 
subsequent short-time high temperature homogeneous heating in a microwave, also 
enhancing the speed of fixation. The process of glutaraldehyde polymerisation in 
function of temperature has been a matter of discussion and disagreement since it 
was reported to increase linearly , or exponentially with temperature .
The effect of pH on glutaraldehyde was also investigated by Rasmussen and
77Albrechtsen . They reported that the polymerisation rate of glutaraldehyde increased 
when the pH was slightly acidic or basic, whilst the rate of polymerisation decreased 
somewhat on addition of buffers. Changes in the pH of commercial glutaraldehyde 
solutions have also been reported to lead to an increase in the amount of
ooglutaraldehyde polymers . The polymers formed in aqueous acidic solutions are 
thought to be largely of the acetal-like structure type89. While acidic solutions of 
glutaraldehyde stored at room temperature in a closed system remain stable (below 
pH 5 polymerisation is reported to be very slow90), polymerisation occurs rapidly 
above pH 8.0 (and even above pH 6.523) with observable reductions in the free 
aldehyde15 91. In basic solutions, glutaraldehyde was reported to form long a,@ - 
unsaturated polymers82 that may include up to eight elementary molecules o f
71glutaraldehyde . Glutaraldehyde concentrations, in freshly prepared alkaline 
solutions, have been shown to fall by approximately 45% in 14 days, indicating 
polymers formation. The rate of polymerisation was reported to be rapid in alkaline 
solutions even at 4°C92. Such polymers have been hypothesised to give long and 
flexible cross-links with proteins chains that increased molecular mobility and 
improved the accessibility of other amino (lysyl) groups93. It has been suggested that
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a polymer chain longer than the five carbons glutaraldehyde monomer is necessary 
to bridge the gap between appropriate amino acids in the collagen molecule. In the 
valve industry, it has also long been believed that at least some glutaraldehyde 
polymer should be present for effective cross-linking77,94. This statement was later 
reiterated by reporting that during the cross-linking reaction, polymerisation was 
needed to bridge larger gaps between two reaction sites95. Excessive polymerisation, 
on the other hand, is considered undesirable since the number of available aldehyde 
groups is greatly reduced94. Additionally, under strong alkaline conditions or in the 
presence of sodium hydroxide, Cannizzaro reaction can take place96 which enables 
the aldehyde groups in polymers of glutaraldehyde to be converted into a carboxyl 
and a hydroxyl group as can be seen in figure 2 .2 .
aOH +
NaOOCo ' hoh2c'
‘O
Figure 2.2: Cannizzaro reaction taking place under strong alkaline conditions (or 
under the presence of sodium hydroxide) on an aldol condensation dimer product.
2.2.2 Review of the various structures of glutaraldehyde in aqueous solutions
2.2.2.1 Hemiacetal formation and polymerisation:
It was found from a *H NMR study of a solution of glutaraldehyde that it undergoes 
rapid hydration in water to form an equilibrium between monomeric glutaraldehyde, 
its mono- and di-hydrates, and the cyclic hemiacetal form, in which equilibrium the
OQhydrates were thought to predominate (see figure 2.3 below). The dihydrate can 
cyclise to form a hemiacetal97, whilst the formation of a poly-cyclic hemiacetal was 
possibly first proposed by Aso and Aito98,99, although the structure given was not 
exactly the one later proposed by Yokota et al85 and then also by Hardy et al89, which 
is now well accepted (see figure 2.3 below). A later UV and *H NMR study showed 
that glutaraldehyde in a 70% v/v solution at 20°C is mostly present as an equilibrium 
between the monomeric glutaraldehyde (<15%), the cyclic hemiacetal and their 
oligomers (n>2) (both accounting for about the last 85%)71. They also reported a 
limited presence of glutaraldehyde hydrates, in contrast to the earlier work. A 13C 
NMR study almost corroborated these results by proposing the following relative 
composition for glutaraldehyde solution at 23°C: 4 %  free glutaraldehyde, 16%
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monohydrate, 9% dihydrate, 35% each of cis and trans isomers of the cyclic 
hemiacetal , which subsequently polymerises as shown in figure 2.3. They also 
attributed a minor contribution to the oligomers postulated by Korn et al71 and a 
major one to the hemiacetal structures. Additionally, they reported that the 
composition varied slightly with concentration and pH, whilst temperature had a 
profound effect. The above composition was slightly refined by a later FTIR and 
NMR study82, where it was demonstrated that at 25°C, a 25% v/v commercial 
glutaraldehyde solution (at pH~3) contains 3% monomeric glutaraldehyde, 79% 
water and 18% hydrated molecules in the form of the unstable cyclic hemiacetal and 
its oligomers (n ^ ), in rapid reversible temperature-dependent equilibria with one 
another. It was reported in a relatively recent UV and light scattering study over the 
pH range 3-8, that a 2-20% v/v glutaraldehyde solution at room temperature 
consisted of 10.8% monomeric glutaraldehyde, 10.4% monohydrate, 2.5% dihydrate, 
76% cyclic hemiacetal and very little hemiacetal polymers100. In contrast, these 
authors in the same study reported that a 70% v/v solution o f glutaraldehyde 
consisted of 7.5% of monomeric glutaraldehyde, 6 .8 % monohydrate, 1.7% 
dihydrate, and 85% in total of mono and polymeric cyclic hemiacetal.
cr ho' c
m onomeric glutaraldehyde m onohydrate OH OHdihydrate
polym eric cyclic hemiacetal
cyclic hemiacetal (cis)
OH
HO cyclic hemiacetal (trans)
Figure 2.3: Hydrated states and cyclic hemiacetal formation of glutaraldehyde as first
onproposed by Hardy et al ; the existence o f the two isomers of the cyclic hemiacetal 
first mentioned by Korn et al71 and first characterised by Whipple and Ruta83; and 
the formation of cyclic hemiacetal polymers as first proposed by Yokota et al85.
Others oligomers have been isolated from aqueous solutions of glutaraldehyde and 
characterised by chemical ionisation-mass spectrometry101,102. They include para- 
glutaraldehyde, which is a trimer and the principal trioxane derivative, along with the
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pentamer and heptamer, which was found in small amounts (see figure 2.4 below). 
Similar compounds consisting of trioxane polymers (oligomers of the trimer) were 
later found in a 2% alkaline commercial sterilising solution of glutaraldehyde (pH7-
n)103.
Figure 2.4: Trioxane-derivative oligomers of glutaraldehyde proposed by Tashima et
a jl01-103
2.2.2.2 Aldol condensation polymerisation:
Polymerisation of glutaraldehyde molecules in aqueous solution with observable 
reductions in free aldehyde have been reported15,104. It was concluded from early 'H 
NMR data in D2O that glutaraldehyde solutions contain polymers formed through 
aldol additions that dehydrate to give a,P-unsaturated aldehydes105, known as aldol 
condensation products106. (These products can also partially cyclise, as shown in
71figure 2.5 below). Others , however, did not noticed the presence of such 
unsaturated polymers using UV and NMR, while Hardy et al stated that unsaturated 
structures could only be a very minor component of the solutions89 (see figure 2 . 6  
below for the structures of the proposed condensation products). Glutaraldehyde 
solutions have nevertheless been reported to contain precipitates that result from 
aldol condensation and, in the pH range 4-8 and above, the free aldehyde is thought 
to undergo base-catalysed aldol condensation followed by dehydration to form a,(3- 
unsaturated oligomers. The dimer, formed by an aldol condensation, is said to be the 
principal polymer in commercial (pH~3) solutions107, an hypothesis that was 
corroborated by infrared and mass spectrometric data revealing the presence of both 
the dimer (MW 182) and trimer (MW 264)82 (both dimer and trimer are shown in 
figure 2.6 below). In contrast, others reported that aldol condensation products could 
only be present in a very small amount (far below 0 .1% by weight), although they 
agreed that polyaldol structures would be likely involved in cross-linking and that 
the presence of amino groups would catalyse the glutaraldehyde polymerisation, thus
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forming the aldol polymers involved in cross-linking95. The statement that the 
polymerisation of glutaraldehyde could be catalysed by the amino groups of the 
collagen was later reiterated100.
'o
*0'o
Aldol trimer with one subsequent cyclisation Aldol trimcr with tw o subsequent cyclisationsAldol trimerAldol dimer
Figure 2.5: Aldol condensation products of glutaraldehyde as proposed by Richards 
and Knowles105.
Aldol dimer (M W  182)
Figure 2.6: Aldol condensation products of glutaraldehyde as proposed by Hardy et 
al89.
The aldol condensation can be both acid and base catalysed106, as can be seen from 
figures 2.7 and 2.8 below, and thus can theoretically occur at all pH values.
enolate ion
a l k o x i d e  io n
0 )  JO O
aldol condensation product 
(a,P-unsaturated aldehyde)
Figure 2.7: Mechanism of the base catalysed aldol condensation of glutaraldehyde 
showing a deprotonation by the base of an alpha carbon of a glutaraldehyde 
molecule forming a carbanion, followed by the nucleophilic attack of an enol form of 
another glutaraldehyde molecule by the carbanion thus forming an alkoxide ion, 
which then rearrange through a protonation and dehydration step.
+  O H
O  H O
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When the aldol reaction is base catalysed, the base abstracts a proton from the a- 
carbon of one molecule of glutaraldehyde to give a resonance-stabilised enolate ion. 
The enolate ion participates in a nucleophilic attack on the carbonyl carbon of a 
second molecule of glutaraldehyde producing an alkoxide ion. The alkoxide ion then 
removes a proton from a molecule of water to form the aldol. The addition product in 
this case readily dehydrates to form the aldol condensation product, which is an a,p- 
unsaturated aldehyde. Dehydration occurs readily because of the acidity of the 
remaining a-hydrogens and because the product is stabilised by having conjugated 
double bonds . For clarity, throughout this thesis, a,P-unsaturated aldehydes will 
be referred to as aldol condensation products.
When the aldol reaction is acid catalysed, the first step of the reaction is the 
protonation of the carbonyl group, which attacks the a-carbon of the enol form of the 
molecule. After rearrangement through a loss of proton and a dehydration step, the 
resulting reaction product is an a,/3-unsaturated polymer of glutaraldehyde (the 
formation of a dialdol condensation product is seen in figure 2 .8  below).
d e h y d r a t i o n
a l d o l  c o n d e n s a t i o n  p r o d u c t  
( a , p - u n s a t u r a t e d  a l d e h y d e )
Figure 2.8: Mechanism of an acid catalysed aldol condensation of glutaraldehyde 
showing the protonation of the carbonyl of a glutaraldehyde molecule, followed by 
the attack of the a-carbon of the enol form of the glutaraldehyde molecule and re­
arrangement through a deprotonation and dehydration step.
Some authors also proposed the chemical structure given below in figure 2.9 (A), as 
a possible structure for poly-glutaraldehyde. From FTIR and UV studies of
glutaraldehyde solutions prepared at pH 7-13.5, hydroxyl groups were identified, 
have indicating that dehydration may not occured at every consecutive step of the 
aldol condensation reaction109. Such semi-dehydrated aldol condensation products 
have also been found by Tashima et al in a commercial sterilising solution of 
glutaraldehyde using chemical ionisation-mass spectrometry103, and their presence 
was also later agreed110 and reported111 by others. It is worth noting that some 
pendant aldehyde groups of the structures shown below (figure 2.9 (B)) could be 
barely hydrated100 since the carbonyl form is stabilised by conjugation.
"O
(A)
Figure 2.9: aldol condensation product where the consecutive dehydration step did 
not always occurred (A), as proposed by Margel and Rembaum109 or where pendant 
non-conjugated aldehyde groups are in their hydrated forms (B), as proposed by 
Kawahara et al100.
Other types o f polymers have been characterised, using UV, IR and NMR 
spectroscopy along with gas chromatography-mass spectrometry, as dimers from an 
aqueous alkaline solution of glutaraldehyde112. Such dimers (see figure 2.10 below) 
are formed by a dimolecular aldol condensation and may exist in equilibrium with 
their cyclic hemiacetal forms.
Figure 2.10: The dimer and its cyclic hemiacetal formed from a dimolecular aldol 
condensation of glutaraldehyde, as proposed by Tashima et al112.
2.2.2.3 Michael reactions:
As well as undergoing aldol condensations along with cyclisation and hydration, 
glutaraldehyde can also undergo Michael reactions with aldol condensation
i Iproducts . The Michael addition is a base-catalysed reaction. The first step o f the 
mechanism involves the abstraction of an activated hydrogen from glutaraldehyde to
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form a carbanion. Conjugate addition of the carbanion to the aldol condensation 
product subsequently occurs, followed by acceptance of a proton113. The mechanism 
of this process is shown below in figure 2 .1 1 .
C a r b a n i o n
A d d i t i o n  o f  a  c a r b a n i o n  t o  
a  d i a l d o l  c o n d e n s a t i o n  
p r o d u c t  o f  g l u t a r a l d e h y d e
M i c h a e l  a d d i t i o n  p r o d u c t
Figure 2.11: Mechanism of a Michael addition of glutaraldehyde to an aldol 
condensation product (dimer).
2.2.3 Factors affecting the reaction between glutaraldehyde and proteins
2.2.3.1 Introduction:
Historically, only the interactions of glutaraldehyde with the amine groups of 
collagen have been studied. The lysine residues in proteins appear to be the only 
amino acid clearly implicated in the reactions with glutaraldehyde (although various 
authors have speculated on the reaction of glutaraldehyde with other amino 
acids)15,69,114. More specifically, it is the 6 -(or e-) amino groups of lysine residues, 
which react18,34,115. Indeed, unlike formaldehyde and glyoxal, glutaraldehyde reacts 
apparently only with lysyl groups to a significant extent82. However, other groups 
such as the guanido group of arginine have been found to react particularly at 
alkaline pH, tyrosine was found to react slightly, whilst no reaction was observed 
between glutaraldehyde and histidine69. Other authors partially contradicted this, by 
stating that glutaraldehyde can react with the amino acids tyrosine, tryptophan and
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phenylalanine116 however the most reactive groups reported were the ce-amino 
groups of glycine, and the a -  and e-amino groups of lysine (although some 
reported117 that there was no evidence for the participation of the a-amino group of 
lysine). Other groups, meanwhile, were found to be less reactive, for example the 
sulphydryl group of cysteine, the phenolic group of tyrosine and the imidazole group 
of histidine, where the presence o f a free amino group seemed to be necessary for 
glutaraldehyde to react with the imidazole group118. Work by Munton and Russell 
has indicated that glutaraldehyde could react with arginine, glutamine,
Q7phenylalanine, serine and threonine , whilst reactions may also occur at alkaline pH.
Later studies showed specifically that the aldehyde groups of glutaraldehyde react 
with amino acid residues of the polypeptide chains o f collagen, such as the 6 -amino 
group o f lysine and hydroxylysine and also the carboxylic group o f aspartic acid and 
glutamic acid17,95,119, to give rise to cross-links120 between the collagen molecules. 
Recently, it was suggested that stable cross-linking with glutaraldehyde could occur 
through hemiacetalisation between hydroxyl groups of hyaluronic acid (and other
191polyols) and aldehyde groups of glutaraldehyde . Glutaraldehyde can also react 
with carboxy, amido and other groups of proteins15,122. The order of reactivity of 
glutaraldehyde with other compounds was reported as follows: Iary
amines>peptides>guanidines>IIaiy amines>hydroxyl groups3. However, the reaction 
of glutaraldehyde with amines and carboxylic acid (Mannich-type addition) was 
even briefly described.
Complete chemical analysis of the cross-linking entities formed by reaction of  
amines with glutaraldehyde has not been successfully achieved because the reaction 
products are extremely heterogeneous and varying the reaction conditions can affect 
the products formed123. Therefore, although the reaction of glutaraldehyde with 
proteins has been extensively studied, it is still not fully understood.
2.2.3.2 Effects o f pH:
The reaction between glutaraldehyde and proteins is known to be affected by 
p j j i  16,124 r p ^ g  incorporation of glutaraldehyde into tissue is dependent upon pH, the 
amount incorporated being lower at acidic pH than at neutral and basic pH34. It has 
been shown that the reaction rate of glutaraldehyde with proteins is inversely 
proportional to the square root of the hydrogen ion concentration , which is in
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keeping with others findings which showed that glutaraldehyde tanned more rapidly
118 1 9 6 1 9 7with increased pH levels ’ ’ . An early study on the application of
glutaraldehyde for tanning showed that in 24 h, 50% of glutaraldehyde reacted at pH 
4, 90% reacted at pH 4-5, 90 to 97% reacted at pH 6-6.5 and that 50% of 
glutaraldehyde was destroyed in 3 hours, possibly because of the pH128.
At acidic pH, the proteins’ binding sites are thought to be present in the acid form 
and the amino terminus would be an ammonium residue, which would not readily
9 6 68react with aldehyde groups of glutaraldehyde ’ . The reaction of glutaraldehyde 
with collagen has been shown to be rapid at neutral pH, but fairly slow at acidic
1 9QpH ; however the data did indicate that effective cross-linking could be achieved at 
low pH. The rate of Schiff base formation between aldehydes and primary amines
130has been shown to be the highest at slightly acidic pH of approximately pH 4.5 
because the second step in the formation of imine, namely the protonation of the 
carbinolamine intermediate and subsequent dehydration, is catalysed by mild acidity. 
If, however, the solution is too acidic, protonation of the amine renders it incapable
of nucleophilic attack (the first step in the reaction). The maximum number o f cross-
68links introduced during tanning with glutaraldehyde was found at pH 6.5 . Also, at
about pH 6.5, a change in the gel filtration properties of glutaraldehyde was observed
81and it was suggested that intra- and inter-molecular changes were occurring .
At high pH, the proteins’ binding sites are hypothesised to be present as the basic 
form of the lysine and hydroxylysine26. It was also reported that alkalination may
Q7 191 199modify the glutaraldehyde molecule and that polymerisation may or may not 
occur under these conditions. In other studies, glutaraldehyde was reported to 
undergo rapid polymerisation forming oligomers15 at pH levels greater than 8 . It is
thought that the increased tendency of the aldehyde to polymerise at pH 8  may limit
68the desired reaction from taking place and that too alkaline a solution would lead to 
a loss of reagent through Cannizzaro-type reactions133. It was even recently reported 
that a glutaraldehyde reaction with collagen membranes was “inhibited” simply by 
exposing the membranes to a pH 9 glycine/borate buffer solution134.
2.2.3.3 Molar ratio:
By studying UV absorbance, loss of lysine residues and loss of glutaraldehyde from 
the solution, it has been shown in-vitro that approximately 4 moles of glutaraldehyde
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are taken up per lysine residue117. However, not all these glutaraldehyde molecules 
seem to be firmly bound and an elemental analysis of the reaction products of 
glutaraldehyde-treated collagen has suggested a ratio of three glutaraldehyde 
molecules per lysine residue. This loss of protein-bound glutaraldehyde was also 
observed in-vivo .
Various molar ratios o f glutaraldehyde to amino acids have also been reported, such 
as 1:1135'136, 1:3136, 2:195'137'138, 3:117’139, 3:2140, 4:171'95’"4, 5:1139, suggesting the 
complexity and difficulty in assessing an exact molar ratio. These differences may be 
explained by the different availability of the appropriate reactive groups o f the 
proteins involved in the various studies; for instance, the lysine residues in collagen 
may not all be accessible to glutaraldehyde, in comparison to those o f a model 
compound in solution. Nevertheless, all these molar ratios lead to the conclusion that 
large structures containing many glutaraldehyde molecules are unlikely to be 
involved in cross-linking.
2.2.3.4 Kinetics of the reaction:
The reaction of glutaraldehyde with various proteins (including bovine serum 
albumin, lysozyme, ovalbumin and a-chymotrypsinogen) in solution has been 
followed by UV spectroscopy125. It was concluded that the reaction kinetics were 
pseudo first-order, that the rate o f formation of glutaraldehyde-protein links per 
protein molecule is about 1 sec' 1 mol*1, that the rates of the reactions increased with 
increasing pH and that the rate o f the reversible reaction was negligible. The 
observed kinetics were thus reported to be different from those o f Schiff s base 
formation, which is commonly believed to be the likely reaction product o f the 
reaction of glutaraldehyde with proteins. Another study o f bovine pericardium found 
a linear relationship between the logarithm of initial glutaraldehyde concentration 
and incubation time, indicating first-order reaction kinetics48. The various cross- 
linking reactions of glutaraldehyde with proteins have also been demonstrated to 
have different rates122, whilst the reactions were reported to be able to proceed for 
days (rearrangements leading to a greater degree o f cross-linking)141.
2.2.3.5 The effect of concentration and penetration:
Although glutaraldehyde reacts rapidly with amino groups, it tends to penetrate 
slowly into tissues24,95. Hence, cross-linking o f the core regions o f densely packed
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molecules, such as collagen tissue fibres, often presents concern when fixing tissues 
for electron microscopy or for use as bioprostheses. Inadequate or heterogeneous 
cross-linking may indeed lead to enhanced enzymatic biodegradation, antigenicity 
and loss of mechanical function120.
Low concentrations of glutaraldehyde reacted with dilute solutions of collagen were 
found to form only intra-molecular cross-links, while higher concentrations formed 
cross-links between two distant groups, including inter-molecular cross-links95. This 
suggested that there were no cross-links formed between 6 -amino functions of lysine 
from different molecules at low concentrations and that the cross-links formed only 
bridged short distances.
At higher concentrations, glutaraldehyde forms long polymeric chains of inter- 
molecular cross-links142 and the reaction is reversible. Cheung et al have shown that 
the rate of formation of these high molecular weight glutaraldehyde polymers is very 
fast and that they are able to generate an inter-molecular network of cross-linking119. 
The authors also demonstrated that low concentrations of glutaraldehyde have a 
better but slower bulk-cross-linking action than high concentrations. This is thought 
to promote rapid surface cross-linking of the tissue with rapid glutaraldehyde 
polymerisation at the site, preventing further diffusion into the bulk of the tissue119. 
It was also shown that treatment of collagen fibres by high concentration of 
glutaraldehyde led to an increase in the molecular length of the glutaraldehyde 
polymers (extending from the initial glutaraldehyde and lysyl residue reaction sites), 
rather than an increase in the actual number of cross-linking sites. It was suggested 
that glutaraldehyde would primarily fix to the surface of the tissue creating a 
polymeric network, which sterically prevents further cross-linking of the interstitium 
of the fibre95,119. Since the physical properties of glutaraldehyde-treated tissue are of 
concern when making bioprostheses143, the effect of glutaraldehyde concentration 
upon its penetration and the cross-links formation is of importance.
2.2.3.6  Duration of exposure:
The extent of cross-linking is also influenced by the duration of exposure to 
glutaraldehyde120,144. Insufficient glutaraldehyde cross-linking can result in loss of 
xenograft strength145, whilst prolonged exposure to glutaraldehyde has the 
advantages of sterilising xenografts as well as increasing their tensile strength.
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2.23.1 Extent of completion:
It has been estimated that 18% of the lysine residues in collagen remain unreacted117. 
It was suggested that these lysine residues lie in the overlap zone of the collagen 
structure and are inaccessible due to steric constraints.
2.2.3 .8  Cross-linking process:
It is postulated from studies of the reaction between glutaraldehyde and collagen, 
that formation of cross-links starts with the reaction of a (likely) lysyl residue with 
glutaraldehyde, followed by subsequent addition of glutaraldehyde molecules onto 
this nucleating site, generating polymeric chains95,123. This process can have two 
negative effects, i.e. steric hindrance of other possible reactive sites (lysyl residues or 
others) and the depletion of glutaraldehyde from the solution, due to polymerisation 
catalysed by free amino groups95. This view is supported by Kawahara et al who also 
stated that glutaraldehyde polymerisation could be catalysed by the presence of 
amino groups100. Recently, Lusty hypothesised that cross-linking would take place in 
two steps: the first would be the formation of a reversible Michaelis complex (refer 
to the enzyme-substrate-like complex) and the second would be an irreversible 
reaction covalently linking glutaraldehyde to the protein146.
2.2.3.9 Optimum treatment:
The actual amount of glutaraldehyde retained in the tissues and the nature and 
distribution of the cross-links formed in tissues are of vital importance because the 
less glutaraldehyde that is introduced, the less chance there is for inflammation and 
calcification to occur. In addition, if glutaraldehyde is not uniformly distributed 
throughout the collagen, the sites of the matrix with fewer cross-links will be subject 
to faster degradation. Therefore, it is important to minimise the amount of 
glutaraldehyde introduced into the implant but also to attain a homogeneous 
distribution of cross-links throughout the thickness of the collagen. For this purpose, 
a more complete understanding of the nature of glutaraldehyde and its behaviour 
when reacted with collagen may provide important information for future approaches 
to limiting calcification.
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2.2.4 Types of reactions occuring between glutaraldehyde and proteins
2.2.4.1 Introduction:
The reaction of glutaraldehyde with proteins has been extensively studied by various 
analytical techniques. Among them, HPLC was reported to be suitable to follow the 
extent of protein cross-linking with formaldehyde, glyoxal or glutaraldehyde93. UV 
spectroscopy was used in early studies and showed the irreversible fixation of 
collagen by glutaraldehyde and the appearance of a characteristic absorption 
maximum at 265nm in the hydrolysate of leather with the likely formation of 
aromatic compounds147,148. Wet chemistry tests were also used in early studies, in 
order to characterise the cross-links between glutaraldehyde and proteins. These 
revealed that the primary amine was converted to a tertiary amine, which was then 
incorporated into heterocyclic compounds and/or polymer formation124.
Small amines, peptides and proteins have been used to model the reaction of  
glutaraldehyde with the 6 -amino functions of lysine and hydroxylysine present in 
collagen. This approach has been adopted by a number of authors and species 
include: glycine123’149, a-aminoglutaric acid150, 6 -amino-n-caproic
acid50,117,123,137,140,151, N-a-acetyl-L-lysine82,137, isopropylamine82, lysine82, poly­
lysine71,117,136, cytochrome ^ 1 5 2 ,1 5 3 ^  i y S O S y m e 125>154? bovine serum 
albumin118,125,152,155, ovalbumin118,125,156,157, gelatin158,159, collagen fibres and 
collagen solution95 and bovine pericardium119. Overall, despite the extensive range of 
publications relating to reactions between glutaraldehyde and various proteins, many 
of the reaction products formed when glutaraldehyde reacts with collagen remain 
unknown and thus to be characterised.
2.2.4.2 Formation o f Schiff bases:
Note that imines are often referred to as Schiff bases since Schiff first discovered the 
reaction in 1864.
The most obvious potential product from the reaction of an aldehyde with a protein 
is a Schiff base, formed by the reaction of an amino terminus of the protein with an 
aldehyde group of glutaraldehyde66,117,160. One reason for this deduction is the 
observation that solutions of protein, (if not already pigmented) reacted with 
glutaraldehyde have a yellow colour, which is attributed to Schiff base (aldimine)
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formation158,161. Upon reduction with sodium borohydride the colour is lost, thus 
confirming the aldimine linkage. Also, during study of the reaction o f glutaraldehyde 
with various proteins in solution by UV spectroscopy, it was postulated that this 
coloration might be due to the formation o f Schiff bases or azomethine125,162. 
Glutaraldehyde was thus extensively reported to be capable of reacting with amino 
acid side chains, particularly with the lysine e-amino group, to form Schiff 
bases163,164. A similar yellow colour and strong blue-white fluorescence has been 
identified with elastin, indicating that glutaraldehyde-treated proteins may form 
similar cross-links to the cross-links o f elastin165. Such hypothetical molecular 
structures could be similar to the desmosine and isodesmosine structures containing 
quaternary pyridinium structures found in cross-linked elastin (see chapter 1 section 
1.6 .2).
Although the formation of an imine is acid catalysed, Schiff bases formed between 
monomeric glutaraldehyde and primary amines have been found relatively stable in 
alkaline media166, but were reported to be hydrolytically unstable under acidic 
conditions. Thus, Schiff bases may not account for the stability of cross-links 
following treatment with acids167. Imine formation is known to be affected by pH 
and is relatively slow at very low and high pH. Indeed, Schiff bases are known to be 
relatively unstable at neutral pH and can even revert to the free amine and aldehyde 
upon an increase in temperature or a decreased in pH66. Some authors claim that 
imines (Schiff bases) are formed as unstable intermediates that are almost 
immediately transformed into more stable chemical structures20,117,168. Others also 
stated that Schiff bases are regarded as the central intermediates from which 
subsequent reactions may occur before a cross-link is formed140.
Nevertheless, the Schiff base can be stabilised (changed into a more stable reduced 
moiety) with the use of typically 0.01M NaBH/ 69 but the use o f such a reducing 
agent might be inappropriate in cases where disulfide bridges in the proteins are 
responsible for maintaining structural integrity and reactivity110. The existence of 
simply a Schiff base from the interaction between glutaraldehyde and an amino 
group is thought precluded because Schiff base formation is reversible and such 
compounds would not survive the laboratory conditions used to assess cross-links 
formed, such as the acid hydrolysis167 for amino acid analysis and over such a wide 
range o f pH and temperature105. Furthermore, it is well known that proteins
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immobilised with glutaraldehyde are sufficiently stable to confirm that the Schiff 
base cannot be operative69, although some authors however, suggest that Schiff bases 
are formed as a stable final linkage under the cross-linking conditions used in valve 
industry95,123.
Therefore the formation of further molecular species had to be considered. For 
instance the reaction of 6 -amino groups of lysine with glutaraldehyde has been found 
to proceed well beyond the stage of a Schiff base69. The authors indicated that no 
lysine derivatives were found in hydrolysates of cross-linked material, suggesting the 
possibility of multiple side reactions and various possible products. It has also been 
observed that at reaction times over 24 hours, all initially formed Schiff bases have 
reacted and hydrolysis is blocked17. Additionally, it was found that, only after 
stabilisation of the initially formed hydrolysable Schiff base, cross-links were 
introduced into the glutaraldehyde-treated collagen matrix. Some recent UV data 
recently have suggested that fast formation of Schiff bases at the beginning of the 
reaction initiates aldol condensation of the carbonyl group of glutaraldehyde to give 
polymeric products150.
The proposed mechanism170 for the formation of a Schiff base from reaction of 
glutaraldehyde with an amino group is shown in figure 2.12. First, the amine adds to 
a carbonyl group of the glutaraldehyde to form a dipolar tetrahedral intermediate. A 
proton transfer from the nitrogen to oxygen occurs to form an amino-alcohol. (It is 
worth noting that this amino-alcohol was recently proposed as a final structure 
involved in the reaction between glutaraldehyde and leather111). A subsequent loss of 
water leads to the formation of the imine (Schiff base), which can undergo a 
tautomeric shift forming an enamine and subsequently cyclise to form a pyridinium
171compound . Some of the Schiff bases formed are thought to undergo cyclisation 
reactions, forming dihydropyridine derivatives, which can undergo oxidation and 
further condensation156,172.
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glutaraldehyde dipolar tetrahedral intermediateamino group
amino-alcoholimine (Schiff base)
enamine dihydropyridine pyridinium ion
Figure 2.12: Mechanism to show the formation of a Schiff base, followed by its 
cyclisation into l-(5-amino-5-carboxypentyl)-l,4-dihydropyridine, and subsequent 
oxidation to the corresponding pyridinium compound as proposed by Hardy et
a l 156,172
The formation of N-alkyl-2,6 -dihydroxy piperidine (see figure 2.13 below) was also 
reported173 and later agreed by others159. Its formation mechanism, although never 
reported, is thought to start from the formation of the amino-alcohol structure (see 
figure 2 . 1 2  above), which would then undergo an intra-rearrangement by starting 
from an attack of the electronic doublet of the nitrogen atom onto the available 
carbonyl group of the molecule, subsequently forming the cyclic aminal.
glutaraldehyde dipolar tetrahedral intermediateamino group
amino-alcohol
Figure 2.13: Formation of the N-alkyl-2,6 -dihydroxy piperidine (cyclic aminal)
dipolar intermediate cyclic aminal
1 0 1
A Mannich-type reaction, between a protonated Schiff base and a glutaraldehyde- 
related enol, has also been proposed66, resulting in the formation of a secondary 
amine (see figure 2.14 (A) below). Further reactions of these Mannich-type reaction 
products with glutaraldehyde through aldol condensations, and with amino groups
1 7(Schiff base), have been reported to lead to the formation of aliphatic cross-links 
such as the one shown in figure 2.14 (B) below.
'oNH
HN'
M o l e c u l e  ( A ) Molecule (B)
Figure 2.14: Mannich type reaction product from reaction of a Schiff base with an 
enol form of glutaraldehyde (A) proposed by Woodroof66; and a molecule resulting 
from the further reaction of (A) with amino groups and glutaraldehyde molecules (B) 
proposed by Olde Damink et al17.
2.2.4.3 Formation of hemiacetal oligomeric structures:
It has been reported that monomeric glutaraldehyde, or one of its hydrated forms 
(likely hemiacetals), is responsible for protein cross-linking76,89. Wet chemistry tests 
on the precipitate obtained from the reaction of glutaraldehyde with a protein 
(noradrenaline) showed the likely presence of such hemiacetal structures (o- 
dihydroxy grouping)124. Some reactions involving other proteins and glutaraldehyde 
under acidic or neutral conditions have also been proposed to involve the oligomeric 
hemiacetal compounds of glutaraldehyde110. Such compounds would not require a 
further reduction step to obtain stable products (e.g. the one shown in the figure 2.15 
below), in contrast to Schiff base formation that requires such a reduction step to 
give a stable product.
Figure 2.15: Possible reaction product (hemiacetal) from the reaction of 
glutaraldehyde with proteins under acidic or neutral conditions.
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Indeed, hemiacetal polymers were also suggested110,159 to undergo Schiff base 
formation through the addition of a monomeric glutaraldehyde molecule. This type 
of product from the reaction between gelatin (protein) and glutaraldehyde is seen in 
figure 2.16 below.
-In H L J n  H
(A) (B)
Figure 2.16: Reaction products (hemiacetal) from the reaction between
glutaraldehyde polymeric hemiacetal and a protein as proposed by Matsuda et a l159 
(structure A), and Walt et al110 (structure B).
Based on spectral data, Aso and A ito" have reported the formation of another 
possible compound with a hemiacetal polymer-like structure (see figure 2.17 below). 
They suggested that glutaraldehyde polymerises as a chain of six-membered 
pyranose rings joined by ether linkages (a-oxypyran rings formed giving tetramers 
and pentamers). This indicated that small oligomers were formed, which on average 
contained three glutaraldehyde residues and one free aldehydic group. It was later 
hypothesised by others that these types of structures may occur in the glutaraldehyde 
cross-links174.
Figure 2.17: a-oxypyran ring polymers, where the ratio of x to y is said to be about 
six to sixteen, as proposed by Aso and Aito99.
The formation of a-oxo-N-alkyl piperidine cross-links (see figure 2.18 below), after 
condensation of the N-alkyl-2,6 -dihydroxy piperidine with a cyclic monohydrated 
glutaraldehyde, has also been suggested173.
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Figure 2.18: a-oxo-N-alkyl piperidine cross-link, suggested as a possible product 
formed by the condensation of the N-alkyl-2,6 -dihydroxy piperidine with a cyclic 
mono-hydrated glutaraldehyde173.
2.2.4.4 Schiff base and Michael-type addition involving aldol condensation products
Cross-links involving aldol condensation products through Schiff base formation 
have been reported89,159 (see figure 2.19 (A) below). It has also been suggested, from 
infrared spectroscopic data, that amino groups react with a,/3-unsaturated aldol 
condensation products formed at alkaline or even at slightly acidic conditions, to 
form stabilised conjugated imino bonds by a resonance effect82,93 (see figure 2.19 (B) 
below). This may account for the observed increased stability of cross-links, because 
the equilibrium constant is usually unfavourable for non-conjugated imine formation
• 17Sin aqueous solution . Furthermore, the incorporation of several moles of 
glutaraldehyde per mole of lysine/hydroxylysine residue indicates that oligomeric 
rather than monomeric glutaraldehyde compounds are involved in the cross-linking 
reaction71. It was suggested that aldol condensates formed with up to 8 
glutaraldehyde molecules could easily establish a bridge between two lysine 
residues82.
•o
(B )(A)
Figure 2.19: Imine formed from an aldol condensation product (A) as proposed by 
Hardy et al89 and Matsuda et al159; and a conjugated imine (more stable) formed from 
an aldol condensation product (B) as proposed by Monsan et al82, and Marquie et 
al93.
Other mechanistic pathways leading to stable products have also been suggested, 
such as the one involving a Michael-type addition of side-chain amino groups to 
aldol condensation molecules105. These Michael-type addition products are thought 
to be stable even under acid hydrolysis. Some cross-links between glutaraldehyde
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and amino groups have been shown to be of the aldol condensation product form, 
with five carbon atoms in a chain between the two nitrogen atoms from the uptake of 
amino acids105 (see figure 2.20 below). The same authors also hypothesised that 
these aldol condensation products could also react at one end by Michael-type 
addition and at the other by reversible Schiff base formation (see figure 2.20 below). 
Others then suggested that the unsaturated aldol-type polymers of glutaraldehyde are 
likely candidates for protein cross-linking reactions in alkaline solutions89, although 
the cross-linking reaction was apparently not dependent on the initial presence of 
unsaturated compounds. The involvement of dimers characterised by Tashima et
1 112al , formed by a dimolecular aldol condensation and that may exist in equilibrium 
with their cyclic hemiacetal forms, have also been proposed110 to be formed in cross- 
linking through Michael-type addition and Schiff base reaction (see figure 2.21 
below).
(C) (D)
Figure 2.20: Stable cross-links formed by the Michael-type addition of amines with 
aldol condensation products, as proposed by Richards and Knowles105 (note that 
further Schiff base formation can still occur with all the above-molecules (A-D), and 
Michael-type additions can still occur in the molecules C and D).
Figure 2.21: Cross-links formed by the Michael-type addition of amines to aldol 
condensation products, as proposed by Walt and Agayn110 (note that further Schiff 
base formation can still occur in all these above-molecules).
However, because of the presence of a resonance-stabilised ethylenic double bond 
with the imino bond formed from the reaction of an aldol condensate and an amino
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acid (such an example can be found above in figure 2.20 (B)), these relatively stable 
molecular compounds are thought not to allow Michael-type addition reactions to 
take place . The aldol condensation mechanism with the Michael addition 
postulated by Richards and Knowles105 (yielding molecular compounds such as the 
ones found above in figure 2.20 (A-D)) was also reported to occur under the 
influence of the protein immediately prior to cross-linking and to represent only a 
minor contribution to the overall cross-linking164,168.
The mechanism for the conjugate addition (Michael-type addition) of an amine to an 
aldol condensation product is shown in Figure 2.22 below. The initial step involves 
nucleophilic attack by the lone pair of electrons of the nitrogen on the P-carbon atom 
of an ce,/3-unsaturated carbonyl acceptor, forming an enolate as the product. The 
enolate then rearranges to give the more stable keto-form by abstracting a proton, 
from the solvent or from the starting nucleophile, to yield the final addition 
product176’177.
keto-form
Figure 2.22: Mechanism for the conjugate addition of an amine to an aldol 
condensation product (dimer).
2.2.4.5 Formation of quaternary dihvdropyridine compounds:
It has been known for some time that the reaction of an aldehyde with an amine can 
lead to the formation of a dihydropyridine that then leads to pyridinium salts178'180. 
The principal product of the condensation o f an aliphatic aldehyde with an aliphatic 
aldimine is a 1,2,3,5-tetraalkyldihydropyridine181 (which has a similar structure to
106
that of isodesmosine found in elastin, see chapter 1). Under appropriate conditions,
1 CO 1 R9pyridines are the major reaction products of aldehyde-amine reactions ’ . Some
findings based on IR, UV and !H NMR data156’168, confirming the previous findings 
of others117, indicated the possible formation o f a quaternary pyridinium system 
(1,3,4,5-tetrasubstituted pyridinium salts as shown in figure 2.23 below) analogous 
to the 1,3,4,5-substitution pattern of desmosine, which is found in acid hydrolysates 
of elastin. They also suggested the likely formation of the 1,2,3,5-substitution 
(isodesmosine analogs). The UV absorption maximum observed for such pyridinium 
structures being at 265nm156, was consistent with the original observation of Bowes 
and Cater117 who first reported the appearance of this UV absorption peak following 
the reaction of glutaraldehyde with amine compounds. It has also been suggested 
that pyridine products represent one of many possible irreversible cross-links created 
by the action of glutaraldehyde with proteins168. They later isolated157,172 a 3-(2- 
piperidyl) pyridinium derivative (shown in figure 2.23 below) from the acid 
hydrolysates o f glutaraldehyde-treated protein (ovalbumin), the structure being 
confirmed by UV, *H and 13C NMR in D2O, and later named anabilysine (shown in 
figure 2.23 below) This pyridinium derivative was the first cross-linking entity to be 
isolated from a glutaraldehyde-treated protein.
1,3,4,5-tetrasubstituted 
pyridinium  salt analogous to the 
substitution pattern o f  desm osine 
(A)
Pyndimum
com pound
(B)
3-(2-piperidyl) pyridinium  
derivative, nam ed anabilysine
(C)
1 1 C 7  1 1 7 9Figure 2.23: Quaternary pyridinium structures proposed by Hardy et al ’ ’ ’ ,
where it can be seen that the molecular structures o f the 1,3,4,5-tetrasubstituted 
pyridinium salt (substitution pattern similar to desmosine (A)), anabilysine (C) and 
even the pyridinium compound, (which is formed from the cyclisation o f a Schiff 
base reaction of an amino group with a monomeric form of glutaraldehyde (see 
mechanism in figure 2.12)), all form stable cross-links.
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More recently, other theoretical chemical structures (see figure 2.24 below) have 
also been proposed183 including a cyclic imminium ion (A), dihydropyridine (B) and 
(C) pyridine-containing molecules.
Figure 2.24: Cyclic imminium ion (A), dihydropyridine (B) and pyridine (C) 
structures proposed by Johnson183.
Those same dihydropyridine structures are also thought to possibly condense with 
each other, instead of with additional glutaraldehyde, to form polymers of 
dihydropyridine (see figure 2.25 (A)), which can lead to the formation of pyridine 
polymers by oxidation (see figure 2.25 (B) below).
Figure 2.25: Polydihydropyridine (A) and polypyridine (B) structures proposed by 
Johnson183.
In addition, quite a recent study151 of the reaction between glutaraldehyde and 6 - 
aminohexanoic acid, using gel filtration and UV spectroscopy, showed that one of 
the separated products by SP-Sephadex corresponded to a pyridinium structure, 
which would be in agreement with the previous work of Hardy et al168. However, 
from their UV data, they concluded that the structure suggested by Hardy et al 
(1,3,4,5-tetrasubstituted-pyridinium-type, similar to desmosine (see earlier figure 
2.23) is quite different to the one they had characterised despite being of similar 
type. Therefore, they proposed a single large polymeric structure molecule with 
multiple pyridinium rings and an average molecular weight of 20000 (MW 5000- 
80000). A new chemical structure was not proposed however, but they referred back
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to a chemical structure proposed previously by Hardy et al168 (see figure 2.26 
below).
Figure 2.26: Chemical structure postulated by Hardy et al168 for a purified product 
obtained from the reaction of glutaraldehyde and amino-containing model 
compounds (R is the radical of the corresponding protein or amino acid).
2.3 Conclusion
As a conclusion, it appears that the chemistry of glutaraldehyde in solution is quite 
complex and not yet clearly defined, and additionally there is sufficient evidence that 
the reaction between glutaraldehyde and protein is not simple, and although the 
characterisation of many structures have already been attempted, there are probably 
still as many to be characterised. Additionally, because of the many contradictions in 
the literature about a consensus of current opinion for the nature of glutaraldehyde in 
solutions and also for the nature of the products from the reaction between proteins 
and glutaraldehyde, this area has been studied in detail in this work and the results 
and discussion of these features can be found respectively in chapters 4 and 5.
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Chapter 3
3 Techniques: theory and applications.
3.1 Introduction
When making a chemical analysis, it is rather difficult to draw definitive conclusions 
from the data obtained from one single technique; but more conclusive data can be 
obtained when several techniques are applied to a problem. For example, making 
definitive assumptions on molecular structure from mass spectrometry (MS) is not 
possible without the help of other techniques such as nuclear magnetic resonance 
(NMR), infrared (IR) or ultraviolet (UV) spectroscopy. Therefore, for this study, it 
was decided to use a large range of techniques in order to be able to draw realistic 
conclusions.
A primary aim of this study was to gain a greater understanding of the chemistry 
involved in the treatment of collagenous valve tissue with glutaraldehyde. Amino 
acids, peptides and proteins were thus used to model potential reactions involved in 
glutaraldehyde treatment of valve tissue. The following techniques were used to 
investigate the reactions and subsequent products: Nuclear Magnetic Resonance 
(NMR), Fourier-Transform Infra-Red (FTIR) and Raman spectroscopy, ElectroSpray 
Ionisation (ESI-MS) and Matrix Assisted Laser Desorption Ionisation-Time-of- 
Flight Mass Spectrometry (MALDI-TOF MS).
The second main aim of this study was to develop a successful method for observing 
the surface morphology of calcified tissue in its native wet state by using the 
Environmental Scanning Electron Microscopy (ESEM) coupled with analysis by 
Energy Dispersive X-ray (EDS). The developed methods were then applied to 
samples from clinical investigations (explanted human calcified valves), in-vivo 
screening (rat subcutaneous implantation model) and in-vitro screening (pericardial
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tissue incubated in a metastable calcification solution) to investigate the calcification 
process. In order to further define the identity of the calcified structures, various 
spectroscopic techniques were used, such as XRD, FTIR-ATR and Raman 
spectroscopy. The quantitative determination of calcium and other metal ions present 
in these calcified tissues was carried out by ICP-OES analysis.
Each technique is only briefly discussed in this section for the sake of the length of 
the thesis, but particular details and relevant applications are given where applicable 
and the reader is directed to more detailed publications.
3.2 Methods
3.2.1 Freeze-drier
3.2.1.1 Theory and methodology:
The basics and theory of the freeze-drying lies in a commonly known-physical 
process, which is the sublimation process.
All samples subjected to freeze-drying (aqueous solutions or wet tissues for instance) 
were frozen for a few hours in an air environment in a -2 0 °C fridge or immersed and 
swirled for a few minutes in liquid nitrogen with the help of a round-bottomed-flask. 
The frozen samples were then quickly removed and placed in the specimen chamber 
of the freeze drier. The frozen samples in the sample chamber were thus allowed to 
warm spontaneously, while the vacuum pump was facilitating a sublimation process. 
A cold trap (or condensing chamber) filled with liquid nitrogen prevented any 
solvent vapour from reaching the vacuum pump (two stages Edwards pump, 
Crawley, UK) where they might condense and cause the cavitation of the pump. The 
freeze-drying process only removed the solvent (water in this study) without altering 
the nature of the diluted species or the wet tissue. A laboratory-built freeze-drier was 
used for these studies. Occasionally, a “Cold Trap 1000” freeze-drier (UK) was also 
used to freeze-dry cardiac valves and pericardial tissue. The laboratory-built freeze- 
drier is illustrated in figure 3.1 below.
119
/  \
7 7Z Z 7 7Z Z
S: Sample Chamber.
CT: Cold Trap filled with liquid nitrogen.
P: Edwards Vacuum Pump.
Figure 3.1: “Laboratory-built” freeze-drier set up.
3.2.1.2 Applications related to this study:
The freeze-drying technique is widely used in the food industry (lyophilised 
products) and in the pharmaceutical industry in order to store products in a reliable 
stable phase. The process however is not yet fully understood. The development of a 
freeze-drying process used for cardiac valves has also been reported1.
The freeze-drying process allows the analysis of solid reaction products resulting 
from an aqueous chemical reaction. The range of concentrations employed in this 
study was relatively low. To increase spectral intensity, samples were freeze-dried 
prior to analysis. To ensure species were unaffected by this process, all unreacted 
species used were first submitted to analysis as a freeze-died aqueous solution and as 
neat compounds. The overall conclusion was that all model compounds (amino 
acids, peptides and proteins) gave the same spectra from a freeze-dried sample as 
from the pure compound.
Also, freeze-dried samples can be readily diluted in other solvents if  necessary. This 
can be particularly useful for concentrating the solution or for dissolving the sample 
in another solvent (especially useful in the case of mass spectrometry and nuclear 
magnetic resonance spectroscopy sample preparation).
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3.2.2 Environmental Scanning Electron Microscopy (ESEM)
3.2.2.1 Theory:
The ESEM has been described in an extensive survey by its principal developer, 
Danilatos G.D. . In comparison to conventional SEM, which requires a high vacuum 
and stable samples at very low pressures and thus prevents wet, moist or dirty 
samples from being imaged, the ESEM uses a vacuum gradient to maintain high 
vacuum conditions at the primary electron source while permitting sample chamber 
pressures to be varied. A schematic representation of the ESEM sample chamber can 
be found below in figure 3.2.
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Figure 3.2: Schematic representation of the simplified “cascade process” occurring 
in the ESEM sample chamber
In the ESEM, an incoming primary electron beam is oriented towards the sample 
surface. When this primary electron beam hits the sample, secondary and 
backscattered electrons are emitted from the sample. The gaseous environment of the 
ESEM sample chamber is then ionised by secondary electrons derived from the 
sample. The resulting ionisation creates additional daughter electrons and positive 
ions. Electrons from ionising gas molecules precipitate a cascade multiplication of
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the imaging current that is monitored by the detector3 (thus the name of “cascade 
process”). A positive bias applied to the detector electrode above the sample attracts 
the secondary electrons from the sample and accelerates them sufficiently to create a 
cascade of ion-electron pairs and to yield considerable amplification before they are 
collected. The positive ions produced upon ionisation of the gas molecules in the 
sample chamber neutralise charges on the sample surface. The elimination of 
charging allows insulators to be observed without the need for conducting coatings, 
unlike the conventional SEM. For further insight into the theory of ESEM, the reader 
is invited to refer to articles by Danilatos4' 6 and Phillips and Toth7.
3.2.2.2 Applications related to this study:
The applications of ESEM are numerous although the number of publications is, as 
yet, relatively low. Applications include colloid characterisation8, bio-corrosion9, a 
study of ice films to simulate stratospheric clouds10, imaging of ink on paper11, 
imaging of albumen photographs12, real-time etching of dental enamel13 and studies 
of micro-organisms14.
Most electron microscopic studies of the calcification process have been limited to 
the study of thin sections of material (cut embedded specimen block), by both 
scanning electron microscopy (SEM) and transmission electron microscopy (TEM), 
thus focusing on calcific deposition within the structures of pericardium such as cells 
and collagen molecules15,16. However, there has been little study of the deposition of 
calcium phosphate on pericardial surfaces and the insides of tissue in the early stages 
of calcification, using SEM and TEM. Moreover, the use of such techniques 
necessitates a particular sample preparation, e.g. transfer over several days from 
aqueous solution to methanol to ensure complete dehydration of the samples, 
followed by critical point drying. Samples have to be mounted on metallic surfaces 
and sputter coated with gold, carbon, etc. to facilitate good conduction. Gold coating 
permits study of the surface with minimal tissue damage in electron microscopy, 
however for the analysis of phosphorus, it can give very poor results because of the 
proximity of the phosphorus K-a and gold L X-ray peaks. Carbon coating, however, 
does not interfere in the X-ray spectrum but even after 4-5 coatings gives poor 
overall results because of the discontinuous conducting surface in comparison to 
gold. This leads to charging effects, causing poor imaging quality and such samples
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can also be damaged quite easily by the primary beam. Additionally, exposure to the 
high vacuum and electron bombardment of calcified tissue is likely to decompose the 
hydrated calcium phosphate salts (making them appear amorphous) or cause 
disproportionation into a more stable mixture of salts17.
Although there are no publications reporting the application of ESEM to the analysis 
of valve tissue and calcified-tissue valves, the use of ESEM has been reported in 
studies of interest to this work. For example, Fulmer et al have reported the use of 
ESEM in the study of the morphologies of the reaction products, (mostly calcium 
deficient hydroxyapatite (Ca^HPCUXPO^OH)), which was formed by the reaction 
of tetracalcium phosphate (CaXPCUXO), monetite (CaFlPC^), brushite 
(CaHPC>4.2H20) and calcium hydroxide (Ca(OH)2)18. The advantage o f using ESEM 
when studying such samples is emphasised when it is reported that the use o f a high 
vacuum environment in SEM or TEM can potentially cause the release o f hydrogen 
and the further conversion of hydroxyapatite to a a-tricalcium phosphate structure19. 
ESEM has also been reported in the analysis of the viability of cells on different 
polymer scaffolds for valve tissue engineering purposes . The same technique was 
also described in the study of the morphology of cacodylic acid-fixed tissue 
fabricated in-vitro and was capable of showing the attachment of cells on the 
polymer scaffold21. Recently, the same group described the construction o f a 
trileaflet heart valve scaffold for tissue engineering, which leads to successful cell 
proliferation and collagen formation. The subsequent evaluation o f the leaflet surface 
and valve conduit implanted in-vivo in a lamb model was carried out with the help of 
ESEM22’23.
3.2.3 ICP-OES (inductively coupled plasma-optical emission spectroscopy)
3.2.3.1 Theory:
The inductively coupled plasma is a flame, which exceeds temperatures normally 
attained by a conventional combustion flame. Its high temperature and stability 
eliminates interferences often associated with conventional flames. A radio 
frequency field generates the plasma within a flow o f argon gas. When an aerosol of 
the sample solution is injected into the plasma through a stream of argon, excitation 
from ground state to the excited electronic state occurs. The ICP was found to be the 
most effective electrodless excitation source24,25. Atoms will relax to their ground
123
states emitting radiation of characteristic wavelengths. Photomultipliers are used to 
detect those wavelengths and convert them into an electrical signal. To be more 
specific, there are two parts for the detection line that can be used simultaneously if  
required, and thus many wavelengths of varying sensitivity are available for the 
determination of one element. The simultaneous part of the detector consists of a 
bank of six photomultipliers that are fixed at certain wavelengths for most common 
analysed elements (Mg, Na, Ni, Fe, Pb, Cu...). The other part o f the detector 
(sequential part) consists of one photomultiplier that scans over a range of 
wavelengths, allowing the analysis o f theoretically all elements at once. The 
detection limits are in the order o f parts per million with a good linear range. Solid 
samples have to be digested using ultra pure acids and either a microwave 
(homogeneous heating) or a hotplate to aid digestion. For a much more detailed 
consideration o f the theory of ICP-OES, the reader is invited to refer to specialised 
publications26'28.
3.2.3.2 Applications related to this study:
In valve calcification studies, calcium determination has generally been carried out 
by atomic absorption spectroscopy at a wavelength of 315.18 nm29,30. Phosphorus 
has been determined by spectrophotometry of the reduction o f phosphovanado- 
molybdic acid complex or another complexing method with ascorbic acid . 
However, in order to detect the presence of many metal ions at once, the use o f ICP- 
OES is ideal and was only recently reported for quantitative analysis o f calcium and 
phosphorous deposits on valve leaflets in a canine in-vivo model33 and an in-vitro 
model34. The amounts of calcium and phosphorus accumulated on retrieved 
glutaraldehyde-treated bovine pericardium from canine vascular implantation for 40 
days were respectively of 13.8±2.3 f ig  o f Ca/mg of tissue and 19.3±4.3 f ig  o f P/mg 
of tissue in the aorta implantation site, and 6.7±0.7 f ig  o f Ca and 12.6±3.4 f ig  o f P in 
the pulmonary artery implantation site . They reported that these values were rather 
low when compared with other reports. On the other hand, a static in-vitro 
assessment of tissue valve calcification (relatively similar model to the one used for 
these studies) exhibited -200 f ig  o f Ca/mg o f tissue and less than a few f ig  o f P/mg 
of tissue (exact values not given)34. These authors observed a difference between the 
results from dynamic in-vitro and static in-vitro testing to study calcification. 
Additionally, they reported a remarkable difference between the results from their in-
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vitro calcification study and in-vivo methods. Apart from calcium and phosphorus, 
the measurement of silicon in biological fluids, which is of relevance for these
or oz:studies, was also reported ’ .
3.2.4 X-Ray Powder Diffraction (XRD)
3.2.4.1 Theory:
In modem XRD instmments, the production of X-rays occurs in an evacuated 
chamber containing a metal target (e.g. Cu), which is stuck by incident high-speed 
electrons from a heated filament. The accelerated electrons strike the inner, more 
tightly bound, electrons of the target and knock them out of their orbital positions, 
away from the influence of the nucleus. This produces electron vacancies, which are 
filled by higher orbit electrons dropping inwards to fill the vacancy. This drop 
involves the production of an X-ray photon, the energy of which is proportional to 
the difference between the energy levels of the orbitals. This energy difference is 
dependent on the number of protons in the nucleus attracting the electrons. The X- 
rays produced are directed at the sample over a range of angles. X-rays are 
electromagnetic waves characterised by an electric field, the strength of which varies 
sinusoidally with time at any point in the beam. This oscillating electric field exerts a 
force on the electrons of an atom causing any electron it encounters to oscillate about 
its mean position. This accelerating and decelerating electron emits electromagnetic 
radiation and it is in this sense that the electron is said to scatter X-rays. The 
scattered beam is simply the beam radiated by the electron under the action of the 
incident beam and has the same frequency as the incident beam. Thus, the scattering 
of X-rays by matter occurs. Scattering of X-rays is proportional to the size of the 
atom, providing that the dimensions of that atom are less than the X-ray wavelength. 
If Bragg’s law is obeyed, diffraction will occur at an angle 6 , if a beam of X-rays 
falls on a series of atom bearing planes within the sample, each a distance d apart. 
Bragg’s law states that nX=2dsin0, where X is the wavelength of the X-ray and n is an 
integer. During an experiment, both the detector and the sample are rotated (with the 
help of a goniometer) in order to reach the required angle. The intensity of the 
scattered X-rays obeying Bragg’s law is measured as a function of the diffraction 
angle (degree 26 or °26) and the orientation of the sample. By rearranging Bragg’s 
equation, the d spacing of a mineral can be obtained by d=nX/2sin0. For further
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insight into the theory, the reader is invited to refer to the publication by Skoog et 
al37.
Although quantitative analysis is possible using XRD, reproducibility is dependent 
upon many key factors including sample thickness, alignment of crystals, 
homogeneity and also the quality of the standards used38. Hence, because o f the 
small amounts of inorganic material available to be analysed, the studies reported in 
this thesis are strictly qualitative.
3.2.4.2 Applications related to this study:
XRD has been reported for use in the study of cross-linked collagen, showing its 
amorphous nature and suggesting that the process of aldehyde-cross-linking 
decreases the crystallinity of collagen39. However, traditionally, XRD is the 
technique of choice for identification and characterisation of apatite-like minerals. 
Hence, the use of XRD is extensively reported in the literature for the determination 
and for the confirmation of the presence and the crystallinity of calcium phosphate 
crystals in calcified (in-vitro or in-vivo) tissues40,41. Usually, XRD shows well- 
separated, relatively sharp peaks and discloses the presence of diffraction peaks, 
which are consistent with apatite. Such characterisation is usually hampered by the 
overwhelming presence of large amounts of organic components from the collagen 
matrix that tend to obscure spectral analyses due to the high background radiation42' 
44. Additionally, the minimum mass fraction of a calcium phosphate phase that can 
be detected by XRD is about 3%, rendering the analysis of poorly calcified samples 
difficult, especially for example the early stages of calcification. Furthermore, the 
low crystallinity and extremely small size of particles prevent a complete three- 
dimensional structural analysis by X-ray or even electron diffraction45. Nevertheless, 
XRD is a useful tool, commonly employed for the analysis of solid powder mixtures. 
However, the broadening of the XRD do not generally allow precise determination 
of the unit cell dimensions in the case of bone or even synthetic apatite-like 
samples46.
The analysis of hydroxyapatite (HAP Caio(P0 4 )6(OH)2) by XRD has received much 
attention47: Reports have shown that the major reflections of the hexagonal 
hydroxyapatite phase correspond48 to (200), (111), (002 26 range 24.5-27° 49), (102), 
(210), (211), (112), (300), (202), (212) and (310 26 range 37.5-42° 49). The region of
126
highest intensity (2d range 30-35°) consists of four unresolved peaks with un­
measurable overlapping breadths49. It was reported that if the (300) reflection, which 
is strong for apatite phases, is diffuse and poorly resolved, then it indicates low 
crystallinity and that the crystal may contain cations such as carbonate, sodium or 
potassium50.
The major dicalcium phosphate dihydrate (DCPD CaHP0 4 .2 H2 0 ) peaks 
correspond51 to (121), (020 0=5.8252), (021 0=1O.4652), (110), (111), (112), (230) 
and (2 0 0 ).
Another important candidate as a possible precursor in cardiovascular mineralisation 
is octacalcium phosphate (OCP CasH2(P0 4 )6.5 H2 0 )53. However, although crystalline 
OCP has several diffraction peaks that are distinct from those of hydroxyapatite, 
poorly crystallised OCP and partially hydrolysed OCP (OCPH) have diffraction 
patterns that resemble that of hydroxyapatite53 and it is usually difficult to 
distinguish between them.
3.2.5 Fourier transform infrared-attenuated total reflectance (FTIR-ATR) 
spectroscopy
3.2.5.1 Theory:
For a detailed account of the theory of FTIR-ATR spectroscopy, the reader is 
directed to several excellent publications54'56.
Reflectance spectroscopy is commonly used for obtaining infrared spectra of 
samples that are difficult to deal with by standard infrared techniques, for example 
solids, powders and films that require grinding to produce nujol mulls or KBr discs. 
Attenuated Total Reflectance (ATR) is particularly useful for the surface analysis of 
such samples and is reported as being a powerful technique in the analysis of 
biopolymers both for chemical identification and for molecular structure 
determinations57. ATR is the only infrared technique that allows the study of proteins 
on surfaces in contact with aqueous medium and hence was chosen for use in this 
study. A simplified FTIR-ATR experimental set-up can be found below in figure 3.3.
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Figure 3.3: FTIR-ATR experimental set-up (simplified)
In FTIR-ATR, an infrared beam passes from a denser medium (ATR crystal with a 
high refractive index, such as zinc selenide, which is represented as a trapezoidal 
orange crystal in figure 3.3) to a less dense (sample) medium and reflection occurs. 
The fraction of the incident beam that is reflected increases as the angle of incidence 
becomes larger and beyond a certain critical angle internal reflectance is complete. It 
has been shown that during the reflectance process the beam acts as if  it penetrates a 
small distance into the less dense medium before reflection occurs. The depth of 
penetration, which can vary from a fraction of a wavelength (micron scale) up to 
several wavelengths, depends upon the wavelength of the infrared beam, the index of 
refraction of the two materials (ATR crystal and sample) and the angle of the 
incident beam (usually 45°) with respect to the interface. The penetrating radiation is 
called the evanescent wave. If the less dense medium absorbs the evanescent 
radiation, attenuation of the beam occurs at the wavelengths of the absorption
58bands . Internal reflectance spectra are similar to ordinary absorption spectra as the 
same peaks occur but the relative intensities differ. The internal reflectance spectra 
absorbance, although dependent upon the angle of incidence, are independent of the 
sample thickness because the radiation penetrates only a few micrometers into the 
sample.
3.2.5.2 Applications related to this study:
3.2.5.2.1 Analysis o f  model compounds:
FTIR can provide information such as the composition, structure and crystallinity of 
the sample. FTIR is widely applied in clinical sciences59 and these applications have 
been reviewed by Putzig et al60. FTIR has been reported for the analysis o f various
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proteins61, some of relevance to these studies such as cytochrome C62, or collagenous 
tissue (human skin63,64). Glutaraldehyde-treated proteins were also investigated by 
infrared spectroscopy such as cotton cellulose65, chitosan66 and gelatin67. The 
respective data from these studies only revealed the presence of imine (Schiff base 
C=N) and ethylenic (C=C) bonds while the presence of imine bonds-stabilised by 
resonance with adjacent ethylenic bonds was thus suggested. A similar conclusion
✓TOwas drawn from studies of glutaraldehyde-treated amino acids (isopropylamine , 6 - 
aminohexanoic acid and N-acetyl-L-lysine69). Additionally, the analysis of
/TOglutaraldehyde was reported by Monsan et al who postulated the presence o f aldol 
condensation glutaraldehyde polymers containing aldehydes, conjugated aldehydes 
and ethylenic functions. Margel and Rembaum70 hypothesised from their FTIR study 
of glutaraldehyde, the presence of similar polymers of glutaraldehyde but where the 
dehydration step of the aldol condensation reaction did not always occurred resulting 
in the presence of hydroxyl. This finding was later corroborated by Tashima et al71,72 
who reported that glutaraldehyde included hydroxyl, carboxyl and a,/3-unsaturated 
formyl groups but the exact structures could not be determined. All these studies are 
thus of particular relevance because one aim of this thesis is to model potential 
reactions and investigate the reactions and subsequent products involved in 
glutaraldehyde treatment of valve tissue by using various amino acids, peptides and 
proteins but also to determine the true nature of glutaraldehyde solutions.
3.2.5.2.2 Analysis o f  valve tissue:
FTIR-ATR is a sensitive technique and has been reported as being especially suitable 
for surface analysis57. Tissue samples such as aortic valve tissue are a few tenths of 
microns thick and thus are not sufficiently transparent for transmission infrared 
analysis. This necessitates the use of an ATR accessory to obtain infrared spectra. 
The application of FTIR-ATR was thus reported for the study and characterisation of 
a new series of polyurethane replacement cardiac valves and their calcification73; for 
the study of aortic wall tissue74 and also for studying the effect of ethanol pre­
incubation as an anti-calcification agent on glutaraldehyde-cross-linked porcine
ncaortic valves . Additionally, cross-linked collagen membranes were also
TOinvestigated with FTIR-ATR . This is of some relevance to studies of this thesis, 
since bioprosthetic heart valve tissue and its calcification is investigated.
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3.2.5.2.3 Analysis o f the calcification o f valve tissue:
FTIR is most commonly employed for the analysis of solid mixtures along with 
XRD, except that XRD, (although a technique of choice for the identification of 
apatitic minerals), does not reveal spatial variations in the mineral structure of
7 —biological tissue specimens , while FTIR spectroscopy has been used to explore the
77  7Qspatial variations in mineral properties ' . Note that “apatitic minerals “ refer to 
materials that have characteristics of apatites such as hydrolysed-octacalcium 
phosphate (OCPH) and hydroxyapatite (HAP). Additionally, the infrared study of 
inorganic powder samples uses only a few milligrams of sample, while the X-ray 
method requires at least twenty five to fifty times as much. In addition, the time for 
the infrared analysis is much shorter than that required for X-ray diffraction 
analysis80.
The infrared spectra of many pure inorganic compounds can be found in the 
literature81. FTIR can provide information on the structure, the near-neighbour 
environment of carbonate and phosphate groups of the mineral phase, and an 
estimate of the degree of crystallinity of the crystal, as well as the organic matrix 
contribution expressed as amide bands82,83. The complex phenomenon of crystal
Af\  78  8A 87maturation (or aging) was studied in both in-vivo and in-vitro systems ’ ’ ' and it 
is known to be manifested through changes in the short range order of the crystals 
and the concentration and location of highly labile, reactive CO 32' and HPO 4 ' groups. 
Such distinctive markers of bone mineral maturation are an increase in CO 3 ' and a
9 Af\  8^ 87decrease of labile CO3 ' and HPO4 ’ ions ’ ’ . Indeed, bone-type mineral was
2 2reported considered as a calcium-deficient apatite containing HPO 4  ' and CO 3 '
0 0ions . The following paragraphs present various CaP-rich inorganic phases that are 
likely to be encountered in the analysis of calcific deposits in bioprosthetic valves.
a) Amorphous calcium phosphate (ACP):
Determining the presence of amorphous calcium phosphate (ACP) is not an easy 
task. However FTIR was reported to be useful in determining the percentage of 
crystallinity in a mixture of amorphous and apatitic calcium phosphates. The infrared 
spectrum of amorphous calcium phosphate presents limited or no splitting of the 600
1 T cocm' infrared band (^(PCU ’) region) that one would expect for crystalline 
hydroxyaptite90. Additionally, infrared spectra of the solids formed in the conversion
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of amorphous calcium phosphate to crystalline hydroxyapatite were reported and 
showed a gradual splitting of the 600 cm ' 1 anti-symmetric bending band (>4(P0 4 3') 
region) from a broad singlet for amorphous CaP to a well-defined doublet for the
Q Afully crystalline solid .
b) Calcium-deficient apatite (Ca9(HP0 4 )(P0 4 )5 0 H))
Calcium-deficient apatite typical bands are91: hydroxyl band at 3569 cm '1; carbonate 
peaks at 1647, 1454, 1412 cm ' 1 (^(CO s2') bands 1650-1400 cm '1) and phosphate
1 1  3peaks at 1092 cm' , 1030 cm' (intense J'3(P0 4 ') bands-almost obscuring the V\ 
carbonate band92), 960 cm ' 1 (jq(P0 4 3") band) and 629, 602, 563cm"1 (intense ^(PCU3" 
) bands 630-560 cm"1) and weak ^(PCU3') band at 473 cm '1.
The bands of calcium-deficient apatite (or non stoichiometric apatite) are quite 
similar in fact to the ones of stoichiometric apatite, but are generally characterised by 
additional bands similar to those found in most biological apatites86 ( 1 0 2 0 , 1 1 0 0  cm" 
’) and sometimes a typical band of H P04' (1143 cm '1) can be found along in these 
apatite-like structures93.
c) a- and /3-tricalcium phosphate91 (TCP Ca8H2(P0 4 )6.5 H2 0 ):
A strong band at 970 cm"1 is usually quite characteristic of the presence or not of
86TCP . Furthermore, it is worth noting that this band is not observed in most 
biological samples and in poorly crystalline synthetic apatites.
d) Octacalcium phosphate (OCP Ca8H2(P0 4 )6.5 H2 0 ):
The OCP spectra, (A and B forms), are somehow similar to the ones of apatite 
structure and a complete assignment of the infrared bands of both A and B form of 
OCP can be found in the literature94. Note that the A and B OCP forms correspond 
respectively to carbonate ions occupying two different sites (respectively Cl" or OH" 
for the A site and PO4 " for the B site) in apatitic structures. Nevertheless, there are 
specific phosphate bands at 1138 cm ' 1 and another for the OCP structure at 913-917 
cm ' 1 94, although this band was attributed later to components of the organic
OAmatrix . Additionally, it has been shown that OCP presents two non-equivalent
2 • 95HPO4 " ions , one attributed in the “apatitic layer” and the other in the “hydrated 
layer”46.
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3.2.5.2.4 Major vibrational spectroscopic regions o f  inorganic CaP-rich phases:
Because the calcific deposits, found in calcified human explanted valves, are 
composed of calcium phosphates, closely related to physiologic bone mineral (see 
chapter 1 in sections 1.4.2 and 1.7), and because no review yet exists, the following 
paragraphs present the major vibrational spectroscopic regions encountered in the 
analysis of bone, enamel and calcific deposits by infrared spectroscopy.
Inorganic orthophosphate ions (HPO42 ) and (PCU3!:
Two inorganic orthophosphate ions were reported to occur in biological apatites 
present in mineralised tissue: P 0 43' and HPO42'.
Hydrogenophosphate ions (H P O /j:
The HPO4 2' ion can be considered to be distorted PO4 3’ tetrahedron, which exhibits 
bands at almost the same frequencies as for the PO4 3' ions (see section below dealing 
with phosphate (P 0 43') vibrational modes). However, the stretching vibration of the 
P-OH band (^3  mode) appears generally as a pronounced band96 at a lower frequency 
(around 860-872 cm '1), where it may be overlapped by the strong ^(CC^2') band in 
biological apatites and cannot generally be observed. The PO-H stretching can also 
give a broad band, between 2400 cm"1 and 3200 cm"1 that was not reported in the 
biological apatites. The V4  mode was reported to give two main bands at 600 and 560 
cm ' 1 and a shoulder at 575 cm '1, generally superimposed on a broad absorption band 
from the components of the organic matrix46. The presence of HPO 4 2" can also be 
identified by two low-wave number bands97 at 520-530 cm"1 and at 540-550 cm"1, a 
very broad band97 that culminates at 730 cm"1 and also by other bands at 1133-1150 
cm '197, and at 1217 cm"197.
Phosphate ions (PO4 j :
Theoretically, there are four vibrational modes present for phosphate PC>43‘ ions (vi_ 
V 4). All these modes are both infared and Raman active.
3 • 1vi(P0 4  ") region: Only a band at 960 cm' was reported in the literature for this 
region.
V2(P0 4 3') region: Only a band at 473 cm"1 was reported in the literature for this
17region .
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V3(P0 4 3') region: Although weak V3(C0 3 2') bands can slightly obscure this region86, 
the V3(P0 4  ") region consists of an intense broad absorption band generally split into 
two main components. The first is seen at 1170-1085 cm ' 1 with several bands 
generally around 1100, 1110, 1125, and 1145 cm '1’ The band (usually a broad 
shoulder) at about 1145cm'1 exists in HPCV-containing apatites and in several non- 
apatitic phosphates such as OCP (1138 cm '1), or TCP (1144 cm '1)86. The bands at 
1110 cm ' 1 and 1125 cm ' 1 do not tend to appear clearly in the spectra of well- 
crystallised synthetic apatites and were considered to be representative of phosphate 
environments in poorly crystalline apatitic calcium phosphates86. For instance, a 
clear band can be observed at 1125 cm ' 1 in the spectrum of the mineral of young
O/Tenamel , while a shoulder would indicate lability of crystals ions.
The second component, that is generally the most intense, is seen at 1085-970 cm '1, 
with two main maxima at 1020 cm ' 1 and 1030 cm ' 1 86. These two bands are present 
in most phosphate salts with an apatitic or non-apatitic structure. The 1030 cm"1 band 
was reported to occur in stoichiometric apatite whereas the 1 0 2 0  cm ' 1 band was 
dominant in non-stoichiometric apatites containing HPO 4 ' or CO 3 2' ions, and was 
interpreted as an indication of the persistence of vacancies. A splitting of the 1030 
cm ' 1 band was reported to reveal a less stable environment of the phosphate ions.
3 * r * * 1V4(PC>4 ’) region: This region (500-650 c m ' ) appears more complex than the V3 
region86. It is composed of five major apatitic bands46 at 534, 560, 578-585 cm '1, and 
two bands at 600-625 cm '1, including a faint one and one generally encountered at 
617 cm '1. The absence of splitting on the 560 cm ' 1 band was reported to be 
characteristic of amorphous calcium phosphates80, and in early calcific deposits this 
band presents an abnormal low intensity46. In addition to H P042', the mineral can 
also exhibit a non-apatitic PO43' environment. The non-apatitic phosphate 
environment detected in poorly crystalline apatite was reported to be characterised 
by two bands near 560 cm"1 and 610 cm’ 1 46. The concentration of non-apatitic 
phosphate ions was also reported to increase during the early stages of mineralisation 
of calcified cartilage, but then to decrease as the mineral content steadily rose until 
full mineralisation was achieved98.
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JCarbonate ions (CCb
Carbonate ions are the third most abundant constituents of bone and tooth mineral 
after calcium and phosphate and were reported to play an important role in several of 
the biological processes concerned with calcification99,100. It has been reported101 that 
as much as 22% carbonate (about three CO32' ions per unit cell) can be incorporated 
into the structure of carbonate-hydroxyapatite. Infrared spectroscopy is more 
sensitive than X-ray diffraction for the detection of calcium carbonate salts102. 
Carbonate ions possess four vibrational modes (V 1.V 4), three of which are observed in 
the infrared spectrum92: the V2(C0 3 2’) and V3(C0 3 2') vibrational modes are observed 
in the infrared spectra while the V4(C0 3 2') bands have very low intensity and are
Q7seldom seen in the infrared spectrum . Only V2 and V3 have really been extensively 
described in the literature (see below for more details). The vi(C0 3 2') region is not 
observable as this region is obscured by phosphate absorption bands97. Additionally, 
although the region occurs in a region un-obscured by strong phosphate 
absorption bands, only very weak IR carbonate bands arise and are barely noticeable 
in apatites with average carbonate content97. The V4  region has thus been mostly
1 0 9  1 0 9roughly described in the literature ’ , however some authors gave a proper
assignment of the bands97.
Carbonate ions can occupy two different sites in apatitic structures (A and B sites). 
The carbonate in apatites can be located in the monovalent anionic A sites which are 
located in channels along the c-axis of the hexagonal structure (and which are 
generally occupied by Cl" 104, or OH" 105), and mainly on trivalent anionic B sites (on 
which the phosphate ions, P0 4 3", are located)106. Carbonate located in monovalent A 
sites have been reported to represent only a minority of the carbonate present in 
apatitic structures, although no quantitative data is available107. However, the charge 
balance due to these substitutions involves complex vacancy formations or cationic 
replacements108,109. Additionally the occurrence of different environments of 
carbonate ions in apatites was reported to result also from the orientation of the ion 
in the site104 and with the heterogeneities of distribution in the solid106,110. Carbonate 
ions associated with apatites have been observed in bones111, and also in fully 
mineralised dental enamel105. Well-crystallised apatite samples are reported to show 
two sets of bands corresponding to the A (1545, 1450 and 880-890 cm '1) and B
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(1465, 1412 and 873 cm '1) types of carbonate ions101,112' 114. These reported results 
are slightly different than the ones for bones, although these two sets of bands have 
been reported not to fully account for the overall spectra115, as discussed below.
^i(C032') region: No assignment was reported in the literature for this region. It is 
usually almost obscured by the intense ^ (P O ^ b a n d s92.
v2 (C 032') region: The out-of-plane bend P2(C 032') FTIR domain (800-900 cm '1) is 
not obscured by the organic matrix or by the phosphate absorption bands110, and it 
shows three carbonate bands observed in apatite and bone mineral at 879, 871, 8 6 8 -
1 110 878 6 6  cm' , which may be assigned to three different locations of the ion in the 
mineral. The second distinct peak at 879 cm ' 1 has been assigned to type A 
carbonate110; the most intense band around 871 cm ' 1 (866-873 cm ' 1) 116 has been 
assigned to type B carbonate46,110; the shoulder at 8 6 6  cm ' 1 (C band corresponding to 
carbonates in unstable locations) was assigned to loosely structured carbonate in 
either an amorphous calcium phosphate-like or surface environment111 and was later 
hypothesised to be due to labile carbonates species in non-apatitic environments110. 
The occupancy of the v2 A sites is thus considered to occur competitively between 
the OH' and C 0 3 ' groups at the interface of growing crystal, while the occupancy of 
the B sites depends on competition between P 0 4 2', HPO 4 ' and C 0 32' 87. The intensity 
ratio of the 879 cm ' 1 and 871 cm ' 1 bands was reported to remain constant in bone of 
any age, and the intensity ratio of the 8 6 6  cm ' 1 band to the 871 cm ' 1 band, was found 
to vary directly and decrease with the age of the mineral87.
p3(C 032') region: The p3(C 032') infrared region shows peaks in the region of 1650- 
1300 cm ' 1 116. However, this region is sometimes obscured by several absorption 
bands of proteins (CH, amide II, COO') or glycosaminoglycans (NH)117. The v3 
vibrational mode is split into three main peaks centred around 1638, 1453 and 1412 
cm ' 1 and the distribution of the carbonate v3 sites depends on the maturation and 
formation of apatite crystals. The occupancy of the v3 sites depends on competition 
between the phosphate and carbonate ions115,116. The position of peaks around 1410- 
1420 cm ' 1 and 1470 cm ' 1 is usually consistent with that of carbonate ions in 
amorphous calcium phosphate110,111,118; while peaks around 1415, 1447 and -1492 
cm ' 1 are characteristic of carbonate ions occupying two anionic sites of the apatitic
135
structure (trivalent anionic sites or type B carbonate; monovalent anionic sites or 
typeA)108’119.
4^(C0 3 2") region: Carbonate apatites show at least five weak bands in the Va 
domain97: 757, 740, 718, 692 and 670 cm'1. The spectrum of pure type A carbonate 
shows two weak bands97 at 766 and 675 cm'1. It was reported that the bands in this 
region are probably due to the presence of ions other than carbonate (such as OH' or 
P2 O74' that have infrared absorptions in the same region), combinations or overtone 
bands of phosphate groups or to calcium carbonate impurities. Thus, the band at 740
1 9cm' can be assigned to both OH' ions and CO3 ' ions.
Hydroxide ions fOHT:
Crystalline apatites generally show OH' bands in their infrared spectra (OH stretch 
around 3570 cm'1, OH libration at 630 cm'1 and OH translation at 343 cm'1)96,111, 
although some infrared data indicated that both native rat bone mineral and also 
synthetic apatites formed at physiological pH were shown to have a high degree of  
structural imperfection. These were extensively deficient in hydroxide ion content. It 
was thus hypothesised that hydroxides ions were sensitive to the presence of 
impurities that distort the trigonal symmetry of the OH' position such as a small 
amount of carbonate that would have a depressing effect on the intensity o f the OH'
17 •bands and it was reported that if some OH ions were present, they would exist m 
varied local atomic environment, resulting in a broadening and marked decrease in 
intensity o f their infrared absorption bands111. The detection of hydroxide ions in 
infrared spectra was also reported to depend on the sample preparation methodology 
employed. For example, it has been reported that when low-temperature and non- 
aqueous deproteinisation is used to decrease the organic matrix background spectrum
by isolating the CaP crystals of both young and mature bone mineral, as well as the
120 121 1 early deposits of enamel mineral ’ , no OH bands (stretching mode at 3570 cm'
or the librational mode band at 630 cm'1) were observed in the corresponding FTIR
spectra122. These reported observations do not however preclude the presence o f OH'
ions as hydrogen bonding with adsorbed water molecules could reduce the intensity
(extreme broadening) of infrared OH bands123. Furthermore, some convincing
evidence that OH groups can be present although they do not give rise to OH bands
in the infrared spectrum was reported124. It was assumed that a similar absence of
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OH peaks in the spectrum of bone does not preclude the presence of hydroxide
i nions . The failure to detect OH bands by FTIR has also been reported to represent an 
actual and extensive OH' ion deficiency in the mineral111,125. It is interesting to note 
that OH' or halide deficiencies have been reported not to be that uncommon in 
apatites126. This was also considered to indicate an inorganic apatite-like mineral 
phase with cationic and/or anionic vacancies111. Indeed, it was reported that the 
presence of type A and B carbonates in bone apatite may contribute to the low
111 197concentration or even the absence of hydroxyl ions in bone mineral ’ . In contrast,
the spectra from hydroxyapatite that has been heated (it is usually the case for 
coatings of hydroxyapatite with implant material applications) show very acute OH 
bands51.
3.2.6 Raman spectroscopy
3.2.6.1 Theory:
Raman spectroscopy has become an important and widely used method for studying 
macromolecules128 since the first experimental observation of Raman scattering in 
1928 by C.V. Raman and his associates. They discovered that the wavelength of a 
small fraction of the radiation scattered by certain molecules differs from that of the 
incident beam and that the shifts in wavelength depend upon the chemical structure 
of the molecules responsible for the scattering. Raman spectroscopy does not involve 
absorption or emission from the energy levels directly, but rather implicates 
intermediate virtual energy states. Unlike in infrared spectroscopy, a vibrational 
mode is Raman active when there is a change in the polarisability during the 
vibration. A dispersive Raman spectrometer consists of a source of monochromatic 
radiation (represented in red in figure 3.4), a dispersing system and a detection 
device. The scattered radiation (including both Rayleigh and Raman scattering) is 
collected at 90° with respect to the incident radiation (see figure 3.4 below).
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Figure 3.4: Dispersive Raman (Renishaw, Wotton-under-Edge, UK) experimental 
set-up (simplified)
At the very most, the intensities of the Raman scattered light is low (0.001% of the 
laser source intensity) and as a consequence the Raman line detection and 
measurement can be difficult. However, Raman spectroscopy is applicable to a wide 
variety of samples yielding high levels of structural information. The optical 
microscope of the Raman system used for these studies provides a spatial resolution
2 129 1of ~l/rm and this system also provides a good spectral resolution (ca. 2  cm' ) 
across a wide range, with full wavenumber scans (lOO-TOOOcm'1). The collection of 
Raman spectra, (using a dispersive instrument), from most polymers, including some 
biological ones, is usually precluded because of the presence of traces of strongly 
fluorescent impurities. This represents the major drawback of Raman spectroscopy. 
However, it can usually be overcome by the use of a “Fourier-transform” in Fourier- 
transform- (FT-) Raman instruments130. FT-Raman spectrometers are now starting to 
be superseded by monochromators (dispersive instruments) equipped with CCD 
detectors (charge coupled device array detector, which has the characteristic of low 
noise and high detection efficiency) and low power lasers, which can thus also allow 
measurements of certain polymers, including biological ones. For further insight into 
the theory, the reader is invited to refer to publications by Skoog et al and Griffiths 
and Urban56,131.
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3.2.6.2 Applications related to this study:
3.2.6.2.1 Analysis o f  model compounds:
The application of Raman spectroscopy to the study of biological systems (amino 
acids, peptides and proteins) has been extensively reported in the literature over the
1 T 9  1 T Tlast few decades ’ . More particularly, the analysis of proteins of relevance to
these studies, such as poly-L-lysine134' 137, lysosyme138' 142 and reconstituted 
collagen141, can be found. In addition, Raman spectroscopy of an amino acid of 
interest (lysine) has been reported143. The use of this technique to study tissue has 
been an area of particular interest, frequently using Raman microscopy144 and a near- 
infrared laser to avoid sample damage145,146. Human skin (mainly constituted of 
collagen) has also been the subject of a study using FT-Raman, which resulted in a 
method to assess the changes induced by chemicals and drugs64. All this is of direct 
relevance to our study, as it has already been emphasised in section 3.2.5.2.1 of this 
chapter.
3.2.6.2.2 Analysis o f  the calcification o f  valve tissue:
The use of FT-Raman has been reported in the literature for the study of vascular 
tissue components145,147’148, in particular elastin, collagen, lipids and calcium 
deposits. One of the main advantages of the FT-Raman technique over conventional 
dispersive Raman spectroscopy is the use of 1064 nm near-infrared excitation, which 
precludes electronic absorption of the excitation radiation, leading to the elimination 
of fluorescence, which is usually a major problem in Raman spectroscopy when 
analysing biomaterials. However, over the past decade, many authors pointed out 
some limitations of FT-Raman spectroscopy and stated that fluorescence may still 
cause problems149. This is especially the case when analysing some (but not all150) 
calcium minerals such as dicalcium phophate dihydrate and hydroxyapatite150. 
Nevertheless, human coronary artery composition and atherosclerotic calcified 
plaques were successfully identified using near-infrared FT-Raman 
spectroscopy151,152, where a small satellite band in the calcified plaque spectrum at 
1070 cm ' 1 was attributed to carbonated apatite. Raman spectroscopy was also used 
for the analysis of kidney stones, where hydroxyapatite is the most common 
component47.
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The (dispersive) Raman spectra of the cortex of the ox tibia have been obtained by
reflection from the surface of a whole piece of ox tibia, which was defatted with
acetone and chloroform and dried141. The resulting Raman lines of the calcified
tissue originated from the phosphate modes (955 cm"1), and from the inorganic
carbonate bands (1451 cm"1 and 1417 cm '1). This led to the suggestion therefore that
the strong Raman scattering associated with calcium phosphate would allow the
possible detection of calcium phosphate in normal and pathological calcified tissue.
Many Raman spectra of various inorganic salts were also obtained by conventional
1Raman spectroscopy and reported .
The dispersive Raman spectra of hydroxyapatite (HAP)154,155, /5-tricalcium phosphate 
(/5-TCP) 156 and other calcium phosphates have also been reported79,157,158 and appear 
similar, although minor differences exist. For instance, due to their structural 
differences, Raman scattering was reported to successfully differentiate between 
HAP and /5-TCP, not only through the detection of vibrational modes associated with 
the OH" group of hydroxyapatite but also by comparing the bands arising from 
internal tetrahedral159 PO42" modes160. In HAP the V2 and V4  bands are separated by 
-55 cm '1, while with /5-TCP the gap is o f -120 cm"1. This represents a characteristic 
spectral feature that can easily be used to distinguish between /5-TCP and HAP. The 
spectra of octacalcium phosphate (OCP) are quite similar to the ones of apatite 
structure and a complete assignment of the Raman bands, obtained with a dispersive 
Raman instrument, can be found in the literature94.
3.2.6.23 Major vibrational spectroscopic domains o f  inorganic CaP-rich phases:
Because the calcific deposits, found in calcified human explanted valves, are 
composed of calcium phosphates closely related to physiologic bone mineral (see 
chapter 1 in sections 1.4.2 and 1.7) and also because no review yet exists, the 
following paragraphs present the major vibrational spectroscopic domains 
encountered in the analysis of calcific deposits, bone and enamel by Raman 
spectroscopy.
Phosphate (PQ43') ions:
The most interesting portions of the spectra of calcium phosphate minerals are the 
phosphate bands, with the four modes being active in Raman spectroscopy.
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I^(P0 43‘) region: A strong ^i(P043') band, corresponding to the symmetric stretching 
vibration of the P-0 bonds (Ai symmetry), occurs as a single Raman band at 960 cm' 
1 and is exhibited by hydroxyapaptite and some other calcium phosphate minerals, 
although it occurs as two peaks and a shoulder with /5-TCP160.
P2(P043') region: ^ (P 043') band corresponding to the doubly degenerate O-P-O 
bending mode (E symmetry) is observed at 435 cm'1 (400-490 cm'1 for HAP) and 
(370-505 cm'1 for /5-TCP).
^ (P 0 4 ') region: A ^ (P 0 4 ') band arises from the triply degenerate T2 mode 
involving anti-symmetric P-0 stretching and also P motion at 1073 cm'1 (1020-1095 
cm'1).
p4(P043') region: A p4(P043') band due to the triply degenerate T2 modes o f mainly 
O-P-O bending character is seen at 590 cm'1 (570-625 cm'1 for HAP) and (530-645 
cm'1 for/5-TCP160).
These internal P 043' bands are centred at frequencies, between 20 to 25 cm'1, higher 
than those of the corresponding free-tetrahedron normal modes. The corresponding 
values for the normal Raman mode frequencies of the phosphate tetrahedron 
obtained in aqueous solution are the following: V \  938 cm'1, V2  420 cm'1, V3  1017 cm' 
\  V4 567 cm'1 161. In addition to the internal P 043' bands, several peaks are detected
1 O x  *3between 50 and 320 cm ', which are due to translational modes o f the Ca and P 0 4 ' 
sub-lattices and rotational modes of the P 043' group154,162. The bond-stretching mode 
associated with the OH' group was also reported in highly crystalline samples 
(difficult to detect in samples with poor crystallinity160) as a sharp peak around 3576 
cm'1, whereas the translational modes associated with the OH' sub-lattice yielded a 
Raman peak at 335 cm'1 154,155. The detection of this latter peak above the noise level 
is however difficult in samples with poor crystallinity160. The resolution o f the 
p4(P04 ') band was reported as being used to assess the degree o f crystallinity o f
no 1 ^3calcific crystals ’ but the relationship was complex and did not always correlate 
with indices o f crystallinity given by the line-broadening from the XRD data80 o f the 
same crystals. The p4(P04 ') domain has been previously shown to be suitable for 
deconvolution procedures46, with three main bands around 560, 575 and 600 cm'1 
assigned to phosphate ions in an apatitic configuration and environment84, a strong 
shoulder at 610 cm'1 that was assigned to a labile non-apatitic environment of
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phosphate ions, which tend to disappear during maturation of the mineral phase in- 
vivo46, and another shoulder of weak intensity at 620 cm ' 1 attributed to phosphate
QOions in an extremely labile environment .
Carbonate (C 0 3 ions:
Carbonate theoretically possesses four vibrational modes (V 1.V 4), only two of which 
(v i(C 032' )and V4(C0 32')) have strong vibrational bands in the Raman spectra92.
Specific features of CaP-rich structures analysed by Raman spectroscopy:
Other specific features can also be found in the Raman spectra of CaP-containing 
crystals. For example, a band at 545 cm ' 1 is found to be present in all HPO4- 
containing apatites as well as in octacalcium phosphate (OCP). Additionally, a band 
at 530 cm-1 can be found in the early stages of mineralisation of both bone and 
calcified cartilage46,98 and appears to be related to the 620 cm ' 1 band. It has also been 
found in dicalcium phosphate dihydrate (DCPD) and OCP but not in HPO4 -
. . . 164containing apatites .
3.2.7 The complementarity of FTIR and Raman spectroscopy
Raman and infrared are said to be complementary techniques and the two are usually 
necessary to completely measure the vibrational modes of molecules. The two forms 
of spectroscopy arise from different physical processes governed by specific 
selection rules. The information content for the two is a function of the molecular 
symmetry and, in a broad sense, of polarity.
3.2.8 Nuclear magnetic resonance (NMR) spectroscopy
3.2.8.1 Theory:
Since the observation of NMR signals in 1945, the technique has evolved to become 
an analytical tool that is used regularly for structural analysis. Although the 
applications have changed, the basic principles remain the same. The presence of a 
nuclear spin (i) in some nuclei leads to a characteristic magnetic moment. When an 
external magnetic field of sufficient strength is applied to atomic nuclei the 
interaction of the magnetic field leads to the nuclei orientating themselves in 2 i + 1 
ways. Atomic nuclei can have a spin number of 1/2, 1, 3/2, etc. They both have a 
spin value of V2 and consequently can orientate in one of two ways, one of higher
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energy state than the other. The difference in the energy is given by AE=h y Bo/27T, 
where h is the Planck constant, 7  is the magnetogyric radiation and Bo is the applied 
magnetic field. Boltzman distribution governs the distribution of nuclei in the two 
energy states. A radio frequency is applied to the nuclei and when the radio 
frequency matches that at which the nuclei magnetic fields are processing, nuclei 
from the lower energy state are excited to the higher state. This promotion in energy 
level leads to some absorption of the applied radio frequency, which can be 
measured. By varying the radio frequency of the magnetic field, a receiving coil can 
measure absorption against frequency.
The NMR instrumentation consists of a spinning tube containing the sample, placed 
between the receiver coils to allow measurement of absorption. Field sweep and 
Shim coils surround the transmitter coils, all of which are ultimately surrounded by a 
super-conducting magnet (cooled by liquid nitrogen). In this study, FT-NMR was 
used, which involves the application of a single pulse of the radio frequency that 
encompasses the range being studied. The pulse disrupts the precession of the nuclei 
and oscillation in the orientation of the magnetic field occurs. This is free induction 
decay (FID), which is recorded during the acquisition period to build up Fourier 
transform, which is in the time domain. The data are then converted into the 
frequency domain. Commonly in NMR spectroscopy, when the signal to noise ratio 
is not good, the FID signal is multiplied by an exponentially decaying function in 
order to remove the noise at longer acquisition times. However, this post-acquisition 
treatment of the data also tends to increase the rate at which the signal decays, thus 
increasing the line width of the signal. Hence this type of data treatment is referred to 
as line broadening. A profile of the coupling within the sample can also be achieved. 
By pulsing the sample with a radio frequency in a single experiment, the data are 
then displayed in a contour plot called a COSY spectrum. For further insight into the 
theory of NMR, the reader is invited to refer to publications by Nordon et a l165, 
Fifield and Kealey166 and Abraham et al167.
3.2.8.2 Applications related to this study:
NMR spectroscopy is a widely used analytical technique for structural elucidation 
and identification of chemical species in the analysis of many different materials 
including organic chemicals, inorganic complexes and large biological molecules165.
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A few reports found in the literature are o f particular relevance to the work 
undergone in this thesis and the major findings are depicted thereafter.
An early *H NMR study of commercial aqueous solution of glutaraldehyde and of 
freeze-dried glutaraldehyde re-dissolved in deuterated water, demonstrated that 
glutaraldehyde is largely polymeric and contains significant amounts o f a,(3- 
unsaturated aldehydes resulting from the loss of water from aldol condensation 
adducts168. Another ]H NMR study of commercial aqueous solution of 
glutaraldehyde by Hardy et al169 showed that glutaraldehyde consists of its monomer 
and of its hydrates and acetal-like structures, but not unsaturated polymer as 
suggested in the previous study. The effect of temperature on various commercial 
glutaraldehyde solutions was also assessed by lH  NMR170 and the glutaraldehyde 
was reported to consists mostly of monomeric glutaraldehyde, hydrates and 
oligomers of hydrates of glutaraldehyde, but of only a small amount o f polymeric 
forms as suggested by Richards and Knowles168. Whipple and Ruta171 reported both 
!H and 13C NMR of a purified 25% v/v glutaraldehyde solution, which was shown to 
consists primarily o f the cyclic hemiacetal, in equilibrium with monomeric 
glutaraldehyde and linear hemihydrate and the dihydrate, while higher order 
oligomers were reported to contribute very little to the equilibrium mixture. Monsan 
et al68 analysed glutaraldehyde solution in deuterated chloroform or carbon 
tetrachloride and concluded that glutaraldehyde consists essentially o f unstable 
hydrates o f glutaraldehyde, but apparently no significant amounts o f o;/3-unsaturated 
aldehydes. The most recent ]H NMR study of glutaraldehyde was reported by 
Holmquist and Lewin172, who failed to characterise five isolated fractions obtained 
after chromatography of glutaraldehyde at pH 8. Therefore it appears that the actual 
content o f aqueous glutaraldehyde solutions has not yet been elucidated, as 
concluded from the review chapter on glutaraldehyde (see chapter 2).
The study of the reaction products of glutaraldehyde with proteins was also 
investigated by both !H and 13C NMR, but it also lead to many contradictory results 
and it too still need to be further elucidated. Monsan et al68 analysed the products of  
the reaction of crotonaldehyde with various amino acids by !H NMR and postulated 
the formation of aldol condensation products stabilised by resonance with the 
ethylenic bonds, but which did not undergo Michael-type addition reactions. Hardy 
et al69’173 investigated the reactions o f glutaraldehyde with the model compounds
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(that are of relevance to these studies) 6 -aminohexanoic acid and N-acetyl-L-lysine 
in unbuffered aqueous solution, but also with protein such as ovalbumin by 'H 
NMR, from which they suggested the presence of reaction products of quaternary 
pyridinium type. They later isolated and characterised by ]H and 13C NMR one of 
these reaction products of quaternary pyridinium type, baptised anabilysine174,175. 
The latest reported data from 1 C NMR, recently evidenced the formation of an 
ethylenic double bond in the chitosan-glutaraldehyde interaction66.
3.2.9 Electrospray ionisation mass spectrometry (ESI-MS)
3.2.9.1 Theory:
In the electrospray ionisation process, a solution of the analyte (sample) is slowly 
pumped through a short piece of capillary tubing. This narrow-bore metal capillary is 
held at approximately 3 kV relative to a counter electrode. The strong electric field at 
the end of the capillary pulls the solution into a Taylor cone and at the tip of the cone 
the solution is nebulised into small charged droplets. As the charged droplets travel 
towards the counter electrode, they pass through a drying gas that aids evaporation of 
the solvent and decreases the size of these charged droplets until they become 
unstable and explode (Coulomb explosion) to form a number of smaller droplets 
with greater charge density. Finally, the field due to the excess charge is large 
enough to cause desorption of an ionised sample molecule to ultimately yield 
molecular ions under atmospheric pressure. The ions are passed through a skimmer 
arrangement and sucked into the vacuum chamber through a small aperture or 
another piece of capillary tubing (which is usually heated to ensure that the ions are 
completely desolvated) for mass analysis. The mass spectrometer determines the 
molecular weight of compounds by separating molecular ions according to their 
mass-to-charge ratio (m/z). This is achieved by inducing either the loss or gain of a 
charge to generate the ions, which are separated according to their m/z and finally 
detected. Electrospray is a very mild ionisation technique, resulting in only limited 
fragmentation of large and thermally fragile biomolecules. A main feature o f 
electrospray ionisation is that the molecular ions recorded are multiply charged (e.g. 
(M+nH)n+ in the positive ion mode). On average, one charge is added per 1000 Da in 
mass. Therefore, an ion of mass 10000 Da, which carried 10 charges would actually 
be recorded at m/z 1000. Consequently the m/z range covered by the mass analyser 
can be smaller than with other ionisation methods176. This means that the m/z values
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are small enough to make them detectable with a quadrupole instrument with a mass 
range of 1500 or less. For further insight into the theory, the reader is invited to refer 
to the publication by Skoog et al1 .
3.2.9.2 Applications related to this study:
1 78ESI-MS is used routinely in the biomedical sciences and it has become one of the 
most important techniques for analysing biomolecules such as peptides, proteins and
1 7Q 1 80oligonucleotides ’ . The only analysis of glutaraldehyde and both glutaraldehyde-
treated amino acid and tissue, by reverse phase high performance liquid
chromatography coupled with ESI-MS, was recently reported by colleagues from 
181Sheffield University . Their analysis of hydrolysates of glutaraldehyde-treated 
pericardium tissue revealed only two peaks (m/z 421 and 411 respectively assigned 
to anabilysine and a di-c^/3 unsaturated aldehyde product of glutaraldehyde via a 
Michael-type addition. Their mass spectral data obtained from reaction of 
glutaraldehyde with 6 -aminohexanoic acid (an amino acid relevant to these studies) 
showed many peaks, from which only nine have been assigned to a compound and 
their corresponding structures given, although a larger panel of techniques than 
solely ESI-MS was used. Nevertheless, apart from this study, a successful 
elucidation of other molecular structures, in relation to glutaraldehyde in solution or 
glutaraldehyde-treated model compounds, from their study by ESI-MS have not yet 
been reported.
However, mass spectrometric analysis of glutaraldehyde has been carried out in the
£8past by double-focusing mass spectrometry , from which only two molecular 
structures with m/z 182 and m/z 264 were identified, corresponding respectively to 
the following formula C 10H 14O3 (aldol condensation dimer product) and C 15H20O4 
(aldol condensation trimer product). Alkaline solutions of glutaraldehyde have been 
also analysed by chemical-ionisation using a gas chromatograph-mass spectrometer
71 79system ’ . Trioxane-type glutaraldehyde oligomers (m/z 318, m/z 518 
corresponding respectively to trimer and pentamer) have thus been assigned, along 
with the characterisation of dimer (m/z 183) and trimer (m/z 264) produced by aldol 
condensation of glutaraldehyde molecules followed by dehydration.
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3.2.10 MALDI-TOF MS (matrix assisted laser desorption ionisation time of 
flight mass spectrometry)
3.2.10.1 Theory:
MALDI-TOF mass spectrometry was developed in the late 1980s182. The sample 
solution (analyte) is incorporated into a solid organic matrix to co-crystallise and the 
mixture is placed on a sample holder that is irradiated with UV laser pulses (e.g. N2 
laser, \=337 nm, pulse width 5 ns). The matrix strongly absorbs the laser radiation, 
thus the laser energy is absorbed by the matrix and then transferred to the analyte. 
This absorption by the matrix controls the energy subsequently deposited in the 
sample molecules and it results in the vaporisation of both the matrix and the 
embedded sample, which thus become desorbed and ionised. The charged molecules 
are then attracted into the TOF mass analyser. Although MALDI is considered to be 
a soft ionisation technique, a substantial amount of energy is involved. The analysis 
of small molecules is usually limited to Mw> 500 Da, because the matrix also tends 
to decompose upon absorption of the laser radiation. Thus MALDI is generally well- 
suited and applied to the analysis of medium to high molecular weight compounds 
such as proteins, although it has been reported to be suitable for the quantitative
1 8Tanalysis of low molecular weight antibiotics with a Mw of less than 500 Da . The 
major disadvantage of MALDI MS is therefore background interference from the 
matrix. It has been reported that one of the most important aspects of MALDI MS is
1 O A 10cthe preparation of a good, homogeneous sample ’ . Thus, it is important to select
the matrix carefully for a given compound because the intensity of the resulting 
signal varies greatly with the matrix. This was not a significant problem in this study 
of glutaraldehyde-treated proteins, which are mostly outside this critical mass range. 
However, when analysing glutaraldehyde in solution, care was taken when assigning 
peaks belonging to the matrix and those belonging to the sample since the molecular 
weight of the monomeric glutaraldehyde molecule as a simple di-aldehyde is 1 0 0 .
The MALDI technique involves pulsed ionisation, making it suited for time-of-flight 
mass analysis. In a time-of-flight (TOF) mass spectrometer, positive ions are 
produced by bombardment of the sample with brief pulses of electrons, secondary 
ions or laser-generated photons. The ions produced are then accelerated into a field- 
free drift analyser tube by an electric field pulse (103- 104 V). Based on the 
relationship between mass and velocity at a given kinetic energy, the instrument
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measures the time taken by each ion of specific mass to travel the length of the field-
1 8^free analyser tube . The resolution is related to the duration of the ionisation pulse, 
to the initial energy distribution of the ions and to the precision with which the time- 
of-flight can be measured. However, a reflectron can also be used to increase the 
resolution achieved, by compensating for kinetic energy distributions. In the 
reflectron (acting as an electrostatic mirror), ions with higher velocities (i.e. higher 
energies) will penetrate deeper into the zone of the electric field than low energy 
ions, which allow ions of the same mass with different energy distributions to be 
collected at the same time. The separation of ions is thus based on their relative mass 
and occurs during their transit to the detector located at the end of the tube, with the 
lighter ions reaching the detector before the heavier ones177. For further insight into 
the theory, the reader is invited to refer to the publication by Skoog et al177.
3.2.10.2 Applications related to this study:
Analysis of proteins and non-covalent protein complexes by MALDI-TOF MS have
1 87  1 88been reported ’ . However, because the matrix environment and laser irradiation
tend to usually dissociate most non-covalent complexes, chemical cross-linking have 
been successfully investigated to solve this problem189,190. Nevertheless, the cross- 
linking agent (usually glutaraldehyde) was reported to contribute in complicating the 
analyses of the masses obtained, especially when highly multimeric proteins are 
studied. By investigating this matter, proteins of known multimericity as standards 
(for example lysosyme, which is of direct relevance for this study) were analysed by 
MALDI-TOF MS to determine the effects o f glutaraldehyde and protein 
concentration on the stabilisation, aggregation and mass determination of the 
complexes191. Horse heart cytochrome C, (which is also a protein of interest in the 
scope of these studies), reacted with glutaraldehyde and analysed by TOF mass
1 Q ") 1 Q 'Jspectrometry was reported by Ohno and Kurusu ’ . These authors were interested
in the electron transfer of the glutaraldehyde-treated protein in poly(ethylene oxide) 
oligomers rather than in the actual cross-linking issue associated with the protein and 
glutaraldehyde, which is of direct interest in these studies. Therefore, no actual 
conclusions were drawn regarding the resulting cross-linking of the protein with 
glutaraldehyde. Furthermore, no analysis of glutaraldehyde by MALDI mass 
spectrometry has been reported so far.
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Additionally, the direct analysis of thin layer chromatography (TLC) by MALDI MS 
was previously reported194’195, however their preparation methodology was different 
from the one reported in this study (primarily results can be found in appendix II), 
and the transfer was accomplished by pressing the matrix onto a previously wetted 
(spraying o f extraction solution) TLC plate. The method of matrix deposition into a 
TLC plate by electrospay deposition, that is used in this study, was developed by 
others from Sheffield Hallam Univeristy196 and was found suitable to allow 
chromatographic information to be obtained from a TLC plate analysed by MALDI- 
TOF-MS197. The application of such a methodology on the samples used in this 
thesis is presently also unreported.
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Chapter 4
4 Investigation of the behaviour of glutaraldehyde in 
solution, at various pH values.
Abstract
Objectives: The mechanism of glutaraldehyde fixation is complex and incompletely 
understood. A potent reason is that the behaviour of glutaraldehyde in aqueous 
solution and the exact content of commonly used glutaraldehyde solutions are 
presently unknown. The objectives were to investigate the behaviour of 
glutaraldehyde in solution at various pH values to further our understanding of the 
nature of this compound and to determine the structures present in aqueous solution 
of glutaraldehyde. Additionally, the application of the techniques used for this study 
for the analysis of glutaraldehyde over a large range of pH remains unreported to 
date.
Methods: Aqueous glutaraldehyde solutions at various pH values (pH 1-11 range) 
were subjected to analysis by electrospray ionisation (ESI-MS) and matrix assisted 
laser desorption ionisation-time of flight (MALDI-TOF MS) mass spectrometry, 
nuclear magnetic resonance (NMR), Fourier-transform infrared (FTIR) and Raman 
spectroscopy.
Results: The common structures found at all pH range in relative quantity were 
mostly the glutaraldehyde hydrates, hemiacetal, acetal cyclic polymer form, mono- 
and di-acid form of glutaraldehyde, various trioxane-type glutaraldehyde oligomers, 
dimers produced by aldol condensation of two glutaraldehyde molecules and their 
cyclic acetal when applicable and oligomers of glutaraldehyde consisting of the a- 
oxypyran ring. The aldol condensation and aldol/Michael addition products,
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however, were found in larger quantity at extreme pH values (pH 1 and 11) along 
with higher polymer chains of some of the above-mentioned oligomeric molecules 
(see appendix III for details).
Conclusion: Glutaraldehyde in solution has been shown to be strongly pH- 
dependent. It is hypothesised that glutaraldehyde, at all analysed pH values, contains 
some similar structures (likely in their hydrated forms) but under extreme pH 
conditions, certain species, containing unsaturated groups, become more prevalent. 
Contrary to a widely held belief, monomeric glutaraldehyde is therefore not the 
major reactive species found in unbuffered commercial glutaraldehyde solutions, 
and commercial glutaraldehyde solution thus contain a complex mixture of 
structures. It is hoped that these results would provide a better insight into the 
chemistry of glutaraldehyde and clarify the existing knowledge. It is believed that an 
understanding of the behaviour of glutaraldehyde in solution is essential if the 
interaction of glutaraldehyde with proteins, and more so with implants such as 
bioprosthetic heart valves, is to be predicted.
4.1 Introduction
Glutaraldehyde is an important chemical reagent used routinely in many fields such 
as the biomedical field where it is extensively used as a cross-linking agent for the 
preparation of bioprostheses, immobilising enzymes, etc. Glutaraldehyde can react 
readily with a large number of the amino groups available in proteins and can span 
various distances between tissue protein molecules. However, the specific chemistry 
of the reaction of glutaraldehyde with proteins is still not fully understood. One area 
of its chemistry that is still at the centre of much debate is the nature of 
glutaraldehyde in solution. The extensive review of the literature that can be found 
in the chapter 2  of this thesis indicates that there is still much disagreement as to the 
structures present in solutions of glutaraldehyde. Aqueous solutions of 
glutaraldehyde were shown by different authors to mostly contain a complex mixture 
of free aldehydes, mono and di-hydrates, monomeric and polymeric cyclic 
hemiacetals and various unsaturated condensation products (see chapter 2  and cross- 
referenced structures found in appendix III). Others attempted to elucidate the exact 
chemical nature of polyglutaraldehyde in solutions by UV, IR and 13C NMR
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spectroscopy, but the nature could not be decided and their results only indicated a 
mixture of oligomers of up to six glutaraldehyde units1. Aqueous solutions of 
glutaraldehyde are thus complex, capable of undergoing many types of reactions. All 
such reactions, that glutaraldehyde can undergo, may contribute to variation in the 
quality of fixation. More fundamental studies on the chemistry of cross-linking using 
glutaraldehyde are therefore needed to elucidate the nature of reactions. This may 
also aid our understanding of some of the problems presently believed to be due to 
this reagent, such as the causes of failure of tissue valves including their 
calcification.
Thus, the aim of this part of the study was to determine the structures present in 
aqueous solutions of glutaraldehyde, using mass spectrometry (ESI-MS, MALDI- 
TOF MS), NMR, FTIR-ATR and Raman spectroscopy, to provide a better insight 
into the chemistry of glutaraldehyde on its own and to clarify the existing 
knowledge. An understanding of the behaviour of glutaraldehyde in solution is 
essential if the interaction of glutaraldehyde with bioprosthetic heart valves is to be 
predicted.
4.2 Materials and methods
4.2.1 Materials
All chemicals and consumables used were of the best commercially available grade.
From BDH, UK: Glutaraldehyde 25%v/v EM grade, potassium dihydrogen 
orthophosphate.
From Sigma-Aldrich, UK: Glutaric acid, methanol, glacial acetic acid, sinapinic acid 
(3,5-dimethoxy-4-hydroxycinnamic acid), 2,5-dihydroxybenzoic acid (DHB), ce- 
cyano-4-hydroxycinnamic acid (o'-CHCA), angiotensin, dipotassium hydrogen 
orthophosphate.
From Fisher, UK: Buffer pH 4 (potassium hydrogen phthalate) 0.05M, buffer pH 9.2 
(disodium tetraborate) 0.01M, hydrochloric acid, sodium hydroxide.
Prepared when required: Buffer pH 7.4 (phosphate) 0.03 M: 4.1 g KH2PO4 in 1 L 
water (stock A); 6.9 g K2HPO4 in 1 L water (stock B); mix 300 mL of stock A with
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700 mL of stock B. pH was adjusted to pH 7.4 with either stock solution, depending 
on resultant pH.
Ultra pure water: MilliQ50 (Millipore, UK) packed with USF liquid pure cartridges. 
The conductivity achieved was 18 MQ/cm .
4.2.2 Sample preparation
Glutaraldehyde solution (electron microscopy grade, 25% v/v in water, BDH, UK) 
was used in these experiments as received. (The glutaraldehyde solution provided 
was said by the supplier to be stable when maintained for a relatively long time at 
refrigeration temperature (4°C)).
Solutions of 0.6% v/v glutaraldehyde (0.6 mL, 6.36* 10' 3 moles) were prepared using 
distilled water and various pH buffers (pH 4, 7.4, 9.2). Unbuffered commercial 
glutaraldehyde solutions of 0.6% v/v (pH 3.8) were also prepared by dilution with 
water. Additionally, solutions of 0.6% v/v glutaraldehyde at pH 1 and pH 11 were 
prepared in water, using respectively dilute hydrochloric acid and sodium hydroxide 
to adjust the pH.
4.2.3 Freeze-drier
A laboratory-built freeze-drier was used and is illustrated in figure 4.1 below. It 
consisted of a rotary vacuum pump (two-stage pump, Edwards, Crawley, UK), 
which achieved a sample chamber pressure of 0.005 mmHg. The condensing 
chamber (or cold trap) was cooled by liquid nitrogen to prevent damage to the 
vacuum pump due to cavitation. The sample chamber could be changed: from a 
round-bottomed flask for large amounts of aqueous samples (up to -100 mL), to a 
desiccator chamber that was used for smaller samples, especially for Raman slides or 
the FTIR-ATR horizontal cell. Samples were first frozen at -20°C overnight and 
then left to freeze-dry for 1 0  hours minimum regardless of the type of sample.
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S: Sample Chamber.
CT: Cold Trap filled with liquid nitrogen. 
P: Edwards Vacuum Pump.
Figure 4.1: “Laboratory-built” freeze-drier set up.
4.2.4 FTIR-ATR analyses
Glutaraldehyde was studied as a solution (commercial 25% v/v solution), and also 
freeze-dried (commercial 25% v/v solution, 0.6% v/v and 0.2% v/v diluted in 
distilled water and in buffers pH 4, pH 7.4, pH 9.2, or in distilled water with 
adjustment of pH to pH 1 and 11 by addition of HC1 or NaOH respectively). All 
spectra were recorded with a Mattson Polaris FTIR spectrometer (ThermoNicolet 
Co, Lanham, MA, USA) with an MCT detector, a KBr beam splitter, and scanned 
between 4000 and 400 cm '1. The apodisation function was triangular and there was a 
Mertz phase correction. All spectra were obtained by accumulation of 1000 scans, at 
a resolution of 4 cm '1 and 45° angle of incidence, after subtracting from the spectra 
of the ZnSe crystal. All spectra were recorded under similar conditions (constant 
temperature) and were corrected for atmospheric water vapour and carbon dioxide 
by subtraction of the appropriate reference spectrum, even though the instrument 
was purged constantly with dried water vapour-free air. The spectra of freeze-dried 
buffer solutions (pH 4, 7.4, 9.2) were subtracted from the spectra of the 
corresponding freeze-dried glutaraldehyde solutions. The ATR device was a 
horizontal multiple reflection ATR (Graseby Specac, St Mary Cray, UK) with a 
ZnSe crystal. This crystal allowed easy sample preparation by pouring a few 
millilitres of the sample into the “pool” of the ATR cell, followed by freeze-drying.
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4.2.5 Raman analyses
The Raman spectra were collected using a Renishaw system 2000 Ramascope 
(Renishaw, Wotton-under-edge, UK). Glutaraldehyde was studied as a solution 
(25% v/v) in a quartz cuvette, and freeze-dried (25% v/v, 0.6% v/v, and 0.2% v/v) 
on a quartz slide. A laser (helium-neon 632 nm) with a power o f 25 mW (-3.4 mW 
at the sample) was used, with a typical scan time of 50 s with 25 accumulations, over 
a wavelength range of 400-4000 cm'1 at a spectral resolution of -2  cm'1. These 
conditions were chosen to allow examination of the weaker features, whilst still 
maintaining stability to laser excitation. The software was Galactic® Grams (Thermo 
Galactic Industries Co, Salem, NH, USA). The Raman spectra were not corrected or 
smoothed.
4.2.6 ESI-MS analyses
A sample (3 x 25 mL) of 0.6% v/v glutaraldehyde in distilled water was freeze-dried 
and re-dissolved in 3 mL of methanol. One drop of glacial acetic acid was added and 
the sample run on a VG Quattro (VG Micromass, Manchester, UK) instrument with 
a quadrupole analyser and operating in electrospray ionisation mode. The samples 
were run almost immediately after their dilution in methanol to avoid any possible 
esterification of free carboxyl groups . The inlet direct infusion of the sample was 
carried out at a rate of 5 /zL.min'1 using a Harvard pump 11 (Harvard apparatus, 
Holliston, MA, USA). The m/z range was 50-550.
4.2.7 MALDI-TOF MS analyses
Samples dissolved in (3 x 25 mL) of 0.6% v/v glutaraldehyde in distilled water and 
in pH 4, pH 7.4 and pH 9.2 buffers were freeze-dried and re-dissolved in 3 mL 
methanol. Several matrices were studied to evaluate their potential to desorb and 
ionise the samples. Thus, the matrix used was DHB (2,5-dihydroxybenzoic acid), 
although other matrices were tried (sinapinic acid (3,5-dimethoxy-4- 
hydroxycinnamic acid), a-CHCA (a-cyano-4-hydroxycinnamic acid)), but DHB 
yielded the best overall spectra and is known to exclude impurities during 
crystallisation3. Matrices such as CHCA and DHB were tested first because they are 
popular and have been shown to be useful matrices for low molecular weight 
compounds4'6. The matrix was selected according to the solubility of the matrix and 
analyte in similar solvents, the relative absence of interfering peaks in the spectral
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regions of interest and reproducible analyte signal intensity from laser spot over the 
target (i.e. good crystal homogeneity). DHB was prepared as a 7 mg.mL ' 1 solution in 
methanol. Samples re-diluted in methanol were mixed with the matrix solution at a 
ratio of 1:1. The samples were run almost immediately after their dilution in 
methanol and mixing with the matrix, to avoid any possible esterification of free 
carboxyl groups . The sample/matrix mixtures were spotted (~1 /iL droplet) onto a 
stainless steel modified 25-well MALDI target and left to air dry. The instrument 
used was a fully automated LaserToF 1500 (Scientific Analytical Instrument, 
Manchester, UK), fitted with a N2 laser and a linear time-of-flight mass analyser 
linked to a dedicated PC for data acquisition and manipulation of results. The 
accelerating voltage was 10 kV. The instrument was calibrated using angiotensin 
(Mw 1047, Sigma, UK). Only the positive mode was used in these investigations. 
The m/z range was generally 0-1000.
4.2.8 NMR analyses
Samples of glutaraldehyde (in distilled water, various pH buffers and at pH 1 and 
11) were prepared by freeze-drying 3 x 25 mL of solution (0.6% v/v or 6 % v/v 
glutaraldehyde solutions) and re-dissolved in 3 mL D2O. A commercial unbuffered 
25% v/v solution of glutaraldehyde in water (BDH, UK) was also analysed, without 
further preparation. When freeze-dried, the samples were immediately re-dissolved 
in D20  and analysed. A Bruker (Bruker Biospin, USA) AC250 NMR spectrometer 
with an E field of 58000 Gauss was used to run JH (250 MHz), and 13C (63 MHz) 
NMR analyses, whilst a Bruker (Bruker Biospin, USA) 400 spectrometer, with an E 
field of 92800 Gauss was used to run 'H (400 MHz) and 13C (100 MHz) NMR 
analyses.
4.3 Results and Discussion
4.3.1 ESI-MS
The analysis of an aqueous commercial solution of glutaraldehyde by ESI-MS 
yielded a complex mass spectrum that can be found in figure 4.2. The peaks appear 
as M and [M+H]+ ions. Also, many structures appear with the addition o f a sodium 
(Mw 23) or potassium (Mw 39) cation, for example [M+Na]+, [M+K]+, [M+Na+H]+
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and [M+K+H]+. All possible molecules (based on prediction reaction pathways 
discussed in chapter 2 ), thought to be present in glutaraldehyde solutions can be 
found in appendix III, where the few molecules that have already been proposed in 
the literature are cross-referenced. The results obtained for the ESI-MS analysis of 
an aqueous commercial solution of glutaraldehyde (pH 3.8) are summarised in table
4.1 where only the m/z peak values are given beside their possible assignments and 
the corresponding molecular weight (the reader is invited to refer to the appendix III 
for structural details).
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Figure 4.2: ESI-MS spectrum of unbuffered commercial aqueous solution of 
glutaraldehyde (pH 3.8), freeze-dried and re-dissolved in methanol. The inlet direct 
infusion of the sample was carried out at a rate of 5 fiL.min'1. The m/z range was 50- 
550.
The spectrum shows the likely presence of various molecules as shown in table 4.1. 
While, other hydrated forms of some of the proposed structures may also exist, but 
are not presented in table 4.1.
m/z Proposed Assignment (Mw) m/z Proposed Assignment (Mw)
101/102 Mol I (100) 301 Mol IX (301); Mol XII (300); Mol XVIb (300); Mol XVIIb (300)
115 Mol XI (116) 305
Mol XVI (264+K); Mol XVIa 
(282+Na); Mol XVII (264+K); Mol 
XVIIa (282+Na); Mol XX (264+K); 
Mol XXXIII (282+Na); Mol XLV 
(264+K)
165
123 Mol I (100+Na) 323/324
Mol IX (301+Na); Mol XII (300+Na);
Mol XVIa (282+K); Mol XVIb 
(300+Na); Mol XVIIa (282+K); Mol 
XVIIb (300+Na); Mol XXXIII 
(282+K)
137 Mol 111(136) 333 Mol XXVII (310+Na)
155 Mol X (132+Na); Mol XI (116+K) 369/370
Mol XVIII (346+Na); Mol XXVI 
(328+K); Mol XLVII (346+Na); Mol 
L (328+K)
165 Mol XXIII (163) 387
Mol XVIII (346+K); Mol XVIIIa 
(364+Na); Mol XXXIV (364+Na); 
Mol XXXVII (364+Na); Mol XLVI 
(364+Na); Mol XLVII (346+K)
183/185 Mol XV (182); Mol XXXI (182); Mol XXXII (182) 401 Mol XVIIIc (400)
201/202 Mol Vila (202); Mol VIII (202); Mol XVa (200); Mol XXIII (163+K) 420 Mol VII (418)
205 Mol XV (182+Na); Mol XXXI (182+Na); Mol XXXII (182+Na) 433
Mol XXVIII (410+Na); Mol XXIX 
(392+K)
223/224
Mol XV (182+K); Mol XVa 
(200+Na); Mol XXXI (182+K); Mol 
XXXII (182+K)
456/457 Mol VII (418+K)
251 Mol XXV (228+Na) 470 Mol XlXa (446+Na)
255/256 Mol V(218+K) 488/489
Mol XlXb (464+Na); Mol XXXV 
(464+Na); Mol XXXVI (464+Na); 
Mol XXXVIIIa (464+Na)
269 Mol XXIV (246+Na); Mol XXV (228+K) 502/503
Mol XIII (500); Mol XlXb (464+K); 
Mol XXXVI (464+K); Mol XlXd 
(500); Mol XXXV (464+K); Mol 
XXXVIIIa (464+K)
283 Mol XVIa (282); Mol XVIIa (282); Mol XXXIII (282) 520/521 Mol XXXVIIIb (482+K)
287/288
Mol XVI (264+Na); Mol XVII 
(264+Na); Mol XX (264+Na); Mol 
XXIV (246+K); Mol XLV (264+Na)
Table 4.1: Proposed structures for the observed ions for the analysis of an aqueous
solution of unbuffered glutaraldehyde in water (pH3.8) by ESI-MS.
The spectrum from the analysis of glutaraldehyde at pH 1 and at pH 11 can be found 
below respectively in figures 4.3 and 4.3. Some m/z values exhibited are similar to 
those seen in the spectrum of commercial glutaraldehyde (pH 3.8) (see figure 4.1).
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Figure 4.3: ESI-MS spectra of glutaraldehyde at pH 1 freeze-dried and re-dissolved 
in methanol. The inlet direct infusion of the sample was carried out at a rate of 5 
/xL.min'1. The m/z range was 50-550.
There are corresponding peaks between the spectrum of glutaraldehyde at pH 1 and 
the one at pH 3.8 (water), but there are exceptions. The main exceptions are the 
presence, at pH 1, of new m/z peaks, corresponding to the possible presence of the 
following molecules (see appendix III):
Molecule II which is a mono-hydrated monomeric glutaraldehyde (mol I), the latter 
being present at pH 3.8; Molecule IV which is a cyclic hemiacetal monomer 
(dehydrated molecule III, being present at pH 3.8); Molecule VI which is a 
hemiacetal trimer, whilst its corresponding dimer (mol V) and monomer (mol IV) 
are both present at pH 3.8; Molecule XVIIIb which is a partially-hydrated aldol 
tetramer, whilst other corresponding hydrated tetramers products are present at pH
3.8 such as mol XVIII, XVIIIa and XVIIIc; Molecule XXX which is a fully-cyclised 
aldol pentamer, whilst its corresponding partially cyclised product is present at pH
3.8 (mol XXIX); Molecule XXXIVa which is a fully-hydrated aldol/Michael 
tetramer, whilst its corresponding non-hydrated product is present at pH 3.8 (mol 
XXXIV); Molecule XXXVila which is a fully-hydrated aldol/Michael tetramer, 
whose corresponding non-hydrated product (mol XXXVII) is present at pH 3.8 and 
mol XXXVIIa which is also an isomer of XXXIVa.
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It thus appears that these above molecules, which are thought not to be present at pH
3.8 because o f the absence of their corresponding m/z values in the spectrum, are in 
fact products formed by hydration/dehydration and/or cyclisation that are originating 
from parent compounds, whose presence was corroborated by mass spectrometric 
results of glutaraldehyde at pH 3.8. Thus, this does not rule out that the additional 
molecules, believed to be present at pH 1, could not also be formed at pH 3.8.
Another exception between the spectrum of glutaraldehyde at pH 1 and the one at pH
3.8 (water) is the absence o f ions corresponding to the following molecules (see 
appendix III):
Molecule X (glutaric acid); Molecule XIII which is a trioxane-type pentamer, whilst 
its corresponding trimer (mol XII) exists at both pH 1 and 3.8; Molecule XlXb 
which is a partially-hydrated aldol pentamer; Molecule XlXd which is a fully- 
hydrated aldol pentamer; Molecule XXIX which is a partially-cyclised aldol 
pentamer, whilst its corresponding fiilly-cyclised product is present at pH 1; 
Molecule XXXV which is an aldol/Michael pentamer product; Molecule XXXVI 
which is an isomer of mol XXXV; Molecule XXXVIIIa which is a partially hydrated 
aldol/Michael pentamer product; Molecule XXXVIIIb which is a fully-hydrated 
aldol/Michael pentamer product.
It thus appears, from the above-list, that at pH 1 the formation o f large aldol 
condensation products (with more than 4 glutaraldehyde monomers) and the 
formation of Michael addition products of aldol products seems to be inhibited in 
comparison to reactions taking place at pH 3.8.
M/z Proposed assignment (Mw) m/z Proposed assignment (Mw)
101/102 Mol I (Mw 100) 302 Mol IX (301); Mol XII (300); Mol XVIb (300); Mol XVIIb (300)
118 Mol II (118); Mol IV (118); Mol XI (116) 311/313 Mol XXVII (310)
123/125 Mol I (100+Na)
325/327/
329/333
Mol IX (301+Na); Mol XII 
(300+Na); Mol XVIb (300+Na); Mol 
XVIIb (300+Na); Mol XXVI (328); 
Mol XXVII (310+Na); Mol L (328)
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136 Mol 111(136) 343 Mol VI (318+Na)
161 Mol III (136+Na) 347/349 Mol XVIII (346); Mol XXVII (310+K); Mol XLVII (346)
163 Mol XXIII (163) 358 Mol VI (264+K)
184 Mol XV (182); Mol XXXI (182); Mol XXXII (182) 365
Mol XVIIIa (364); Mol XXXIV 
(364); Mol XXXVII (364); Mol 
XLVI (364)
201 Mol XVa (200) 384 Mol XXXVIIa (382); Mol XVIIIb (382); Mol XXXIVa (382)
223/225
1221
Mol V ila (202+Na); Mol VIII 
(202+Na); Mol XVa (200+Na); Mol 
XV (182+K); Mol XXXII (182+K)
397 Mol XXX (374+Na)
243 Mol V (218+Na); Mol Vila (202+K); Mol VIII (202+K) 411 Mol XXVIII (410)
251 Mol XXV (228+Na) 425 Mol XVIIIc (400+Na)
265 Mol XVI (264); Mol XVII (264); Mol XX (264); Mol XLV (264) 444 Mol VII (418+Na)
269 Mol XXIV (246+Na); Mol XXV (228+K) 458 Mol VII (418+K)
283 Mol XXXIII (282); Mol XVIa (282); Mol XVIIa (282)
Table 4.2: Proposed structures for the observed ions for the analysis by ESI-MS of 
an aqueous solution of glutaraldehyde with an adjustment of pH to pH 1 by addition 
of HC1 (see appendix III for details of structures).
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Figure 4.4: ESI-MS spectrum of glutaraldehyde at pH 11, freeze-dried and re­
dissolved in methanol. The inlet direct infusion of the sample was carried out at a 
rate o f 5 jiL.min'1. The m/z range was 50-550.
From figure 4.4 and table 4.3, one can see that the solution of glutaraldehyde at pH 
11 contains many chemical structures that are similar to those found at pH 3.8. 
However there are some molecules that are apparently present at pH 11 which were 
not seen in the analysis o f glutaraldehyde at pH 3.8. These include the following 
molecules:
Molecules II which is a glutaraldehyde monohydrate being also present at pH 1; 
Molecule IV which is a cyclic hemiacetal being also present at pH 1, whilst the 
corresponding dihydrate (mol III) can be found at pH 1, pH 3.8 and pH 11; Molecule 
VI which is a hemiacetal trimer being also present at pH 1, whilst both 
corresponding dimer (mol V) and tetramer (mol VII) are present at pH 1, pH 3.8 and 
pH 11; Molecule XVIIIb which is a partially hydrated tetramer aldol product being 
also present at pH 1, whilst the same aldol product -more or less hydrated- (mol 
XVIIIa and XVIIIc) can be found at pH 1, pH 3.8 and pH 11; Molecule XIXc which 
is a partially hydrated pentamer aldol product, whilst the same aldol product -m ore 
or less hydrated- (mol XlXb and mol XlXd) can be found at pH 3.8 and pH 11; 
Molecule XXXIVa which is a fully hydrated aldol/Michael pentamer being also 
present at pH 1, whilst the corresponding non-hydrated product (XXXIV) is present 
at pH 1, pH 3.8 and pH 11; Molecule XXXVIIa which is a fully hydrated 
aldol/Michael pentamer being also present at pH 1, whilst the corresponding non- 
hydrated product (XXXVII) is present at pH 1, pH 3.8 and pH 11; Molecule 
XXXVIII which is an aldol/Michael pentamer, whilst the corresponding hydrated 
product (mol XXXVIIIa) is present at pH 3.8 and pH 11; Molecule XLVIII which is 
an aldol/Michael cyclised hexamer and Molecule LI which is an aldol/Michael 
cyclised hexamer.
It thus appears that these above molecules, which are thought not to be present at pH 
11  because of the absence of their corresponding m/z values in the spectrum, are in 
fact products formed by either hydration/dehydration and/or further reaction 
(particularly through Michael addition) that are originating from parent compounds, 
whose presence was corroborated by mass spectrometric results of glutaraldehyde at
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pH 11. Thus, this does not rule out the possibility that these molecules could not also 
be formed at pH 11.
In contrast, some molecular structures appear not to be present at pH 11 in 
comparison to pH 3.8, for example molecules XXVII which is an aldol tetramer fully 
cyclised whilst the corresponding partially cyclised product (mol XXVI) is present at 
pH 1, pH 3.8 and pH 11; Molecule XXVIII which is an aldol pentamer partially 
cyclised whilst the corresponding further-cyclised molecule (mol XXIX) is present at 
pH 3.8 and pH 11.
In addition, it is worth noting that at high pH (and particularly in the presence of 
sodium hydroxide) there is a great likelihood that Cannizzaro reactions would take 
place7,8, affecting the resultant spectra by turning the pendant aldehyde groups into 
primary alcohol and carboxyl groups. Such Cannizzaro products are not represented 
below in table 4.3, except by molecules XXI and XXII (see appendix III for detailed 
structures).
M/z Proposed assignment (Mw) M/z Proposed assignment (Mw)
100/101 Mol I (Mw 100) 305/307
Mol XVI (264+K); Mol XVIa 
(282+Na); Mol XVII (264+K); Mol 
XVIIa (282+Na); Mol XX (264+K); 
Mol XXI (266+K); Mol XXXIII 
(282+Na); Mol XLV (264+K)
120/122 Mol 11(118); Mol IV (118) 319 Mol VI (318)
132 Mol X (132) 323/324
Mol IX (301+Na); Mol XII (300+Na);
Mol XVIa (282+K); Mol XVIb 
(300+Na); Mol XVIIa (282+K); Mol 
XVIIb (382+Na); Mol XXXIII 
(282+K)
142 Mol II (118); Mol IV (118+Na) 353/355 Mol L (328+Na); Mol XXVI (328+Na)
155 Mol XI (116+K); Mol X (132+Na) 369/370
Mol XVIII (346+Na); Mol XXXIV  
(364+K); Mol XLVII (346+Na); Mol 
L (328+K)
161/163 Mol III (136+Na); Mol XXIII (163) 383 Mol XVIIIb (382); Mol XXXIVa (382); Mol XXXVIIa (382)
173 Mol X (132+K) 387
Mol XVIII (346+K); Mol XVIIIa 
(364+Na); Mol XXXIV (364+Na); 
Mol XXXVII (364+Na); Mol XLVI 
(364+Na); Mol XLVII (346+K)
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183 Mol XV (182); Mol XXXI (182); Mol XXXII (182) 395 Mol XXIX (392)
187 Mol XXIII (163+Na) 402 Mol XVIIIc (400)
205 Mol XV (182+Na); Mol XXXI (182+Na); Mol XXXII (182+Na) 404/406
Mol XVIIIa (364+K); Mol XVIIIb 
(382+Na); Mol XXXIV (364+K); Mol 
XXXIVa (382+Na); Mol XXXVII 
(364+K); Mol XXXVIIa (382+Na); 
Mol XLVI (364+K)
223/224 Mol XV (182+K); Mol XVa (200+Na); Mol XXXI (182+K) 420 Mol VII (418)
243 Mol V (218+Na); Mol Vila (202+K); Mol VIII (202+K) 423
Mol XVIIIb (382+K); Mol XVIIIc 
(400+Na); Mol XXXIVa (382+K); 
Mol XXXVIIa (382+K)
255/257 Mol V(218+K) 455/457 Mol VII (418+K)
269 Mol XXIV (246+Na); Mol XXV (228+K) 470
Mol XlXa (446+Na); Mol XXXVIII 
(446+Na); Mol XLVIII (446+Na); 
Mol LI (428+K)
283 Mol XVIa (282); Mol XVIIa (282); Mol XXXIII (282) 483
Mol XIXc (482); Mol XXXVIIIb 
(482)
287
Mol XVI (264+Na); Mol XVII 
(264+Na); Mol XX (264+Na); Mol 
XXIV (246+K); Mol XLV (264+Na)
488/489
Mol XlXa (446+K); Mol XlXb 
(464+Na); XXXV (464+Na); Mol 
XXXVI (464+Na); Mol XXXVIII 
(446+K); Mol XXXVIIIa (464+Na); 
Mol XLVIII (446+K)
301/303
Mol IX (301); Mol XII (300); Mol 
XVIb (300); Mol XVIIb (300); Mol 
XXII (302)
502 Mol XIII (500); Mol XlXd (500)
Table 4.3: Proposed structures for the observed ions for the analysis by ESI-MS of 
an aqueous solution of glutaraldehyde with an adjustment of pH to pH 11 by 
addition of NaOH (detailed structures can be found in appendix III).
4.3.2 MALDI-TOF MS
The MALDI-TOF MS data obtained from the glutaraldehyde solutions at various pH 
values (pH 3.8 -9.2) exhibited spectra very similar to each other and are shown below 
in figure 4.5. The characteristic ions were quite similar to those shown in table 4.1 
(above) with the ions being mostly attributable to protonated molecules such as 
[M+H]+ and adduct ions such as [M+Na]+, [M+K]+, [M+Na+H]+ and [M+K+H]+. 
However, although the use of MALDI also allowed the analysis of solutions 
containing buffers (pH 4, 7.4, and 9.2), the spectral quality was less than that 
obtained with ESI-MS, which was to be expected.
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Figure 4.5: Examples of MALDI-TOF MS spectra obtained from the analysis of 
glutaraldehyde at various pH values: unbuffered commercial glutaraldehyde solution 
at pH 3.8 (top left), glutaraldehyde at pH 4 (top right), glutaraldehyde at pH 7.4 
(bottom left) and glutaraldehyde at pH 9.2 (bottom right). All solutions were freeze- 
dried and re-dissolved in methanol. The matrix (DHB) was prepared as a 7 mg.mL ' 1 
solution in methanol. Samples re-diluted in methanol were mixed with the matrix 
solution at a ratio of 1 :1 .
The MALDI-TOF MS results (see figure 4.5) show that there is some differences in 
spectra, which implies that glutaraldehyde is affected by pH. Nonetheless, it seems 
that the m/z values of the ions seen in the spectra from glutaraldehyde at various pH 
values (3.8-9.2) appear virtually identical, which indicates that similar molecules are 
formed in this pH range. The summary of such results obtained from the analysis of 
glutaraldehyde in pH range 3.8-9.2 by MALDI-TOF MS can be found below in table 
4.4 (please refer to appendix III for the structures of the various molecules). These 
findings do not, however, rule out the possibility that different molecules, not yet 
assigned in this work, with very similar molecular weights may form at different pH 
values.
The MALDI-TOF MS results from glutaraldehyde in solution (over a wide pH 
range) indicate that species containing a maximum of eight molecules of
%
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glutaraldehyde could be found in solution possibly in the form of an aldol 
condensation/Michael addition reaction product (see molecule XLIII with Mw 728 in 
appendix III). The largest aldol condensation product of glutaraldehyde detected 
involved a maximum of five molecules of glutaraldehyde (see molecule XIX with 
Mw 428 in appendix III). The presence of cyclic hemiacetals was also detected with 
a maximum of four glutaraldehyde molecules (see molecule VII with Mw 418 in 
appendix III).
The absence of molecule I (monomeric glutaraldehyde with Mw 100) in the MALDI 
data is in agreement with others who stated that no monoaldehyde was identified in 
the analysis of aqueous unbuffered glutaraldehyde by GC-MS9. However, the other 
conclusion to be drawn is that the MALDI-TOF MS methodology does not allow the 
correct analysis of molecules with a molecular weight in the vicinity of m/z 1 0 0 , 
since its presence was detected by ESI-MS analysis of aqueous unbuffered 
glutaraldehyde.
Molecules H20 pH 4 pH 7.4 pH 9.2 Molecules h 2o pH 4 pH 7.4 pH 9.2
M oll X Mol XlXb X
Mol II X X X X Mol XIXc X X X
Mol III X X X Mol XlXd X X X
Mol IV X X X X Mol XX X X X X
Mol V X X X X Mol XXIII X X X
Mol VI X X MolXXIV X X X X
Mol VII X Mol XXV X X X
Mol Vila X X X X MolXXVI X X X X
Mol VIII X X X X MolXXVII X X X X
Mol IX X X X MolXXXI X X X X
174
Mol X X X X X MolXXXII X X X X
Mol XI X X X X MolXXXIII X X X X
Mol XII X X MolXXXIV X X
Mol XIII X X X MolXXXV X
Mol XV X X X X MolXXXVI X
Mol XVa X X X X MolXXXVII X X
Mol XVI X X X X MolXXXVIII X X
Mol XVIa X X X X MolXXXVIIIa X
Mol
XVIb X X
Mol
XXXVIIIb X X X
Mol XVII X X X X Mol XLI X
Mol
XVIIa X X X X Mol XLV X X X X
Mol
XVIIb X X Mol XLVI X X
Mol
XVIII X X X X
Mol
XLVII X X X X
Mol
XVIIIa X X Mol XLIX X X
Mol
XVIIIc X Mol L X X X X
Mol XIX X X Mol LI X X
Mol XlXa X X Mol LII X
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Table 4.4: Proposed structures for the observed ions for the analysis of an aqueous 
solution of glutaraldehyde solution at various pH values (pH 3.8, pH 4, pH 7.4 and 
pH 9.2) by MALDI-TOF MS. The data given only indicates the presence or not 
(represented by a cross) of molecules according to their m/z found present in 
relevant spectra. The structure of the molecules referred to can be found in appendix 
III.
4.3.3 NMR
4.3.3.1 *H NMR:
Some researchers have already analysed glutaraldehyde in D2O using 'H NMR10,11. 
A similar experimental procedure was followed because glutaraldehyde is supplied 
as an aqueous solution and cross-linking with proteins is also carried out in aqueous 
media. As the use of anhydrous solvents might shift or change the equilibrium of the 
species present in glutaraldehyde solutions, freeze-drying followed by reconstitution 
in D20  was used in virtually all our studies. The exception was an initial experiment 
where a proton NMR spectrum was measured on the sample as it was obtained in 
unbuffered aqueous solution, even though the water absorption obscured a part of the 
spectrum (50% D20  and 50% aqueous glutaraldehyde solution). There were two 
main reasons for doing this. First it was our desire to examine the reagent without 
any alteration to it, and secondly, it was felt that changing the solvent to deuterium 
oxide might not only cause an exchange of deuterium for hydrogen bonded to 
oxygen but also for hydrogen bonded to carbon in the a-positions of glutaraldehyde. 
In fact, after having freeze-dried and re-dissolved the commercial solution of 
glutaraldehyde in a few millilitres of D20 , the 'H NMR spectrum obtained was the 
same (results not shown) and no such effects as the ones cited above seemed to have 
altered the spectrum. The freeze-drying process thus did not alter the spectra 
obtained.
The proton NMR spectrum of a commercial unbuffered glutaraldehyde solution (pH 
3.8) in water (see figure 4.6 below) exhibited some well-defined peaks and also 
some very broad unresolved and overlapping peaks. The latter are characteristic of 
the abundance of molecular structures containing similarities, which result in the 
broad aspect of the major regions.
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Figure 4.6: 'H NMR of a commercial unbuffered glutaraldehyde solution (0.6% v/v) 
in water (pH 3.8), freeze-dried and re-dissolved in D2O.
The broad peaks rendered a tentative assignment of the peaks extremely difficult and 
the 'H NMR spectra obtained were mostly used to support the findings obtained by 
13C NMR. However, some conclusions could be drawn and the major finding, from 
the above spectrum, was the absence of aldol condensation products (a,/3-unsaturated 
structures) expected in the 6 - 8  ppm region. This is in agreement with Kawahara et 
a l12, who stated that the concentration of these unsaturated structures was negligible 
between pH 2 and 8 , which is almost the pH range studied here. Their presence at 
low concentrations is not fully precluded, however, as they might be below the level 
of detection of the NMR instrument. Furthermore, the mass spectrometric data 
(presented in sections 4.3.1 and 4.3.2) exhibit the possible presence of such 
unsaturated molecular structures, based on their m/z values.
The spectrum also shows the likely presence of exchangeable hydroxyl protons, 
along with methylene and central methylene protons represented by the broad 
absorption centred at 1 .6  ppm, with some partially separated multiplets on both the 
down- and up-field sides. We can also identify the possible presence of groups (with 
a-methylene) such as -C-CH2-C=C-, -C-CH2-CO-R, -C-CH2-C C -C O , -C=C(CH2-)- 
CO around 2.4 ppm, other groups such as -C-CH2-OH and -C-CH2-OR around 3.1- 
3.3 ppm, along with -C=CH-, -CH=CO, hydroxyl and hydrated aldehyde protons13 in 
the 4.5-5.2 ppm region. The strong doublet signal at ca. 5.00 ppm can be assigned14
to acetol and acetal protons absorbing at different places because of the different 
chemical species involved, along with the possible existence of cis and trans 
geometrical acetal isomerism15 and aldehyde protons around 9.4 ppm. The !H NMR 
spectra obtained from the same unbuffered commercial (25% v/v) solution of 
glutaraldehyde at pH 3.8, freeze-dried and re-dissolved in D2O, confirmed the above 
results.
NMR spectra obtained from glutaraldehyde at pH 4, pH 7.4 and pH 9.2 appear 
different (see figure 4.7 below) to each another indicating a pH dependence. It would 
appear, however, that a similar class of material is producing a NMR pattern at the 
same position, thus indicating that structures with similar reacting groups are formed 
over this pH range (4-9.2). It is believed that many molecules assigned for the 
analysis of unbuffered glutaraldehyde at pH 3.8 would also be present in 
glutaraldehyde solutions under the pH range analysed (pH 4-9.2), which is backing 
up our data obtained from MALDI-TOF MS analysis of glutaraldehyde solutions 
under a similar pH range.
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Figure 4.7: ]H NMR of glutaraldehyde at various pH values: unbuffered commercial 
glutaraldehyde solution at pH 3.8 (top left), glutaraldehyde at pH 4 (top right), 
glutaraldehyde at pH 7.4 (bottom left) and glutaraldehyde at pH 9.2 (bottom right). 
All solutions were freeze-dried and re-dissolved in D2O.
The !H NMR spectra obtained from glutaraldehyde at pH 1 and pH 11 are of greater 
interest (see figures 4.8 and 4.9 below). Both spectra obtained at pH 1 and 11 are 
extremely different from each other, more so when compared to the spectra obtained 
at pH 3.8-9.2, especially in the 8-10 ppm region. This reveals a strong influence of 
pH on the behaviour of glutaraldehyde solution, especially at extreme pH values.
The spectra both show some alkene protons (C=CH-CO, CH=C-CO) around 6.4-6.8  
ppm, while no traces of alkenes were apparently visible in the !H NMR spectra 
obtained from glutaraldehyde at the pH range 3.8-9.2. The spectrum at pH 1 shows 
an intense peak at 8.1 ppm, which could be assigned to the presence of -CH(OH)-0- 
C or -C H (=0)-0-C -, along with many aldehyde bands, indicating the presence of 
many different environments of these carbonyl protons. The spectrum obtained at pH 
11 is quite similar to the one obtained at pH 3.8 in the 0.8-1.8  ppm and 4.4-5.4 ppm 
regions, while major changes occur in the 2.0-4.0 ppm region where extra peaks 
appear such as the triplet around 2  ppm and more intense and resolved peaks 
between 3.2-4.0 ppm. It is also worth noting that the signals of hydrated aldehyde 
protons and of the olefinic protons o f hypothetical aldol condensates can be hidden 
behind the water/OH signal16. In addition, more intense and resolved aldehyde peaks 
appear in the 9.10-9.93 ppm region. These peaks were barely noticeable in the 
spectrum obtained at pH 3.8. Overall, this could indicate that the formation of similar 
chemical structures took place at these extreme pH values but with different ratios.
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Figure 4.8: JH NMR spectra of glutaraldehyde solution at pH 1, freeze-dried and re­
dissolved in D2O.
Figure 4.9: *H NMR spectra of glutaraldehyde solution at pH 11, freeze-dried and re­
dissolved in D2O.
4.3.3.2 13C NMR:
4.3.3.2.1 C NMR analyses o f glutaraldehyde at pH  3.8-9.2 range:
It has been reported that direct comparison of the peak intensities is not quantitative
1 ^  17in C NMR . No quantification was carried out in this study, although others have 
attempted this14, and found that an aqueous glutaraldehyde solution (pH 3.5-4)
contained approximately 4% monomeric glutaraldehyde (mol I), 16% of the
monohydrate (mol II), 9% of the dihydrate (mol III) and around 71% of the
monomeric hemiacetal (cis (mol IVa) and trans (mol IVb) isomers). They also tried
to assign the 13C NMR (22.63 MHz) spectrum by considering only the presence of
the above-cited compounds. In this work, detailed correlation tables and CS
CHEMNMR prediction software (Upstream solution GmbH scientific software
engineering, Hergiswil, Switzerland), which has been tested with known standards,
1 ^were used to tentatively assign some of the C NMR peaks by considering a much 
wider variety of possible molecular structures (see appendix III) that are thought to 
be present in glutaraldehyde solutions rather than those reported previously in the 
literature.
The 13C NMR spectra of glutaraldehyde in the range of pH 3.8-9.2 appear very 
similar, although their corresponding !H NMR spectra appeared different one to 
another. Typical C spectra of glutaraldehyde at various pH values, representative of 
the spectra obtained in this pH range, can be found in figure 4.10 below.
M f
1JlJ l —J l
JL J l 1J i — JUU
i oFigure 4.10: C NMR of glutaraldehyde at various pH values: unbuffered
commercial glutaraldehyde solution at pH 3.8 (top left), glutaraldehyde at pH 4 (top
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right), glutaraldehyde at pH 7.4 (bottom left) and glutaraldehyde at pH 9.2 (bottom 
right). All solutions were freeze-dried and re-dissolved in D2O.
The line assignment is shown below in table 4.5, with the structure of the molecules 
referred to being found in appendix III.
Peak position (ppm) Proposed assignment
1 signal at 13.43 Molecules I; XII; XIII; XIV
4 signals at 15.81-16.35 Molecules II; III; IVa; V; VI; VII
5 signals at 17.91-19.11 Molecules IVb; V; VI
9 signals at 28.01, 28.04, 28.27, 28.43, 29.16, 
29.50, 29.83, 30.34 and 30.53 Molecules IVa; IVb; V; VI; XIII; XIV
5 signals at 34.17, 34.68, 35.18, 35.78 and 36.18 Molecules II; III; VII; XII; XIII; XIV
2 signals at 41.67 and 42.18 Molecules I; II; XII; XIII; XIV
5 signals 90.14, 90.39, 90.56, 90.63 and 90.89 Molecules II; III; IVb; V; VI; VII
10 signals at 91.13, 91.36, 91.64, 93.26, 93.71, 
94.06, 94.12, 95.12, 95.81 and 97.52 Molecules IVb; V; VI; XII; XIII; XIV
3 signals at 206.56, 207.18 and 207.32 Molecules I; II; XII; XIII; XIV
Table 4.5: Line assignment along with the proposed corresponding assignment of a 
13C NMR spectrum of an aqueous commercial solution of glutaraldehyde (pH 3.8) 
(structure of the molecules referred to being found in appendix III).
Some studies have reported the 13C chemical shifts for the carbonyl carbon in a
1 0 .variety of organic compounds, such as aldehydes and carboxylic acids , and hence it 
is possible to differentiate between the resonance of carbonyl carbons of conjugated 
aldehydes and non-conjugated aldehydes. The resonances o f conjugated aldehydes 
are shifted by ca. 1 0  ppm to higher field than those in the saturated compounds and 
this shielding effect is comparable for a,/3-unsaturated and aromatic systems19. 
Additionally, free carboxylic acids exhibit the carboxyl carbon resonance peak at a 
somewhat higher field than aldehydes (i.e. 9-20 ppm). Therefore, in the spectrum of 
glutaraldehyde in water at pH 3.8, only some saturated aldehyde carbon peaks seem 
to appear (see above table 4.5). No unsaturated aldehyde carbons or carboxylic acid 
carbons can be noticed in the spectrum, although their presence can not be precluded 
since their characteristic signals may be below the level of detection of the 
instrument.
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The presence of aldol condensation products (for example, molecules XV, XVI, 
XVII, XVIII, XIX and XX) and also the aldol/Michael condensation products 
containing double bonds (such as molecules XXXIV, XXXVII, XXXVIII, XXXIX 
and XLI), are also excluded because of the absence of signal around 100-160 ppm, 
which is characteristic of alkenes or deshielded carbon in the neighbourhood of 
carbonyl (-50 ppm) in the 13C NMR spectrum. This is supported by the absence of 
signal in the appropriate region of the !H NMR spectrum.
The results also indicate the absence of some unsaturated aldol and some unsaturated 
aldol/Michael condensation products that have not undergone a systematic 
dehydration step (for example, molecules XVIa, XVIIa, XVIIIa, XVIIIb, XlXa, 
XlXb, XIXc, XXXVIIIa, XLIa, XLIb and XLIIa) because of the absence of 
deshielded carbons in the 55-65 ppm region and of ethylenic carbons. The presence 
of similar saturated structures (all dehydration steps of the aldol condensations did 
not take place) is also not confirmed due to the absence of deshielded carbons 
signals. Such structures would have been for example molecules XVa, XVIb, XVIIb, 
XVIIIc, XlXd, XXXIVa, XXXVIIa, XXXVIIIb, XXXIXa, XLIc and XLIIIa.
The presence of dimers (e.g. molecules XXXI and XXXII), formed by a di- 
molecular aldol condensation, is excluded because of the absence of signal due to 
conjugated aldehyde (around 190 ppm) and especially because of the absence of 
signal from the conjugated ethylenic bonds in the 120-150 ppm region. To 
corroborate this, the !H NMR spectrum does not show any signal between 1.75 and 
1.95 ppm corresponding to the deshielded proton near the OH for molecule XXXI 
(or near the C-O-C for molecule XXXII) and the conjugated double bonds of the 
molecule, whilst the proton characteristic of the ethylenic double bond (-6.50 ppm) 
is also absent.
The presence of cyclised aldol condensation products, (such as molecules XXIII, 
XXIV, XXV, XXVI, XXVII, XXVIII, XXIX, XXX, XLV, XLVII, XLVIII, L), 
along with partially cyclised aldol condensation unsaturated products having carried 
out Michael addition (such as molecules LI, LII) is also unlikely because o f the 
absence of signal from the conjugated ethylenic double bond in the 140-150 ppm 
region and around 45-55 ppm in the 13C spectra. This is also supported by the 
absence, in the ]H spectra, of signals around 1.75-1.95 ppm. Saturated partially
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cyclised aldol condensation products having carried out Michael additions (e.g.
molecules XLVI, XLIX) are also deemed to be absent because of the absence of 
• 1 ^signal around 45-55 ppm, in the C spectra and to the absence o f signals around 
1.70-1.90 ppm, in the ]H spectra.
The presence of (saturated) molecules formed by Michael addition on aldol 
condensation products (for example, molecules XXXIII, XXXV and XXXVI) is also 
excluded because of the absence of characteristic signals around 50-55 ppm.
Furthermore, molecules such as Vila, VIII and IX are thought not to be present 
because of the absence of NMR signals at 62-67 ppm (deshielded carbon C-C-OH 
and/or C-C-0-). This is supported by the absence of signal around 170 ppm 
corresponding to -0-C£=0)-C-, in the 13C NMR spectra, along with the absence of 
signals in the ]H NMR spectra at 4 ppm (CFL-CFL-O-h which are expected to be 
seen from molecules VIII and IX.
Additionally, the presence of glutaric acid (molecule X) and the monoacid form of 
glutaraldehyde (molecule XI) are also rather excluded because of the absence of 
signal from carboxylic carbon in the 165-185 ppm region. However the 'H NMR 
spectrum alone could not provide enough information regarding their non-existence.
One must, however, keep in mind that the presence of all the above-mentioned 
structures cannot be categorically ruled out, as they may be present at very low 
concentrations and hence be below the detection limit of the NMR instrument. 
Furthermore, the majority of these structures have been suggested from the presence 
of their corresponding ions in the mass spectrometric spectra (see sections 4.3.1 and 
4.3.2).
To conclude, it seems that only molecules I, II, III, IVa, IVb, V, VI, VII, XII, XIII 
and XIV would appear to be present (in large enough quantities to be detected)
i  nsolely according to both H and C NMR data from the analysis of glutaraldehyde 
solutions under the pH range 3.8-9.2.
4.3.3.2.2 13 C NMR analyses o f  glutaraldehyde at p H  1 and at p H  11:
The presence of a solid light-yellow precipitate in the solution of glutaraldehyde at 
pH 1 made it impossible to obtain a 13C NMR spectrum. Assignment of the 
compounds present in such a sample solely on the NMR analysis was therefore
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quite difficult. However, the 13C NMR analysis of glutaraldehyde in solution at pH 
11 was carried out (no precipitates formed) and a tentative assignment of the signals 
seen is given below.
The signals obtained at pH 11 agree with a previously reported 13C NMR spectrum 
from the study of a polymeric glutaraldehyde preparation in D20 , although no 
attempts were made in that study to assign their signals1. The only conclusion drawn
ITwere that their combined C and elemental analysis results seemed to indicate the 
presence of a mixture of oligomers of up to six glutaraldehyde units but the absence 
of any free di-aldehyde. Indeed, the complex pattern seen in the 13C spectrum 
obtained is essentially thought to be mostly due to the presence of oligomeric 
structures or condensation products of higher order compared to the data obtained 
from glutaraldehyde at pH 3.8-9.2. Unfortunately, the signal to noise ratio was not 
optimum enough to allow full determination of all the C signals found in our 
spectra. Nevertheless, about at least one hundred and one 13C signals can be clearly 
identified above the signal to noise level. Many others are thought to be present but 
their intensities are not sufficient to be characterised.
,JSSS*S53SSJS£!.«?2iv«
s. - .. .. .u .. '• * "* * '* *'*Figure 4.11: C NMR spectra of an aqueous glutaraldehyde solution at pH 3.8
(unbuffered-/^/?) and pH 11 (pH adjusted with NaOH-right), freeze-dried and re­
dissolved in D20 .
1 TAn interesting observation is that some similar signals to those found in the C 
NMR spectrum of glutaraldehyde in water (pH 3.8) can be observed (see figure 4.11 
above for a direct comparison) in the spectrum of glutaraldehyde at pH 11. This 
would underline the possible presence of similar chemical structures to those 
previously described and tentatively assigned to molecules such as molecules I, II, 
III, IVa, IVb, V, VI, VII, XII, XIII and XIV.
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However, other signals can also be observed in the spectrum of glutaraldehyde at pH 
11 in comparison to the ones obtained at pH 3.8-9.2. These signals are found below 
in table 4.6. This indicates one more time the strong pH dependence of the behaviour 
of glutaraldehyde in solution.
Peak position (ppm) Proposed assignment
20-28ppm Deshielded aliphatic carbons
50-80 ppm Deshielded aliphatic carbons
139 and 154 ppm Carbon signals in the alkene region (120-160 ppm)
183-184 ppm Presence o f unsaturated aldehydic carbons
196-197, 207-208, 209 and 210 ppm Weak signals o f some likely saturated aldehydic carbons
Table 4.6: Line assignment of a C NMR spectrum of glutaraldehyde at pH 11.
Our findings indicate the likely presence of chemical structures containing typical 
alkene bonds, such as aldol condensation products (molecules XV, XVI, XVII, 
XVIII and XIX) and also aldol condensation/Michael-type addition products 
(molecules XXXIII, XXXIV, XXXV, XXXVI, XXXVII, XXXVIII, XXXIX, XL, 
XLI, XLII and XLIII), in addition to dimers formed by a di-molecular aldol 
condensation (molecules XXXI and XXXII), along with partially cyclised 
aldol/aldol-Michael structures (molecules XXIII, XXIV, XXV, XXVI, XXVII, 
XXVIII, XXIX, XXX, XLV, XLVI, XLVII, XLVIII, XLIX, L, LI, LII and LIII).
Nevertheless, only two signals can be identified in the alkene region (at 139 and 154 
ppm). This led us to the hypothesis that some aldol condensation and some 
aldol/Michael-type addition condensation reaction products may contain other 
characteristic functions than only the ethylenic bonds. The aldol condensation might 
have not fully involved the proper dehydration step usually occurring at every 
consecutive step, which is yielding ethylene linkages conjugated with aldehyde 
functions. Some “fully hydrated” molecules containing hydroxyl pendant groups, 
(such as molecular structures XVa, XVIb, XVIIb, XVIIIc, XlXd, XXXIVa and 
XXXVIIa, XXXVIIIb, XXXIXa, XLIc and XLIIIa), would exhibit carbon signals 
around 55-80 ppm instead of the ethylenic characteristic signals around 140-150 
ppm. In addition, the corresponding ]H NMR of glutaraldehyde at pH 11 also 
corroborates this hypothesis with the signals around 3.45 ppm and 2.45 ppm, 
meaning that most of the structures enumerated above might be predominantly in 
their “hydrated” form. Thus the presence of partially hydrated structures, still
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containing alkene groups could also be present, although it is less likely than their 
fully hydrated counter parts. Such partially hydrated species would include 
molecules XVIa, XVIIa, XVIIIa, XVIIIb, XlXa, XlXb, XIXc, XX, XXXVIIIa, 
XLIa, XLIb and XLIIa.
An even better fit for the two carbon signals at 139 and 154 ppm is the presence of 
unsaturated aldol condensation products that have carried out a Cannizzaro reaction 
at high pH (e.g. molecules XXI and XXII), more so in the presence of NaOH. Such 
species involve the formation of primary hydroxyl and carboxylate groups, leading 
to the alkene signals being slightly shifted to values very close to the ones found in 
our spectrum.
The NMR signals observed from the analysis of glutaraldehyde at pH 11 also 
corroborate the potential presence of trioxane-type glutaraldehyde species, including 
molecules XII, XIII and XIV, because of the presence of the characteristic signal 
around 95ppm (-CH2-CH2-CH(-0-CH-)-0-CH-).
Additionally, we can conclude that molecule Vila is likely to be present because of 
the l3C NMR signals about 65-70 ppm (C-C-0-) and because of the !H NMR signals 
around 3-4 ppm (-CH7-CH7-O-T while molecules VIII and IX are unlikely to be 
present because of the absence of the characteristic NMR signal of these molecules 
at about 170 ppm (C-C(=0)-0-) from the 13C NMR spectrum. Molecules X and XI 
(mono and di-acid forms of glutaraldehyde) are also unlikely to be present because 
of the absence of a characteristic signal of the carboxylic acid from the 13C NMR 
spectrum.
4.3.4 Raman and FTIR-ATR analyses
4.3.4.1 Analysis of an aqueous commercial unbuffered solution of glutaraldehyde 
(pH 3.8):
The Raman spectrum obtained from a commercial solution of glutaraldehyde (25% 
v/v) revealed a fairly similar pattern to that seen in the corresponding infrared 
spectrum (see below figure 4.12 and table 4.7).
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Figure 4.12: Raman (top) and FTIR-ATR (bottom) spectra obtained from an 
unbuffered commercial aqueous glutaraldehyde solution (25% v/v).
Peak positions 
(Raman spectrum)
Peak positions 
(Infrared 
spectrum)
Assignment
3436 cm '1 -
Broad and intense doublet with a maximum at 3436 cm' 
', most likely to be due to water environment but may 
also be due to the presence o f OH groups
2960,2931 and 
2876 cm '1
2960, 2931 and 
2876 cm '1 CH stretching region
2750 cm '1 2750 cm '1 Weak absorption assigned to CH stretching o f an aldehyde group
1711 cm '1 1711 cm '1 Absorption arising from a C = 0 stretching vibration
1637 cm '1 - Most likely due to water environment
1463, 1443, 1350 
and 1258 cm '1
1463,1443, 1350 
and 1258 cm '1
Possibly due to various deformation vibrations of the 
CH2 or CH groups
1200-800 cm '1 1200-800 cm '1
Unresolved absorption bands possibly assigned to the 
presence of polymeric “impurities” in the commercial 
glutaraldehyde solution
Table 4.7: Major peak positions and corresponding vibrational spectroscopic
assignment (Raman and infrared) from the analysis of an unbuffered commercial 
aqueous glutaraldehyde solution (25% v/v).
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4.3.4.2 Analysis of freeze-dried aqueous solutions of glutaraldehyde at a range of pH
values:
The infrared spectroscopic data obtained from freeze-dried solutions of 
glutaraldehyde (0.6% v/v and 0.2% v/v) were the same as one another. And hence, 
only the results obtained from solutions of 0 .6 % v/v glutaraldehyde are shown here. 
For doing so, solutions of glutaraldehyde were firstly diluted, (in distilled water or in 
pH 4, pH 7.4, pH 9.2 buffers, or even in distilled water with adjustment of pH to pH 
1 and 11 by addition of HC1 or NaOH respectively), and then subjected to freeze- 
dried and immediately analysed.
Figure 4.13 shows the various infrared spectra obtained from freeze-dried 
glutaraldehyde solutions at a range of pH values, while figure 4.14 shows an 
expansion of the 1230-1850 cm ' 1 spectral region.
jSilver trace: G lutaraldehyde (pH 1)
Black trace: U nbuffered G lutaraldehyde (pH 3.8) 
Blue trace: Buffered G lutaraldehyde (pH 4)
1 -:Green trace : Buffered G lutaraldehyde (pH 7.4) 
R ed trace: Buffered G lutaraldehyde (pH 9.2) 
Purple trace: G lutaraldehyde (pH 11)
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Figure 4.13: FTIR-ATR spectra of freeze-dried glutaraldehyde solutions at various 
pH values (unbuffered glutaraldehyde at pH 3.8, 1 and 11; and buffered 
glutaraldehyde at pH 4, 7.4 and 9.2).
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iSilver trace : G lutaraldehyde {pH 1)
Black trace : U nbuffered G lutaraldehyde (pH 3.8) 
Blue trace : Buffered G lutaraldehyde (pH 4)
jGreen trace : B uffered G lutaraldehyde (pH 7.4) 
R ed trace : Buffered G lutaraldehyde (pH 9.2) 
Purple trace: G lutaraldehyde (pH 11)
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Figure 4.14: FTIR-ATR spectra of freeze-dried glutaraldehyde solutions at various 
pH values (expansion of the 1230-1850 cm ' 1 spectral region).
The major bands along with their corresponding assignments are found below in 
table 4.8.
Peaks 
found 
at pH 1
( c m 1)
Peaks 
found at 
pH 3.8
(cm ')
Peaks 
found at 
pH 4
( c m 1)
Peaks 
found at 
pH 7.4
(c m 1)
Peaks 
found at 
pH 9.2 
( c m 1)
Peaks 
found at 
pH 11
(c m 1)
Assignment
3426b 3426b 3426b 3426b 3426b 3426b
OH stretching due to water, a 
carboxylic group (due to 
oxidation of the glutaraldehyde 
molecules) or an alcoholic 
hydroxyl group due to the 
presence of hydrated 
structures, aldol condensation 
products which did not 
undergo all the dehydration 
steps, or even due to the enol 
forms of the aldehyde moieties 
in the glutaraldehyde 
structures
2947i 2947i 2947i 2944i 294 li 2946i Antisymmetric stretching of the CH2
2873i 2872i 2874i 2874i 287 li 2872i Symmetric stretching o f thec h 2
2724i 2725m 2723m 2724m 2725vw 2725m Antisymmetric stretching of the CH of the aldehyde group |
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1723i 1722i 172 i 172 li
1715bm 
(band 
shifted)
1722i
Stretching of the C =0 groups 
of non-conjugated aldehydes 
and/or carboxylic acids 
overlapping each other
1683m 1683w 1683w 1683m 1680bm 1682m Stretching o f the C = 0 group of conjugated aldehydes
- - - 1637w 1636m 1635m
Assigned to stretching o f the 
O C  ethylenic linkage group 
conjugated with an aldehyde, 
formed from the dehydration 
step o f an aldol condensation
161 lbw - - - - -
May be due to the presence of 
undetermined polymers 
formed specifically at very 
acidic pH
- - - 1563bm 1562bi 1568ib
Assigned to the antisymmetric 
stretching o f the COO o f the 
carboxylate group, possibly 
due to the presence of carboxyl 
functions in the form of 
sodium salts20. The carboxylic 
acid groups possibly being 
formed by Cannizzaro 
reactions
Various 
bands at 
1500- 
1200
Various 
bands at 
1500- 
1200
Various 
bands at 
1500- 
1200
Various 
bands at 
1500- 
1200
Various 
bands at 
1500- 
1200
Various 
bands at 
1500- 
1200
Various bands at 1500-1200 
including the main ones at 
-1460, 1441, 1352, 1327 and 
1258 cm '1 can be assigned to 
the deformation vibrations of 
the CH2 or CH groups
141lshv 
w 1410vw - 1410m
1410w 
sh / 
1403bi
1408m
May be assigned to the 
symmetric stretching o f the 
COO o f the carboxylate group 
(sodium salt)
Various 
bands at 
1200- 
900
Various 
bands at 
1200- 
900
Various 
bands at 
1200- 
900
Various 
bands at 
1200- 
900
Various 
bands at 
1200- 
900
Various 
bands at 
1200- 
900
Some strong, unresolved 
absorption bands around 1200- 
900 cm '1 may be assigned to 
ether bonds (different C -0  
bendings), which may, indicate 
the presence o f “impurities” in 
the aqueous commercial 
solution consisting most likely 
o f polymers with ether 
linkages
1113m 1111m 111 lw 1111m 1109m 1110m Secondary alcohol (C -0  bend)
1067m 1067m 1067 vw 1067m 1067w 1067m Primary alcohol (C -0  bend)
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858i 857i 857m sh 857i 858w 857i
The two bands fit with 
previous findings21 of the 
possible presence o f molecules 
such as molecule Vila. The
and and and and and and
authors assigned two bands at 
805 and 855 cm-1 as
808m 808i 806i 808i 808i 808m corresponding to the 811 and 872 cm-1 bands of 2-ethoxy-
cyclohexane, which indicated 
the presence o f molecule Vila 
(see appendix III for details)
Table 4.8: Assignment of the major peaks found from the infrared spectra (see figure 
4.10 and 4.11) of freeze-dried glutaraldehyde solutions at various pH values (pH 
range 1-11). Note: vw: very weak; w: weak; m: medium; i: intense; b: broad; sh: 
shoulder.
The spectra shown in figures 4.13 and 4.14 are quite different. However, from the 
summary of results presented above in table 4.8, it appears that a similar class of 
material is absorbing at the same frequency and thus many similarities can be 
observed. This reveals that there are similar groups (and likely similar molecules) 
present over a large pH range. This would agree with our previous findings (mass 
spectrometry, nuclear magnetic resonance).
The spectra from both samples (unbuffered glutaraldehyde at pH 3.8 and buffered at 
pH 4) are very similar and show the same pattern, considering the presence of buffer. 
This behaviour was expected since the unbuffered commercial glutaraldehyde has a 
pH value (3.8) close to pH 4. The infrared spectrum obtained from glutaraldehyde at 
pH 7.4 is also similar to that of glutaraldehyde at pH 4. However, some new bands in 
the 1800-1400 cm ' 1 region seem to differ and might be due to the presence of 
polymers of glutaraldehyde. It is thought that at physiological pH, a considerable 
amount of glutaraldehyde is polymerised through the aldol condensation mechanism 
(see chapter 2). The spectra obtained from freeze-dried solutions of glutaraldehyde at 
pH 9.2 did not reveal new bands in comparison to the spectra of glutaraldehyde at 
pH 7.4, except that their intensities differ, indicating that similar polymeric species 
are formed at these pH values (pH 4-9.2). The spectrum obtained from 
glutaraldehyde at pH 11 also shows a similar pattern to the one obtained at pH 9.2.
For example, the presence of a broad band at 3426cm'1 (stretching of the OH due to 
water, carboxylic groups, or alcoholic hydroxyl groups) can be partly explained 
because glutaraldehyde and its impurities (polymers of glutaraldehyde) have been
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reported to always contain variable amounts of water, even after drying under high
99vacuum . It seems that a similar statement can be made from our data obtained with 
freeze-dried samples. Comparison of the spectra from freeze-dried samples of 
glutaraldehyde with that from glutaric acid (not shown here), revealed that there was 
apparently no great presence of glutaric acid (molecule X, di-acid form of 
glutaraldehyde) as an impurity formed by oxidation, as has been hypothesised
23previously . The spectrum does not however rule out the hypothetical presence of 
the mono-acid form of glutaraldehyde (mol XI). Thus, it is most likely that the band 
at 3426 cm '1, is due to the presence of hydroxyl groups and/or the presence of water. 
However, and especially at high pH, this band may also be due to the presence of 
polymers containing some carboxylic groups (e.g. molecules that might have 
undergone Cannizzaro reactions).
Some strong, unresolved absorption bands, around 1200-900 cm '1, may be assigned 
to ether C -0 bonds, which may, for example indicate the presence of impurities in 
the aqueous commercial solution consisting of polymers with ether linkages. In 
addition, the presence of alcohol groups might be indicated by a band at 1067 cm '1, 
which is thought to be due to primary alcohol, and another one at 1115 cm '1, which 
may be due to secondary alcohol.
However, some dissimilarities can also be spotted, especially in spectra of 
glutaraldehyde at extreme pH values (pH 1 and 11) in comparison to other spectra. 
The weak, broad band found at 1611 cm ' 1 may be due to the presence of 
undetermined polymers formed specifically at very acidic pH (e.g. pH 1). No 
molecular structures of such undertermined polymers could be deduced from the 
analysis of glutaraldehyde at pH 1 because no 13C NMR data were available.
Additionally, a weak band at -1635 cm ' 1 and another band at -1568 cm ' 1 were not 
present in the spectra of glutaraldehyde at pH of less than 7.4. The band at -1568 
cm ' 1 is possibly due to the presence of carboxyl functions in the form of sodium
9  Asalts (see figure 4.15 below proposing a likely mechanism), the carboxylic acid 
groups possibly being formed by Cannizzaro reactions. A band at 1410 cm’ 1 can also 
be better observed with spectra at pH values above 7.4 and may thus be assigned to 
the symmetric stretching of the COO of the carboxylate group (sodium salt).
193
Figure 4.15: Mechanism of uptake of sodium cations by carboxylic acid
Also, the presence of some insoluble white glassy solid precipitates at high pH24 has 
been previously reported, although no precipitates were observed with our samples 
under these conditions. Such precipitates have been identified as trioxane-type 
glutaraldehyde oligomers also existing in glutaraldehyde solution as an impurity. 
Such copolymers existence was supported, in a later study by the same authors, by 
the existence of two absorptions at 1720 cm ' 1 and 1680 cm"1, assignable to O O  of 
saturated and unsaturated aldehydes25. Although no glassy solids were observed in 
our samples, the presence of such polymers is not totally precluded since it has 
already been reported that both insoluble and soluble polymers can coexist22 and one 
might be in the presence of the soluble type in our samples. It is also widely held that 
when the pH of glutaraldehyde solutions is increased to an alkaline value, the 
formation of polymers is likely favoured through aldol condensation reactions22,26 
(see chapter 2). Our spectra indeed corroborate the finding of such polymers (both 
aldol condensation and trioxane-type ones) with the presence of a weak band at 
-2725 cm"1 corresponding to a conjugated aldehyde (but not typical of the presence 
of such polymers), a band at -1722 cm ' 1 and two others that are more typical of the 
presence of such polymers. These were an intense band at 1683 cm ' 1 and a weaker 
band at 1635 cm"1, both of which are in agreement with the findings o f Monsan et 
al26.
4.3.5 Overall discussion of data obtained
Despite the impressive amount of literature available regarding the use of 
glutaraldehyde as a fixative for cells and tissues, there is still no definitive agreement 
about the main reactive species present in glutaraldehyde solutions during the cross- 
linking process. It is now generally agreed that commercially available aqueous 
solutions of glutaraldehyde are complex mixtures of the free aldehyde (reported no 
more than 4% 14), mono- and di-hydrated glutaraldehyde, monomeric and polymeric 
cyclic hemiacetals and various o;/3-unsaturated polymers; in addition, impurities can 
be detected in small quantities such as ethanol, methanol, acrolein, butyraldehyde,
97  70glutaraldoxime and glutaric acid ' . Furthermore, other structures, such as cyclic
glutaraldehyde oligomers with trioxane-type skeletons, have been reported24. 
However, the exact composition of glutaraldehyde in solution is still a matter for 
discussion, despite the publication of many reports over the last three decades (see 
chapter 2  for a complete review).
The ESI-MS results in this study from the analysis of a commercial unbuffered 
glutaraldehyde solution (pH 3.8) appear quite similar to those reported recently 
elsewhere31. However, our more detailed investigation of the mass spectral data 
allowed the determination of the hypothetical presence of other molecular structures, 
additional to the ones already reported by Southern et al31, such as monomeric and 
polymeric cyclic hemiacetal products, as well as aldol, di-aldol and single 
aldol/Michael condensation products. The analysis by ESI-MS of glutaraldehyde 
solutions at extreme pH values (pH 1 and 11) revealed different spectra to the one 
obtained from commercial glutaraldehyde solution (at pH 3.8), indicating the great 
influence of pH on the behaviour of glutaraldehyde in solution. A similar conclusion 
was derived from the data obtained using MALDI-TOF MS, along with the finding 
of the presence of many similar products formed in the pH range 4-9. This suggested 
that, in the pH range 4-9, some identical products are formed disregarding of the pH, 
while other structures seem to be more dependent on the pH of the solution. Our data 
suggest that the molecular weight of the largest molecules of glutaraldehyde 
oligomers does not exceed 700 (molecule XIV), which is similar to what was 
suggested by others based on gel permeation chromatographic data32, but different 
from what was reported by Southern31.
Despite the fact that it has recently been reported that no polyaldol condensation 
products of glutaraldehyde in solution were detected by NMR or even mass
33spectrometry , some m/z values were found corresponding to some polyaldol 
condensation products in both our ESI-MS and MALDI-TOF MS data 
(glutaraldehyde analysed under a pH 1-11 range). Our results suggest a large number 
of different aldol and aldol/Michael addition products, the majority o f which 
detected involving the equivalent of a maximum of five units of monomeric 
glutaraldehyde and in various hydrated states. However, some weaker signals 
corresponding to aldol and aldol/Michael products with an equivalent of a maximum 
of eight units of monomeric glutaraldehyde were also rarely detected. The formation 
of aldol condensation products is in agreement with some authors10,26 but in contrast
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to others34 who do not believe that such structures exist in unbuffered aqueous 
solutions of glutaraldehyde under the conditions studied. This conclusion may also 
differ from the findings of Southern31, who studied a similar unbuffered commercial 
glutaraldehyde solution solely by ESI-MS, reporting no long chain polymers of 
glutaraldehyde but who did not further confirm their findings with data from 
complementary techniques such as NMR and FTIR.
Our NMR data did not necessarily corroborate the mass spectrometric results, which 
agrees with Kawahara et al34. However, the low sensitivity of the NMR technique in 
comparison to that of mass spectrometry may account for the lack of signal 
attributable to aldol and aldol/Michael condensation products when glutaraldehyde 
was analysed over the pH range 3.8-9.2. The possible existence o f aldol and 
aldol/Michael addition products was however corroborated by NMR when 
glutaraldehyde at extreme pH values (pH 1 and 11) was analysed. Therefore it has 
been hypothesised that at extreme pH values, aldol and aldol/Michael addition 
products are formed in higher ratios than when under the pH range 3.8-9.2. Despite, 
these possible discrepancies, our results agreed with earlier NMR studies (]H NM R11 
and l 3C NMR14) and suggest the definite presence of the monohydrate, di-hydrates 
and cyclic hemiacetals which is also in accordance with various other authors15,35,36. 
Our data also indicate the possible presence of glutaraldehyde oligomers such as 
trioxane derivatives24,37 and other types of dimers38.
It is known that the polymerisation of glutaraldehyde is pH-dependent, with 
increasing polymerisation at higher pH. Our study clearly showed that 
glutaraldehyde solutions were prone to strong pH dependence. As the pH is 
increased in the range 4-8 and above, the free aldehyde is said to undergo base- 
catalysed aldol condensation followed by dehydration to form (2 ,/3-unsaturated 
oligomers. The more basic the solution, the more susceptible will be the aldehyde to 
condensation . At physiological and higher pH, the likely polyglutaraldehyde 
structures are thus aldol condensation reaction products (non-conjugated and 
conjugated aldehydes both identified from the infrared data), along with the 
possibility of additional Cannizzaro reactions at high pH leading to aldehyde 
pendants groups being replaced by hydroxyl and/or carboxyl groups39.
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Our data showed that these statements are not necessarily applicable to 
glutaraldehyde in solution. It appears from our mass spectrometric but especially 
from our NMR data, that glutaraldehyde has a strong tendency to polymerise at 
extreme pH values such as pH 11 but also at pH 1, comprising a;/3-unsaturated 
oligomers. The presence of possible Cannizzaro reaction products has also been 
identified in infrared and mass spectrometric data in this study. It is worth noting that 
air oxidation of the aldehyde groups of glutaraldehyde at relatively high pH values 
may also yield additional carboxyl groups.
At pH range 4-8, the presence of polymers is not as prevalent as at extreme pH 
values (NMR data), but many polymers of glutaraldehyde are thought to exist in 
solution (FTIR, MS data). The aldol condensation mechanism yielding ethylene 
linkages conjugated with aldehydes, along with the possible Cannizzaro reactions 
appear to be the best mechanism to explain the occurrence of these polymers of 
glutaraldehyde in the physiological pH range. This conclusion is supported by the 
possible presence of primary hydroxyl and carboxyl groups (infrared results) that can 
be explained by the occurrence of a Cannizzaro reaction. However, the results do 
also seem to indicate that the dehydration step of the typical aldol condensation 
reaction does not always occur at every consecutive step. This is supported by the 
lack of double bonds conjugated with aldehyde functions (seen from the NMR and 
FTIR data) and also the possible presence of secondary hydroxyl groups (seen in the 
FTIR data) that would be explained by this incomplete aldol condensation. Our 
findings thus agree with a previous report, where it was suggested from infrared and 
ultraviolet spectroscopic results that polyglutaraldehyde formed in the pH range 7-
9913.5, could be of this hydrated aldol form . Mass spectrometric data revealed the 
possible presence of such aldol and/or aldol/Michael polymeric structures in their 
hydrated states.
The MS results also show that the dimer is not the only polymer mainly present in 
commercial solutions of glutaraldehyde, as was previously reported40, but that many 
different molecular structures involving many glutaraldehyde molecules (possibly up 
to seven glutaraldehyde monomers) coexist in aqueous solution over a large pH 
range. Despite the possible formation of Cannizzaro products in solution at high pH 
(pH 11), the polymeric molecules of glutaraldehyde formed under a wide pH range 
(pH 1-11) would still remain reactive to further cross-linking and thus monomeric
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glutaraldehyde is not the only species capable of reacting at acidic or neutral pH in 
the cross-linking of proteins, as widely held and as stated by others41.
At acidic pH, a previous report34 stated that dilute glutaraldehyde solutions at acidic 
pH were almost monomeric, the major portion (-76%) taking the cyclic hemiacetal 
structure (the rest being monomeric glutaraldehyde ( 1 0 .8 %), mono- and di-hydrate 
glutaraldehyde (10.4% and 2.5% respectively)). Our mass spectrometric data did not 
corroborated these statements because, although some monomeric glutaraldehyde 
was found along with its hydrates, many other compounds are thought to be present 
in higher quantities. Additionally despite the fact that it has been mentioned34 that 
monomeric glutaraldehyde can only be converted to polymeric forms by the action 
of amino groups, species thought to correspond to some aldol/Michael addition and 
aldol condensation-like products were found (without any presence of amino groups 
to catalyse the reaction as it is believed34) at pH 4-9, using ESI-MS, MALDI-TOF 
MS and FTIR spectroscopy. These species were also identified on analysis of 
glutaraldehyde at pH 1 (ESI-MS results), with the findings being corroborated by the 
]H NMR and FTIR spectroscopic results.
4.4 Conclusion
Glutaraldehyde solution studied in a wide pH range was found to be extremely 
dependent on pH. Overall, the aqueous glutaraldehyde solutions (in the pH range 
3.8-9.2) appear to be extremely complex but also to contain similar molecular 
species. These consist essentially of glutaraldehyde hydrates, monomeric and 
polymeric cyclic hemiacetal products, and trioxane-type oligomers (molecules I, II, 
III, IVa, IVb, V, VI, VII, XII, XIII and XIV), but apparently do not contain large 
amounts of aldol, di-aldol, aldol/Michael condensation products or their 
corresponding hydration products, if one considers the NMR results as a determinant 
factor. The solutions of glutaraldehyde at extreme pH (pH 11 and also possibly at pH 
1) tend to behave differently, although the reactions may yield similar species but 
with different relative concentrations. At pH 1 and 11, the NMR data indicated the 
presence of similar structures as for glutaraldehyde solutions in the pH range 3.8-9.2, 
but also the greater prominence of species containing alkene unsaturated groups.
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Thus we can infer the likely presence of aldol and aldol/Michael condensation 
products, the majority of which would have undergone complete dehydration.
It therefore appears that the glutaraldehyde used in these experiments contains 
various amounts of a range of species, which are different from the “pure” 
monomeric glutaraldehyde form. This is in agreement with a previous report by 
Gillet and Gull23, where the relative glutaraldehyde polymer content of commercial 
unbuffered glutaraldehyde solutions was ascertained by spectrophotometric analysis. 
They found that many “high quality” commercial glutaraldehyde solutions (electron 
microscopy grade) contained large amounts of impurities that absorb at 234 nm and 
that they were under the specified standard of quality claimed by the suppliers42. The 
complexity of glutaraldehyde solutions should not however discourage its wide 
application, because all characterised forms of glutaraldehyde present in solution, 
including those identified in this study, seem to exhibit the ability to readily react 
and cross-link proteins.
It is believed that these results will provide a better insight into the chemistry of 
glutaraldehyde and to clarify the existing knowledge. Additionally, an understanding 
of the behaviour of glutaraldehyde in solution is thought to be essential if the 
interaction of glutaraldehyde with tissue such as bioprosthetic heart valves is to be 
predicted. In this respect, an entire chapter (chapter 5) will be dedicated to the 
investigation of the chemistry of the reactions of glutaraldehyde with proteins and 
more specifically bioprosthetic heart valves.
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Chapter 5
5 Investigation of the cross-linking occurring in 
glutaraldehyde-treated valve tissue.
Abstract
Objectives: A number of studies have investigated the reactions of glutaraldehyde 
with a range of model compounds, from the simplest amino acids to complex 
collagenous tissue. A number of structures for reaction products have been proposed 
but at present there is no definitive understanding of the process that take place. An 
understanding of the interactions between glutaraldehyde and tissue is thought to be 
essential in order to comprehend why bioprostheses calcify and ultimately fail. 
Furthermore, the exact mechanism of in-vivo calcification of glutaraldehyde-treated 
bioprostheses is unknown, although a great deal of effort has been directed at various 
aspects of the problem. Much of the work has been approached in an empirical 
fashion, due to the lack of specific knowledge regarding the mechanism of 
calcification. It is likely that the mechanism involves, amongst other factors, a 
contribution from the collagenous tissue itself and aldehyde fixative (glutaraldehyde) 
used routinely in the manufacture of bioprosthetic valves. Thus the objectives of this 
study were to investigate the reactions between glutaraldehyde and amines, peptides 
and proteins, to determine the molecular structures of the likely reaction products, 
and to extrapolate these to those occuring during the glutaraldehyde pre-treatment of 
bioprosthetic valves.
Methods: The reactions between glutaraldehyde and amines, peptides and proteins 
were investigated at a range of pH values (4-9.2) and subjected to analysis by matrix 
assisted laser desorption ionisation-time of flight mass spectrometry (MALDI-TOF
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MS), nuclear magnetic resonance (NMR), Fourier-transform infrared (FTIR) and 
Raman spectroscopy.
Results: Our results indicate that glutaraldehyde reacts with the amino groups in a 
wide range of pH (pH 4-9.2). The mass spectral, along with the NMR and FTIR data 
obtained for the products of the reaction between glutaraldehyde and small amines 
and peptides showed the presence of a rich palette of compounds such as aldol and 
aldol/Michael condensation products of glutaraldehyde, Schiff base moieties 
(including cross-links) and various cyclisation products incorporating pyridinium 
and dihydropyridine ring structures (see appendix IV for structural details). The 
results indicate the likely presence of 29 stable mono-bound structures along with 25 
stable multi-bound (cross-linking) entities including the anabilysine-like compounds, 
which is the only stable cross-linking entity reported so far in the literature. In 
addition, although the presence of stable structures was shown, other less-stable 
chemical entities were also characterised, which brought the hypothesis of their role 
in the tissue failure of bioprostheses (likely from in-vivo degradation of cross-linked 
tissue) but also of their potential role in the initiation of mineralisation from the 
presence of many free pendant electronegative groups.
Conclusion: The molecular structures of the likely reaction products formed between 
glutaraldehyde and amino groups are quite complex. Many new structures were 
proposed in addition to those already reported in the literature. Successful 
characterisation of some possible chemical structures involved in the reaction of 
glutaraldehyde and proteins, and their cross-linking is hoped to bring new insights 
into the complex model that represent the cross-linking of collagenous tissue used in 
many biomaterial applications. In addition, characterisation of unstable cross-links 
entities is also believed to give some reasonable hints as to why cross-linked 
bioprosthetic valves fail when implanted in-vivo.
5.1 Introduction
Commercial bioprosthetic heart valves fabricated from porcine aortic valves are 
usually treated with a low concentration glutaraldehyde solution (typically around 
0.5 %) for more than 24 hours to ensure optimum fixation1. Despite its wide use over
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the last three decades, the mode of action of glutaraldehyde has been the focus of 
many investigations2’4 (see chapter 2) and is still of concern these days. Although 
many physical factors influencing the cross-linking reactions have been elucidated, 
the chemical aspect of the actual cross-linking process is unknown. The 
discrepancies in the literature and the uncertainties in the chemical mechanism of the 
reaction of glutaraldehyde with proteins seem to be due to the complexity of the 
reaction. Isolation and characterisation of the reactions products would seem to be 
the most direct approach to understanding the mechanism, but the complex nature of 
the reaction suggests the difficulty of this approach. The problems encountered in 
determining the course of the reaction and the difficult characterisation of the 
products formed have thus impeded the complete elucidation o f the reaction 
mechanism involved5,6.
Calcification is the predominant cause in the failure of valve bioprostheses and 
although it is thought to be caused by a number of factors (see chapter 1 ), the 
mineralisation process has been attributed to the glutaraldehyde cross-linking
7 10process ' . It is thought to occur as a result of the formation of molecular species, 
which are believed to play a significant role by creating potential points that can trap 
foreign particles that may lead to nucleation centres for calcium and other ions 
involved in the mineralisation process.
The reaction of glutaraldehyde with the collagenous tissue of bioprosthetic tissue 
valves is heterogeneous and therefore difficult to study. Glutaraldehyde has been 
shown to react with a number of amino acids11,12 but in proteins, amino acid analysis
nhas shown that only the 6 -amino functions of lysine react to any significant extent . 
Small amines and peptides that mimic the lysine residues of proteins have therefore 
been chosen to model the reaction of glutaraldehyde with the 6 -amino functions of 
lysine present in collagen. 6 -amino-n-caproic acid was chosen, as its structure is 
similar to lysine but without the a-amino function. For the same reason N-a-acetyl 
lysine was chosen because the a-amino group is blocked. Additionally, the peptides 
(N-acetyl Gly Lys methyl ester acetate salt and N-acetyl Phe Lys) both contain a 
lysine moiety but with the a-amino function blocked leaving only the 6 -amino (6 - 
amino) group to potentially react. The study was also extended to include proteins 
that contain several lysine residues, for example lysozyme (containing six lysine
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residues) and cytochrome C (containing nineteen lysine residues), to determine the 
reaction products formed with glutaraldehyde in a more complex system.
5.2 Materials and methods
5.2.1 Materials
All chemicals and consumables used were of the best commercially available grade.
From BDH, UK: Glutaraldehyde 25% EM grade, pure ethanol, potassium 
dihydrogen orthophosphate.
From Sigma-Aldrich, UK: 6 -amino-n-caproic acid (also called amino-hexanoic acid) 
(Mw 131.2), N-a-acetyl lysine (Mw 188.2), N-acetyl Gly Lys methyl ester acetate 
salt (total Mw 319.4), N-acetyl Phe Lys (Mw 335), cytochrome C, lysozyme.
Methanol, trifluoroacetic acid, sinapinic acid (3,5-dimethoxy-4-hydroxycinnamic 
acid), 2,5-dihydroxybenzoic acid (DHB), a-cyano-4-hydroxycinnamic acid (a- 
CHCA), dipotassium hydrogen orthophosphate.
From Fisher, UK: Buffer pH 4 (potassium hydrogen phthalate) 0.05M, buffer pH 9.2 
(disodium tetraborate) 0.01M.
Prepared when required: Buffer pH 7.4 (phosphate) 0.03 M: 4.1 g KH2PO4 in 1 L 
water (stock A); 6.9 g K2HPO4 in 1 L water (stock B); mix 300 mL of stock A with 
700 mL of stock B. pH was adjusted to pH 7.4 with either stock solution, depending 
on resultant pH.
Ultra pure water: MilliQ50 (Millipore, UK) packed with USF liquid pure cartridges. 
The conductivity achieved was 18 MQ/cm3.
5.2.2 Sample preparation
The various model compounds used in this study (see figure 5.1 below for the 
corresponding structures) were fixed using an unbuffered solution of 0 .6 % v/v 
glutaraldehyde in water and in various aqueous pH buffers (pH 4, 7.4 and 9.2) for 14 
days in the dark at 37°C (see table 5.1 for details). Unbuffered commercial 
glutaraldehyde (0 .6 % v/v) in water was used as a control and was left under similar 
conditions for 14 days prior to being analysed. It has already been reported that the
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reactions of glutaraldehyde with proteins are complete after 7 days14. The solution of 
glutaraldehyde was diluted immediately before use from a 25% v/v commercial 
glutaraldehyde solution.
Model compound names 
(0.1% w/v) Glutaraldehyde (0.6% v/v) Solvents
6-amino-n-caproic acid 
(0.025 g, 1.90*1 O'4 moles) (0.6 mL, 6.36* 10'3 moles)
In buffers pH 4, 7.4, 9.2 and 
unbuffered in H20
N-a-acetyl lysine 
(0.025 g, 1.33*10'4 moles) (0.6 mL, 6.36* 10‘3 moles)
In buffers pH 4, 7.4, 9.2 and 
unbuffered in H20
N-acetyl Phe Lys 
(0.025 g, 7.46* 10‘5 moles) (0.6 mL, 6.36* 10'3 moles)
In buffers pH 4, 7.4, 9.2 and 
unbuffered in H20
N-acetyl Gly Lys methyl ester 
(0.025 g, 9.65*10'5 moles) (0.6 mL, 6.36*10'3 moles)
In buffers pH 4, 7.4, 9.2 and 
unbuffered in H20
Cytochrome C 
(0.025 g, 2.02*1 O'6 moles) (0.6 mL, 6.36*1 O'3 moles) Unbuffered in H20
Lysozyme 
(0.025 g, 1.75* 10"6 moles) (0.6 mL, 6.36* 1 O'3 moles) Unbuffered in H20
Table 5.1: Model compounc s fixation methodology.
The optimum molar ratio for the reaction of 0.1% w/v (0.025 g, 1.90*1 O' 4 moles) 6 - 
amino-n-caproic acid and glutaraldehyde reacted in water for 14 days was also 
investigated using FTIR-ATR. The molar ratio was changed by increasing the 
glutaraldehyde molar concentration as follows: (1:2), (1:4), (1:8), (1:11) and (1:33).
NH C = 0
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Figure 5.1: Molecular structures of some of the model compounds used in this study 
compared to lysine. (A) lysine; (B) 6 -amino-n-caproic acid; (C) n-acetyl-l-lysine; 
(D) n-acetyl phenylalanine lysine; (E) n-acetyl glycine lysine methyl ester.
5.2.3 Freeze-drier
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The freeze-drier used and the procedure employed were the same as the one stated 
previously in chapter 4 (section 4.2.3).
5.2.4 FTIR-ATR analyses
The methodology employed in this study was as described in chapter 4 (section 
4.2.4).
5.2.5 Raman analyses
The samples were freeze-dried on a quartz slide and analysed directly under the 
microscope of the Raman instrument. The instrument and methodology employed in 
this study were as described in chapter 4 (section 4.2.5).
5.2.6 NMR analyses
For the study of amino acids and peptides reacted or not with glutaraldehyde in water 
and in various pH buffers, the samples were prepared by freeze-drying 3 x 25 mL of 
solution (0 .1% w/v solution of amino-containing compounds, reacted or not with 
0.6% v/v glutaraldehyde). The samples were immediately re-dissolved in 3 mL of 
D2O and analysed. ]H (250 MHz) and 13C (63 MHz) NMR were then run on these 
samples. The NMR spectrometer used was a Bruker AC250 (Bruker Biospin, USA). 
The E field was of 58000 Gauss.
For the study of proteins (lysosyme and cytochrome C), reacted or not with 
glutaraldehyde in water and in various pH buffers, the samples were prepared the 
same way as for amino acids and peptides (see above). !H (400 MHz) and 13C 
(100MHz) NMR were then run on these samples. The NMR spectrometer used was a 
Bruker 400 (Bruker Biospin, USA). The E field was of 92800 Gauss.
5.2.7. ESI-MS analyses
The instrument and methodology employed in this study were as described in 
chapter 4 (section 4.2.6).
5.2.8 MALDI-TOF MS analyses
For the analysis of amino acids (6 -amino-n-caproic acid, N-a-acetyl lysine) and 
peptides (N-acetyl Phe Lys, N-acetyl Gly Lys methyl ester), samples (3 x 25 mL) of 
0.6% v/v glutaraldehyde-treated compounds in distilled water and in pH 4, pH 7.4
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and pH 9.2 buffers were freeze-dried and re-dissolved in 3 mL methanol. The 
instrument and methodology used in the amino acids and peptides study were as 
described in chapter 4 (section 4.2.7).
For the analysis of the proteins (lysosyme and cytochrome C), the matrix solution 
(DHB) was prepared as a 7 mg/mL solution in ethanol. A volume of 2 /xL of the 
proteins samples (0 .1% w/v) reacted or not with glutaraldehyde (0 .6 % v/v) was 
mixed with 20 /xL of the DHB matrix solution. One drop of trifluoro-acetic acid 
(0.1% v/v TFA) was added to facilitate the formation of a protonated molecular ion. 
The sample/matrix mixtures were spotted (~1 /xL droplet) onto a stainless steel 
modified 25-well MALDI target and left to air dry. The instrument used was a 
Finnigan Vision 2000 Reflectron MALDI-TOF MS (Finnigan Mat Ltd., Hemel 
Hempstead, Herts, UK) with a N2 (A=337 nm) laser and a linear time-of-flight mass 
analyser linked to a dedicated PC for data acquisition and manipulation of results. 
Only the positive mode was used in these investigations.
5.3 Results and discussion
5.3.1 Determination of optimum molar ratio
The optimum ratio for the reaction of ACA (6 -amino-n-caproic acid, an aliphatic 
amine mimicking the behaviour of lysine/hydroxylysine residues in tissue) with 
glutaraldehyde in solution was investigated by FTIR spectroscopy, altering the molar 
ratio by increasing the amount of glutaraldehyde in solution and keeping the amount 
of the aliphatic amine constant. The results obtained can be seen in figures 5.2 and
5.3 below. Figure 5.2 shows the various infrared spectra (expansion of the 3600- 
2 0 0 0  cm ' 1 region) obtained from freeze-dried glutaraldehyde-treated 6 -amino-n- 
caproic acid solutions at a range of molar ratios, while figure 5.3 shows an expansion 
of the 1800-600 cm ' 1 spectral region.
In figure 5.2, one can notice the presence of aromatics (band at 3060 cm '1) due to 
reaction products appearing at the 1:4 ratio (blue trace) but the intensity o f the peak 
clearly increases at the 1:8 ratio (green trace). The position of the 2929 cm ' 1 band 
(CH2 anti-symmetric stretch) characteristic of ACA (6 -amino-n-caproic acid) found 
in the silver trace is shifted slowly through the various increasing ratios until
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reaching 2932 cm ' 1 at the 1:33 ratio (brown trace). The ACA characteristic peak at 
2895 cm ' 1 disappears fairly quickly with increasing ratios: it is still observed at the 
1:2 ratio (black trace) but is barely seen at the 1:4 ratio (blue trace). The ACA band 
at 2856 cm ' 1 (CH2 symmetric stretch) is gradually shifted as the ratio increases, for 
example it is seen at 2860 cm ' 1 at the ratio 1 :2  (black trace) and at 2868 cm ' 1 at the 
1:33 ratio (brown trace), which are still thought to correspond to the symmetric 
stretching of CH2 . Many other peaks characteristic of the presence of 6 -amino-n- 
caproic acid (e.g. 2849, 2768, 2703, 2653, 2560 and 2496 cm '1) tend to disappear as 
the amount of glutaraldehyde is increased, i.e. these peak are still observed at the 1 :2  
ratio (black trace), are barely observed at the 1:4 ratio (blue trace) and can not be 
seen at ratios of 1:8 (green trace) and above. However, a band at 2724 cm ' 1 (anti­
symmetric stretching of the CH of an aldehyde group) looks present at the 1:11 ratio 
(red trace) and is definitely present at the 1:33 ratio (brown trace), which would 
indicate a large excess of glutaraldehyde at these ratios since this band is 
characteristic of glutaraldehyde (pink trace). In addition, the NH3+ stretch band at 
2 2 1 1  cm ' 1 disappears gradually with increasing ratio, being weaker at the 1 :2  ratio 
(black trace), just observed at the 1:4 ratio (blue trace), but not observed at ratios of 
1:8 (green trace) and above. This indicates uptake of the amino group in the reaction 
with glutaraldehyde.
Molar ratio study of the reaction between amino-n-caproic acid and glutaraldehyde
Black: 1:2 ratio 
Blue: 1 :4 ratio
Green: 1:8 ratio 
Red: 1:11 ratio
Brown: 1:33 ratio
Pink: 0:33 ratio (0.6%v/v Glutaraldehyde)
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Figure 5.2: FTIR-ATR spectrum (expansion of the 3600-2000 cm ' 1 region) obtained 
from the molar ratio study of the reaction between 6 -amino-n-caproic acid and 
glutaraldehyde (freeze-dried unbuffered aqueous solutions).
Molar ratio study of the reaction between amino-n-caproic acid and glutaraldehyde
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Figure 5.3: FTIR-ATR spectrum (expansion of the lSOO-bOOcm’ 1 region) obtained 
from the molar ratio study of the reaction between 6 -amino-n-caproic acid and 
glutaraldehyde (freeze-dried unbuffered aqueous solutions).
In figure 5.3 above, as soon as glutaraldehyde reacts with the aliphatic amine, the 
characteristic ACA band at 1683 cm ' 1 (possibly assigned to a v(C=0) acid mode) 
disappears, along with bands at 1651 and 1624 cm ' 1 (NH bending of the amine) and 
the ones at 1103 cm ' 1 (NH3+ rock/NH2 twist) and 1043 cm ' 1 (C-N stretch). These 
losses are expected because of the reaction of glutaraldehyde with the amino group 
of the aliphatic amine. Instead, other peaks appear in the region indicative of the 
reaction of the aliphatic amine with glutaraldehyde. For example, a band at 1710 cm' 
1 appears weak as early as at the ratio 1 :2  (black trace) and gets more intense with 
increasing ratio (from 1:2 to 1:11 ratios). However, this peak becomes a shoulder at 
the 1:33 ratio since another band at 1721 cm"1 (stretching of the CO groups of non­
conjugated aldehydes and possibly carboxylic acids) becomes more prominent from 
the 1:4 ratio to the 1:33 ratio. This seems to be indicative of the presence of excess of 
glutaraldehyde since this band is also present in the glutaraldehyde spectrum (pink 
trace). A new band at 1631 cm ' 1 can also be observed clearly at the 1:11 ratio (red
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trace) and could possibly be assigned to the formation of pyridinium ions, while the 
two characteristic peaks of the aliphatic amines at 1651 and 1624 cm ' 1 slowly 
disappear (see the 1:2 ratio, black trace). The characteristic doublet (1536 and 1560 
cm’1) assigned to the v(COO') anti-symmetric mode that can be observed in the ACA 
spectrum (silver trace), disappears as soon as glutaraldehyde is introduced (see the 
1:2 ratio, black trace), while a single unassigned band at 1562 cm ' 1 appears as early 
as at the 1:4 ratio (blue trace). A shoulder appears also at 1501 cm ' 1 at the 1:4 ratio 
(blue trace). The three characteristic peaks of ACA at 1469, 1452 and 1436 cm ' 1 
(assigned to 6 (CH2) mode) disappear slowly with an increasing ratio but can be still 
observed at the 1:2 ratio (black trace). However, two bands at 1460 and 1441 cm ' 1 
appear as a partially separated broad band (ratio 1:4, blue trace) and appear sharper 
with increasing ratio (ratio 1:33, brown trace). These bands can thus be assigned to 
the deformation of CH2 and CH groups, due to an excess of glutaraldehyde since 
bands at the same frequency are found in the spectrum of glutaraldehyde (pink 
trace). The sharp and intense characteristic band of ACA at 1388 cm ' 1 also 
disappears slowly (see ratio 1:2 black trace and ratio 1:4 blue trace), until it has 
disappeared completely at the ratio 1 :8  (green trace) leaving new bands that appear 
to belong to the reaction products (see appendix IV).
The overall results suggest an optimum molar ratio between about 1:2 and 1:4, with 
a preference for the 1:4 ratio. It would appear therefore that a molecule of an amino 
compound reacts with two to four molecules of glutaraldehyde, though this 
stoichiometric relationship may well vary depending on the amino compound used 
for the reaction study. Our data (molar ratio between about 1:2 and 1:4) agree with 
others who also tried to clarify the stoichiometric factor of the reaction between an 
aliphatic amine and glutaraldehyde in aqueous solution and who proposed the 
following molar ratio: 1 mole of amino residue: 3 moles of glutaraldehyde6, 2 moles 
of amino residues: 3 moles of glutaraldehyde5, 1 mole of amino residue: 4 moles of 
glutaraldehyde3,15’16.
5.3.2 General characteristics of the reactions of model compounds with 
glutaraldehyde
The products of the reaction of glutaraldehyde with amino compounds exhibit a 
yellow colour in solution at any pH studied. However, this colouration becomes
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more intense with an increasing pH. The extent of this colour production with lysine 
has been reported to be proportional to the glutaraldehyde concentration, when 
measured by UV absorbance at 460 nm, when reaction times were kept constant17. In 
this study, we observed a dark amber colouration at basic pH, and a yellow and pale 
whitish-yellow colour at physiologic and acidic pH respectively, which is in 
agreement with the statements of others7. Other likely explanation is that the colour 
is due to conjugated condensation products of glutaraldehyde or to oxidation 
products of pyridinium compounds and more probably the former because of the 
presence of double ethlenic bonds.
Monitoring the pH before and after combining glutaraldehyde and amino-model 
compounds in solution showed that immediately after combining them, the pH of all 
the reaction mixtures decreased slightly (the pH drop being more pronounced in the 
absence of buffer), a fact that was already underlined by others18,19. This can be 
partly explained by the uptake of basic amino groups in the reaction with 
glutaraldehyde. Alternatively, the solutions become more acidic because of 
deprotonation of the amino groups19. The reaction of glutaraldehyde with free amino 
groups causes the following dissociation equilibrium to be shifted to the right7 and 
thus neutral or basic pHs enhance this reaction20,21:
Protein-NH3+ O  Protein-NH2 + H+
This release of hydrogen ions contributes to the pH change in the tissue/model 
compounds during fixation with glutaraldehyde. One can consider that the isoelectric 
state (zwitterion) of the model compounds studied in this study would be observed 
over a wide pH range (4-8) similarly to glycine19. Since the amino groups, in order to 
react with glutaraldehyde, need to be deprotonated, this can explain the change in 
colour between pH 4-9 (more intense at high pH) because it would be easier for the 
reaction to take place at higher pH rather than at lower pH levels. Also, in order to 
explain this drop in pH, it has been previously documented that purified 
glutaraldehyde contains about 0 . 0 0 2  equivalents of hydrogen ions per mole of 
glutaraldehyde, the total amount of hydrogen ions released when added to
amines/proteins solutions being proportional to the concentration of primary
22amines . This could explain the slight drop in pH observed with all our samples 
(amino-containing compounds reacted with glutaraldehyde).
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5.3.3 Study of the reaction of glutaraldehyde with small amines and peptides
5.3.3.1 6 -amino-n-caproic acid reacted with glutaraldehyde:
5.3.3.1.1 ESI-MS:
A typical mass spectrum of the products of the reaction between 0.1% w/v 6 -amino- 
n-caproic acid and unbuffered 0.6% v/v glutaraldehyde in water (resulting pH of 
4.76) after 14 days is shown in figure 5.4 below. It appears that the reaction yields 
quite a complex palette of products, more complicated than what was previously
23reported , where the mixture was found to be composed of at least 1 2  unidentified 
compounds. A recent mass spectrometric study of the reaction products of 6 -amino- 
n-caproic acid and glutaraldehyde allowed the determination of ten molecular 
structures24,25, which represent only a few out of the ones depicted in this study (see 
table 5.1 and appendix IV for details of the m/z values and corresponding molecular 
structures, including references for some structures that have previously been 
assigned by others).
Scan ES+
1
.5 1 ?  543
Figure 5.4: ESI-MS spectrum of an unbuffered aqueous solution of glutaraldehyde- 
treated 6 -amino-n-caproic acid (resulting pH of 4.76). The inlet direct infusion of the 
sample was carried out at a rate of 5 /tL.min'1. The m/z range was 50-550.
For the sake of clarity, the characteristic ions in the mass spectrum obtained are 
summarised in table 5.2 (see appendices III and IV for details). The ions include
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protonated molecules [M +H]and [M+Na]+, and [M+K]+ adduct ions. Most spectra 
are dominated by intense [M+H]+ ions.
I T ) / /
Proposed 
assignment (Mw) m/z
Proposed 
assignment (Mw) m/z
Proposed 
assignment (Mw)
101 Mol 1(100) 308/309
Mol XVIa (282+Na), 
mol XVUa 
(282+Na), mol 
XXXIII (282+Na)
423
Mol XVIIlb 
(382+K), mol XVIlie 
(400+Na), mol 
XXXIVa (382+K); 
mol XXXVlIa 
(382+K)
183
Mol XV (182), mol 
XXXI (182), mol 
XXXII (182)
328
Mol LXI (326), mol
XXVI (328), mol L 
(328)
429
Mol XIX (428), mol 
LI (428), mol XCVII 
(390+K), mol 
XCVIII (389+K), 
mol CXVI (390+K)
194/195 Mol LXV (195), molLXVI (194) 342
Mol VI (318+Na), 
mol IX (301+K) 461
Mol CXIV (459), 
mol CLV (460), mol 
CLIX (459)
223
Mol XV (182+K), 
mol XVa (200+Na), 
mol XXXI (182+K), 
mol XXXII (182+K)
344 Mol LXXIII (344) 477 Mol CLXIX (477), mol CLXX (477)
238
Mol LX (223+Na), 
mol CLXXIII 
(214+Na)
360 Mol VI (318+K) 492/493
Mol CVIII (490), 
mol CXII (490), mol 
CXXIII (490), mol 
CXX1X (490), mol 
CXLVII (490), mol 
CLXVIII (490)
255
Mol LXII (231+Na), 
mol LXVII 
(231+Na), mol 
LXXII (231+Na), 
mol CLXXIII 
(214+K)
376/377/378
Mol CVI (377), mol 
CVII (377), mol 
CVIIa (377), mol 
CXI (377), mol 
CXXII (377), mol 
CXLIX (377), mol 
CXLIXa (376), mol 
CL (377), mol 
CLXVI (377), mol 
CLXXIV (378) mol 
CLXXV (376)
506
Mol XIXc (482+Na), 
mol XXXVIIIb 
(482+Na)
269
Mol XXIV 
(246+Na), mol XXV 
(228+K)
391/392/395
Mol XXIX (392), 
mol XCVII (390), 
mol XCVIII (389), 
mol CXVI (390), 
mol CXLI (395), mol 
CXLVIII (395), mol 
CLXIV (395)
509
Mol CXLII (508), 
mol CXLV (507), 
mol CXLVI (508), 
mol CLI (508), mol 
CLXV (508)
214
276/278 Mol CXV (277) 405
Mol XVIIIa
(364+K). mol 
XVI 11b (382+Na), 
mol XXXJV 
(364+K), mol 
XXXIVa (382+Na), 
mol XXXVII 
(364+K), mol 
XXXVlIa (382+Na), 
mol XLVI (364+K)
543 Mol Cl (520+Na)
294/295
Mol XCI1 (295), mol 
CIII (295), mol CIV 
(295), mol CV (295), 
mol CXIX (295), 
mol CXXXVII 
(295), mol CXXXIX  
(295)
410/411/
413/414
Mol XXVIII (410), 
mol LXIX (414), 
mol LXXVI (414), 
mol LXXX (413), 
mol XCIII (408), 
mol XCVI (408), 
mol CXVII (408), 
mol CXXXVIII 
(408)
Table 5.2: Proposed structures for the observed ions (see spectrum in figure 5.4) for
the analysis by ESI-MS of an unbuffered aqueous solution of glutaraldehyde-treated 
6 -amino-n-caproic acid. The molecule numbers refer to the molecular structures 
found in appendices III and IV (molecules in blue are due to excess glutaraldehyde, 
while the ones in black belong to the reaction products formed between 
glutaraldehyde and 6 -amino-n-caproic acid).
From the ESI-MS spectrum, one can assume that all the 6 -amino-n-caproic acid has 
totally undergone reaction with glutaraldehyde since no protonated molecular ion is 
observed (expected at ~m/z 132). The spectrum indicates the presence of various 
molecular structures, including the reaction products of the amino-compound with 
glutaraldehyde (in black in table 5.1) and also the presence of excess glutaraldehyde 
(in blue in table 5.2). The most intense ions that can be observed in figure 5.4 are 
discussed below, however a more complete account of all the molecules present in 
the spectrum according to their m/z values and structures can be found in table 5.2 
and appendices III and IV, respectively.
The intense ions detected at m/z 194/195 could indicate the presence o f molecule 
LXVI (quaternary pyridinium compound: 5-(pyridin-l-yl) caproic acid with Mw 
194), and the corresponding dihydropyridine (molecule LXV with Mw 195).
The intense signal of ions at m/z 391/392/395 could be due to the anabilysine-like 
compound (molecule XCVII with Mw 390 and molecule XCVIII with Mw 389) or 
an aldol dimer of glutaraldehyde that underwent two Schiff base reactions (molecule
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CXVI with Mw 390). They could also be indicative of a trialdol condensation 
product which underwent a Michael-type addition of the amine (molecule CXLI with 
Mw 395); a dialdol condensation product of glutaraldehyde that underwent a Schiff 
base addition and a Michael addition (molecule CXLVIII with Mw 395, or a dialdol 
condensation product that underwent a Mannich-type reaction forming a stable 
secondary amine (molecule CLXIV with Mw 395). These ions could also be due to 
the presence of an aldol condensation pentamer product of glutaraldehyde partially 
cyclised (molecule XXIX with Mw 392).
The molecule CXLVIII is also an intermediate in the formation of molecule CXLIXa 
with Mw 376 and the corresponding dihydropyridine molecule CXLIX (Mw 377), 
with m/z 376/377/378).
Relatively intense ions seen at m/z 276/278 may correspond to molecule CXV with 
Mw 277 (glutaraldehyde aldol dimer that underwent a Schiff base reaction).
The intense peaks at m/z 294/295 could indicate the presence of molecule XCII with 
Mw 295 (Schiff base on an dialdol condensation product), molecule CIII with Mw 
295 (Michael-type addition on a dialdol condensation product with a subsequent 
cyclisation), molecule CIV with Mw 295 (isomer of CIII with a different 
cyclisation), molecule CV with Mw 295 (isomer of CIII with a different cyclisation), 
molecule CXIX with Mw 295 (Michael-type addition on an aldol dimer of 
glutaraldehyde), molecule CXXXVII with Mw 295 (Schiff base addition on an aldol 
condensation product) or molecule CXXXIX with Mw 295 (dehydrated product of 
CXXXVII).
The intense signals at m/z 492/493 may be indicative of molecules CVIII with Mw 
490 (di-Schiff base addition on an aldol trimer), molecule CXII with Mw 490 (same 
as CVIII but with a subsequent cyclisation step), molecule CXXIII with Mw 490 (di- 
Michael-type addition on an aldol trimer), molecule CXXIX with Mw 490 (Michael- 
type addition and Schiff base on an aldol trimer), molecule CXLVII with Mw 490 
(di-Michael-type addition on an aldol trimer with a subsequent cyclisation step) or 
molecule CLXVIII with Mw 490 (Mannich-type addition followed by a cyclisation 
step and a Schiff base addition).
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Overall, there was also evidence of various Schiff base cross-links involving 
between two and five molecules of glutaraldehyde, along with more complicated 
structures (see table 5.1 and appendix IV).
5.33.1.2 MALDI-TOFMS:
The characteristic ions in the MALDI-TOF mass spectra (a typical MALDI spectrum 
is shown below in figure 5.5) of 6 -amino-n-caproic acid reacted with glutaraldehyde, 
buffered at pH 4, 7.4 and 9.2 for 14 days (see table 5.3 for summary of results) 
appeared to present many similarities in comparison to the ones obtained with 
glutaraldehyde-treated 6 -amino-n-caproic acid reacted in water (both ESI and 
MALDI mass spectra), suggesting the formation of similar reaction products. For 
instance, the two most intense peaks observed in the ESI-MS spectrum of unbuffered 
glutaraldehyde-treated 6 -amino-n-caproic acid (see above figure 5.4) also correspond 
to the most intense peaks in the MALDI-TOF spectrum (see below figure 5.5). These 
intense ions detected at m/z 194/195 could indicate the presence of molecule LXVI 
(quaternary pyridinium compound: 5-(pyridin-l-yl) caproic acid with Mw 194), and 
the corresponding dihydropyridine (molecule LXV with Mw 195). The intense peaks 
at m/z 391/392 could correspond to the anabilysine-like compound (molecule XCVII 
with Mw 390 and molecule XCVIII with Mw 389) or an aldol dimer of 
glutaraldehyde that underwent two Schiff base reactions (molecule CXVI with Mw 
390). These ions could also be due to the presence of an aldol condensation pentamer 
product of glutaraldehyde partially cyclised (molecule XXIX with Mw 392).
The spectra included protonated molecules i.e. [M+H]+ and [M+Na]+ and [M+K]+ 
adduct ions, with most being dominated by intense [M+H]+ ions. Similar m/z values 
to those discussed above (section 5.3.3.1.1) were observed allowing the conclusion 
that similar molecules to the ones already mentioned were present.
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Figure 5.5: Typical MALDI-TOF mass spectrum obtained from the analysis of 0.1% 
w/v 6 -amino-n-caproic acid reacted with 0 .6 % v/v unbuffered glutaraldehyde. 
Samples were freeze-dried and re-dissolved in methanol. The matrix (DHB) was 
prepared as a 7 mg.mL ' 1 solution in methanol. Samples rediluted in methanol were 
mixed with the matrix solution at a ratio of 1 :1 .
The MALDI-TOF MS analyses also allowed the investigation of the effect of pH on 
the reaction products of glutaraldehyde-treated 6 -amino-n-caproic acid. The effect of 
pH on the reaction of glutaraldehyde with 6 -amino-n-caproic acid has already been
9  f \reported by Ishii et al . They observed that after being reacted for 60 minutes, only 
40.2%, 88.1% and 86.1% of 6 -amino-n-caproic acid reacted with glutaraldehyde at 
pH 4, 7, and 10 respectively, and that the reaction products at pH 4 behaved 
differently (dye affinity assay) in comparison with the reaction products at pH 7 and 
10. However, when the reaction was continued further, the reaction products at pH 4 
bound the dye in a similar fashion to those at other pHs. We believed that, 
immediately after mixing chemicals together (glutaraldehyde and amino acid for 
example), the observed dark amber colouration at basic pH, the yellow and pale 
witish-yellow colour at physiologic and acidic pH respectively are due to the extent 
of reactions taking place in solution. In fact, all solutions at any kind of pH were 
recorded to exhibit a similar dark amber colour after being left for 14 days to react. 
Thus, our results agree undirectly with the findings of Ishii et al, since after the 
reaction has been allowed to proceed for 14 days, the reaction products would appear 
to be similar disregarding the pH (see below table 5.3). This led to the hypothesis of
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a time dependence of the reaction kinetics of the reactions involving glutaraldehyde 
and amino acids in solution at a pH range 4-9.
M/z 
(reactions 
products 
formed in 
H20 )
m/z 
(reactions 
products 
formed at 
pH 4)
m/z 
(reactions 
products 
formed at 
pH 7.4)
m/z 
(reactions 
products 
formed at 
pH 9.2)
Proposed Assignment (Mw)
23/24 23 23/24 23/24 Sodium (Na) cation
40/41 39/41 39/41 39/41 Potassium (K) cation
117 116/117 - 116/117/118 Mol XI (116)
- 120 119 120/122 Mol If (118); mol Iva and Ivb (118)
130 132/133 132 132/133 Mol X (132)
138 138 137 138 Mol 111(136)
- 142/144 144 141/144/145 Mol 1 (100+K); mol II (1 18+Na); mol IV (1 18+Na); mol XI(116+Na)
- 156/157 157/158/159 154/155/156
Mol 11 (1 18+K); mol III (136+Na); 
mol IVa and IVb (1 18+K); mol X 
(132+Na); mol XI(116+K)
- 168/169 164/166/168 161/163 Mol XXIII (163)
- 177 175/177 177/178 Mol III (136+K)
- - - 187/188/189 Mol XXIII (163+Na)
194/195/196 193/194/195 193/195 192/193 Mol LXV (195); mol LXVI (194)
- - 197/199 198/199/200 Mol XVa (200)
206 204/205 - 204/205
Mol Vila (202); mol VIII (202); mol 
XV (182+Na); mol XXIII (163+K); 
mol XXXI (182+Na); mol XXXII 
(182+Na)
- 212/215/217/218 212/214/215
212/213/215  
/2 16/217
Mol LX (213); mol LXV (195+Na); 
mol LXVI (194+Na); mol CLXXIII 
(214); mol V (218)
221 223 - 220/221
Mol LXV (195+Na); mol V (218);
mol XV (182+K); mol XVa 
(200+Na); mol XXXI (182+K); mol 
XXXII (182+K)
226 - - 225/227 Mol Vila (202+Na); mol VIII (202+Na); mol XVa (200+Na)
- 228/229 - 228/229 Mol XXV (228)
234 234 231/233 -
Mol LXII (231); Mol LXV (195+K); 
mol LXVI (194+K); mol LXVII 
(231); mol LXXII(231);
240 240/243 240/241 240/243
Mol V (218+Na); mol Vila (202+K); 
mol VIII (202+K); Mol XVa 
(200+K)
- - - 245/246/247 Mol XXIV (246)
- 252 - 252/256 Mol LX (213+K); mol LXXII (231+Na); mol XXV (228+Na)
- 265 266 264 Mol XVI (264); mol XVII (264); mol XX (264); mol XLV (264)
- - - 271/272
Mol LXII (231+K); mol LXVII 
(231+K); mol LXXII (231+K); mol
XXIV (246+Na)
276/278 277/279 276/278 - Mol CXV (277)
283 281/283 281/283 283/284 Mol XVla (282); mol XVIIa (282); mol XXXIII (282)
- - - 289
Mol XVI (264+Na); mol XVII 
(264+Na); mol XX (264+Na); mo! 
XLV (264+Na)
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294 294/295 294 -
Mol XCII (295); mol CIII (295); mol 
CIV (295); mol CV (295); mol CXIX 
(295); mol CXXXVII (295); mol 
CXXXIX (295)
304 304/305/306 305/306 303/304
Mol IX (301); mol XVI (264+K); 
mol XVIa (282+Na); mol XVII 
(264+K); mol XVIIa (282+Na); mol 
XVIa (282+Na); mol XX (264+K); 
mol XXXIII (282+Na); mol XLV 
(264+K)
309/311 308/312 - 311/312 Mol XXVII (310)
320 - - -
Mol XCII (295+Na); mol CIV 
(295+Na); mol CV (295+Na); mol 
CXIX (295+Na); mol CXXXVII 
(295+Na) mol CXXXIX (295+Na);
mol VI (318)
323/324 - - 324
Mol IX (301+Na); mol XII 
(300+Na); mol XVIa (282+K); mol 
XVIb (300+Na); mol XVIIa 
(282+K); mol XVIlb (300+Na): mol 
XXXIII (282+K)
332 332 332/333 332 Mol LXIII (332); mol LXXIV (331);mol XXVII (310+Na)
- 336/337 336 -
Mol LXVIII (314+Na); mol XCII 
(295+K); mol CII (313+Na); mol 
CIII (295+K); mol CIV (295+K); mol 
CV (295+K); mol CXIX (295+K);
mol CXXXIV (313+Na); mol 
CXXXV (313+Na); mol CXXXVII 
(295+K); mol CXXXIX (295+K); 
mol CXL ( 3 13+Na); mol CLXIII 
(313+Na)
339 340/341 342 -
Mol LXVIII (314+Na); mol VI
(3 18+Na); mol IX (301+K); mol XII 
(300+K); mol XVIb (300+K); mol 
XVIlb (300+K)
349 - 348 - Mol XVIII (346); XXVII (3 10+K)
368 - 368 368/371 Mol LXXII I (344+Na); mol XXVI (328+K); mol L (328+K)
376/377/378 377/379 377/379 378
Mol CVI (377); mol CVII and CVIIa 
(377); mol CXI (377); mol CXXII 
(377); mol CXLIX (377); CXLIXa 
(376); mol CL (377); mol CLXVI 
(377); mol CLXXIV (378); mol 
CLXXV (376)
- - - 383/385
Mol LXXII I (344+K); mol XVIII
(346+K); mol XVIIIb (382); mol 
XXXIVa (382); mol XXXVIIa (382); 
mol XLVII (346+K)
391/393 392/394 391/393 -
Mol XCVII (390); mol XCVIII 
(389); mol CXVI (390); mol XXIX 
(392)
- - 394/395 - Mol CXLI (395); mol CXLVIII (395); mol CLXIV (395)
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- - - 398/400/402
Mol CV1 (377+Na); mol CVII and 
CVIIa (377+Na); mol CXI (377+Na); 
mol CXXII (377+Na); mol CXLIX 
(377+Na); mol CL (377+Na); mol 
CLXVI (377+Na); mol CLXXIV 
(378+Na); mol CLXXV 
(376+Na);mol XVIIIc (400); mol 
XXX (374+Na)
- - - 406/407 Mol XVIIIb (382+Na); mol XXXIVa (382+Na); mol XXXVIIa (382+Na)
- 410 - 411
Mol XCIII (408); mol XCVI (408); 
mol CXVII (408); mol CXXXV1II 
(408); mol XXVI11 (410)
- - - 422/424
Mol XVIIIb (382+K); mol XVIIIc 
(400+Na); mol XXXIVa (382+K); 
mol XXXVIIa (382+K)
- 430 429 430
Mol XCVII (390+K);mol XCVIII 
(389+K); mol CXVI (390+K); mol
XIX (428); mol LI (428)
- - - 440/442
Mol LXIX (414+Na); mol LXXVI 
(414+Na); mol VII ( 4 18+Na); mol 
XVIIIc (400+K)
- - - 453
Mol LXIX (414+K); mol LXXVI 
(414+K); mol LXXX (413+K); mol
XIX (428+Na); mol LI (428+Na)
- 472 - 471/472
Mol LXXV (431+K); mol CLII 
(472); mol CLXVII (472); mol XlXa  
(446+Na); mol XLVIJl (446+Na)
475/478 477 478 477
Mol CXXVIII (455+Na); mol CLII 
(472); mol CLXIX (477); mol CLXX 
(477)
- - 482 -
Mol CXIV (459+Na); mol CLIX 
(459+Na); mol XIXc (482); mol 
XXXVIIIb (482)
491/493 491 - -
Mol CVIII (490); mol CXII (490); 
mol CXXIII (490); mol CXXIX 
(490); mol CXLVII (490); mol 
CLXVIII (490)
- - - 506 Mol XIXc (482+Na); mol XXXVIIIb (482+Na)
522 - - -
Mol XCIV (521); mol C (521); mol 
Cl (520); mol CXVIII (521); mol
(XIXc (482+K); mol XXXVIIIb 
(482+K)
575 - 574/576 - Mol CLXXVIII (574)
603 - - -
Mol CIX (603); mol CXXVI (603); 
mol CXXX (603); mol XXXIXa  
(564+K); mol XLIb (564+K)
638 - - - Mol LXXXIII (613+Na)
667 - - - MolXLII (628+K); mol LI 11 (628+K)
672 - - - Mol CLVII (672)
Table 5.3: Proposed structures for the observed ions for the analysis by MALDI- 
TOF MS of aqueous solutions of glutaraldehyde-treated 6 -amino-n-caproic acid
unbuffered in water and buffered at pH 4. 7.4 and 9.2. The molecule numbers refer 
to the molecular structures found in appendices ill and IV (molecules in blue are due
to excess glutaraldehyde, while the ones in black belong to the reaction products 
formed between glutaraldehyde and 6 -amino-n-caproic acid).
5.3.3.1.3 NMR:
The 'H NMR spectra of glutaraldehyde-treated 6 -amino-n-caproic acid obtained at 
various pH values can be found in figure 5.6 below.
Figure 5.6: 'H NMR spectra of unbuffered aqueous solution of glutaraldehyde- 
treated 6 -amino-n-caproic acid at pH 4.76 (top left), buffered at pH 4 (top right), 
buffered at pH 7.4 (bottom left) and buffered at pH 9.2 (bottom right). The samples 
were freeze-dried, re-dissolved in D2O and then analysed. Note that the strong extra 
bands (7.30-7.60 ppm) found in the spectrum at pH 4 correspond to the buffer 
(potassium hydrogen phthalate).
The proton NMR spectra, shown above in figure 5.6, although different to one 
another, exhibit many similar features. The broad peaks rendered the assignment of 
the peaks extremely difficult and the data obtained were mostly used to support the 
findings obtained by 13C NMR. Nevertheless, a rough tentative assignment was 
made and is shown below in table 5.4.
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Peak positions Proposed assignments
Broad absorption (1-2.2 ppm) 
centered at 1.6 ppm
Assigned to exchangeable hydroxyl proton, methylene and 
central methylene protons
Signals between 2.2-2.5 ppm Assigned to -C-CH 2-CO-N-R, -C-CH2-C=C-, -C-CH2-CO-R, - C-CH2-C=C-CO-, -C=C(CH2-)-CO or -C-CH2-N
Multiple weak signals between 
2.6-4.3 ppm
Assigned to -C-CH 2-OH, -C-CH2-OR, -CH2-N=, -CH2-C =0 or
=CH-N=
Complex broad absorption 
between 4.3-5.6 ppm
Assigned to -C=CH-, -CH=CO, hydroxyl, hydrated aldehyde 
protons and olefinic protons of aldol condensates
Signals at 7.4-8.5 ppm Assigned to aromatic protons and these of imine functions
Protons signals at 8.5-10 ppm Assigned to aldehyde bands indicating the presence of many different environments of these carbonyl protons
Table 5.4: Line assignment of H NMR spectra (spectra found in figure 5.6) of 
aqueous solutions of glutaraldehyde-treated 6 -amino-n-caproic acid at various pH 
values (pH 4-9.2). The samples were freeze-dried, re-dissolved in D20  and then 
analysed.
The NMR data corroborate the mass spectral results since it appears that all the 6 - 
amino-n-caproic acid has undergone reaction with glutaraldehyde (signals 
characteristic of the NMR analysis of 6 -amino-n-caproic acid (spectrum not shown) 
can not be found), whilst signal attributable to excess glutaraldehyde was also seen. 
Additionally, the presence of pyridinium compounds could be inferred from some 
characteristic peaks, for example the unresolved band at ~ 1 .2  (inside the broad band 
centered at 1 .6  ppm) could be considered as diagnostic for aromatic protons. 
Additionally, a band at -5 .4  can be assigned to the CH2 groups adjacent to N+, since 
the corresponding protons in cross-linking structures found in elastin (desmosine and 
isodesmosine) were reported to absorb at 5.5 and 5.45 respectively27. Peaks at 8-9 
ppm support the presence of substituted- and poly-substituted pyridine. However, 
our high-resolution NMR data failed to demonstrate the definite presence of 
polyaldol condensation products with almost no peaks detected at 6 - 8  ppm, but since 
these seem to be present from the MS data, they may be present at levels below the 
detection limit of this NMR experiment.
1 ^The C NMR spectra of glutaraldehyde-treated 6 -amino-n-caproic acid obtained at 
various pH values can be found in figure 5.7 below. Note that the extra bands
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(131.89, 133.25, 137.09 and 176.69 ppm) found in the spectrum at pH 4 correspond 
to the buffer (potassium hydrogen phthalate).
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1 oFigure 5.7: C NMR spectra of unbuffered aqueous solution of glutaraldehyde-
treated 6 -amino-n-caproic acid at pH 4.76 (top left), buffered at pH 4 (top right), 
buffered at pH 7.4 (bottom left) and buffered at pH 9.2 (bottom right). The samples 
were freeze-dried, re-dissolved in D2O and then analysed. Note the presence of the 
organic phtalate buffer in the spectrum at pH 4.
The C NMR spectra shown in figure 5.7 appear different to each another indicating 
a pH dependence. It would appear, however, that a similar class of material is 
producing a NMR pattern at the same position, thus indicating that structures with 
similar reacting groups are formed over this pH range (4-9.2). The major difference 
between the spectra is the peak intensities. There has been limited 13C NMR data 
related to the reaction between amino-containing compounds and glutaraldehyde 
reported in the literature, except for the spectrum of anabilysine , which is thought 
to be one likely cross-linking chemical structure. In an attempt to identify the 
chemical structures of the cross-links between hyaluronic acid and glutaraldehyde,
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1 "2C NMR spectra in the hydrated state were also measured but no convincing 
evidence for the nature of the cross-link was found29. Our 13C NMR data however 
contain evidence for the molecular structures already proposed from the mass
spectral data in this study. The chemical shifts of alkanes30, heterocyclic
2 1 2-2compounds and alcohols have already been reported and were of some use in 
assigning some of the signals and identifying the various organic compounds present 
in solution. Unfortunately, the signal to noise ratio was not optimum enough to allow
I T *full determination of all the C signals found in our spectra. Nevertheless, about at
I T *least fifty two C signals can be clearly identified above the signal to noise level. 
Many others are thought to be present but their intensities are not sufficient to be 
characterised. A tentative assignment was performed, the results of which are shown 
in table 5.5 below.
Peak positions Number of signals Proposed assignments
0-20 ppm 4 signals possibly assigned to -C H 2-CH2-CH(CHO)-CH= CH2-CH2-CH2- CH(CHO)=CH-, -C H 2-CH2-CH2-, -CH2-CH2-CH= or -CH2-CH2-C
20-32 ppm 10 signals
possibly assigned to =CH-CH2-CH(CH=)-CHO, -CH2-CH2-CH2, - 
CH2(=CH)-CH-CH2-, -CH2-CH2-CH=, =CH-CH2-C(-CH=)=CH-, - 
CH2-CH2-CH=N-, -CH2-CH2-C(-CH=)=CH-, -CH2-CH2-CH-(- 
CH=)-0-, -CH2-CH2-CH(-CH=)-N= or =CH-CH2-CH=
32-40 ppm 7 signals
possibly assigned to -C H 2-CH2-CH (-0-)-0-, -CH2-CH2-C (=0)-0-, 
-CH2-CH2-CH (-C4-N =, -CH2-CH2-CH(-0-)-NH-, -c h 2-c h 2- 
CH(-OH)-0-, C-CH-CH2-C, =CH-CH(-CH2-)-CH=, -CH2-CH(- 
CH=)-CH2-, -CH2-CH2-CH(-OH)-N=, -CH2-CH2-CH(-OH)-NH- 
or CH2-CH2-N=
40-70 ppm 7 signals
possibly assigned to -C H 2-CH2-NH-, -CH2-CH2-CHO, -CH2- 
CH=CH-N=, -CH2-CH(-N=)-CH=, -CH2-CH(CHO)-CH=, -CH2- 
CH2-NH-, =CH-CH(-CH2-)-N=, -C H 2-C H 2-N + s= -NH(-CH2-)-CH- 
C(-CH=)=CH-, -CH2(=CH-)-C-CH(-CH=)-N=, -CH2-CH(-C)-N=, 
-CH2-CH=CH(-CH2-)-CH=, -CH2-CH2-OH or -CH2-CH2-0 -
70-90 ppm 5 signals possibly assigned to -C H 2-CH(-CH=)-0-, -CH2(-OH)-CH-CH=, - NH-CH(-CH2-)-0-, -CH2-CH(-OH)-NH or -0-CH(-CH2-)-OH
90-130 ppm 9 signals
possibly assigned to -0-CH(-CH2-)-0-, -CH2(-OH)-CH-N+, -CH2- 
CH=CH-N=, =C=CH-N=, -CH2-CH-C=, -CH2-C(=CH-)-CH=, 
=N-CH=C(-CH2-)-CH=, =N-CH=CH- or -CH=CH-CH=
130-150 ppm 5 signals
possibly assigned to -C H 2-CH=CH-NH-, -CH2-CH=CH-N=, - 
CH2-CH=CH-N+ ^  =C(-CH2-)=C-N+ ^  -CH2(=CH-)-C=CH-, - 
CH2-CH=C(-CHO)-CH2-, =CH-CH=CH- or -CH-C(-CHO)-CH2-
150-200 ppm 1 signal possibly assigned to -N=CH-CH2-, -N=CH-CH=, -N=CH-C, -O- C(=0)-CH2-, -CH2-COOH or -CH2-CH(=CH-)-CH=0
200-220 ppm 4 signals possibly assigned to -C H 2-CH2-CH =0 or =CH(-CH2-)-CH-CH=0
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1 3Table 5.5: Line assignment of C NMR spectra of aqueous solutions of 
glutaraldehyde-treated 6 -amino-n-caproic acid (spectra found in figure 5.7). The 
samples were freeze-dried, re-dissolved in D2O and then analysed.
These results suggest that probably not only the double imine bond (C=N) 
characteristic of the Schiff base is formed, but also a double ethylenic bond (C=C) 
characteristic of unsaturated structures such as aldol polymers. In addition, the NMR 
results corroborate the findings obtained by mass spectrometry, providing further 
evidence for the proposed structures of the molecules. Our data also seem to show 
the presence of some aldol polymers of glutaraldehyde involved in cross-linking and 
possibly in their free form, since glutaraldehyde is found in excess. This may 
disagree with previous work6, where only a low amount of aldol polymers was 
reported to be formed in the solution during cross-linking, which suggested only a 
small contribution of these molecules to the cross-linking. Nevertheless, the presence 
of such aldol polymers formed in glutaraldehyde aqueous solution was shown in 
chapter 4 (according to the NMR data) to represent apparently a small contribution 
to the overall content of the glutaraldehyde solution (in the pH range 4-9), and they 
thus could only account for a small amount of cross-linking structures when reacted 
with the amino-compound, except if one assumes that the presence of the amino 
compound could catalyse a further formation of glutaraldehyde polymers. This has 
been suggested by others who reported that monomeric glutaraldehyde can only be 
converted to polymeric forms by the action of amino groups. But this is hard to 
confirm because the data obtained were not quantitative.
5.3.3.1.4 Raman spectroscopy:
The use of the dispersive Raman instrument was of limited value. All the samples 
reacted with glutaraldehyde (amino acids, peptides and proteins) showed a high 
degree of fluorescence, which totally masked the presence of Raman bands. Despite 
the use of a CCD camera and the known potential of the near-infrared laser to 
minimise fluorescence, successful analysis of the glutaraldehyde-reacted samples 
was not achieved. However, the spectra of all unreacted samples were recorded and 
kept for comparison with the infrared spectra of untreated samples. They were also 
used in the assignment of the infrared spectra of the freeze-dried glutaraldehyde- 
treated samples.
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5.3.3.1.5 Fourier-transform infrared spectroscopy:
The spectra of 6 -amino-n-caproic acid reacted with glutaraldehyde at various pH 
values (pH 4-9) are quite complex, but show very similar peaks (see figure 5.8 below 
for an example spectrum).
The bands at 2941 and 2868 cm ' 1 are CH stretching vibrations bands. Regarding the 
bands in the 1720-1600 region, previous authors34 reported some infrared bands in 
this region that were characteristic of the reaction of glutaraldehyde with aliphatic 
amino compounds (isopropylamine). They showed that an imine (Schiff base) was 
formed, by condensation between the amine and the aldehyde function. A band at 
1621 cm ' 1 was assigned to a conjugated imine, a shoulder at 1625 cm"1 was assigned 
to an alkene C=C bond or a conjugated imine, a broad peak at 1655 cm ' 1 was 
assigned to a double C=N bond (imine) and the band at 1720 cm"1 was assigned to a 
non-conjugated aldehyde function. The bands at 1625 and 1655 cm ' 1 were reported 
to be conjugated with each other35.
Our spectra also show the presence of aromatic groups (3057 cm '1), which could be 
assigned to the presence of pyridinium compounds, that are known to exhibit some 
characteristic bands at -3050 cm ' 1 (v CH), 1637-1630 cm ' 1 or 1538-1528 cm ' 1 (v 
ring). Thus the band at 1635 cm ' 1 can be tentatively assigned to pyridinium 
compounds, while the band at 1665 cm ' 1 can be attributed to an ethylenic bond 
(C=C). The presence of many peaks in the 1800-1400 cm ' 1 region did not facilitate 
their assignment, since they are generally broad and overlap each other. 
Nevertheless, the main peaks present in this region can definitely be assigned to the 
reaction products since they do not appear in the spectra of the starting materials (not 
shown here). Additionally, the peak at 1460 cm ' 1 may be due to the absorption of an
•j c 1aldimine . The complex pattern between 1200-800 cm' is reminiscent of the 
infrared spectrum found with glutaraldehyde (see chapter 4), which was attributed to 
polymeric forms of glutaraldehyde. This indicates the contribution of the 
glutaraldehyde in the protein-glutaraldehyde reaction and supports the theory that 
glutaraldehyde is present in excess.
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Figure 5.8: FTIR-ATR spectrum of a freeze-dried unbuffered aqueous solution of 6 - 
amino-n-caproic acid (0.1% w/v) reacted with 0.6% v/v glutaraldehyde (resulting pFl 
of 4.76).
5.3.3.2 N-acetyl-L-lysine and glutaraldehyde:
There was a general similarity between the reactions of the various model 
compounds (N-a-acetyl lysine and 6 -amino-n-caproic acid) with glutaraldehyde, a 
fact that had been observed previously by others . The same reactions seemed to 
occur between glutaraldehyde and 6 -amino-n-caproic acid acid or N-a-acetyl lysine, 
however, the final structures formed differed due to differences in the radical groups 
(R) of the two compounds (see appendix IV).
5.3.3.2.1 ESI-MS:
The results can be seen in figure 5.9 and table 5.6 below.
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Figure 5.9: ESI-MS spectrum of a freeze-dried unbuffered glutaraldehyde-treated N- 
acetyl-L-lysine solution in water (resulting pH 3.96). The inlet direct infusion of the 
sample was carried out at a rate of 5 pL.min"1. The m/z range was 50-550.
m/z Proposed assignment (Mw) m/z
Proposed assignment 
(Mw) m/z
Proposed assignm ent 
(Mw)
120/
123
Mol I (100+Na), mol II 
(118), mol IVa and IVb 
(118)
324
Mol IX (301+Na), mol XII 
(300+Na), mol XVIb 
(300+Na), mol XVIlb 
(300+Na)
448
Mol XlXa (446), mol 
XXXVIII (446), mol 
XLVIII (446)
155 Mol X (132+Na), mol XI (116+K) 333 Mol XXVII (3 10+Na) 453
Mol XIX (428+Na), mol 
LI (428+Na). mol CXLI 
(452), mol CXLVIII (452), 
mol CLXIV (452)
201 Mol XVa (200) 336 Mol CXV (334) 466/468
Mol XIX (428+K), mol 
XI Xb (464), mol XXXV 
(464), mol XXXVI (464), 
mol XXXVIIIa (464), mol 
LI (428+K)
206
Mol XV (182+Na), mol 
XXXI (182+Na), mol 
XXXII (182+Na)
351/
352
Mol XXVI (328+Na), mol 
XXVII (310+K), mol L 
(328+Na). mol XCII (352), 
mol CIII (352), mol CIV 
(352), mol CV (352), mol 
CXIX (352), mol 
CXXXVII (352), mol 
CXXXIX (352)
480 Mol LXI (440+K)
229
223/
224
Mol XV (182+K), mol 
XVa (200+a), mol XXXI 
(182+K), mol XXX11 
(182+K)
365
Mol XVIIIa (364), mol 
XXXIV (364). mol 
XXXVII (364), mol XLVI 
(364)
485
Mol XlXa (446+K), mol 
XIXc (482), mol XXXVIII 
(446+K), mol XLVIII 
(446+K). mol LXIII 
(446+K)
251/
252
Mol XXV (228+Na), mol 
LXV (252), mol LXVI 
(251)
385/
387
Mol XVIII (346+K), mol 
XVIIIa (364+Na), mol 
XXXIV (364+Na), mol 
XXXVII (364+Na), mol 
XLVI (364+Na), mol 
XLVII (346+K)
506/
507
Mol XIXc (482+Na), mol 
XXXVII la (464+K), mol 
XXXVIIIb (482+Na), mol 
XCVII (504), mol CXVI 
(504)
273 Mol LX (270), mol CLXXIII (271) 401 Mol XVIIIc (400) 520 Mol CLV (517)
282
Mol XVIa (282), mol 
XVIIa (282), mol XXXIII 
(282)
417/
419
Mol VII (418), mol XXIX 
(392+Na) 528
Mol XLI (528), mol LII 
(528), mol LXXV 
(488+K), mol XCVII 
(504+Na), mol XCVIII 
(503+Na), mol CXVI 
(504+Na)
305
Mol XVI (264+K), mol 
XVIa (282+Na), mol XVII 
(264+K), mol XVIIa 
(282+Na), mol XX 
(264+K), mol XXXIII 
(282+Na), mol XLV 
(264+K)
433/
434
Mol XXVIII (4 10+Na), 
mol XXIX (392+K), mol 
CVI (434), mol CVII 
(434), mol CVIIa (434), 
mol CXI (434), mol CXXII 
(434), mol CXLIX (434), 
mol CXLIXa (433), mol 
CLXVI (434), mol 
CLXXV (433)
Table 5.6: Proposed structures for the observed ions (see spectrum in figure 5.9) for 
the analysis by ESI-MS of a freeze-dried unbuffered solution of glutaraldehyde- 
treated N-acetyl-L-lysine (molecules in blue are due to excess glutaraldehyde, while 
the ones in black belong to the reaction products formed between glutaraldehyde and 
6 -amino-n-caproic acid). The molecule numbers refer to the molecular structures 
found in appendices III and IV.
The mass spectral results obtained from the products o f the reaction of 
glutaraldehyde with N-acetyl-L-lysine are very much like the ones already described 
(see section 5.3.3.1) for the reaction between glutaraldehyde and 6 -amino-n-caproic 
acid. The major ions detected, at m/z 251/252, again indicated the presence of 
molecule LXVI (a quaternary pyridinium compound with Mw 251), the 
corresponding dihydropyridine structure (molecule LXV with Mw 252) and possibly 
the presence of the glutaraldehyde-based aldol trimer molecule XXV (Mw 228 + 
sodium adduct). The other most intense peaks, at m/z 506/507, could be assigned to 
the presence of molecule XCVII (an anabylisine-like compound with Mw 504) and 
an aldol dimer of glutaraldehyde that underwent two Schiff base reactions (molecule
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CXVI with Mw 504), along with the presence of glutaraldehyde molecules in excess 
in solution, such as molecules XIXc (fully hydrated aldol condensation pentamer 
product with Mw 482 + sodium adduct), XXXVIIIa (partially hydrated aldol 
condensation/Michael pentamer product with Mw 464 + potassium adduct) and 
XXXVIIIb (fully hydrated aldol/Michael pentamer product with Mw 482 + sodium 
adduct).
5.3.3.2.2 MALDI-TOF MS:
The characteristic ions seen in the MALDI-TOF mass spectra of the reaction 
mixtures at various pH values (pH range 4- 9.2) were virtually the same as the ones 
observed by ESI-MS for the analysis of unbuffered glutaraldehyde-treated N-acetyl- 
L-lysine (pH 3.96). The spectra included protonated molecules i.e. [M+H]+, along 
with [M+Na]+ and [M+K]+ adduct ions. Most spectra were also dominated by 
intense [M+H]+ ions and exhibited peaks with similar m/z values to those seen in 
table 5.5 (e.g. very intense peaks at m/z 252 or m/z 506). This therefore led to the 
conclusion that species to those identified from the reaction between glutaraldehyde 
and 6 -amino-n-caproic acid were present. These Maldi-TOF MS data were quite 
identical to those observed for the MALDI analysis of glutaraldehyde-treated 6 - 
amino-n-caproic acid (e.g. the intense peak observed below at m/z 607 in figure 5.10 
correspond to the peak at m/z 491 found in figure 5.5). A typical MALDI-TOF mass 
spectrum obtained from the analysis of unbuffered glutaraldehyde-treated N-acetyl- 
L-lysine is shown below in figure 5.10.
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Figure 5.10: Typical MALDI-TOF mass spectrum obtained from the analysis of 
0.1% w/v N-acetyl-L-lysine reacted with 0.6% v/v unbuffered glutaraldehyde. 
Samples were freeze-dried and re-dissolved in methanol. The matrix (DHB) was 
prepared as a 7 mg.mL ' 1 solution in methanol. Samples re-diluted in methanol were 
mixed with the matrix solution at a ratio of 1 :1 .
53.3.2.3 NMR:
The NMR data obtained in the study of glutaraldehyde-treated N-acetyl-L-lysine 
revealed similar peak patterns to those found in the study of 6 -amino-n-caproic acid.
1 TTypical C NMR spectra of glutaraldehyde-treated N-acetyl-L-lysine, obtained at 
various pF[ values, can be found in figure 5.11 below.
  1 1T •There was a general similarity between the NMR spectra ( H and C) from reactions 
of glutaraldehyde-treated N-a-acetyl lysine and those from the analysis of 
glutaraldehyde-treated 6 -amino-n-caproic acid (see figures 5.6 and 5.7 in section 
5.3.3.1.3). All four NMR spectra are different from one another, revealing the pH 
dependence of the reactions of glutaraldehyde with amino acids. However they 
contain many similarities in their pattern, indicating the presence of similar reactive
ngroups in reaction products. The assignment of the C signals were found very 
similar to those proposed for the analysis of glutaraldehyde-treated 6 -amino-n- 
caproic acid (found in table 5.4 in section 5.3.3.1.3). This suggests that the NMR 
results also corroborate the findings obtained by mass spectrometry, providing 
further evidence for similar structures of the molecules to those proposed for the
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analysis of the reaction products of glutaraldehyde-treated 6 -amino-n-caproic acid. 
The same reactions therefore seemed to occur between glutaraldehyde and lysino 
group-containing model compounds such as 6 -amino-n-caproic acid and N-acetyl-L- 
lysine.
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Figure 5.11: 13C NMR spectra of unbuffered glutaraldehyde-treated N-acetyl-L- 
lysine at pH 3.96 (top left), buffered at pH 4 (top right), buffered at pH 7.4 (bottom 
left), buffered at pH 9.2 (bottom right). Note that the extra bands (at ca. 132, 133, 
137 and 177 ppm) found in the spectrum at pH 4 correspond to the buffer (potassium 
hydrogen phthalate). The samples were freeze-dried, re-dissolved in D2O and then 
analysed.
53.3.2.4 Fourier-transform infrared spectroscopy:
The infrared spectra obtained from the products of the reaction of N-acetyl-L-lysine 
with glutaraldehyde at various pH values (pH 4-9) are quite complex, but appear to 
display similar peak patterns to one another. Figure 5.12 shows an example 
spectrum. In addition, this pattern appears to be almost identical to the one described 
previously for the analysis of glutaraldehyde-treated 6 -amino-n-caproic acid. This 
therefore allows the hypothesis that similar chemical structures species are formed
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during the reaction between glutaraldehyde and -acetyl-L-lysine, as seen been 
glutaraldehyde and 6 -amino-n-caproic acid.
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Figure 5.12: FTIR-ATR spectrum of a freeze-dried unbuffered aqueous solution of 
0.1% w/v N-acetyl-L-lysine reacted with 0.6% v/v glutaraldehyde (resulting pH 
3.96).
5.3.3.3 Peptides (N-acetyl glycine lysine methyl ester, N-acetvl phenylalanine 
lysine) and glutaraldehyde:
The data obtained from the analyses of the reaction of two peptides with 
glutaraldehyde were similar to those reported in sections 5.3.3.1 and 5.3.3.2 and 
hence are not shown here. It can however be concluded that similar compounds to 
those reported for the reactions of 6 -amino-n-caproic acid and N-acetyl-L-lysine 
with glutaraldehyde are formed.
5.3.4 Study of the reaction of glutaraldehyde with proteins (cytochrome C and
lysosyme)
5.3.4.1 MALDI-TOF MS results and discussion from the study of proteins:
5.3.4.1.1 MALDI-TOF M S data from the study o f  lysosyme:
The first of the two proteins studied was lysosyme; it contains 7 primary amino 
groups ( 6  lysines and one amino terminus). The results obtained from the MALDI- 
TOF MS analyses showed some interesting features and indicate the suitability of
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MALDI-TOF MS in the determination and analysis of the multimericity of proteins 
after cross-linking with glutaraldehyde. Both non-cross-linked and glutaraldehyde- 
cross-linked proteins were analysed (see figure 5.13 below).
Figure 5.13: MALDI-TOF mass spectra of (on the left) non-cross-linked lysosyme 
(1.75 /xmol), and (on the right) 1.75 /rniol lysosyme cross-linked with 0.6% v/v 
glutaraldehyde (6.36 mmol). All samples were freeze-dried, re-dissolved in pure 
ethanol and mixed with DHB matrix solution in the ratio 1:10. One drop of TFA was 
added to facilitate the formation of a protonated molecular ion.
The non-cross-linked lysosyme spectrum shows signals at m/z 7244 corresponding
2_j_ _l_to [M+2H] and m/z 14279 corresponding to [M+H] . There are also some laser- 
induced multimers at m/z 28571 ([2M+H]+), m/z 42813 ([3M+H]+), m/z 56866 
([4M+H]+), along with a weaker signal at ca. m/z 70000 which corresponds to 
[5M+H]+. Thus, the MALDI-TOF MS results may show that the proteins can 
undergo dimerisation, possibly due to attractive interaction between specific charged
n ,groups, similar to other protein behaviour already reported in the literature . Since 
after treatment with glutaraldehyde, the standard peaks obtained for lysosyme were 
no longer present, it was inferred that all the protein had undergone reaction with 
glutaraldehyde. The peaks obtained from glutaraldehyde-treated lysosyme indicate 
the addition of about 12 or 15 glutaraldehyde molecules if we consider (disregarding 
the likely presence of oligomers of glutaraldehyde) its monomer mass to be 82 Da or 
64 Da by assuming that one or both of the aldehyde groups have reacted. Peaks are 
observed at m/z 7756 ([M+2H]2+ +512  Da); m/z 15263 ([M+H]+ + 983 Da, which 
corresponds to either -12  or -15 glutaraldehyde molecules); m/z 30623 ([2M+H]+ + 
2064); m/z 46122 ([3M+H]+ + 3286 Da); m/z 61827 ([4M+H]+ + 4709 Da); and a 
small weak hump possibly corresponding to [5M+H]+ + glutaraldehyde molecules. 
The mass increase is almost linear, which is to be expected. The observed multimers
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that are thought to be laser-induced, could also be seen as possible intermolecular 
cross-links, since mono-, di-, tri- and tetramers of glutaraldehyde-treated lysosyme 
have already been hypothesised by others who used chemical cross-linking with 
glutaraldehyde to study crystallizing lysosyme solutions by gel electrophoresis 
(SDS-PAGE). This does, however, it seems unlikely in our work since some 
multimers are also observed in the MALDI-TOF mass spectrum of the untreated
'inprotein. The number of bound glutaraldehyde molecules observed by Wang et al 
somewhat exceeded the number of amino groups present, and hence they suggested 
that some of the amino groups reacted with previously formed glutaraldehyde 
oligomers. Our data agree with this statement because the number of bound 
glutaraldehyde molecules somewhat exceeded the number of amino groups.
If we consider that theoretically all 6  lysine groups are available to react with 
glutaraldehyde, then it would appear that about 2-3 glutaraldehyde molecules reacted 
per lysine residue. Our results are thus in agreement with some work from previous
1 0authors who reported the successful application of MALDI-TOF MS for studying 
cross-linked proteins, emphasizing the main advantages of the method i.e. its 
rapidity, simplicity and relative accuracy. By studying various proteins, including 
egg white lysosyme, Helin et al thus reported that there was no observable protein 
concentration dependence on the binding of glutaraldehyde (over the lysosyme 
concentration range 5-80 jidVI), however, they did not study lysosyme at the low 
concentration (1.75 fiM) used in this study. In addition, no laser-induced multimers 
in either untreated or glutaraldehyde-treated lysosyme were observed in their mass 
spectra. Nevertheless, although the exact value was not given, the major signal 
obtained at their lowest lysosyme concentration (5 fiM) reacted with 0.6% v/v 
glutaraldehyde appeared to be in the vicinity of our data (-15225 m/z by 
interpolation, which corresponds to [M+H]+ with in addition -14  glutaraldehyde 
molecules). Therefore, it would appear that at such a low concentration of lysosyme, 
there is also no protein concentration dependence in the binding of glutaraldehyde 
since the m/z value for the major peak found in this study appears to corroborate the 
work of Helin et al.
5.3.4.1.2 MALDI-TOF MS data from the study o f  cytochrome C:
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The second of the two proteins studied was cytochrome C; it contains 19 lysine 
groups. Both non-cross-linked and glutaraldehyde-cross-linked proteins were 
analysed (see figure 5.14 below).
Figure 5.14: MALDI-TOF mass spectra of (on the left) non-cross-linked cytochrome 
C (2.02 /miol), and (on the right) 2.02 /xmol cytochrome C cross-linked with 0.6% 
v/v glutaraldehyde (6.36 mmol). All samples were freeze-dried, re-dissolved in pure 
ethanol and mixed with the DHB matrix solution in the ratio 1:10. One drop of TFA 
was added to facilitate the formation of a protonated molecular ion.
The non-cross-linked cytochrome C spectrum shows main signals at m/z 12360 
corresponding to [M+H]+, followed by some laser-induced multimers at m/z 24719 
([2M+H]+), m/z 37123 ([3M+H]+), m/z 49471 ([4M+H]+) and at m/z 61879 
([5M+H]+), along with other weaker signals, which probably correspond to [6 M+H]+ 
and [7M+H]+. Since after treatment with glutaraldehyde, the standard peaks obtained 
for cytochrome C were no longer present, this indicated that all the protein had 
undergone reaction with glutaraldehyde. After cross-linking, the mass spectra exhibit 
broadening of the peaks (a decrease in resolution), which may imply a more 
heterogeneous sample. This could be seen as various reaction products around the 
same m/z and the addition of different numbers of glutaraldehyde molecules but 
resulting in a relatively similar m/z. The peaks obtained from glutaraldehyde-treated 
cytochrome C indicate the addition of about 32 or 41 glutaraldehyde molecules if we 
consider (disregarding the likely presence of oligomers of glutaraldehyde) its 
monomer mass to be 82 Da or 64 Da by assuming that one or both of the aldehyde 
groups have reacted. Peaks are observed at m/z 15005 ([M+H]+ + 2645 Da, which 
corresponds to either ~32 or ~41 glutaraldehyde molecules); m/z 30125 ([2M+H]+ + 
5406 Da); m/z 45376 ([3M+H]++ 8253 Da); m/z 60682 ([4M+H]++ 11211 Da); m/z 
76092 ([5M+H]+ + 14292 Da); and some small weaker humps possibly
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corresponding to [6 M+H]+ and [7M+H]+ with a corresponding molecular mass 
increase. The general mass increase is almost linear. The number of bound 
glutaraldehyde molecules somewhat exceeded the number of amino groups 
(similarly to what was found with glutaraldehyde-cross-linked lysosyme), and this 
suggests that some of the amino groups reacted with previously-formed 
glutaraldehyde oligomers incorporating several glutaraldehyde monomeric moieties. 
If we consider that theoretically all 19 lysines groups of the protein are available to 
react with glutaraldehyde, then it would appear that about 2  glutaraldehyde 
molecules reacted per lysine residues.
Our data disagree with the results reported by Ohno and Kurusu39,40, who studied the 
electrochemical response of cross-linked cytochrome C in PEO oligomers with the 
same concentration of cytochrome as the one used in this study (0.1 g.L"1). Their
9-4-results do not reveal any laser-induced multimers and only show the [M+2H] and 
[M+H]+ signals at m/z 6203 and 12413 for untreated cytochrome C and at m/z 6289 
and 12561 for treated-cytochrome C, which involves an increase in molecular mass 
of only 8 6  and 148 Da respectively for the [M+H]+ and [M+2H]2+ signals. From 
these results, they only concluded the presence of a specific intramolecular cross- 
linking, involving only the mass equivalent of two glutaraldehyde monomeric 
molecules per cytochrome C. In contrast, our results clearly suggest a mean of about 
36 glutaraldehyde monomeric molecules involved in intramolecular cross-linking, 
which corresponds to about 2  glutaraldehyde molecules per lysine residue of the 
cytochrome C. Furthermore, the multimers observed could also be seen as possible 
intermolecular cross-linking, although this seems unlikely since some multimers are 
also observed with the untreated proteins and are attributed to a laser-induced effect. 
Nevertheless, if one of the aldehyde groups of a monomeric glutaraldehyde 
theoretically binds to a lysine on one protein molecule and the other aldehyde binds 
to a lysine on another protein molecule, then the two proteins are linked together by 
one glutaraldehyde, forming an intermolecular cross-link and roughly doubling the 
molecular weight. Also, if the protein contains many more than two lysines, another 
glutaraldehyde molecule can propagate a branch to a third protein molecule and this 
can branch yet again, resulting in a star-shaped polymer, still by inter-molecular 
cross-linking. Such inter-molecular cross-links have already been deliberately
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produced with another protein (bovine serum albumin) for use as molecular weight 
markers to calibrate electrophoresis gels41.
5.3.4.2 MR results and discussion from the study of proteins:
The NMR spectra ( ]H and 13C) of glutaraldehyde-treated proteins, (see figure 5.15 
below, where only the NMR spectra from the analysis of glutaraldehyde-treated 
lysosyme are shown), were observed to be very different to those from unreacted 
proteins (results not shown here), indicating that a reaction took place and that the 
majority of the protein (if not all) may have reacted with glutaraldehyde. Generally, 
however, the spectra from the glutaraldehyde-treated proteins were quite weak and 
unfortunately did not allow proper discrimination of all the peaks. Nevertheless, 
some interesting features can be outlined.
Due to the large excess of glutaraldehyde present in the reaction mixture of
13 1glutaraldehyde-treated lysosyme (molar ratio of 1:3634), both C and H NMR 
spectra (observed below in figure 5.15) exhibit mostly the characteristic signals of 
glutaraldehyde (see chapter 4). There are, however, some very weak signals that 
indicate that a reaction between glutaraldehyde and the protein may have taken 
place. For example, the signal observed at 3-4 ppm in the proton NMR spectrum 
may possibly be assigned to -CH2-N= or =CH-N=, whilst the presence o f weak 
signals in the 50-70 ppm region of the 13C NMR spectrum may also possibly be 
assigned to -CH2-N= or =CH-N=, which would point to the likely presence of Schiff 
base species. A similar conclusion could be drawn from the data obtained from the 
analysis of glutaraldehyde-treated cytochrome C.
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1 13Figure 5.15: H (left) and C (right) NMR spectra of unbuffered aqueous solution of 
lysosyme (0.1% w/v) unbuffered aqueous solution. The samples were freeze-dried, 
re-dissolved in D2O and then analysed.
5.3.4.3 Infrared results and discussion from the study of proteins:
The infrared spectra obtained from lysosyme or cytochrome C reacted with 
glutaraldehyde are very different from the spectra of the original proteins42, 
indicating that the proteins have reacted with glutaraldehyde (see below figure 5.16). 
This observation is in contrast to the findings for various films (e.g. 
glycosaminoglycan (hyaluronic acid), alginic acid, amylopectin, PVA) treated with 
glutaraldehyde, where no appreciable IR spectral changes were observed after cross-
9Qlinking with glutaraldehyde .
The spectra obtained from the reacted proteins were virtually identical, indicating the 
formation of similar reaction products with the same IR absorption pattern. 
Comparison with the corresponding spectra from the unreacted proteins showed that 
major new bands appeared, such as the band at 1721 cm ' 1 related to a free aldehydic 
group, the one at 1656 cm '1, which can be attributed to an imine bond (C=N), the 
peak at 1636 cm ' 1 (possibly associated with an imine) and the peak at 1460 cm '1, 
which can be assigned to an aldimine absorption. The complex pattern observed 
between 1200-800 cm ' 1 is similar to the infrared pattern found with glutaraldehyde 
(see chapter 4), which can be explained by the large excess of glutaraldehyde in 
comparison to the proteins.
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Figure 5.16: FTIR-ATR spectra of freeze-dried unbuffered aqueous solutions of 
0.1% w/v lysosyme and cytochrome C reacted with 0.6% v/v glutaraldehyde.
5.3.5 Overall discussion of data obtained
One can quote the following “the success of glutaraldehyde as a cross-linking agent 
is based on the large number of different types of molecules present simultaneously 
in the reagent solution”43, in order to express the fact that the chemistry of 
glutaraldehyde reacted with model compounds in aqueous solutions is more than, or 
at least, as complex as the chemistry of glutaraldehyde itself in solution (see chapter 
4). Although glutaraldehyde has been used extensively as a fixative for many 
applications, the way solutions of glutaraldehyde react with proteins and the nature 
of the reagent are still under debate. In addition, many reported reactions of 
glutaraldehyde with proteins are actually assuming reactions of the monomeric form 
(molecule I in appendix III), despite the definite presence of polymers in 
glutaraldehyde solutions, as concluded in chapter 4. Also, many authors disagree 
whether the reactive species are the monomeric form of glutaraldehyde or its 
polymers. However, it does appear that “polyglutaraldehyde” is more efficient in 
cross-linking proteins than with purified (monomeric) glutaraldehyde44. The amount 
of polymeric structures was reported to be less than 0.05% of that of glutaraldehyde5, 
and is thought not to be responsible for the reactivity of glutaraldehyde as has been 
indicated by others16’45, a fact that we strongly disagree with because our results 
provided evidence for the presence of many polymeric structures in both 
glutaraldehyde solutions (see chapter 4) and also in glutaraldehyde-treated amino 
compounds solutions.
Our data on the elucidation of the chemical structures present in glutaraldehyde 
solutions (see chapter 4), in addition to those reported in this chapter, lead to the 
general conclusion that glutaraldehyde (under many different forms more complex 
than the simple monomeric form) reacts primarily with amino groups forming Schiff 
bases. These are known to be unstable in aqueous solutions, but more stable 
structures involving one or more amino compounds also occur (some of them 
originating from Schiff base moieties). These have the ability to form more stable 
cross-links through electronic resonance effects, additional Michael-type reactions or 
cyclisation steps.
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In contrast to previous findings, where it was stated that the anabylysine compound 
(molecule XCVIII m/z 391) was the only detectable stable cross-link found by mass
25spectrometry from the analysis of glutaraldehyde-treated 6 -amino-n-caproic acid , 
there is evidence from our mass spectral data of other types of stable cross-linking 
structures involving at least two amino acid residues. For example, major mass 
spectrometric peaks have been attributed to molecules (see appendix IV for 
structural details) such as CXII (di-Schiff base addition on an aldol trimer with a 
subsequent cyclisation step), CXXVIII (di-Michael-type addition on an aldol 
glutaraldehyde trimer), CXLVII (di-Michael-type addition on an aldol trimer with a 
subsequent cyclisation step), CLII (cyclised dialdol condensation product that 
underwent a Michael addition and two Schiff base additions), CLVII (1,3,4,5 
tetrasubstituted pyridinium structure that underwent aldol, Michael and a Schiff base 
reaction) and CXVII (aldol dimer that underwent a Schiff base and a Michael-type 
addition). Our FTIR and NMR data are consistent with the presence of such cross- 
linking structures. However, we have seen no evidence for the formation of the 
larger complex stable cross-links proposed by Hardy’s group23’46, or those proposed 
by Johnson47 (see figures 2.25 and 2.26 in section 2.2.4.5 of chapter 2 for detailed 
structures). Our results would therefore seem to indicate that the formation of cross­
links may consist of several steps including reversible and multi-molecular steps 
involving several moieties, with the composition of the reaction products being 
distributed slightly heterogeneously, depending on reaction conditions.
Our data also show that glutaraldehyde (in its multivariate structural forms) reacts 
with amino groups over a wide range of pH, which is in agreement with the 
statement of others5 who reported that glutaraldehyde reacts with amino groups at 
pH 3 and above. This is worth mentioning because some authors have claimed that a 
low pH interferes with the reaction of glutaraldehyde with amino groups and have 
concluded that the best reaction conditions are at neutral or basic pH34. In our work, 
the reactions of glutaraldehyde with model compounds do not seem to be very much 
affected by pH in the range pH 4-9, which is consistent with literature statements6. 
The fact that the various model compounds seem to yield similar species when 
reacted with glutaraldehyde across the pH range (4-9) could simply come from the 
fact that the 6 -amino group of lysine (known to react primarily with glutaraldehyde), 
modelled in this study by various analogous molecules, has a pKa of about 10.
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Thus a change in pH in this range should have little effect on the reactivity of lysine- 
like molecules with glutaraldehyde .
The polymers of pyridine-like structures are proposed as important cross-linkers in 
glutaraldehyde-treated proteins since such formation of branched polymer products 
is thought to provide the flexibility required for intra-molecular cross-linking23,46 and 
such cross-linking entities are found with elastin (e.g. desmosine, isodesmosine27,49). 
In contrast, the monomeric pyridine-like structures are not functional cross-linkers 
since only one amine group is incorporated into the monomer. Our data suggest the 
presence of both polymers and monomers of pyridine-like and dihydropyridine-like 
structures that represent some kind of stable reaction products (e.g. molecules LXV 
and XCVII). This is partially in agreement with the data of Hardy et al23 who found 
that the reaction of glutaraldehyde with aliphatic amines yielded a mixture of at least 
1 2  chemical entities including postulated stable quaternary pyridinium derivatives, 
although these were not fully characterised. In addition, our results are in agreement 
with previous work, which reported the presence of a mono-bound (molecule CXLI, 
tri-aldol condensation product which underwent a Michael-type addition of the 
amine) and a cross-linked chemical structure (molecule XCVIII, anabilysine 
compound) from the analysis of glutaraldehyde-treated bovine pericardium tissue . 
They also indicated the likely differences that would be observed between the studies 
of model compounds and tissue because of the greater constraints present in the 
tissue reaction (stereochemical effects).
Our results also provide a multiplicity of evidence for the formation of mono-Schiff 
base compounds, di-Schiff base (and also a few tri-Schiff base) cross-linking 
structures involving glutaraldehyde and its condensation products, along with many 
other structures involving Schiff base addition, aldol condensation, Michael and 
Michael-type addition products (see appendix IV for details of structures). In 
contrast to other work , some of the cross-links proposed by Richards and 
Knowles50 involving Michael-type additions of the amine to aldol condensation 
products (molecules CXXII (di-Schiff base addition on an aldol trimer with a 
subsequent cyclisation step), CXXIII (di-Michael-type addition on an aldol trimer) 
and CXLV (Schiff base and Michael-type addition on a glutaraldehyde aldol trimer)) 
were found in this study. Additionally, other structures based on Michael-type 
addition with various aldol condensation products of glutaraldehyde were also found,
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such as the molecules proposed by Walt and Agayn51 CXXXIV, CXXXV and 
CXXXVI, along with other molecules such as CD, CXIX, CXL, CXLI and CXLVI. 
In addition, the data obtained showed that stable cross-links could also be formed 
from Michael-type addition reactions, for example molecules CXX and CXXIII (di- 
Michael-type addition on an aldol dimer and trimer respectively).
The largest cross-link observed involved a total of five molecules of glutaraldehyde 
(molecule CLVII). The largest glutaraldehyde-based molecules present in the 
glutaraldehyde-treated amino compound mixtures mostly involved a total of five 
molecules of glutaraldehyde (e.g. molecules XIX, XIXc, XXVIII, XXIX, XXXVIIIb 
and LI), which is similar to what was reported for the analysis of glutaraldehyde 
solutions (see chapter 4).
Similar glutaraldehyde structures were found from the analysis of glutaraldehyde- 
treated amino compounds as from the analysis of pure glutaraldehyde solution (see 
chapter 4) over a similar pH range (pH 4-9), although no quantitative data have been 
retrieved. Our data showed that glutaraldehyde species in presence of amino groups 
do not seem to evolve further through the formation of polymers and the amino 
groups do not seem to play a catalytic role for the formation of such polymers, as 
was hypothesised by Kawahara et al .
No long chain polymers of glutaraldehyde were present in the reaction solutions over 
the range of pH conditions employed from our MS data. This is in disagreement with 
the hypothesis of Cheung et al3’4, who stated that very high molecular weight 
glutaraldehyde polymers were formed in the presence of excess aldehyde and that 
these long polymeric glutaraldehyde chains were generating inter-molecular cross­
links.
Although some unsaturated chromophoric products, such as the 1,3,4,5-substituted 
pyridinium salt, that represent some of the possible cross-linking structures23, have 
been reported not to affect either tissue stability or its calcification7 (pericardium 
tissue calcification was found to occur at the same levels despite a borohydride 
reduction), we believe that many structures characterised in this study are likely to 
induce calcification, simply due to the presence of carbonyl groups or other reactive 
groups in their backbones (a study of the calcification potential of the chemical 
groups of glutaraldehyde, model compounds and glutaraldehyde-treated model
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compounds is presented in chapter 6 ). Such pendant carbonyl groups can form a 
potential initiation site for mineralisation for example. In addition, despite the 
presence of some stable cross-linking structures, the existence of other chemical 
structures involving Schiff bases that are readily hydrolysed may give a reasonable 
explanation for a gradual reduction through time in tissue stability towards stress and 
enzymatic attack in-vivo, thus being potentially responsible for cross-linked 
bioprosthetic valves failure in-vivo. Furthermore, the in-vivo oxidation of pendant 
aldehyde groups within glutaraldehyde-treated tissue can also form potential binding 
sites for initialising tissue calcification and this issue is discussed in a dedicated 
study in chapter 6 .
5.4 Conclusion:
Our results indicate that glutaraldehyde reacts with amino groups over a wide pH 
range and the results from studies of the reaction of glutaraldehyde with 6 -amino-n- 
caproic acid, N-a-acetyl-L-lysine and peptides broadly agrees with previous work of 
various authors ’ ’ ’ ’ ’ , although some differences are brought forward. The 
mass spectral data, along with the results of the NMR and FTIR analyses, obtained 
for the products of the reaction between glutaraldehyde and small amines and 
peptides showed the presence of a rich palette of compounds. These compounds 
included aldol and aldol/Michael condensation products of glutaraldehyde, Schiff 
base moieties (including cross-links) and various cyclisation products incorporating 
pyridinium and dihydropyridine ring structures. The results (found in appendix IV) 
indicated the likely presence of about 25 stable cross-linking (multi-bound) entities 
including an anabilysine-like compound, along with about 29 stable mono-bound 
entities. The stability of which is mainly due to the presence of cycles, Michael-type 
additions-resulting products or electronic resonance effects. However, our data also 
showed the presence of other less stable types of mono- and multi-bound structures, 
essentially due to the presence of Schiff bases.
Despite the presence of many stable structures, other less stable chemical entities 
were also characterised, which brought about the hypothesis of their role in the 
initiation of mineralisation because these less stable entities could break up easily in- 
vivo and lead to failure and calcification of cross-linked-tissue used in bioprostheses
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manufacture. This led to the study found in the chapter 6 , where the potential of 
glutaraldehyde, but also its oxidised forms (e.g. glutaric acid), to initiate the 
mineralisation was investigated, along with the possible uptake of calcium 
(calcification) by amino acids and other molecular compounds, mimicking the 
behaviour of collagenous tissue, will be studied by attenuated-total reflectance 
infrared spectroscopy (FTIR-ATR). In addition, the role of the cross-linker and 
tissue factors in the mineralisation process of cardiac bioprostheses will be further 
discussed in chapter 6 . Furthermore, the use of FTIR-ATR microscopy was thought 
to able us to see chemical differences between glutaraldehyde-treated and untreated 
collagen, by allowing us to investigate the surface grouping and to find any relations 
between chemical groups of the valve tissue (essentially made of collagen type I) 
and their calcification potential. These preliminary results can be found in the 
appendix I.
The study of glutaraldehyde-treated proteins showed the suitability of MALDI-TOF 
MS in the determination and analysis of the multimericity of proteins after cross- 
linking with glutaraldehyde. A further study of the reaction products of
glutaraldehyde with the model compounds was performed using TLC-MALDI-TOF 
MS. The data are included in appendix II, however, we can conclude that the 
application of TLC-MALDI-TOF MS is shown successful for the study of the 
separated reactions products from complex reactions involving small amino acids or 
peptides with glutaraldehyde.
In conclusion, the successful characterisation in this study of some possible chemical 
structures involved in the reaction of glutaraldehyde with proteins and their cross- 
linking has led to new insights into the complex model that represents the cross- 
linking of collagenous tissue (see chapter 2 ) and its application for cardiac 
bioprostheses.
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Chapter 6
6 Infrared spectroscopy in the evaluation of the 
calcification potential of molecular models.
Abstract
Objectives: Glutaraldehyde is the only chemical cross-linker exclusively used in the 
bioprosthetic valve industry today. It also has many other important applications in
various fields. However, there is evidence to suggest that glutaraldehyde plays a
12 • critical role in tissue calcification ’ and subsequent mechanical degeneration of
bioprosthetic heart valves in-vivo3. The specific mechanisms by which
glutaraldehyde fixation facilitates calcification, however, are not fully understood4.
In addition, collagenous valve tissue is believed to have the potential to initiate the
mineralisation process because it has been reported that both collagen and bovine
pericardium can take up calcium and phosphate in-vitro in the absence o f host
factors5'7. Furthermore, it has been reported that glutaraldehyde-treated collagen has
potential calcium-binding sites (e.g. amino, carbonyl and/or carboxylic groups) and
therefore may have a natural tendency to calcify8; these sites being normally
protected by glycosaminoglycans and proteoglycans that are lost during the
glutaraldehyde treatment process. One of the main objective was thus to investigate
the potential of glutaraldehyde, along with its di-acid form (glutaric acid), to initiate
mineralisation by complexing some relevant ions such as calcium. Other objectives
were to investigate the possible uptake of calcium (calcification) by amino acids and
other molecules that can mimic the behaviour of collagenous tissue and also to
comment on the role of the cross-linker and tissue factors in the mineralisation
process of cardiac bioprostheses.
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Methods: The possible uptake of calcium (calcification) by model compounds was 
investigated using Fourier-transform infrared-attenuated total reflectance (FTIR- 
ATR) spectroscopy. Any significant binding of a metal ion such as calcium to a 
specific functional group of a molecule might be detected, either by a shift in 
wavenumber of the relevant peak or by a variation in the relative size of the peak. 
Hence, binding sites relevant to calcification should be identified. Additionally, the 
formation of a salt could be discriminated by infrared bands from the different 
groups (COOH, COO' and C=0) involved in such a salt formation.
Results: Glutaraldehyde and oxidised glutaraldehyde (glutaric acid) have been 
shown to have the potential to induce mineralisation by attracting cations (potentially 
calcium) from a metastable calcifying solution, although the two compounds seem to 
behave differently. It is ironic that the glutaraldehyde treatment itself, presently used 
in commercial valve processing, might be a calcification initiator. The FTIR spectra 
of glutaraldehyde-treated model compounds, incubated in a calcifying solution, were 
very complex and hence could not be interpreted. It was therefore not possible to 
identify the amino or carbonyl groups of the molecules backbone as binding sites for 
phosphate and calcium respectively. Nevertheless, the spectra do not rule out the 
likely possibility that glutaraldehyde-treated model compounds mimicking 
glutaraldehyde-treated tissue would also attract calcium ions. Model compounds not 
reacted with glutaraldehyde were shown to bind calcium, probably via the carbonyl 
oxygen atoms of their backbones.
Conclusion: The ability of glutaraldehyde to cross-link is unfortunately opposed to 
its increasingly believed potential to intrinsically facilitate tissue mineralisation, 
which was demonstrated in-vitro by the results from this study. Results from the 
analysis of glutaraldehyde and oxidised forms of glutaraldehyde (e.g. glutaric acid) 
demonstrated a strong potential for their involvement in the mineralisation process of 
glutaraldehyde-treated tissues. Whilst amino acid residues of collagenous tissue 
could also have a role to play in the mineralisation process, further studies would be 
required to confirm this hypothesis. Nevertheless, the overall results bring forward 
some new insights into the hypothetic primary processes of mineralisation of tissue 
and may help to clarify the involvement of the tissue and cross-linking reagent in 
calcification.
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6.1 Introduction
Collagen has been reported to be implicated in the mechanisms of calcification2,9 and 
to be a major site for the calcification of glutaraldehyde-treated cardiac
O # # 1 Abioprostheses . According to Glimcher et al collagen fibrils are potential nucleation 
sites for calcium crystal formation. Early mineral deposits are predominantly 
localised to transplanted connective tissue cells and their remnants, found in the 
collagen/elastin matrix. However mineral deposits also involve extracellular collagen 
fibres11.
1 9Another predominant site for calcification in aortic tissue is elastin . The concept of 
“neutral binding site/charge neutralisation” has been proposed from studying the
n  #calcification of aortic elastin. Long et al bound calcium to neutral purified elastin 
and studied the distribution of calcification throughout the bulk, upon exposure to 
solutions containing phosphorus. The carbonyl oxygen sites of the peptide backbone 
were thus hypothesised to bind positively charged calcium and subsequently to 
attract phosphate to maintain the overall charge neutrality. This can act as a potential 
initiation site for the mineralisation of tissue and, theoretically, a similar process 
could be expected with collagen, as reported by Urry14.
A likely candidate for a general calcification mechanism therefore is cation-chelation 
by groups present in the material containing lone pairs of electrons susceptible to 
interacting with electron-deficient species. Such a process of cation-chelation in the 
sorption of metals by polyurethanes has been proposed by Hamon et al15. Their 
hypothesis was that phophate was carried along in this process as the accompanying 
anion to maintain charge neutrality and the polyether segments of the polyurethanes 
provided binding sites for the complexation of cations such as calcium. This calcium 
complexation mechanism associated with polyurethanes has been investigated using
i  zr i  nthe analysis of model compounds ’ but so far no equivalent study has been carried 
out using model compounds of collagenous tissue.
Phosphate moieties can also bind at the N-termini of helices in proteins, 
corresponding to an optimal interaction of the helix dipole and the charged 
phosphate18. This brings another factor to the puzzle of mineralisation i.e. proteins
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could also bind phosphate, which could eventually trigger the subsequent attraction 
of calcium ions. X-ray and neutron diffraction investigations of calcifying turkey leg 
tendons have shown that apatite crystal formation was initiated in the gap zones of 
the collagen type I fibres. This suggests that the N-termini telopeptides (forming the 
gap zones) or substances adsorbed to these sites were actively involved in crystal 
nucleation and growth19.
Previous studies have already presumed that glutaraldehyde pre-treatment of
90 91bioprosthetic heart valves is a critical determinant in their calcification ’ . Schoen et
99al have also reported a significant correlation between the glutaraldehyde treatment 
of tissue materials used in bioprosthetic heart valves and in-vivo calcification. The 
presence of reactive aldehydes has also been shown to be essential for bioprosthetic 
tissue calcification in subcutaneous implants in rats2,23. Golomb et al24 determined 
the minimum amount of glutaraldehyde in valve tissue required to initiate calcium 
deposition in a subdermal model, to be 100 nM/mg. The amount o f glutaraldehyde in 
bovine pericardium rat implants has also been shown to have a quantitative 
relationship with calcific deposits. The hypothesis that glutaraldehyde could be a 
nucleating site for calcium ions has also been proposed to account for the in-vivo
• • 9dystrophic calcification of bioprosthetic tissue .
Aqueous glutaraldehyde solutions in the pH range 3.8 - 9.2 were shown in chapter 4 
to consist essentially of glutaraldehyde hydrates, hemiacetals, acetal cyclic polymers, 
mono- and di-acid forms of glutaraldehyde and various glutaraldehyde oligomers. 
Figure 6.1 below shows such molecular structures. These primarily include trioxane- 
type oligomers, dimers produced by aldol condensation of two glutaraldehyde 
molecules and their cyclic acetal, oligomers of glutaraldehyde consisting of the a- 
oxypyran ring, some (apparently much smaller amounts of) different unsaturated 
aldol condensation products and aldol/Michael addition products. All these 
structures (see chapter 4 and appendix III for further details) exhibit many carbonyl 
pendant groups that could act as theoretical nucleating sites, in a similar way to 
polyether segments of polyurethanes that were found to instigate calcium 
complexation25,26. Calcium complexation may lead to site-specific increases in 
calcium ion concentration that can then initiate a sequence leading to the formation
97of calcium phosphate salts and the subsequent crystallisation of mineral .
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Mol XXV
Mol XXIV
internal
Mol I ~ monomeric 
glutaraldehyde
Mol XV dialdol condensation 
product
trialdol condensation product 
with two internal cyclisation
trialdol condensation product with 
cyclisation
Mol XVIa 
hydrated trialdol condensation product
Mol XXXII 
dehydrated dialdol condensation oligomer
Mol XXXI 
hydrated dialdol condensation oligomer
Mol XII 
trioxane-type oligomer
Mol XXXIII 
Michael-addition on a dialdol 
condensation product
Figure 6.1: Structures of molecules thought to be predominant in aqueous 
glutaraldehyde solutions (pH 3.8 -  9.2). (Extracted from the results found in chapter 
4 and appendix III). Structure numbers correspond to those used in appendix III.
The reaction of glutaraldehyde with valve collagenous tissue and other matrix 
components was also assumed by Cheung, Nimni et al to yield products with 
functional groups that were hypothesised to be correlated with the calcification 
process of valve tissue. That is, the final form of the cross-linked tissue tends to 
contain nucleophilic residues such as carbonyl oxygens28'31. In a more recent study, 
tissue valve calcification has also been hypothesised to correlate with the calcium- 
binding ability of glutaraldehyde polymers that are present on the surface o f treated 
tissue25. Furthermore, it has been suggested that the reaction of glutaraldehyde with 
lysine side chains (lysyl and hydroxylysyl residues of collagenous tissue) may lead 
to an impaired balance between positively and negatively charged functional groups
^ 9  o cin the collagenous tissue, thus favouring calcium ion deposition ' . Many reports 
have indicated a role for aldehyde-induced intra- and inter-molecular collagen cross­
links in initiating tissue mineralisation36'39. For instance, it has been reported that the 
treatment of tissue by glutaraldehyde would result in the formation of Schiff bases 
which are likely to be susceptible to hydrolysis40 under physiological conditions and 
could generate free formyl groups that could in turn be readily oxidised to form
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carboxyl groups41 (probably as carboxylate anions). To corroborate this statement, 
Southern et al investigated the presence of oxidation products in hydrolysed cross- 
linked collagenous tissue42 Various oxidation products (including carboxylic acids) 
were found and were hypothesised to play a role in the calcification of the tissue, as
31previously suggested by Urist et al . Our study of model compounds reacted with 
glutaraldehyde (see chapter 5 and appendix IV for further details), suggested the 
presence of many different molecular structures. These included Michael-addition 
products, Schiff base moieties (including cross-links) associated with various 
aldol/Michael condensation products of glutaraldehyde and some cyclisation 
products incorporating pyridinium and dihydropyridine ring structures. All these 
structures contain free pendant carbonyls that can form carboxylic groups under 
physiological conditions43. Some of the major structures identified from the analysis 
of the products of the reaction between glutaraldehyde and model compounds similar 
to the lysine residue (chapter 5 and in appendix IV) are reproduced below in figure 
6 .2 .
\
Mol LXVI 
Pyridinium structure
Mol XCVIII 
Pyridinium structure
Mol CXLVII1 
Schiff base structure
‘OH
Mol CXXXIX 
Schiff base structure MolCXLI Michael-type addition structure
Mol CXIX 
Michael-type addition structure q' Mol CLXIV 'q Mannich-type addition structure
Figure 6.2: Some chemical structures from the reaction between the 6 -amino group 
of lysine and glutaraldehyde thought predominantly present under the pH range 3.8 - 
9.2. (Extracted from the results found in chapter 5 and appendix IV). Structure 
numbers correspond to those used in appendix IV.
The pyridinium structures identified, being quaternary amines, could potentially 
attract phosphate ions because of the positive charge on the structures44 and also
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because compounds similar to pyridinium were found in bone-derived collagen45. 
For example, quaternary pyridinium-type cross-links found in both elastin and 
collagen are thought to serve as a nucleation point for calcification46. Moreover, a 
dipyridine structure has been suggested to be involved in calcification of 
glutaraldehyde cros-linked collagen as well as accounting for the high stability of the 
cross-links47. This hypothesis was also confirmed by Van Luyn et al48, who showed 
the possible involvement of cyclic cross-links as nucleation point for calcification.
The air oxidation of aldehydes has also been well documented49,50 and 
glutaraldehyde can be hypothesised to behave similarly, forming 4-formylbutanoic 
acid or glutaric acid. This was confirmed by our findings reported in chapter 4 of this 
thesis, where traces of mono- and possibly di-acid (glutaric acid) forms of 
glutaraldehyde were both found in aqueous glutaraldehyde solutions under 
physiological conditions. Bioprosthetic valves (during their manufacture) are 
floating in large pools, containing glutaraldehyde that can be readily oxidised 
because of the large surface area in contact with air. Additionally, despite the 
presence of isotonic phosphate buffer in these pools (to avoid any swelling or 
shrinkage of tissue due to osmotic effects), if one makes the assumption of the large 
size of these pools and the natural acidity of glutaraldehyde, a buffer o f about 0.2 M 
(currently used in valve manufacture) would probably not be enough to maintain the 
pH at a neutral physiological value. Additionally, it can be hypothesised that a 
resulting drop of pH, such as the one observed in-vitro from the reaction between 
glutaraldehyde and proteins (see chapter 5), could affect the overall pH of these 
pools and favour the formation of acid forms of glutaraldehyde such as glutaric acid. 
Unfortunately, this can only be a hypothetical statement because of the lack of 
communication with the different valves manufacturing companies on this potential 
matter.
Carboxylate anions formed from the oxidation of aldehyde groups can readily bind 
cations such as calcium by electrostatic interaction forming salts, which could act as 
an initiation site for subsequent mineralisation41. (Theoretically, a calcium ion 
(radius of about 1 0 0  pm51) can be bound by carbonyl groups, similarly to magnesium 
ion that was shown favoring oxygen donor ligands, especially the phosphate 
groups ). Computer modelling of the calcification of polyurethane valves (calcium 
complexation providing initiation sites for the ultimate formation of calcific
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deposits) has been successfully demonstrated25. The authors of the study proposed 
that the potential exists for similar calcium complexation of glutaraldehyde-treated 
tissue valves, driven by the formation of a crown-like complex of polymeric forms of 
glutaraldehyde with calcium. Their data support the hypothesis that a key initiator in 
mineral formation is the presence of binding sites within the bulk and at the 
blood/material surface.
The aim of this study therefore was to determine spectroscopically whether 
glutaraldehyde and its di-acid form, glutaric acid, have the potential to initiate 
mineralisation by complexing some relevant ions such as calcium. Additionally, the 
possible uptake of calcium by amino acids and other molecules mimicking the 
behaviour of collagenous tissue was investigated using Fourier-transform infrared- 
attenuated total reflectance (FTIR-ATR) spectroscopy.
6.2 Materials and Methods
6.2.1 Calcification studies
The chemicals and consumables used were the following:
From BDH, UK: Glutaraldehyde 25% EM grade.
From Sigma, UK: Glutaric acid, 6 -amino-n-caproic acid, N-acetyl-L-lysine, N- 
acetyl-Phe Lys.
Calcification solution preparation: Sodium chloride (BDH, UK) 7.9 g, calcium 
chloride dihydrate (BDH, UK) 0.294 g, potassium dihydrogen orthophosphate 
(BDH, UK) 0.163 g, MOPS buffer (3-N-morpholinopropanesulfonic acid) (Sigma, 
UK) 0.010 g, in 1 L of distilled water.
Experiments were carried out in sterile closed sample vials, kept in the dark at 37° C 
and shaken in a Gallenkamp orbital incubator at 100 rev/min.
Glutaraldehyde (0.2% v/v and 0.6% v/v in water) was incubated in a calcification 
solution (pH 7.4). A similar protocol was carried out with 0.1% w/v glutaric acid in a 
calcification solution in order to study the possibility that oxidised glutaraldehyde
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(glutaric acid is the di-acid structure of glutaraldehyde, as can be seen in figure 6.3 
below) might attract calcium ions.
( m o n o m e r i c  g l u t a r a l d e h y d e )
o x i d a t i o n
o x i d a t i o n
( g l u t a r i c  a c i d )
Figure 6.3: the oxidation of monomeric glutaraldehyde (A) into the mono-acid form 
(B) and the di-acid form (glutaric acid) of glutaraldehyde (C).
In order to model the behaviour of collagen towards a calcification solution, the 
same type of experiment was carried out using amino acids and a peptide. This 
would indicate whether the collagen itself can be considered responsible for 
initiating calcification. Thus, 6 -amino-n-caproic acid, N-acetyl-L-lysine and N-acetyl 
phenylalanine lysine (unreacted and reacted with glutaraldehyde) were studied by 
Fourier-transform infrared spectroscopy. The structures of these model compounds 
can be found in figure 6.4 below.
h2n — c — c — c — c — ch2
H, H, H, H,
c = o
OH
H2N C------C----- C-----C---- CH CH3
h2 h2 h2 h2
c = oB IOH
H2N C------C----c — C--------------C— N H
H2 h2 h2 h2
Figure 6.4: Chemical structures of 6 -amino-n-caproic acid (also called
aminohexanoic acid) (A), N-acetyl-L-lysine (B), and N-acetyl phenylalanine lysine 
(C).
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6.2.2 Freeze-drier
The freeze-drying procedure was similar to the one described previously in chapter 4 
section 4.2.3.
6.2.3 Infrared spectroscopy
All spectra were recorded with a Mattson Polaris FTIR spectrometer (ThermoNicolet 
Co, Lanham, MA, USA) with an MCT detector, a KBr beam splitter, and scanned 
between 4000 and 400 cm '1. The apodisation function was triangular and there was a 
Mertz phase correction. All spectra were obtained by accumulation of 1000 scans, at 
a resolution of 4cm ' 1 and 45° angle of incidence, after subtracting the spectra of the 
ZnSe crystal. All spectra were recorded under similar conditions (constant 
temperature) and were corrected for atmospheric water vapour and carbon dioxide 
by subtraction of the appropriate reference spectrum, even though the instrument was 
purged constantly with dried, water vapour-free air. The ATR device was a 
horizontal multiple reflection ATR (Graseby Specac, St Mary Cray, UK) with a 
ZnSe crystal. This crystal allowed easy sample preparation by pouring a few 
millilitres of the sample into the “pool” of the ATR cell, followed by freeze-drying.
6.3 Results and discussion
6.3.1 Calcification of glutaraldehyde
Glutaraldehyde is usually considered as a monomeric dialdehyde molecule of 
molecular weight 100. However, we showed in chapter 4 that commercial 
glutaraldehyde solutions contain many more chemical species than just monomeric 
glutaraldehyde (see appendix III for detailed chemical structures). The FTIR-ATR 
results obtained from a time dependent study of glutaraldehyde (0 .6 % v/v or 0 .2 % 
v/v) incubated in a calcifying solution showed a singular pattern in the 1850-1550 
cm"1 region. The overall spectra can be seen in figure 6.5, while figure 6 . 6  shows 
expansions of the 1850-1250 cm ' 1 spectral region.
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Black: Glutaraldehyde day 0
Blue: Glutaraldehyde day 1
Red: Glutaraldehyde day 3
Green: Glutaraldehyde day 7
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Figure 6.5: FTIR-ATR spectra from the calcification of glutaraldehyde (0.6% v/v 
glutaraldehyde solution plus calcifying solution, freeze-dried).
.3 Black: Glutaraldehyde day 0
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Figure 6 .6 : Expansion of the 1850-1250 cm ' 1 spectral region of the FTIR-ATR 
spectra from the calcification of glutaraldehyde (0 .6 % v/v glutaraldehyde solution 
plus calcifying solution, freeze-dried).
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At day 0 (non-incubated glutaraldehyde in aqueous solution), the interpretation of 
the infrared spectra is as shown in table 6 .1  below, although a fuller account can be 
found in chapter 4.
Peak position 
(c m 1) Assignment
3426
Assigned to the presence of bulk water (although the sample was freeze-dried) but 
also possibly to the presence of alcohol (hydrated oligomers o f glutaraldehyde) or 
acid groups due to the oxidation of the aldehydes o f the glutaraldehyde molecules
2947 Assigned to anti-symmetric stretching of the CH2 group
2872 Assigned to symmetric stretching of the CH2 group
2725 Weak band assigned to anti-symmetric stretching of the CH of the aldehyde group
1722 Main sharp and intense peak assigned to stretching of the C = 0 groups o f non- conjugated aldehydes and carboxylic acids overlapping with each other
1683
Very weak band assigned to stretching of the CO group o f conjugated aldehyde due 
to the presence of some polymeric glutaraldehyde structures (see chapters 2 and 4 
for detailed account o f the structures). However this band is also observed in the 
spectrum of glutaric acid assigned for the C = 0 of the carboxyl group and could 
therefore be due to the presence of the mono- or di-acid form (glutaric acid) of 
glutaraldehyde
Table 6.1: FTIR peaks and their corresponding assignments, from the analysis of
glutaraldehyde in aqueous solution (not incubated in calcification solution). See also 
figures 6.5 and 6 .6 .
As early as day one of incubation, one can observe some major changes in the 1800- 
1500 cm ' 1 region, while no other changes take place in the rest of the spectrum. The 
band at 1722 cm"1 (stretching of the C =0 groups of non-conjugated aldehydes and 
carboxylic acids overlapping with each other) is still present (though perhaps 
reduced in size) but the band at 1683 cm ' 1 has disappeared while a broad band at 
1641 cm ' 1 has appeared (possibly assigned to stretching of the C =0 group of a 
carboxylic acid).
After 3 days incubation, the peak at 1722 cm"1 broadened, possibly indicating an 
uptake of a cation such as calcium from the calcifying solution and the broad peak at 
1641 cm ' 1 was still present.
After 1 week of incubation, the peak assigned to the stretching of the C =0 groups of 
non-conjugated aldehydes was shifted to 1716 cm ' 1 and was broader than that 
observed at day 0 or 1. The broad, weak peak at 1641 cm ' 1 (observed from day 1 of 
incubation) appears now as a definite intense, but broad, peak.
These results with glutaraldehyde thus bring the hypothesis of a possible uptake of 
cation (e.g. calcium) through a likely mechanism such as the one shown in figure 6.7 
below.
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Figure 6.7: Mechanism of uptake of calcium by a carboxylic acid.
6.3.2 Calcification of glutaric acid
The FTIR-ATR spectra of glutaric acid mixed with a calcifying solution are shown 
in figure 6 .8  below; only the 1850-1000 cm ' 1 region is shown as this is where the 
spectral changes take place. When carboxylic acids are converted to alkaline salts, 
the bands of the carboxylic acid group vanish and tend to be replaced by two bands 
of the COO' group at lower wavenumbers. However, since the nature of the cation 
has little effect on the frequency of the bands, it is usually difficult to assess whether
c - ja calcium salt or another cation is present' .
Black: Glutaric acid day 0
Blue: Glutaric acid day 1
Green: Glutaric acid acid day 7
Pink: Glutaric acid day 28
Red: Glutaric acid day 35
.04
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Figure 6 .8 : FTIR-ATR spectra from the in-vitro calcification of 0.1% w/v glutaric 
acid (expansion of the 1850-1000 cm ' 1 spectral region).
At day 0 (non-incubated glutaric acid in aqueous solution), the interpretation of the 
infrared spectra is as shown in table 6 .2  below.
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Peak position 
(cm 1) Assignment
1692 Most intense and sharp peak of the spectrum. Assigned to stretching of the C = 0 mode of the carboxylic acid
1464 Corresponds to the scissoring absorption mode of the “intermediate” CH2 group found in the middle o f the glutaric acid molecule
1441 and 1305 Assigned to the coupling of the OH in plane deformation and to the C -0  stretching vibration occurring in the plane of the ring formed by the dimeric carboxyl groups^3
1407 Can be due to the strong scissoring mode of the CH2 group close to the carboxylicgroup
Table 6.2: FTIR peaks and their corresponding assignments, from the analysis of 
0 .1% w/v glutaric acid in aqueous solution (not incubated in calcification solution). 
See also figure 6 .8 .
After 1 day of incubation, the peak at 1692 cm ' 1 became broader and shifted to a 
lower wavenumber (1686 cm '1). This shifting is possibly due to the uptake of a 
cation such as calcium from the calcifying solution because the width of the peak at 
half height is doubled. This leads to the hypothesis of the uptake of a cation 
(calcium) by the mechanism shown in figure 6.9:
. 0  Ca2+
_____ \ OH
Figure 6.9: Mechanism of uptake of calcium by carboxylic acid.
A weak but broad band at -1553 cm ' 1 also appeared (anti-symmetric stretching of 
the COO' of the carboxylate group) and is likely to be due to the presence of 
carboxyl functions in the form of salts54, while the slight shift of the band at 1430 
cm ' 1 (formerly 1441 cm ' 1 at day 0 of implantation) could be due to a symmetric 
stretching of the COO' of the carboxylate group (salt), which leads to another 
hypothetical mechanism, as shown in figure 6 . 1 0  below.
  Ca2+
\ q8-
Figure 6.10: Mechanism of uptake of calcium by carboxylate anion by electrostatic 
interaction, forming a salt.
It is however rather difficult to be sure about the presence of the COO' group 
symmetric stretch at 1430 cm ' 1 because of the large number of bands occurring in 
this region. The peaks at 1430 cm ' 1 and 1302 cm ' 1 could correspond to the former
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bands at 1441 cm"1 and 1305 cm ' 1 shifted because of a chelate formation. Intense 
peaks at 1207 and 1116 cm ' 1 were the only bands observed due to the absorption of 
the calcifying solution in this region (spectrum not shown).
At day 7, and up to 35 days of incubation, the peak at 1686 cm"1 became slightly 
broader and the peak at -1553 cm ' 1 was still present. No other changes in the spectra 
could be observed.
The spectra thus show the possible uptake of cations such as calcium from the 
surrounding calcifying metastable solution. Hence, it can be concluded that glutaric 
acid (the di-acid form of glutaraldehyde) is capable of attracting cations (such as 
calcium) and forming some sort o f complex.
6.3.3 Calcification of an amino acid and peptide
Any significant binding of a metal ion such as calcium to a specific functional group 
of an amino acid or peptide might be detected, either by a shift in wavenumber of the 
relevant peak or by a variation in the relative size of the peak, hence binding sites 
relevant to calcification could thus be identified. Additionally, the formation of a salt 
can be discriminated by infrared bands from the different groups involved in such a 
salt formation (COOH, COO' and C=0). It has been reported that a shift o f up to 100 
cm ' 1 between the carboxylic band and the corresponding carboxylic anion band 
involved in complex formation, may be observed in the case of complex formation 
between a metal ion and the carboxylate residue of the amino acid glycine55,56. The 
most reactive amino acids available in valve tissue are lysine residues, which have 
only limited ce-amino groups available to react (most are involved in peptide bonds), 
in comparison to their e-amino (or 6 -amino) groups (see chapter 2). A typical FTIR 
series of spectra of an amino acid (6 -amino-n-caproic acid, mimicking a lysine group 
of collagenous tissue but without an a-amino group), incubated in a calcifying 
solution is shown in figure 6.11 below. The region 1850-1000 cm ' 1 only is shown as 
this included the major peaks of interest.
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Figure 6.11: FTIR-ATR spectra from the in-vitro calcification of 0.1% w/v 6-amino- 
n-caproic acid (expansion of the 1850-1000 cm '1 spectral region).
An interpretation of the major bands found in the spectrum (not fully shown in figure 
6.10 above) of non-incubated 6-amino-n-caproic acid (day 0 of incubation) follows 
in table 6.3, below.
Peak position 
( c m 1) Assignment
2211
The amino acid appeared to be predominantly in its zwitterionic form, 
because of the presence of the characteristic NH-f symmetric stretching 
band (part o f the spectrum not shown here)
1683 C =0 acid group stretch mode
1651 Possibly assigned to a NH bending mode (amine group)
1624 Possibly assigned to a NH bending mode (amine group)
1560 and 1534 Doublet assigned to C = 0 anti-symmetric stretching mode (COO’ group)
1469, 1452 and 1436 Possibly CH2 group scissoring modes
1388 Possibly a C =0 group symmetric stretching mode
1330, 1309 and 1291 Possibly CH2 groups wagging modes
1103 Assigned to a NH3+ group rocking mode/NH2 group twisting mode
1043 Possibly a C-N group stretching mode.
Table 6.3: FTIR peaks and their corresponding assignments, from the analysis of 6-
amino-n-caproic acid in aqueous solution (not incubated in calcification solution). 
See also figure 6.11.
As early as day one of incubation in the calcium-containing solution, many changes 
were seen in the FTIR spectrum. The appearance of a broad and relatively weak peak 
around 1710 cm '1 could be assigned to the presence of chelation mechanism between
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acid groups of the molecule and a cation such as calcium from the calcifying 
solution. The structure of the complex formed is likely to be shown below in figure 
6.12. Such a metal complex structure is expected to exhibit a characteristic C=0 
infrared absorption frequency around about 1700 cm '1, as it was suggested in the
literature55.
X> Ca2+
Figure 6.12: Chelation mechanism of a carboxylic acid and a metal cation such as 
calcium.
The appearance of a peak at 1616 cm ' 1 is most likely to be due to the infrared 
absorption of the calcifying solution in this region (spectrum not shown), but could 
also be assigned to a NH bending mode (or a deformation mode of the NH3+ group), 
which could also be involved with the chelation of phosphate. The appearance of a 
shoulder at -1508 cm '1, which became more prominant with increasing incubation 
time is likely to be due to the presence of carboxyl functions in the form of salts54 
(anti-symmetric stretching mode of the C =0 of the carboxylate group), while the 
appearance of an intense band around 1402 cm ' 1 could be due to the symmetric 
stretching mode of the C =0 of the carboxylate group (salt)56. These findings could 
also suggest the hypothetic presence of another mechanism for the attraction of 
cations by amino acids, as is shown in figure 6.13 below.
JX -
 Ca2+
\ 0 5-
Figure 6.13: Mechanism of uptake of calcium by carboxylate group, forming a salt.
The peak at -1508 cm ' 1 could also be assigned as the second peak of the NH bending 
mode indicating the presence of an amino group (NH2/NH3+), which could possibly 
also be involved in a chelation mechanism with phosphate. It is more likely however 
that this peak is covered by the COO' anti-symmetric vibration mode peak.
Other model compounds studied were also incubated in-vitro in a calcifying 
solution, (i.e. N-acetyl-L-lysine and N-acetyl phenylalanine lysine). Despite the 
complexity of the spectra obtained (results not shown), especially the one of the
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peptide, they appeared to behave similarly and exhibited similar features such as the 
broad, weak band around 1710-1730 cm '1, the presence of carboxylic acid salts 
(deduced from the presence of the anti-symmetric stretch around 1500-1580 cm '1) 
and also the hypothetical presence of some protonated amino groups. All o f these 
assignments suggest the possibility of uptake of cations such as calcium but possibly 
also phosphate anions from the incubation medium.
6.3.4 Calcification of glutaraldehyde-treated amino acids and peptide
FTIR spectra of glutaraldehyde-treated model compounds (6 -amino-n-caproic acid, 
N-acetyl-L-lysine and N-acety 1-phenylalanine lysine) were extremely complex and 
hence could not be fully interpreted. It has not been possible therefore to identify a 
possible interaction of the amino or carbonyl/carboxyl groups of the molecules 
backbones as binding sites for phosphate and calcium respectively. However, since 
the attraction of calcium by both glutaraldehyde and model compounds on their own 
was observed using FTIR-ATR spectroscopy, it can be strongly hypothesised that 
glutaraldehyde-treated model compounds would behave similarly.
6.3.5 Overall discussion of data obtained
Glutaraldehyde in solution was shown in chapter 4 to consist of various molecular 
entities, comprising essentially of glutaraldehyde monomers, acetals, hydrated 
structures, aldol polymers, Michael-addition polymers and also some possible acid 
forms of glutaraldehyde. The infrared spectroscopic study of glutaraldehyde, 
incubated in a calcification solution, revealed the potential character of 
glutaraldehyde to uptake a cation (calcium or potassium from the metastable 
calcifying solution) from its carboxylic acid. This cation uptake could well be an 
initiator for the mineralisation process. It was also shown in chapter 4, however, that 
the amount of carboxylic acid forms of glutaraldehyde oligomers was small. 
Therefore the mechanism of cation uptake by carboxylic acid groups cannot be 
considered to be the only one to account for the potential o f glutaraldehyde to attract 
cations such as calcium and hence to be an initiator of the mineralisation process. 
Thus, other mechanisms involving carbonyl groups are likely to be alternatives to the 
cation uptake observed by FTIR spectroscopy in this study, although this mechanism 
could be valid in-vivo.
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Our data would agree with the suggestions of Thoma et al , who proposed from a 
theoretical molecular modelling study that some glutaraldehyde polymers in 
glutaraldehyde-treated tissue valves could have the potential to form a crown-like 
complex with calcium. The pendant carbonyl groups would act as binding sites, 
assuming that the most likely form of polyglutaraldehyde in solution would be based 
on hemiacetal polymerisation. Formation of such a complex could be one key 
initiator for mineral formation in glutaraldehyde-treated valve tissue. The presence 
of such hemiacetal glutaraldehyde structures was also observed in our study (see 
chapter 4) and this mechanism could well be considered valid. Furthermore, it can be 
hypothesised that other glutaraldehyde species present in solution could form similar 
complexes with a cation such as calcium. This is because of the presence of 
electronegative sites due to the oxygen-rich environment of the polyglutaraldehyde 
structures, such as the ones found in our study (see chapter 4). It is expected that 
such complex formation, would exhibit similar behaviour to that seen in the infrared 
spectroscopic analysis of the calcified glutaraldehyde solution and would thus 
represent further candidates to explain the potential o f glutaraldehyde to attract 
cations.
The mechanism of cation uptake by chemical groups in glutaraldehyde-treated valve 
tissue (essentially those containing lone pairs of electrons, such as carbonyl, 
carboxyl and amino groups) is a likely candidate for the initiation of mineralisation 
of valve tissue, according to the results of this study. Those groups are readily 
available in the collagen backbone, especially the carbonyl oxygens that are very 
susceptible to interactions with cations such as calcium. It is suggested that 
phosphate ions could be attracted by this micro-electric field because of the 
unbalanced charge. This would help to maintain overall charge neutrality and thus 
create the potential for hydroxyapatite formation (hydroxyapatite [C as^O ^O FI] 
being the main inorganic phase observed in heavily calcified tissues). It could also 
facilitate formation of other precursors of the calcification process containing 
essentially calcium and phosphorus.
The cytotoxic effect of the glutaraldehyde fixation treatment has been implicated in 
an extrinsic form of calcification where the cytotoxicity of glutaraldehyde causes cell 
death and formation of extrinsic calcific nodes. However, the most significant tissue 
failure mechanism relates to intrinsic calcification4, where the calcific deposits form
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deep within the tissue matrix. The various cation chelation mechanisms proposed in 
this study give a reasonable explanation why both intrinsic (calcification directly 
associated with the material) and extrinsic calcification (in association with debris 
and located at the surface of the material) may be observed. The material 
components (such as elastin and predominantly collagen, in the case of valve tissue) 
are probably the main cause of intrinsic calcification, while debris on the surface of 
the material could have identical properties and hence possess similar possible 
binding sites. This mechanism could therefore affect the fragile equilibrium of the 
metastable state of the ions involved in mineralisation, by shifting the equilibrium 
towards the spontaneous precipitation of calcium phosphate. The cation chelation 
mechanism induces a slight local increase in the calcium phosphate product, taking it 
above the critical level needed for precipitation, allowing growth of crystal structures 
once precipitation is initiated. Once crystals are formed, the reaction would be 
irreversible since the products tend to be insoluble and the mineralisation mechanism 
would certainly continue.
6.4 Conclusion
Glutaraldehyde and oxidised glutaraldehyde (glutaric acid) have been shown to have 
the potential to induce mineralisation by attracting cations (potentially calcium) from 
a metastable calcifying solution. The two species do, however, seem to behave 
differently.
The FTIR spectra from glutaraldehyde-treated model compounds, were extremely 
complex and hence too difficult to fully interpret. Therefore identification of possible 
interactions of the amino or carbonyl groups as binding sites for phosphate and 
calcium respectively was not possible but could not be ruled out. However, the same 
model compounds not reacted with glutaraldehyde were shown to bind calcium. It is 
most likely that the carbonyl oxygen atoms contained in their backbones facilitate 
binding, although other chemical groups, such as the protonated amino groups, could 
also be involved in the mineralisation process by potentially binding phosphate. 
Collagen is thought to have the potential to behave similarly. A study of type I 
collagen films and their subsequent calcification was thus carried out and the early 
results, including the successful methodology, can be found in the appendix I.
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Overall, the data shown in this chapter bring forward some new insights into the 
hypothetical primary processes of mineralisation of tissue. They may also help to 
explain the involvement of glutaraldehyde and tissue in the calcification process of 
valve bioprostheses.
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Chapter 7
7 Characterisation of the calcification of cardiac 
valve bioprotheses by environmental scanning 
electron microscopy, x-ray diffraction and 
vibrational spectroscopy.
Abstract
Objectives: Cardiovascular implant mineralisation involving bioprosthetic materials 
such as glutaraldehyde cross-linked tissue valves is an important clinical problem. 
The objectives of this part of the study, therefore, were to develop methodology to 
investigate heart valve tissue and associated calcification in its natural state, using 
environmental scanning electron microscopy (ESEM) and to comment on future 
applications of ESEM in tissue bioprostheses research. The use of energy dispersive 
X-ray (EDS), X-ray diffraction (XRD), Fourier-transform infrared (FTIR) and 
Raman spectroscopy were sought to characterise the various calcific deposits 
observed with ESEM. Additionally, the application of EDS via the ESEM remains 
unreported for microanalytical studies of explanted heart valve tissue to date. The 
major elements present in calcified valves were analysed by inductively coupled 
plasma-optical emission spectroscopy (ICP-OES). In order to better understand the 
precursors formation of the calcific deposits, these results from the elemental 
analyses were statistically correlated.
Methods: The surface morphology of unimplanted and explanted cardiac 
bioprostheses was observed using ESEM. Each valve was also subjected to EDS 
analysis, which focused mainly on the calcification of the valves. The nature of the 
crystal phases of the calcific deposits was also investigated using XRD, FTIR and
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Raman spectroscopy. Calcified explanted valves were subjected to a quantitative 
study using ICP-OES.
Results: Analysis of valve tissue by ESEM gives valuable results. However some 
problems may be encountered with the EDS analysis. The water environment can 
reduce the EDS signal intensity and there is an apparent signal from the water, 
preventing semi-quantification using the oxygen peak. A predictable skirting effect 
can also be present. Despite these problems, ESEM revealed the presence of four 
broad types of calcium phosphate crystal morphology. These were classified 
according to their size as sub-microns crystals, aggregates ranging from sub-micron 
up to 5 /mi, micronodules of 5-10 /mi and large aggregates (found on heavily 
calcified valves) that can grow up to 1 0 0  /mi in size and cover the entire collagen 
matrix. The crystals were found attached to the dense collagen bundles, following 
their orientation throughout the tissue and within the fibrils. Additionally, two main 
patterns of organisation of calcific deposits were observed associated with the 
collagen fibres: spherical aggregates ( 1 - 1 0  /mi) found along collagen fibrils and in 
interfibrillar spaces, and needle-like crystal structures (sub-micron, micron scale). 
The EDS microanalysis identified the crystals observed by ESEM as salts containing 
mainly calcium and phosphate with varying ratios from 1.340 (possibly octacalcium 
phosphate (OCP) which has a Ca/P ratio of 1.336) to 2.045 (possibly hydroxyapatite 
(HAP) with incorporation of carbonate and metal ion contaminants, such as silicon 
and magnesium, in the crystal lattice). The presence of silicon and magnesium in the 
EDS spectra confirmed this view and raised the possibility of the presence of 
precursor phases associated with the embryonic stages of calcification. The 
crystalline calcium phosphate salts found on heavily calcified valves had a mean 
Ca/P ratio of 1.676, which is very close to crystalline hydroxyapatite with a Ca/P 
ratio of 1.670. XRD patterns from these same calcium deposits showed a poorly 
crystalline hydroxyapatite-like pattern. Raman and FTIR spectroscopy also identified 
the presence of carbonate and the analyses showed spectral features very similar to a 
crystalline hydroxyapatite spectrum, thus refuting the presence of precursor phases 
such as /5-tricalcium phosphate (/5-TCP), OCP and dicalcium phosphate dihydrate 
(DCPD). However, it is still possible that these precursor mineral phases might have 
been formed but transformed too quickly into other phases to be detected by these 
techniques.
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Conclusion: ESEM allows the imaging of hydrated heart valve bioprostheses with 
minimal manipulation and without the need for conducting coatings. It may also play 
an important role in developing our understanding of the calcification of heart valve 
bioprostheses and a similar methodology to the one described here is thought to be 
appropriate for the study of new tissue-engineered heart valves.
7.1 Introduction
The ESEM is an instrument that enables the examination of the surfaces of hydrated, 
unfixed specimens with a depth of field, resolution and magnification equivalent to 
that typically afforded by scanning electron microscopy (SEM)1,2. With the 
conventional scanning electron microscope, the electron beam is brought to a focus 
on the surface of the sample. The beam is scanned across the sample and a detector 
picks up the signal of secondary electrons that emerge from the surface, this signal 
being used to build up an image of the sample. The sample chamber, in addition to 
the electron optics, is held at high vacuum. Analysis of insulating specimens has 
always been something of a challenge because surface charging generated by the 
impinging electron beam has to be continually neutralised to prevent any distortion 
of the image. Specimen charging is usually overcome by the deposition of a thin 
metallic coating on the specimen to provide a conducting path to ground. Typically, 
imaging insulating materials such as valve tissue requires special coatings (C, Au or 
Pt) or the use of very low accelerating voltages (0.3 kV to 1.5 kV). Unfortunately, 
under these conditions, elemental micro-analysis via characteristic X-ray emission 
(EDS) is quite restricted. For example, peaks from the coatings may mask or overlap 
certain spectral features, while although X-ray generation is theoretically possible at 
low accelerating voltages, it is rather difficult to generate peaks at all.
The development and principles of ESEM were first described by Danilatos3,4. The 
ESEM operates under similar principles to conventional SEM but allows samples to 
be viewed in their natural states, at high accelerating voltages, without the need for 
coating or other specimen preparation. The ESEM differs from conventional SEM in 
two major ways: the use of differential pumping allows the specimen chamber to be 
at a low pressure while the electron gun chamber still achieves a very high vacuum 
environment; and the mode of secondary electron detection. The ESEM employs a
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two-stage differential pumping system (the ESEM-field electron gun (ESEM-FEG) 
employs a three-stage system) by which the gun chamber remains at high vacuum 
while the specimen chamber pressure can be as high as 30 Torr (1 Torr =133 Pa)5. 
At pressures of 1-30 Torr, the scattering of the primary electron beam by the gas 
adds a broad skirt to the central beam but does not alter the Gaussian distribution of 
the remaining focused beam. Thus high quality images can be produced without any 
interference from the skirting effect and, under optimum conditions, a resolution of 5 
nm can sometimes be achieved. Detection of the secondary electron signal is 
achieved with the help of a gaseous secondary electron detector (GSED). A 
moderate electric field is applied to the detector, causing secondary electrons to be 
drawn towards it. As the secondary electrons move towards the GSED, they collide 
with neutral gas molecules and ionise them, creating a cascade multiplication of the 
secondary signal. The surface charging of the specimen under study is effectively 
neutralised by the positive ions created in the gas. Consequently, specimens may be 
viewed at any accelerating voltage without coating or sample preparation. The 
ESEM is particularly suited to the use of energy dispersive X-ray analysis systems 
(EDS), especially to identify high atomic number elements in insulators. The X-ray 
signal is relatively unaffected by the gas present in the sample chamber, although it 
can be affected by gas pressure and ESEM mode conditions. Thus, quantitative as 
well as qualitative data can be obtained using EDS coupled to the ESEM.
In term of tissue preparation for both light and electron microscopy, soft tissues are 
often freeze-dried, frozen in liquid nitrogen, freeze-fractured or embedded in acrylic 
blocks and sectioned into micron-thick slides before being scanned. Bone samples 
might be demineralised and dried, or broken via freeze-fracturing techniques. Most 
of these steps can alter the results, the interpretations and thus the understanding of 
the scientific evidence. In fact, there is no simple way to determine whether the 
structures of interest are altered or masked by the preparation process. However, by 
comparing the data obtained from studies using SEM and ESEM, it was reported that 
sample preparation had altered the structure of the samples6'8. All these findings 
agree with the warning given by other scientists against the sample preparation of 
biological tissues9' 11.
Although some detailed histopathological studies ' and some ultrastructural 
studies by SEM17'20, TEM21' 23 and high resolution SEM24 carried out on
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bioprosthetic valves, revealed that calcification involved sub-cellular organelles, cell 
membrane debris and extracellular connective tissue (particularly collagen fibres), 
the pathogenetic mechanisms of calcium deposition in the bioprosthetic valve tissues 
are still poorly understood. Thus, the main objectives of this part of the study were to 
determine appropriate methodology to allow ESEM analysis of tissue samples and 
later to apply this to bioprosthetic heart valves and their calcification. The data 
produced were compared with those from earlier studies using conventional scanning 
electron microscopy (SEM). It was hoped that the information obtained from the 
ESEM analyses would provide a new insight into the understanding of biological 
calcification. The nature of the crystal phases associated with the calcific deposits 
was also investigated using ICP-OES, XRD, FTIR and Raman spectroscopy.
7.2 Materials and Methods
7.2.1 Materials
Explanted calcified valves, explanted non-calcified valves and unimplanted valves 
were kindly provided by Dr P. Lawford from the Royal Hallamshire Hospital, 
Sheffield. Leaflet samples were retrieved from the clinical bioprosthetic explants. 
The calcified areas of some heavily calcified valves were often even visible to the 
unaided eye.
Standards of what were thought to be potential precursor phases of calcification ((3- 
tricalcium phosphate standard (97%+) and hydroxyapatite standard (99%+)) were 
obtained from Rose Chemicals Ltd. (Sheffield, UK), and Fluka (Gillingham, UK). 
Saline water was phosphate buffer saline (PBS, Baxter, USA) and ultra pure water 
was obtained from a MilliQ50 (Millipore, UK) packed with USF liquid pure 
cartridges. The conductivity achieved was 18 MQ/cm3. Acids (HCL and HNO3) used 
for the hydrolysis of samples prior to ICP-OES analysis were both Aristar grade and 
obtained from BDH, UK.
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7.2.2 Low Energy Radiography
After retrieval at re-operation or at post-mortem, the bioprosthetic valves studied 
were examined radiographically for shadowing caused by calcification. Gross 
visualisation of mineral deposition was carried out using low energy radiography 
with a Hewlett Packard 43855A Faxitron machine (Faxitron, Hewlett Packard, 
Birmingham, UK). The tube voltage was set at 25 kV and the diagnostic film was 
exposed for 3 seconds with an intensity of 3 mA. The Kodak Industrex M films were 
developed using a Kodak RP X-OMAT processor (Kodak, Eastman Chemical Co. 
Kingsport, TN, USA). The data obtained from low energy radiography helped in the 
selection of the area where the calcification was the most obvious to be analysed by 
ESEM, although other areas, not showing any apparent signs of calcification, were 
analysed too.
7.2.3 Electron Microscopy
ESEM was used to observe the surface morphology of explants. Much effort was 
placed on describing the morphology in as quantitative a manner as possible, to give 
an objective interpretation of our findings. Predominantly, the external surfaces of 
explants were analysed. ESEM was also used in combination with energy-dispersive 
X-ray microanalysis (EDS) to compare the structure and chemical nature of both 
embryonic and advanced calcific deposits in these tissues in their native hydrated 
state, with minimal sample preparation after micro-dissection. The presence and 
distribution of calcium, phosphorus and other metal ions were thus assessed. For 
comparison, some calcified human explants were analysed by conventional SEM 
(work performed with courtesy of the Royal Hallamshire Hospital, Sheffield), and 
additionally, some synthetic CaP materials (hydroxyapatite and /3-tricalcium 
phosphate) were analysed under the same conditions as tissue samples using the 
ESEM. These synthetic standards are two of the CaP species that have been 
suggested as the initial CaP solid mineral phases deposited during bone and tooth 
formation and possibly during the dystrophic calcification of tissue (see chapter 1 
section 1 .6 ).
7.2.3.1 SEM analyses and sample preparation:
The SEM was a Philips 501 (Philips, The Netherlands), operated at an accelerating 
voltage of 15 kV. The processing protocol for tissue preparation was as follows. The
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sample was first washed with 0.1 M sodium cacodylate buffer. The tissue was then 
subjected to treatment with 1% osmium tetroxide in 0.1 M sodium cacodylate buffer, 
followed by dehydration with a series of ethanol:acetone solutions and culminating 
in dehydration in 100% acetone. The sample was then transferred into a Polaron 
3000 Critical Point Drier (Quorum Technologies, Newhaven, UK) through acetone. 
Finally, it was mounted on an aluminium stub using double-sided carbon adhesive 
disks and sputter-coated with gold (sputter-coating unit Edwards S I50, analyses 
typically operated at 50 mA for 1 min).
7.2.3.2 ESEM analyses:
The ESEM was a FEI Philips (Philips, The Netherlands) XL30 ESEM-FEG 
(environmental scanning electron microscope-field electron gun). An accelerating 
voltage of 20 kV was selected because it is a common voltage for coated specimen 
work in SEM and ESEM and it provided sufficient penetration of the primary 
electron beam into the bulk of the samples. In addition, this accelerating voltage 
gave good results with the X-ray analysis (good signal and a reduced skirting effect 
under the hydrated condition used). Samples required no sample preparation and 
were kept wet in a saline solution until the time of analysis, when they were rinsed 
several times with deionised water. The ESEM imaging gas was water vapour, at a 
pressure of 3.9-5.0 Torr. At these pressures, and by cooling the sample surface to 
around 5°C by means of a Peltier stage, fully hydrated conditions were established in 
the ESEM chamber. The samples were then controlled for dehydration during the 
anlysis.
An ED AX Oxford Instrument (Oxford Instrument, High Wycombe, UK) was used to 
perform a semi-quantitative analysis of the samples studied. The operating 
programme identified peaks by position in the spectrum and shape of the count 
distribution, matching these to a stored reference library of elemental peak spectra 
and their derivatives. Accurate quantification depended on the identification of every 
peak present in the spectrum: count data was collected for all detected peaks and 
calcium and phosphorus quantified as their proportions present in the region of 
interest relative to the other elemental species present. Data were automatically 
corrected for atomic number (software ISIS 300, Oxford Instrument, High 
Wycombe, UK), absorption and fluorescence, and provided atomic compositions of
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data points, allowing comparative examination of spectra. Raw count data were 
checked for anomalies which were then rejected, such as in the case of low count 
rates due to the sample topography which can sometimes shield the detector from the 
generated X-rays (shadowing effect).
The major parameters requiring optimisation in order to obtain decent quality 
secondary electron images are the gaseous pressure, the working distance (also 
called the beam gas pathlength), gas type and composition, the primary beam voltage 
and the detector voltage.
The gaseous secondary electron differential voltage (detector voltage) was of high 
setting and varied between 200 and 500 eV (by changing the contrast, the voltage on 
the GSED was changed, while the brightness corresponds to the gain after the signal 
has been detected). The primary electron beam voltage was varied between 15 and 
25 kV, with a mean value of 20 kV. The gas type was water vapour whilst the 
working distance was 8-16 mm. The most demanding part of the instrument set-up 
was the control of the gas (water) pressure in order to control the dehydration of the 
samples. The hydrated sample was placed on a Peltier cooling stage, allowing the 
stage temperature to be regulated in the sample chamber. The sample chamber can 
be seen in figure 7.1 below. The vacuum pump was activated until the chamber 
pressure reached 10 Torr. The sample chamber was then subjected to three or four 
floodings by decreasing the water pressure to 4 Torr and then increasing it to 10 
Torr. During this process, the CCD camera was used to check the state of the sample, 
particularly whether it tilted because of the surrounding water pressure. The pressure 
was then decreased to 4 Torr and the GSED switched on instead of the CCD camera. 
The sample was then slowly dehydrated by carefully and progressively lowering the 
gas chamber pressure, thus slowly removing the water layers covering the sample, 
until its complete disclosure. Using an electronic pressure-servo system, the chamber 
pressure was kept steady at the desired level with an accuracy of 0.1 Torr. The final 
working pressure was usually around 4 Torr, although it varied between samples 
from 4 to 2 Torr.
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Figure 7.1: ESEM sample chamber of a FEI Philips XL30 ESEM-FEG instrument. 
This picture obtained with a CCD camera shows the sample (center of the picture) 
kept cool by means of a Peltier stage. The GSED can be observed right above the 
sample.
7.2.3 X-ray diffraction (XRD)
The tissue samples were analysed in a freeze-dried state and the calcified deposits 
were also extracted from the freeze-dried organic matrix with the help of a 
magnifying lens and a scalpel. The resulting isolated crystals were turned into fine 
powder using a pestle and mortar and were analysed as pressed powders on a quartz 
slide. Usually, samples that are to be examined with XRD are turned into ashes so 
that the organic matrix is removed and the resulting spectrum essentially shows 
inorganic diffraction peaks without any organic amorphous background. However, it 
was decided not to do so for this study simply because at the temperatures needed to 
turn the samples into ashes (calcination temperatures), the apatite-like crystals 
(calcific deposits) may transform to the low temperature polymorph of tricalcium 
phosphate (|8 -TCP) at around 740°C, with a loss of water25. This is the same reaction 
as described by the following equation for the formation of TCP-ceramics26: 
Ca9(HP0 4 )s(0 H) -> 3 Ca3(PC>4)2 + H2O. The high temperatures could also lead to the
25transformation into the high temperature polymorph, oT C P, at around 1100°C .
The analyses were undertaken at room temperature with a Philips (Philips, The 
Netherlands) PW1710 X-ray diffractometer operating with Bragg-Brentano 
geometry. Experimental conditions were 40 kV and 40 mA, with Cu-Kai^ radiation. 
The diffraction patterns were recorded with an angle range of 5 to 100° 26 and using
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the step-by-step method with a step width of 0 . 0 2  degrees and a counting time of 1 0  
seconds per step. The comparison analyses were performed against synthetic mineral 
standards.
7.2.4 Fourier-transform infrared (FTIR) spectroscopy
All spectra were recorded with a Magna IR 860 Nicolet FTIR spectrometer (Nicolet, 
Warwick, UK) at a resolution of 4 cm '1, 1000 scans, with a horizontal ATR device 
(“Golden Gate” apparatus) from Graseby Specac (St Mary Cray, UK) and a single 
reflection diamond ATR crystal with a 45° angle of incidence, scanned between 
4000 and 400 cm '1. The apodisation function was Happ-Genzel and there was a 
Mertz phase correction. All spectra were recorded under similar conditions and were 
corrected for atmospheric water vapor and carbon dioxide transmittance by 
subtraction of the appropriate reference spectrum.
The freeze-dried calcified tissues were analysed as they were and, similarly to the 
samples used for XRD, the calcified deposits were also extracted from the freeze- 
dried organic matrix with the help of a magnifying lens and a scalpel, and the 
resulting isolated crystals were turned into fine powder using a pestle and mortar. 
The analyses were also performed against synthetic mineral standards (such as 
hydroxyapatite and /5-tricalcium phosphate).
7.2.5 Raman spectroscopy
In this study, (dispersive) Raman spectroscopy was used to characterise the type of 
calcium phosphate phase formed in the samples and to identify the presence of 
carbonate or other inorganic species such as hydrogenophosphate or hydroxide ions. 
The Raman instrument used was a Renishaw Ramascope 2000 (Renishaw, Wotton- 
under-edge, UK), with a red laser (633 nm). Spectra were scanned between 4000 and 
100 cm ' 1 at a resolution of 4 cm '1.
7.2.6 Inductively coupled plasma-optical emission spectroscopy (ICP-OES)
Glutaraldehyde-treated explanted calcified valves were subjected to a quantitative 
study using ICP-OES. Prior to be analysed, the valves were washed five times, each 
for a period of 5 minutes in phosphate-buffered saline and then distilled water. All 
the samples were lyophilised with a Cold trap 1000 freeze-drier (achieving a 
pressure of 75 mbar (0.35 atm) with a temperature of approximately -40°C),
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weighed and subsequently hydrolysed with a mixture of 3 mL of HC1 (Aristar grade, 
BDH, UK) and 1 mL of HNO3 (Aristar grade, BDH, UK) simmering/boiling for 5 
hours. A final sample volume of 10 mL was made up using de-ionised water. The 
samples were then submitted for ICP-OES using a FC1400 Spectro analytical 
instrument (Spectro, Germany). The presence of silicon, calcium and magnesium 
was thus estimated quantatively. It was decided not to analyse the phosphorus 
content because of the phosphate-buffered saline solution (PBS, Baxter, USA) used 
to store the bioprosthetic valves prior to analysis.
7.3 Results and discussion
7.3.1 ESEM imaging
The ESEM imaging methodology described in section 7.2.3.2 was successfully 
applied to valve analysis. Figure 7.2 (left) represents a valve sample totally covered 
by water, before it was slowly dehydrated by carefully and progressively lowering 
the gas chamber pressure until complete disclosure of the sample was achieved. The 
typical appearance of collagenous valve tissue obtained finally by ESEM imaging 
can be seen in figure 7.2 (right).
Figure 7.2: Left: ESEM secondary electron image of a tissue valve totally covered by 
a thin layer of water, prior to dehydration. Right: ESEM secondary electron image of 
a hydrated unimplanted bioprosthetic valve.
The intrinsic low atomic number of biological valve samples provided little 
resistance to transmission of signal from underlying materials since heavy metal 
coatings were absent. ESEM imaging of uncoated biological specimens has already 
been reported to provide good information about internal or overlapping structures27.
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Heavier elements appear brighter than elements of low atomic number. For instance, 
calcium phosphate crystals appear brighter than the collagen background of the 
valve.
The valve structure, when analysed by ESEM, is essentially undisturbed and the 
samples appear to be stable during prolonged exposure to the electron beam. A major 
difference can be observed between the secondary electron images obtained from 
similar valve sample using ESEM (see figure 7.2 above) and conventional SEM (see 
figure 7.3 below). The net difference lies in the arrangement of the collagen bundles 
that appear totally collapsed when analysed with the conventional SEM. A similar 
ESEM image to the one obtained with SEM could be obtained when a sample was 
dried out extensively by decreasing the sample chamber pressure o f the ESEM 
instrument.
Figure 7.3: SEM secondary electron image of a calcified bioprosthetic heart valve 
(x2500, accelerating voltage of 15 kV, sample critically point dried and sputter 
coated with gold). The dried collagen mesh appears to be collapsed.
Secondary electron imaging along with EDS analysis with the ESEM revealed 
several forms of accumulated calcium phosphate mineralisation on explanted 
calcified bioprosthetic valves. The figures 7.4-7.17 show various characteristic forms 
of calcification. These forms include the ordered growth of crystals of 0.2-2 fim  size 
distributed along collagen fibrils and also within the collagen structure (figures 7.4, 
7.5, 7.6).
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Other crystalline structures were also often found arranged into discrete aggregates 
of 1-10 /im (see figures 7.7, 7.8 and figure 7.9), large nodules of 20-30 fim (see 
figures 7.10-7.14), or even forming sheets (see figure 7.15). Crystals were observed 
either underneath the collagen surface (see figure 7.5), attached to the surface of 
individual collagen fibres (and possibly sometimes elastin), (see figures 7.7, 7.8 and 
7.15), or in the interfibrillar space. Calcific crystals were seen to form parallel arrays 
following the longitudinal axis of the collagen fibrils (see figure 7.15).
Figure 7.4: ESEM secondary electron image of an explanted calcified valve, 
showing formation of small particles of 100-500 nm in size that seem to grow from 
the inside of the collagen surface.
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Figure 7.5: ESEM secondary electron image of an explanted calcified valve (left), 
showing inorganic growth occurring underneath the collagenous valve surface. The 
crystals are about 1-3 jiim in size. The corresponding EDS trace (right) indicates the
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presence of Ca, P, Mg, and possibly Si in the crystal, in addition to the organic 
matrix components (C, O and S). Note: Na and Cl are from the saline solution, used 
to store the valves.
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Figure 7.6: A particle of about 2 f im  in size can be seen on the secondary electron 
image (left) with a poor contrast that indicates that it is located underneath the tissue 
surface. The EDS spectrum (right) shows it is rich in Ca and P with some trace of Si.
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Figure 7.7: ESEM secondary electron image of an explanted calcified valve (left), 
showing a crystal growth of less than 1 /mi in size on a collagen bundle (possibly an 
elastin bundle). The corresponding EDS spectrum (right) shows it is rich in Ca and 
P.
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Figure 7.8: ESEM secondary electron image of an explanted calcified valve (top 
left), showing a particle of about 10 pm in size and rich in Ca and P. Other smaller 
areas also rich in Ca and P can be observed underneath the surface thanks to the EDS 
mapping, although unnoticed with the secondary electron imaging. The brighter the 
colour, the more present an element. The elements analysed were oxygen, sodium, 
phosphorus, chlorine and calcium.
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Figure 7.9: ESEM secondary electron image of an explanted calcified valve (left), 
showing a calcific nodule (up to 10 pm) rich in Ca and P growing off a collagen 
bundle and its corresponding EDS spectrum (right). The crystal growth seems to 
follow the collagen plane formed by the bundle.
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Figure 7.10: ESEM secondary electron image of an explanted calcified valve with a 
low (left) and higher (right) magnification of an inorganic particle of about 1 0  /xm in 
size rich in Ca and P (EDS trace not shown here). The crystal growth is seen 
growing off the collagen bundles (partially covered with a film of water, which 
appears as small black pools), along smaller calcific nodules of micron size.
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Figure 7.11: The secondary electron image of a calcified valve shows the 
simultaneous presence of particles (rich in Ca and P-EDS spectrum not shown here) 
ranging from 1 - 2 0  /xm in size.
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Figure 7.12: ESEM secondary electron image of an explanted calcified valve (top 
left), along with the corresponding EDS map, showing various nodules rich in Ca 
and P on and underneath the collagen surface with a particle size of less than 1 
micron and a large calcific aggregate of up to 20 pm in size. Note the pool of water 
(rich in oxygen) located on the right hand side.
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Figure 7.13: ESEM secondary electron image of an explanted calcified valve (top 
left), along with the corresponding EDS elemental mapping, showing a calcified 
nodule of about 10-20 pm in size rich in Ca and P.
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Figure 7.14: ESEM secondary electron image of an explanted calcified valve 
showing an aggregate of 30 /xm on the collagen surface. Its corresponding EDS 
spectrum shows it is rich in Ca and P.
Figure 7.15: ESEM secondary electron images of an explanted calcified valve, 
showing that the valve calcification extends onto and along collagen and elastin 
fibrils (left), by following their planes. The valve calcification is also found to occur 
in the interfibrillar spaces (right) and eventually to form large plaques rich in Ca and 
P (EDS spectrum not shown here).
289
Figure 7.16: ESEM secondary electron images of an explanted calcified valve, 
showing different inorganic growth structures that can be differentiated. Some plate­
like aggregate structures with a typical crystal growth very similar to bone growth 
morphology (left), and one with a fluffy aspect (right), which is very similar to the 
appearance of a crystalline hydroxyapatite standard run under the same experimental 
conditions.
Figure 7.17: ESEM secondary electron images of a heavily calcified explanted valve, 
showing the valve surface extensively calcified. Large aggregates are covering the 
entire collagenous surface of the valve.
Calcium-rich calcific deposits have been previously described in bioprosthetic valves 
in association with collagen, especially sites of collagen disorganisation and/or 
disintegration21,28. Our photomicrographs confirmed that calcification was initiated 
within the tissue of the valves, with calcium-containing crystals often present just 
underneath the disrupted surface and then propagated towards the outer surface of 
the tissue as calcification proceeded. The most common form of crystal morphology 
present were as spherical shapes, found mainly in the collagen interstitium, similar to 
that reported previously with high-resolution electron microscopy24. Less commonly, 
the calcific deposits were also observed as needle-like (fluffy aspect) or plate-like 
structures, showing well-developed basal pinacoids (a clear-cut morphologic finding 
consistent with the hexagonal nature of apatite). The observed arrangement of plate­
shaped crystals (assigned to apatite structure) and their predominant association with 
the interfibrillar spaces are similar to the findings of a study of calcifying turkey leg 
tendons29, and have been reported in an SEM study of bioprosthetic heart valve
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tissue22. The needle-like morphology of some of the calcific deposits observed in 
calcified explanted valves was similar to that reported for in-vitro synthesised 
deficient hydroxyapatite observed by ESEM, where both plate-like and needle-like
on mstructures were seen . In addition, the morphology of standard hydroxyapatite, 
observed under similar conditions to those which the explanted valves were analysed 
under, also appeared as needle-like crystals. This suggested that explanted calcified 
valves, based strictly on morphology, seem to contain poorly crystalline apatite 
crystals, amongst others. Moreover, the observed irregular morphology of many 
calcific deposits and the abutting of small and large crystals tend to support the 
hypothesis that a hydrolytic process could occur during the calcification30,31 (a 
precursor phase could be fully or partially hydrolysed for the benefit of the formation 
of another until the morphology and Ca/P ratio approach those of apatite-like 
material, almost those of hydroxyapatite). The varied morphology of the calcific 
crystals observed in our study shows similarities with that of DCPD31, hydrolysed 
OCP32' 34 or possibly more likely a morphological variation of the apatite structure35. 
The calcification process is thought to involve phase transformations of 
thermodynamically unstable calcium-phosphate salts to more stable ones34,36'38, 
hence the likelihood of seeing several different morphological structures.
7.3.2 Energy dispersive X-ray (EDS) analysis
It has been reported that the semiquantitative EDS analysis of hydrated biological 
materials can be undertaken when EDS is coupled with an ESEM39. The surface 
geometry of the samples, the heterogeneity of the distribution of elements in 
biological valve samples and the semiquantitative nature of EDS, tend to limit the 
elemental analysis of samples using ESEM-EDS. However, in this study, it was 
possible to obtain maps, which revealed the presence of accumulated calcium 
phosphate mineralisation, showing different Ca/P ratios. The EDS results were 
processed so that the software gave the atomic Ca/P ratios. No calculations of the 
Ca/PC>4 ratios were made because of the use of water vapour in the sample chamber, 
would affect the observed oxygen content. The stoichiometric atomic Ca/P ratios 
(see table 7.1 below) were used to identify the crystal phases present.
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Inorganic CaP Phases 
commonly encountered
Atomic Ca/P ratios (as usually 
reported in the literarture)
Hydroxyapatite (HAP) 
Ca10(PO4)6(OH)2
1.670
B-Tricalcium Phosphate (j8- 
TCP) Ca3(P 0 4)2
1.500
Octacalcium Phosphate (OCP) 
Ca8H2(P 0 4)6.5H20
1.330
Dicalcium Phosphate Dihydrate 
(DCPD) CaH P04.2H20
1.000
Table 7.1: Common inorganic CaP-rich phases and their corresponding atomic Ca/P 
ratios
In the case of heavily calcified valves, EDS analysis identified the components of 
calcification as calcium and phosphorus in an atomic ratio typical of hydroxyapatite. 
The spectra obtained were comparable to those collected in an extensive EDS 
analysis of a crystalline hydroxyapatite standard, run under the same conditions (see 
figure 7.18 below). The atomic Ca/P ratio of an heavily calcified tissue valve 
obtained from the corresponding EDS trace (figure 7.18 left) appears very similar to 
the one (Ca/P: 1.675) of a pure crystalline hydroxyapatite standard run under the 
same conditions (figure 7.18 right). The results are in in agreement with the 
theoretical calculated data (Ca/P: 1.670).
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Figure 7.18: (left) EDS spectrum obtained from a heavily calcified tissue valve. 
(right) EDS spectrum obtained from a pure crystalline hydroxyapatite standard 
analysed under the same conditions.
The high values of the atomic molar ratios of Ca/P, obtained for the various mineral 
deposits on the valves analysed in this study (see figure 7.19 below) ranging from 
1.340 to 2.115 with a mean value of 1.676, may be attributed to the substitution of 
the calcium and phosphate ions by other ions40 (e.g.: sodium, magnesium, carbonate 
and silicon). Unfortunately, substitutions of calcium and phosphate lattice ions, with
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nonmetallic (carbonate, acidic phosphate) and metallic (a, Mg, Si) components, 
render the simple stoichiometric analysis of isolated calcific deposits difficult to 
provide conclusive evidence for the nature of different calcium phosphate phases 
coexisting at each stage of the calcification process. However, the EDS analysis of 
an hydroxyapatite standard, analysed under the same conditions as the valve 
samples, showed that reasonably accurate Ca/P ratio data could be obtained, which 
was in agreement with the theoretical calculated data (see figure 7.18 above). This 
suggests that the EDS analyses, although prone to complications because of the 
water vapour environment, do yield reliable results.
Histogram (Explanted Calcified Heart Valves)
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Figure 7.19: Histogram showing the frequency of occurrence versus the atomic Ca/P 
ratios from the EDS analyses of calcific deposits found on various calcified tissue 
valves analysed by ESEM.
EDS analysis of the calcium phosphate deposits also showed the substantial 
incorporation of silicon and magnesium in calcified tissue valves. Many EDS traces 
of calcific deposits reported in this chapter corroborate this statement. However, the 
hypothetical presence of sodium (its incorporation in the inorganic calcific phases) 
could not be confirmed because the valves were stored in saline solution prior to 
analysis.
The presence of Si appears to be in agreement with the above-hypothesis, which 
states that substitutions of calcium and phosphate lattice ions with metallic 
components can occur. The presence of Si is also in agreement with various
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reports41'44, where it has been shown that a reduced weight gain and pathological 
changes to bone and connective tissue in rats and chickens (maintained on silicon- 
depleted diets) could be reversed by silicon (silicate) supplementation in their diet. It 
was thus reported that silicon was required as an essential trace element in bone and 
connective tissue formation, and that it also participated in many other important 
metabolic processes45, . A role for silicon in osteogenesis had already been 
suggested by observing that silicon was uniquely localised at the mineralisation front 
in bones of young rats47. Silicon was found specifically in connective tissue cells and
AOin isolated osteocytes of young rats . It was thus suggested that silicon has a 
physiological role in bone calcification and that it is involved in the early stages of 
mineralisation, where a direct relationship appears between silicon and calcium. 
Silicic acid (Si(OH)4) is the physiologically active species that was reported to be 
capable of binding calcium in-vitro49, with a plasma concentration in humans 
ranging from 5 to 20 mM. However this concentration can rise to above 100 mM in 
renal diseases50, in which calcification of the patient’s valves is thought to be 
particularly acute (see chapter 1 sections 1.3 and 1.7). Calcium and silicon have also 
been found co-deposited in senile plaques50,51. Whether there is a direct correlation 
between silicon and calcification remains to be proven. Silicon can be observed in 
the EDS spectra of calcified valves in a paper by Glasmacher et al . However, no 
explanation for its presence was given. It was reported that at later stages of 
mineralisation, where the Ca/P ratio tends towards the value of mature 
hydroxyapatite, the relationship between calcium and silica falls markedly or that as 
the calcium content increases the silicon content becomes less important. The fact 
that silicon might play a part in the initiation of mineralisation was also 
demonstrated in-vitro by Damen et al and in-vivo using a rat subcutaneous 
implantation model53. In our study, the significance of silicon in the initial 
calcification of tissue valve bioprostheses was investigated. It was personally 
hypothesised that silicon does play a role in the calcification of bioprosthetic heart 
valves, most likely being incorporated into a mineralisation precursor phase54.
Magnesium, in this study, was also found in the early stages of calcification of 
bioprosthetic valves. This is in agreement with earlier work which reported that 
magnesium may substitute for calcium within the crystalline matrix of 
hydroxyapatite55. This would therefore explain the levels of magnesium seen here.
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Magnesium can also be observed in the EDS spectra of calcified valves analysed by 
SEM in the literature24, although no explanation for its presence was given. 
However, Suh et al56,57 stated its presence in their EDS spectra and reported that 
Ca/P ratios indicating a higher calcium content composition than that of crystalline 
hydroxyapatite can be explained by the formation of calcium phosphate crystals 
incorporating magnesium and possibly sodium and carbonate58. They believed that 
these species, following crystal aggregation, grow to form the calcified nodules that 
result in valve dysfunction and failure. In addition, others think that in the very early 
stages of calcification, magnesium stabilises amorphous calcium phosphate in the 
vesicles (where the process of mineralisation is thought by some authors to be 
initiated)59. Hence, nucleation of hydroxyapatite would not occur until the membrane 
of the vesicles was ruptured, releasing the magnesium and exposing the complex to 
the extracellular fluid. For this reason, we also hypothesised that there might be a 
correlation between phosphate and magnesium in the early stages of calcification 
but, because of the presence of phosphate in saline solutions, the phosphate level was 
not assessed in this study and therefore this hypothesis is strictly theoretical. The 
possible incorporation of sodium in the calcific deposits was also impossible to study 
because the valves had been stored in phosphate buffered saline prior to being 
analysed.
7.3.3 X-ray diffraction (XRD) analysis
Freeze-dried explanted calcified valve samples, analysed without any further sample 
preparation, showed a pattern in keeping with hydroxyapatite (Caio(P0 4 )6(OH)2). 
However, because of the large amount of organic tissue, the background radiation 
was particularly high. This can be seen in figure 7.20 below, which shows the 
diffraction pattern of an intact explanted calcified valve along with the 
hydroxyapatite pattern given by the Philips XRD library. Also, included is the 
diffraction pattern of a crystalline hydroxyapatite standard unground and spread 
unevenly over the quartz slide (to mimic the tissue sample).
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Figure 7.20: XRD data from an “intact” freeze-dried calcified valve showing a 
diffraction pattern consistent with hydroxyapatite. Calcified valve (magenta)’, 
hydroxyapatite standard (blue); hydroxyapatite library pattern (black). Diffractions 
patterns recorded with a 40 kV voltage and 40 mA intensity, an angle range of 5 to 
1 0 0 ° 2 0  using a step-by-step method with a step width of 0 .0 2 ° and a counting time 
of 1 0  seconds per steps.
It was decided therefore to extract the calcific deposits from the organic collagen 
matrix and the resulting isolated crystals were powdered. As a result of this, the 
XRD spectrum showed sharp peaks, which is in keeping with well-crystallised 
apatite precipitates. Figure 7.21 shows the diffraction pattern of the extracted calcific 
deposits of the same valve as analysed previously (figure 7.20), along with the 
diffraction pattern of a crystalline hydroxyapatite standard prepared in the same way 
as the sample. The presence of octacalcium phosphate (OCP, CasFbCPO^AFfO) in 
the valve sample is rather excluded because of the absence of the most prominent 
(100) OCP reflection (d=18.6A around 4.75° 20) and of other peaks. However the 
pattern shows some similarities with the pattern of the hydrolytic OCP product
I TOCPH '.  The pattern does not however show the coexistence of tricalcium phosphate 
((3-TCP, Ca3(P 04)2), since some typical reflections, such as (214) d=3.2lA at 27.77° 
20 and (220) d=2.607A at 34.38° 20, are absent.
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Figure 7.21: XRD data from extracted calcific deposits from a calcified valve (blue) 
showing a diffraction pattern very similar to the hydroxyapatite standard run under 
the same conditions (magenta). Diffractions patterns recorded with a 40 kV voltage 
and 40 mA intensity, an angle range of 5 to 100° 20 using a step-by-step method with 
a step width of 0 .0 2 ° and a counting time of 1 0  seconds per steps.
7.3.4 FTIR-ATR and Raman analyses
7.3.4.1 FTIR-ATR analyses:
A typical FTIR-ATR spectrum from an explanted calcified valve can be observed 
below in figure 7.22. The peak positions and their assignments are reported in table 
7.2.
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Figure 7.22: A typical FTIR-ATR spectrum from an “intact” calcified bioprosthetic 
valve, exhibiting a major contribution from the organic matrix. ( 1 0 0 0  scans, 
resolution of 4 cm '1, horizontal ATR device with a single refletion diamond ATR 
crystal with a 45° angle of incidence).
P eak position  
( c m 1) A ssignm ent
-3400-3100 NH stretching
2924 Anti-symmetric stretching of the CH2 group
2850 Symmetric stretching of the CH2 group
1738 C=0 stretching mode typical of phospholipids
1635 Amide I (C=0 stretching)
1529 Amide II (N-H stretching)
1443 CH2 group scissoring modes
1391 C=0 symmetric stretching mode
1309 CH2 group wagging modes
1028 P-0 stretching in the ^3(P043') domain
872 Out-of-plane band of the ^2(C032') domain
Table 7.2: FTIR peak positions and their corresponding assignments from an “intact”
explanted calcified bioprosthetic valve (freeze-dried), (see figure 7.22 for spectrum). 
(1000 scans, resolution of 4 cm '1, horizontal ATR device with a single refletion 
diamond ATR crystal with a 45° angle of incidence).
The spectrum shown in figure 7.22 demonstrates that infrared spectroscopy of an 
“intact” (“intact”, in this case, denotes no further sample preparation) calcified valve
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can detect the presence of calcium phosphate with a band of absorption at 1028 cm’ 1 
(P-0 stretching in the V3(P(V ')), as was reported by Shen et al60. The assignment of 
the inorganic bands is however rendered difficult because of the strong absorption of 
the organic matrix. Unfortunately, other typical bands of the V4(P0 4  ') region 
expected at -602 cm’ 1 (bending) and -561 cm’ 1 (bending), cannot be determined 
from our FTIR data because of the detector and beam splitter limits. However, the 
presence of lipids can be identified by the appearance of a band at 1738 cm '1, while 
the presence of proteins can be detected from the absorbance of the amide I (C=0 
stretching) at 1635 cm’ 1 and from the amide II (N-H stretching) at 1529 cm '1. The 
sharp peak at 872 cm ' 1 could be due to the V2 vibrational band of the carbonate ion 
(expected at 850-880 cm '1), which is usually relatively free of absorption by organic 
substituents. However, other carbonate peaks are difficult to assign because they are 
unresolved from other broad absorption bands. The absence of a band at 910 cm '1, 
which is usually considered characteristic of OCP, refutes the theoretical presence of 
an OCP phase in the calcified valve.
The FTIR-ATR spectrum of the extracted calcific deposits from calcified explanted 
valves allows a much better assignment of the inorganic peaks, although there is still 
some evidence of the organic matrix. Such a spectrum can be found in figure 7.23 
below.
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Figure 7.23: FTIR-ATR spectrum of extracted calcific deposits from a calcified 
explanted valve (balck trace), along with the spectrum of a stoichiometric crystalline 
hydroxyapatite standard (blue trace). (1000 scans, resolution of 4 cm '1, horizontal 
ATR device with a single refletion diamond ATR crystal with a 45° angle of 
incidence).
Apatitic structure:
Of interest when analysing the mineralised tissue or the calcific minerals themselves 
by FTIR are the V\ and Vi phosphate peaks (900-1200 cm '1), as it is the only 
accessible area with the spectrometer used for this study (mercury cadmium telluride 
(MCT) detector and KBr beamsplitter, cutting the signal at 650 cm '1, preventing the 
analysis of the V4(P0 4  ’) region). To resolve underlying bands, second derivative 
spectra can be calculated, facilitating the determination of peak positions ' , which 
in turn may be used to identify the presence of acid phosphates or non-stoichiometric 
apatites64. Comparison of the FTIR spectra obtained from calcific deposits extracted 
from explanted calcified valves with the spectra of standards such as /3-TCP, OCP, 
brushite (DCPD) and HAP, raised some interesting points. First of all, the theoretical 
presence (see chapter 1 section 1.6.4) of (3-TCP, brushite and OCP is refuted because 
of the differences in the spectra. For example, the characteristic (3-TCP band at 970 
cm ' 1 64 is absent, as is the brushite band at 1128 cm ' 1 64, the OCP band (HPO42' ion 
of OCP) at 1138 cm ' 1 64 and another specific band for the OCP structure at 913-917
1 zrc ^cm' . The presence of HPO 4 ' -containing apatite is also refuted because of the 
absence of the typical absorption band at 1143 cm '1, which has generally been 
assigned to HPO 4 2’ ions66. Nevertheless, the spectra from the explanted calcified 
valves do contain some similarities with that from pure crystalline hydroxyapatite, 
suggesting the presence of an apatic phase (see figure 7.23). However, the hydroxyl 
stretch observed at 3572 cm ' 1 in the spectrum from the hydroxyapatite standard is 
not observed in the spectrum of the calcified valve. The stoichiometric 
hydroxyapatite standard shows well known sharp absorption bands exhibiting 
maxima in the ^(PCU ’) region at 1 0 2 0  and 1086 cm' , while a non-stoichiometric 
apatite-like structure usually shows bands at 1110 and 1125 cm ' 1 that are considered 
as representative of phosphate environments in poorly crystalline apatitic calcium 
phosphates64. For instance, a clear band can be observed at 1125 cm ' 1 in the 
spectrum of the mineral of young enamel64, while a shoulder would indicate lability
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of crystals. Despite the presence of a relatively broad phosphate band at -1020 cm ' 1 
in the spectrum of the explanted calcified valve (such a band has also been 
interpreted as an indication of the persistence of vacancies in non-stoichiometric 
apatites containing impurity ions64), the absence of bands around 1100-1125 cm ' 1 
indicates the possible presence of a mixture of stoichiometric and non-stoichiometric 
apatite structures. Additionally, other bands, such as the peaks at 1647 cm '1, at 1452 
and 1412 cm ' 1 (carbonate ^ (C 0 3 2')bands) that are assigned to non-stoichiometric
apatites, lead to the conclusion that calcium-deficient apatite is present. The band at
1 ^960 cm' can be assigned to the zq(P0 4  ') band, the rest of the v\ domain being
hidden behind the intense ^(PCU3’) bands. The bands of calcium-deficient apatite (or
non-stoichiometric apatite) are quite similar in fact to the ones of stoichiometric
apatite but they are generally characterised by additional bands similar to those
found in most biological apatites64 (around 1020 and 1100 cm '1). Such bands can be
identified, using second derivatives, at 1016, 1059, 1074 and 1097 cm ' 1 in the FTIR
spectrum obtained from the calcific deposits of explanted valves. This leads to the
general conclusion therefore that the calcific deposits consist of calcium-deficient
apatites.
Carbonate and hydroxyl-containing apatite:
The FTIR-ATR spectra from extracted calcific deposits found in valves (see figure 
7.23) indicate the presence of carbonate. For example, bands are observed in the
9 1 1^(CCb ') domain (two main ones at 1639 cm' and 1412 cm' , along with others
1 1 1  2 \ around 1492 cm' , 1470 cm' and 1452 c m '). Bands are also seen in the ^ (C 0 3  ')
region, which is composed of three main FTIR shifts at 871 cm '1, a shoulder at 8 6 6
cm ' 1 (corresponding to a labile carbonate environment) and another at 879 cm '1.
Most of these carbonate bands observed in our spectrum, also substantiate the fact
that lattice-bound carbonates can substitute for phosphates, as it has already been
reported in the literature67,68. Thus, the calcific deposits of calcified valves appear to
be of a B-type carbonated-apatite69 (carbonate ions substituting for phosphate ions in
the apatic structure). However, the presence of the shoulder at 879 cm ' 1 may also
indicate the possible presence of some type A carbonate, a fact that could be
corroborated by the presence of other typical peaks in the ^(CC^2') domain assigned
to type A carbonate70 (carbonate ions substituting for the OH' ions in the apatic
structure). This leads to the conlusion that, as with bone, the environment of
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carbonate ions in the calcified valves might be a mixture of type A and type B- 
carbonate. Unfortunately, the infrared spectral range scanned in this study does not 
allow the definite determination of the apatite carbonate-type that would had been 
facilitated by assignment of bands in the V4(P0 4 3') domain (500-650 cm '1). Although 
no quantitative data are available, the main carbonate location appears to be in the 
phosphate sites (type B), with minor amounts in the monovalent anionic sites (type 
A). The fact that some carbonate was found to be present in the calcific deposits is 
not surprising as the incorporation of carbonate in calcified valves, analysed as KBr 
pellets, has been previously reported34.
The presence of type A and B carbonates in the calcific deposits of calcified valves 
may contribute to the absence or very low concentration of hydroxyl ions observed
71 72in the spectra. Again, this is quite similar to what is observed with bone mineral ’ . 
However, the absence of bands indicative of the OH group in our spectra does not 
preclude the presence of hydroxide ions, as it was previously reported73,74. Some 
convincing evidence that OH groups can be present although they do not give rise to 
OH bands in the infrared spectrum was reported75. Also, hydrogen bonding with 
adsorbed water molecules could reduce the intensity (extreme broadening) of 
infrared OH bands76.
7.3.4.2 Raman analyses:
The Raman spectra obtained from “intact” calcified valves showed a strong 
fluorescent background, masking the entire pattern. This is thought to be due to a 
yellow colouration of the tissue caused by the glutaraldehyde treatment. A typical 
spectrum of such a calcified valve can be found in figure 7.24. Only the expected 
relatively strong vibrations can be seen above the fluorescence background (as 
assigned in table 7.3).
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Figure 7.24: Raman spectrum of an “intact” explanted calcified bioprosthetic valve. 
Spectrum scanned between 4000 and 100 cm ' 1 at a resolution o f 4 cm '1, with a red 
laser (633nm).
Peak position  
( c m 1) A ssignm ent
3061 Amide B (contribution from the organic matrix)
2932 CH stretching (contribution from the organic matrix)
1448 Possible carbonate band i>3(C032')
1070 Anti-symmetric P-0 stretching ^(PO ^)
959 Symmetric stretching vibration of the P-0 bonds i'i(P0 4 3') band
Table 7.3: Peaks positions and their corresponding assignments from the Raman 
spectrum (see figure 7.24) of an “intact” explanted calcified bioprosthetic valve 
(freeze-dried). Spectrum scanned between 4000 and 100 cm ' 1 at a resolution of 4 cm" 
\  with a red laser (633nm).
Extraction of the calcific deposits from the calcified valves by removing the majority 
of the collagen matrix yielded much better spectra with minimal fluorescent 
background (see figure 7.25 below). In addition, and in comparison to the FTIR 
study that did not allow bands to be characterised below 650 cm '1, the Raman spectra 
were collected over a wider spectral range. The V4(P0 4 3') region was therefore 
visible and able to reveal interesting features, which were not visible in the FTIR 
spectra. In addition, V4(CC>32') bands, which have very low intensities and are seldom 
seen in infrared spectra77 (no peaks were observed in this study in this region), have 
strong vibrational bands in Raman spectra and hence could be observed. Similarly,
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the v ,(C 032') region is not observable in the FTIR spectra as this region is obscured 
by strong phosphate absorption bands77, however the vi(C0 3 2" ) vibrational mode
nohave also strong vibrational bands in the Raman spectra and hence can be 
observed. A typical spectrum of extracted calcific deposits from a calcified valve can 
be seen in figure 7.25 below. The presence of some traces of the organic matrix is 
easily observed. For example, the broad band around 3300 cm ' 1 is attributable to NFI 
whilst bands at 3061 and 2932 cm ' 1 can be assigned to the amide B and CH 
stretching, respectively.
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Figure 7.25: Raman spectra of extracted calcific deposits of a calcified explanted 
valve (black trace) and of hydroxyapatite standard (blue trace). Spectra scanned 
between 4000 and 100 cm ' 1 at a resolution of 4 cm '1, with a red laser (633nm).
Apatitic structure:
The intense, and single band at 958 cm ' 1 corresponds to the symmetric stretching 
vibration of the P -0  bonds (vi(P0 4  ')) and hence refutes the hypothetical presence of 
p-TCP, which exhibits two peaks and a shoulder instead of a single peak. A similar 
single, intense peak at 961 cm ' 1 can be found in the hydroxyapatite standard 
spectrum.
The single band at 430 cm ' 1 is assigned to the doubly degenerate O-P-O bending 
mode (V2(P0 4  ')). This band appears very much similar to the hydroxyapatite 
V2(P0 4 3') mode.
The single but quite broad band with a maximum at 1070 cm ' 1 may be assigned to 
anti-symmetric P -0  stretching (>3(P0 4  ')). In the same region, the hydroxyapatite 
standard exhibits a sharp, intense peak at 1075 cm ' 1 and a shoulder at 1068 cm '1, 
which might explain the width of the band observed in the spectrum from the calcific
3 1deposits. In another region of the ^ (P 0 4  ") mode (between 1055 and 1020 cm' ), 
hydroxyapatite standard peaks at 1046, 1028 and a shoulder at 1038 cm ' 1 can be 
compared to the broad, weak bands observed in the same region of the spectrum of 
the extracted calcific deposits (peaks not annotated in spectra for sake of clarity).
The broad singlet (with possible splitting) around 590 cm ' 1 (^(PCU3’)) can be 
assigned predominantly to the anti-symmetric O-P-O bending frequency. It 
corresponds roughly to an “advanced” amorphous calcium phosphate form, since the 
conversion of amorphous calcium phosphate to a fully crystalline solid is usually 
accompanied by a gradual splitting of the Raman band into a well-defined doublet
7Q • • •for the fully crystalline material . In fact, the crystalline stoichiometric 
hydroxyapatite standard shows a doublet (590 and 578 cm '1) with a shoulder at 575 
cm ' 1 in this region. The presence of such an “advanced” amorphous calcium 
phosphate phase in the calcific deposits is corroborated by the absence of a band at 
530 cm '1, which is usually found in the early stages of mineralisation of bone and 
enamel80,81.
Carbonate and hydroxyl-containing apatite:
1 2 The strong band at 1448 cm' may be assigned to a carbonate band ^(CCb '). Some
1 2 bands at 879, 851 and 828 cm' can be assigned to the out-of-plane bending ^(CCb '
) mode, which is not obscured by the organic matrix or by any phosphate absorption
bands70. No band corresponding to an HPC^-containing apatite can be observed
(expected at 545 cm '1), which excludes the hypothetical presence of OCP. Thus, we
can conclude that the calcific deposits are made up of calcium-deficient apatite
containing CO32' ions but no HPO42'. The band at 757 cm ' 1 can be assigned to a
4^(C0 3 2') mode. The stretching mode of OH" found with crystalline samples is
present at 3572 cm ' 1 in the spectrum of the hydroxyapatite standard. This band is
0 9  0 4known to be difficult to detect in poorly crystalline samples ' and is absent from 
the Raman spectrum of the calcific deposits from the calcified valve, thus indicating 
the presence of a poorly crystalline apatite phase in the calcific deposits. Hence, the
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calcific deposits from the calcified valve are more likely to be assigned to carbonate 
apatite, although the absence of OH peaks in the spectrum does not preclude the 
presence of hydroxide ions as it was previously reported for bone analysis74.
7.3.5 ICP-OES analysis
The results obtained with the in-vivo study can be found in the table 7.2 below.
Valve / elements 
analysed Silicon Oimol/g) Magnesium (fimol/g) Calcium (/rmol/g)
Cardiac Valve 1 0.098 0.552 29.042
Cardiac Valve 2 0.046 0.302 17.415
Cardiac Valve 3 0.210 1.491 65.494
Cardiac Valve 4 0.045 0.320 18.189
Cardiac Valve 5 0.066 0.784 39.122
Cardiac Valve 6 0.039 0.251 13.223
Cardiac Valve 7 0.114 1.490 85.903
Table 7.2: Elemental analyses (silicon, magnesium and ca cium) of explanted
calcified human bioprosthetic heart valves by ICP-OES.
The correlation of the elements analysed was calculated and a two-tailed statistical 
test carried out for each pair of elements to be correlated. The corresponding results 
can be found in table 7.3 below.
Pair of elements to be 
correlated
r value (estimator of 
the population 
correlation 
coefficient)
t value (statistic for 
the test of significance 
for the correlation 
coefficients)
Conclusion of the 
statistic under the 
null hypothesis
Ca/Si 0.73899 2.45273
poor evidence for 
correlation only at 10% 
level o f significance
Mg/Si 0.85287 3.65260
evidence for 
correlation at 2% level 
o f significance
Mg/Ca 0.97636 10.09951
Strong evidence for 
correlation at 0.02% 
level o f significance
Table 7.3: Correlation data from the elemental analyses (Ca, Si and Mg) of explanted 
calcified human bioprosthetic heart valves by ICP-OES.
From these results, it appears that silicon is somehow correlated to magnesium, both 
being possibly involved as important precursors in the calcification of bioprosthetic
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tissue valves. Furthermore, magnesium definitely appears to correlate with calcium, 
indicating the strong role that magnesium might play during the calcification of 
tissue valves. Unfortunately, no published data on levels of Ca/Mg/Si in calcified 
material is available for comparison. Nevertheless, one may suggest the hypothesis 
therefore that magnesium is involved with both the early precursors and the later 
stages of calcification. No strong correlation was found between calcium and silicon. 
The use of ICP-OES was only recently reported for quantitative analysis of calcium 
and phosphorous deposits on valve leaflets in a canine in-vivo model85 and an in- 
vitro model86, but not on explanted human calcified valves as in this study, which 
renders a direct comparison extremely difficult.
7.4 Conclusion
The ESEM study revealed different patterns of calcification in explanted cardiac 
valves that can be considered as a sequence of events in the calcification process. In 
the first stage, the calcific deposits were located either within or on the surface of the 
collagen fibrils. Such deposits were found to have various morphologies and sizes 
with various Ca/P ratios. It is hypothesised therefore that they might represent some 
calcium phosphate-rich precursor phases (possibly containing silicon and magnesium 
based on the results obtained with EDS and ICP-OES analyses), explaining their 
wide range of morphologies, sizes and Ca/P ratios. In the second stage, the calcific 
deposits (poorly crystalline apatite containing carbonate and possibly hydroxyl ions 
based on the XRD, infrared and Raman data) were found to be more likely to occur 
along the collagen bundles and also to be distributed in the interfibrillar spaces, 
where they accumulate. This gave, on secondary electron images, the morphological 
appearance of some electron-dense homogeneous phases corresponding to localised 
patches of calcification, which appeared (in the case of heavily calcified valves) to 
be like mature hydroxyapatite crystal sheet from the EDS analyses. From this study, 
it is thus hypothesised that calcification in the collagen interstitium proceeds via the 
formation of small particulates rich in calcium phosphate. These have a range of 
Ca/P ratios hence indicating the involvement of a number of precursors. These 
particulates subsequently aggregate to form larger nodules, which are then 
transformed into the apatite crystal structure.
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This study has demonstrated the application of the ESEM technique to the 
investigation of complex and delicate samples (the imaging of hydrated or 
dehydrated biological samples) with minimal manipulation and without the need for 
the sample preparation associated with conventional SEM. ESEM coupled to EDS is 
thought to be useful in the investigation of the pathogenesis and prevention of 
bioprosthetic heart valve calcification. However, because studying calcification of 
bioprosthetic tissue valves explanted from patients or retrieved at post-mortem is 
difficult, the use of tissue samples subdermally implanted into rats (in-vivo) and also 
calcified in-vitro, may constitute the basis for further studies (see chapter 8  of this 
thesis).
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Chapter 8
8 In-vitro and in-vivo calcification of pericardial 
tissue characterised by environmental scanning 
electron microscopy.
Abstract
Background and objectives: While the calcification of bioprosthetic valves presents a 
well-known major clinical problem, the mechanism of calcification remains unclear. 
Host factors can influence both the extent of the calcification and its progression. 
The calcification process can also be observed in-vitro that is without the interaction 
of these host factors. It is not certain however, whether these in-vitro calcific 
deposits are similar to those found in-vivo. Therefore the objectives of this study 
were to, define the progressive chemical and morphologic sequence of mineralisation 
in glutaraldehyde-treated pericardial tissue, implanted subcutaneously in rats and 
incubated in-vitro in a metastable calcifying solution.
Methods: Calcification obtained in a static in-vitro model was compared with that 
produced in-vivo (subcutaneous animal model). Each sample underwent gross and 
X-ray examination, histology (Von Kossa staining) and predominantly analysis by 
environmental scanning electron microscopy (ESEM) coupled with energy 
dispersive X-ray analysis (EDS). The semi-quantitative data obtained by ESEM- 
EDS were compared with those obtained by inductively coupled plasma-optical 
emission spectroscopy (ICP-OES).
Results: Secondary electron photomicrographs from pericardial tissue calcified in- 
vivo confirmed that calcification initiated in the internal region of the tissue and then 
extended, with time of implantation, towards the outer surface. The calcific crystals
312
were found to occur preferentially by following the collagen fibril bundles 
arrangement and also in the sub-surface collagen structure. The ESEM-EDS analyses 
confirmed progressive calcification, beginning in the early specimens (7 days 
minimum) with progressive multifocal inter- and intra-fibrillar collagen calcification 
(nodules of 2 /mi). Larger deposits (up to 10 /mi) and then confluent nodular regions 
became more and more prominent until covering the majority of the collagen matrix 
at day 1 0 0 .
ESEM micrographs of in-vitro calcified tissues revealed several forms of 
accumulated calcium on the tissue surface with different sizes (ranging from < 1  up 
to 30 /im) of crystal phases. Some were in contact with collagen tissue fibres and 
possibly some with elastin. However the micrographs did not reveal any calcification 
inside the tissue, with calcific deposits only seen on the surface of the tissue in 
relation to the collagen structure.
Calcification was thus found to involve mostly collagen fibres and interfibrillar 
spaces in both the in-vitro and in-vivo models. EDS confirmed the presence of 
calcium phosphate-rich deposits with various Ca/P ratios in both models. A picture 
of the onset of tissue mineralisation in-vivo was hypothesised involving precursors 
containing various amounts of calcium and phosphate, along with silicon and 
magnesium. These evolved with the time of implantation, to a poorly crystalline 
form of hydroxyapatite (as found in late stage calcification). Calcification in the 
static in-vitro model was however mostly composed of calcium associated with low 
amounts of phosphorus and often potassium.
Conclusion: Intrinsic calcification of glutaraldehyde-treated pericardial tissue was 
induced both in-vivo and in-vitro. ESEM-EDS analysis in both models showed the 
presence of hydroxyapatite-like crystallisation with a similar morphology to that 
observed in explanted valves analysed under the same conditions. Analyses of the 
static in-vitro calcification model gave a low Ca/P ratio and calcification was limited 
even after 100 days of incubation. This meant that the calcific deposits could not be 
studied using techniques such as FTIR, Raman and XRD because the amounts 
present were below the limit of detection. The relative heterogeneity of the tissue 
calcification also made analysis difficult, bringing into question the reliability of the 
in-vitro model.
313
8.1 Introduction
A large number of bioprosthetic valves implanted into humans for a period of at least 
4 years become calcified1. The current rather limited knowledge of the causes and 
mechanisms of the formation of calcific deposits in implanted cardiac bioprostheses 
makes its prevention a difficult task for manufacturers. Calcification is a multi- 
parametric process and many chemical, biological and mechanical factors seem to be 
involved and might play a significant role (see chapter 1 section 1.7).
Although the extent and progression of calcification depends on host factors such as 
age, renal function, pregnancy and other determinants, the host-tissue graft 
relationship is not essential for tissue mineralisation. Indeed, calcification can be 
reproduced in-vitro statically or using pulsatile testing apparatus (dynamically) with 
an appropriate calcium-containing solution2,3. The formation of calcium phosphate 
mineral is thought to proceed, provided there is a stimulus to initiate calcification, 
since the plasma medium in contact with the tissue contains levels of salts sufficient 
to propagate the salts formation.
Since the various calcium phosphate phases thought to be present in valve 
calcification have markedly different solubilities, precipitation is hypothesised to 
proceed through the formation of unstable precursor phases. The identity of these 
calcification precursors is still a matter for discussion, despite many relevant studies 
in the literature (see chapter 1 section 1.6.4). Elucidation of the calcification 
mechanism and the identification of its precursors is important in order to 
successfully design the right prevention strategy. As studying the early phases of 
calcification in explanted calcified valves is difficult, in-vivo and in-vitro 
calcification models can be used as alternatives.
Over recent years, a number of experimental in-vivo and in-vitro models have been 
proposed (see chapter 1 section 1.6.5). It is known that the biochemical and 
morphologic features of extensive intrinsic tissue calcification in subcutaneous 
implants are analogous to those seen in clinical explants4'6. This is despite the fact 
that calcium and phosphorus are accumulated at a clearly accelerated rate in the
7 Q • •former ' . Generally, in-vivo models are relatively expensive in comparison to m-
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vitro models but it is not certain whether the latter are as reliable and fast as we 
might wish. Furthermore, although both types of model appear to give relatively 
similar calcification end products, whether the mineral deposition is the same and 
involves similar precursors is also unknown.
The aim of this research was to study the process of calcification by comparing in- 
vivo and in-vitro models. ESEM-EDS, optical microscopy and ICP-OES were used 
to achieve both qualitative and quantitative data and also to compare the mineral 
deposits formed.
8.2 Materials and methods
8.2.1 Materials
Bovine pericardium tissue was obtained from a local abattoir (Doncaster, UK).
Glutaraldehyde 25% v/v EM grade, formaldehyde, along with Analar grade sodium 
chloride, calcium chloride dihydrate, potassium dihydrogen orthophosphate, Aristar 
grade nitric acid and hydrochloric acid, paraffin wax, ethanol, silver nitrate, sodium 
thiosulphate, picric acid and acid fuchsin were obtained from BDH, UK.
MOPS Buffer (morpholino propanesulphonic acid) and methanol were obtained 
from Sigma, UK.
Xylene was obtained from Fisher Scientific, UK.
/5-Tricalcium phosphate standard (97%) was obtained from Rose Chemicals Ltd, 
UK.
Hydroxyapatite standard (99%) was obtained from Fluka, UK.
Buffer pH 7.4 (phosphate) 0.03M (see chapter 4 section 4.2.1) and the calcification 
solution were prepared when required. The calcification solution was based on work 
from Wadkins and Luben10 and Bemacca11 and was prepared as follows. Sodium 
chloride 7.9g (135mmol.L_1), calcium chloride dihydrate 0.294g (2mmol.L'1), 
potassium dihydrogen orthophosphate 0.163g (1.2nrniol.L-1), MOPS buffer O.OlOg 
(O.OSmmol.L'1) were dissolved in 1 litre of distilled water. The atomic Ca/P ratio 
was thus 1.670, as in pure stoichiometric crystalline hydroxyapatite.
315
Ultra pure water was obtained using a MilliQ50 (Millipore, UK) packed with liquid 
pure cartridges (USF). The conductivity achieved was 18 MQ/cm. Saline was a 
phosphate buffer saline (PBS, Baxter, USA).
8.2.2 Tissue fixation
The bovine pericardial tissue used in this study was prepared similarly to the 
standard process used by Carpentier-Edwards for their clinical glutaraldehyde-fixed 
valves. It was fixed using a solution of 0.2% v/v glutaraldehyde in 0.1 mol.L ' 1 
phosphate buffer at pH 7.4, for 48 hours at room temperature. The solution of 
glutaraldehyde was diluted immediately before use from 25% v/v glutaraldehyde. 
After fixation, the tissue was rinsed in cold PBS (phosphate buffered saline, Baxter, 
USA) and then sterilised using a solution of 4% v/v formaldehyde for an hour, 
followed by three saline washes (each of 10 minutes). Pieces of bovine pericardial 
tissue (density around 1.75) were cut (20 x 7.5 x 4 mm), and rinsed three times, for 2 
minutes each, in saline and then used for in-vitro or in-vivo studies.
8.2.3 In-Vitro Calcification Study
Static in-vitro calcification of tissue samples was carried out in clean, sterile screw- 
top sample vials. Small samples of tissue (similar in size to the ones implanted 
subcutaneously in rats) were first washed in 0.9% saline solution and then placed in 
individual vials in the calcification solution buffered to pH 7.410’11. The tests were 
carried out at 37°C and the vials were shaken slightly in a Gallenkamp orbital 
incubator at 100 rev/min. The calcifying solution was not changed during this 
period, nor was the vial opened before the end of the test. This test protocol avoided 
the addition of antibacterial or antifungal agents that might affect the calcification 
process. On completion of the tests, samples were washed in three changes of 
distilled water to remove traces of unbound inorganic material. The retrieved 
samples (at 0, 14, 21, 28, 90 and 100 days) were then processed for analysis.
8.2.4 In-vivo Calcification Studies
Calcification of glutaraldehyde-treated pericardial tissue was evaluated using the rat
12subdermal model because it is a convenient model that mirrors human calcification . 
The rat subcutaneous static in-vivo model has mainly been used to determine the 
propensity for in-vivo calcification. Despite its simplicity the effectiveness o f the
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subdermal implantation model for investigating calcification is accepted even in the 
absence of or minimal contact with blood13. This procedure was conducted at the 
Royal Hallamshire Hospital, Sheffield, complying with Home Office Regulations. 
Five-week-old male Wistar rats (35 days old on arrival) were used for this study. 
Individual rats were assigned a unique number and those considered suitable for use 
in the study were also identified by cage tags and tail tattoos. Within 2 days of 
receipt, the animals were examined by a clinical veterinarian and representative 
animals were subjected to a pre-test health screen that included full necropsy, an 
examination for intestinal parasites, histology of selected tissues, clinical pathology 
and serum viral antibodies. Prior to subcutaneous implantation, the remaining rats 
were anaesthetised using Halothane (Mallinkrodt, UK) gas. Halothane was applied 
initially at a concentration of 5 mol.L"1 at a rate of 4 L.min ' 1 as the sleep-inducing 
dose, then at 2 mol.L ' 1 at 2 L.min ' 1 as the maintenance dose. There were no deaths. 
After the animals were anaesthetised, their dorsum was shaved using clippers and 
swabbed with 70% alcohol. Using an aseptic technique, up to four incisions per rat 
were made through the epidermis and dermis of the skin (see figure 8 . 1  below). 
Subcutaneous pouches were created between the skin and muscle layers using blunt 
dissection and a sample of treated tissue (7.5 x 20 mm) was placed inside each one, 
well away from the incisions. Dorsal implantation was preferred as it has been 
reported that it is much more difficult for the animals to disturb the implant sites and 
the incisions, and that dorsal implantation results in greater mineralisation than 
abdominal implantation14. The location of the different types o f test sample was 
rotated in each consecutive animal to ensure that the results were not influenced by 
site-specific reactions. Each animal contained one control and three test tissues. The 
incisions were closed using Ethibond 5/0 braided polyester sutures (Ethicon, UK). 
During acclimation, the rats were allowed free access to food and water ad libitum. 
Water was delivered by Nalgene water bottles with stainless steel sipper tubes. Food 
was ground certified rodent chow. The rats were sacrificed by cervical dislocation, 
complying with Home Office Regulations, at various time intervals post-operatively 
(at days 7, 14, 21, 28, 35 and 100) and the tissue specimens were then excised for 
analysis.
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Figure 8.1: The positions of incisions in the dorsum of the rat.
8.2.5 Low Energy Radiography
At the end of the in-vivo and in-vitro calcification tests, pericardial tissues were 
examined radiographically for shadowing caused by calcification. Gross 
visualisation of mineral deposition was carried out on the excised tissue samples 
using low energy radiography with a Hewlett Packard 43855A Faxitron machine, 
Hewlett Packard, Birmingham, UK. For the in-vivo study samples, the tube voltage 
was set at 25 kV and the diagnostic film was exposed for 3 seconds with an intensity 
of 3 mA. For the in-vitro study samples, the tube voltage was set at 18 kV and the 
diagnostic film was exposed for 3 seconds with an intensity of 3 mA. The Kodak 
Industrex M films (Kodak, Eastman Chemical Co. Kingsport, TN, USA) were 
developed using a Kodac RP X-OMAT processor (Kodak, Eastman Chemical Co. 
Kingsport, TN, USA).
8.2.6 ICP-OES (Inductively Coupled Plasma-Optical Emission Spectroscopy)
For the quantitative study, the glutaraldehyde-treated and non-treated tissues from 
the in-vitro study were retrieved at 0 and at 100 days of incubation. Prior to analysis, 
the samples were washed five times for 2  minutes each time in distilled water.
In parallel, sample implants from the in-vivo study were retrieved at 0, 7, 14, 28, 35 
and 100 days. The surrounding tissue was carefully removed and the samples were 
washed five times for 2 minutes each time in saline and distilled water. Pieces of 
untreated unimplanted pericardial tissue were also subjected to ICP analysis.
All samples were lyophilised with a Cold Trap 1000 freeze-drier, achieving a 
pressure of 75 mbar (0.35 atm) with a temperature of approximately -40°C and 
weighed. They were then hydrolysed with a mixture of 3 mL HC1 and 1 mL HNO 3 , 
simmering/boiling for 5 hours. A final volume of 10 mL was made up using
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deionised water. The samples were then submitted to ICP analysis. The presence of 
silicon, calcium, magnesium and potassium was thus determined quantatively by 
ICP-OES. The phosphorus content was not determined because of the use of the 
phosphate-buffered saline solution to store the tissues prior to being analysed. It was 
believed that the phosphorus content of the buffer might possibly interfere with the 
results despite the washes carried out. The ICP-OES was a FC1400 Spectro 
analytical instrument (Spectro, Germany).
8.2.7 Histological study
For the histology study, pericardium tissue samples from the in-vitro calcification 
study were retrieved after 14, 28, 90 and 100 days. The samples (glutaraldehyde- 
fixed ones only) were then processed for examination by light microscopy using Von 
Kossa’s silver method for calcium deposits, as reported elsewhere15. Specimens were 
embedded in paraffin wax and sections were cut as slices of 5 [im thickness. These 
were then stained using a silver Von Kossa test, which stains calcium phosphate to 
brown-black, osteoid, cell nuclei and collagenous tissue in red, muscle will appear in 
yellow and cytoplasm in pink16.
The methodology was as follows. The sections were dewaxed in two consecutive 
baths of xylene for 5 min each, rehydrated through 100%, 96% and 70% alcohol for 
5 min each, transferred to distilled water, placed in 1% aqueous silver nitrate 
solution and exposed to strong light (e.g. anglepoise lamp) for 60 min. They were 
then washed in 3 changes of distilled water, treated with 2.5% aqueous sodium 
thiosulphate for 5 min, washed in distilled water, counterstained with Van Gieson 
stain for 5 min (Van Gieson is composed of 90 mL aqueous picric acid and 10 mL 
1% aqueous acid fuchsin), dehydrated in alcohol, immersed in xylene for 5 min and 
mounted. The stained sections were then examined under a light microscope. The 
Von Kossa method is in fact a silver reduction technique, which demonstrates 
phosphates and carbonates, but since the demonstrable forms of these anions are 
almost invariably found combined with calcium, it is usually regarded as a method 
for calcium.
8.2.8 ESEM
ESEM was used to observe the surface morphology of in-vitro and in-vivo calcified 
pericardial tissue samples. The samples were analysed on both external and internal
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sides. Samples were cut longitudinally, following the collagen planes, prior to the 
analysis in order to access and examine internal tissues. Much effort was placed on 
describing the morphologic observation in as quantitative a manner as possible for an 
objective interpretation of our findings. The presence and distribution of calcium, 
phosphorus and other metal ions were assessed using energy dispersive X-ray 
analysis (EDS) coupled to ESEM. For comparison, some synthetic CaP materials 
(hydroxyapaptite and /5-tricalcium phosphate) were run under the same conditions in 
the ESEM. The ESEM was a FEI Philips (Philips, The Netherlands) XL30 ESEM- 
FEG (environmental scanning electron microscope-field electron gun), operating at 
an accelerating voltage of 20 kV. Samples required no preparation and were kept wet 
in saline solution, until the time of analysis when they were rinsed several times with 
deionised water. The sample preparation and technical parameters were as already 
described in chapter 7 (sections 7.2.2.2 and 1 2 2 3 ) .
The EDS results were processed so that the software gave the atomic Ca/P ratios as 
described in chapter 7 (section 7.3.2) and the stoichiometric atomic Ca/P ratios were 
used to identify the crystal phases present. It has been shown, by extensive analysis 
of standards of stoichiometric hydroxyapatite (chapter 7), that ESEM-EDS gives 
reliable data concerning the Ca/P ratio with the practical Ca/P ratio obtained being 
similar to the theoretical one.
8.2.9 XRD
Analyses were undertaken at room temperature with a Philips (Philips, The 
Netherlands) PW1710 X-ray diffractometer operating with Bragg-Brentano 
geometry. Experimental conditions were 40 kV and 40 mA, with Cu-K ai,2 radiation. 
The diffraction patterns were recorded with an angle range of 5 to 100° 26 and using 
the step-by-step method with a step width of 0 . 0 2  degrees and a counting time of 1 0  
seconds per step. The samples were freeze-dried prior to analysis.
8.3 Results and Discussion
8.3.1 Low energy radiography
Soft X-ray analysis of in-vitro calcified samples showed no sign of calcification, 
probably because the degree of calcification was below the limit of detection of the
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technique. However, radiography of the in-vivo calcified samples showed some 
signs of calcification after 28 and 1 0 0  days of implantation.
8.3.2 ESEM analysis
8.3.2.1 In-vivo samples:
Secondary electron photomicrographs of pericardial tissue calcified in-vivo indicated 
that calcification initiated in the internal region and then extended with time of 
implantation towards the outer surface of the tissue. This is in opposition to the 
findings of Tinghei et al17, who implied that calcification started from the surface of 
tissue samples implanted subcutaneously. ESEM-EDS analyses of the early samples 
calcified in-vivo showed that calcium phosphate deposits were present at various, 
random locations inside the tissues examined. Generally relatively large, medium 
and small size crystals co-existed in the neighbourhood of the calcification sites. 
ESEM micrographs showed the existence of different sizes (less than 1 and up to 30 
/mi) of crystal phases in contact with collagen tissue fibres and possibly sometimes 
with elastin fibres. The calcification seemed to be limited to the collagen mesh itself, 
as already reported by others18.
At day 7 of implantation, particles of a few microns (figure 8.2) were identified 
attached to the collagen matrix. These were rich in phosphorus and silicon, but 
apparently lacked calcium. Other crystal growth was also observed associated with 
collagen and was found to be rich in phosphorus and magnesium (see figure 8.3).
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Figure 8.2: Secondary electron micrograph (left) and the corresponding EDS 
spectrum from the inside of an in-vivo sample implanted for 7 days (right) showing
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particles of a few microns attached to the collagen matrix. The particles are rich in 
phosphorus, silicon and possibly sodium (the latter might come from the saline 
solution). Note: the carbon, oxygen and sulfur content come from the collagen 
matrix.
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Figure 8.3: Secondary electron micrograph (left) and the corresponding EDS 
spectrum from the inside of an in-vivo sample implanted for 7 days (right) showing 
particles of a few microns in size attached to the collagen matrix. The particles are 
rich in phosphorus and magnesium. Note sodium and chlorine are likely to arise 
from the saline solution.
At day 14, particles of a few microns in size and with an irregular morphology were 
observed (see figure 8.4). These were quite rich in calcium but contained much less 
phosphorus and silicon than the day particles. Some crystal growth of less than 10 
/im  in size, with a different morphology, can also be seen (see figure 8.5). These also 
contained silicon but also with a higher calcium and phosphorus content. Such a high 
Ca/P ratio may be explained if one takes into account the presence of silicon and 
possibly other ions in the lattice that tend to increase the Ca/P ratio.
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Figure 8.4: Secondary electron micrograph (left) and the corresponding EDS 
spectrum from the inside of an in-vivo sample implanted for 14 days (right) showing 
a particle with an irregular contour morphology of a couple of microns in size, rich 
in Ca with traces of phosphorus and silicon.
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Figure 8.5: Secondary electron micrograph (left) and the corresponding EDS 
spectrum from the inside of an in-vivo sample implanted for 14 days (right) showing 
a particle of less than 1 0  /tm in size associated with the collagen matrix, rich in 
calcium, phosphorus, with traces of silicon and possibly sodium.
At day 28, crystals ranging from 5 to 10 /mi in size were observed growing on 
collagen bundles. These contained low but significant amounts of calcium and 
phosphorus (see figures 8 . 6  and 8.7).
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Figure 8 .6 : Secondary electron micrographs from the inside of an in-vivo sample 
implanted for 28 days showing particles of 5-10 /mi in size associated with collagen 
bundles.
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Figure 8.7: Secondary electron micrograph (left) and the corresponding EDS 
spectrum from the inside of an in-vivo sample implanted for 28 days (right) showing 
particles of about 5-10 /mi in size forming along the collagen fibres, rich in calcium, 
phosphorus, silicon and possibly magnesium.
At day 100, the morphology of the majority of crystals was similar to that of the 
crystals obtained from explanted calcified bioprosthetic valves (see chapter 7). The 
calcific deposits had Ca/P ratios ranging between 1.609 and 1.943, with a mean of 
1.702, which is very similar to the theoretical Ca/P ratio for a crystalline 
hydroxyapatite standard (1.670) analysed under the same conditions. The histogram 
of frequency vs. the atomic Ca/P ratios obtained from samples at day 100 of 
implantation (see figure 8 . 8  below) was however different to the one obtained from 
explanted calcified valves (see chapter 7 section 7.3.2). In the case of the explanted 
valves, the Ca/P ratios showed a greater range, revealing the existence of phases 
probably resulting from the incorporation of impurities in the crystals. These 
impurities, such as sodium, carbonate, magnesium and silicon, come from the diet of 
the individuals19,20. The diet of the rats is more controlled and thus the narrower 
range of Ca/P ratio values obtained may be explained. However, the relatively high 
Ca/P ratios obtained in the rat experiment also suggest the incorporation of 
impurities in the apatite crystals, although the mean value (1.702) indicates the 
predominance of an apatite phase similar to crystalline hydroxyapatite in relation to 
its Ca/P ratio (1.670).
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Figure 8 .8 : Histogram representing the frequency versus the atomic Ca/P ratios 
obtained from the EDS analyses of calcific deposits from an in-vivo rat calcification 
experiment (at day 1 0 0 st implantation).
The typical morphology of crystals found at day 100 was a tabular hexagonal shape, 
growing from collagen, which was also consistent with apatite (see figure 8.9 
below).
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Figure 8.9: ESEM secondary electron micrograph of the inside of a day 100 of 
implantation sample (left), showing the tabular hexagonal-shape crystal growth 
found on collagen fibrils, which is consistent with apatite morphology. Its 
corresponding EDS spectrum (right) shows the presence of Ca, P, Mg and Na, whilst 
exhibiting a Ca/P ratio of 1.657, which is very close to that of hydroxyapatite.
These data led to the hypothesis that early precursor phases, containing essentially 
silicon, magnesium and phosphorus, tend to accumulate and attract calcium. They 
then form other larger precursor phases with an irregular morphology, all leading to
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the final apatite-like structure. It has been reported recently that magnesium and 
sodium may participate in the calcification process21, which partially agrees with our 
findings. In the later stages of in-vivo calcification, calcific deposits were observed 
to form in parallel arrays following the longitudinal axis of the fibrils, possibly 
indicating the significance of the molecular structure of the collagen fibrils on the 
arrangement of calcific crystals.
The Ca/P ratios for the majority of calcific deposits found in the in-vivo samples 
(particularly at 1 0 0  days of implantation) were usually relatively high compared to 
the theoretical values for pure calcium phosphate phases. These high values may be 
attributed to non-stoichiometric apatite and the substitution of the calcium and
99phosphate ions by other ions , such as carbonate, magnesium and/or silicon, as 
discussed in chapter 7. Alternatively, the Ca/P ratios could be explained in terms of 
rapid co-precipitation of the two main calcium phosphate compounds: apatite and the
99metastable octacalcium phosphate (OCP) . The hypothetical presence of OCP 
would agree with the de novo precipitation of hydroxyapatite and with the 
mechanism of the non-energy requiring calcium trap by phospholipids, as described 
in cartilage mineralisation24. Althought no OCP was found when analysing calcified 
explanted valves (see chapter 7), which are likely to represent the later stages of 
calcification, this does not rule out the absence of such a phase in earlier stages of 
calcification. Additionally, it would be quite difficult to differentiate early OCP from 
a hydroxyapatite phase solely from atomic Ca/P ratios. However, whether OCP 
could be present in earlier stages of valve calcification is strictly hypothetical and 
remains to be observed experimentally.
8.3.2 A .1 Pattern o f  in-vivo mineralisation stages (subcutaneous model):
When focusing our attention on the day 100 samples, a calcification model was 
postulated by creating virtual contour lines (concentric circles labelled from 1 to 1 0 ) 
starting from the obvious calcified area of a sample (identified by X-ray radiography 
and labelled contour line 1) and moving away from it (see figure 8.10 below). A 
summary of the observations at each contour line is given in table 8 .1 .
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Contour linesCalcified area
Figure 8.10: Sketch representing a calcified glutaraldehyde-treated pericardium 
sample after 1 0 0  days of subcutaneous implantation, showing the only calcific area 
identified by X-ray radiography and the corresponding theoretical contour lines 
moving away from that area and labelled 1- 1 0 .
Contour Observations from ESEM and EDS analyses
10/9/8/7/6 Collagen was not found to be calcified
5/4
Sub-/xm particles forming on collagen bundles/in the interfibrillar spaces. 1 -2 /mi 
particles embedded in the collagen matrix. EDS showed the presence o f Ca and P,
along with traces o f Si.
3
Aggregates o f a few /im with particular morphology (tabular hexagonal, plate-like, 
spherical-shaped) erupting from the collagen matrix and growing along collagen 
bundles. EDS showed the presence of high levels of Ca and P, along with traces of
Mg.
2
Spherical nodules and needle-like particles accumulating in the interfibrillar space, 
following collagen bundle arrangements. EDS showed the presence of high levels o f 
Ca and P. Ca/P ratios suggested incorporation of “impurity” ions in the crystal
structure.
1
Accumulating calcific deposits are filling gaps between collagen bundles, covering 
most o f the surface. EDS exhibited Ca/P ratios very close to that o f crystalline
hydroxyapatite.
Table 8.1: Summary of observations from the ESEM analysis of a calcified 
glutaraldehyde-treated pericardium sample after 1 0 0  days of subcutaneous 
implantation.
The ESEM data (summarised in table 8.1) showed that soft X-ray radiography failed 
to detect minor calcification sites, indicating the difficulty in definitely detecting 
calcification in-vitro and at early in-vivo calcification stages using this technique.
They also showed that the calcification distribution is not uniform within the tissue,
21which is in agreement with Suh et al .
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Ten major contour lines were drawn theoretically (as shown in figure 8.10) and the 
inside of tissue samples were analysed from these regions. Although no dynamic 
analysis was performed, a pattern of the calcification process was set up as follows 
from the static pictures and EDS analyses.
Contours 10/9/8: The collagen is seen uncalcified or “intact” (see figure 8.11 (left), 
which also shows a cross section of the sample).
Contours 7/6: The collagen is still found “intact” (see figure 8.11 (right)). No traces 
of calcification were observed in these contours from the ESEM-EDS analyses.
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Figure 8.11: ESEM secondary electron micrographs showing the intact collagen 
inner surface from a day 100 of implantation sample. Micrograph (left) corresponds 
to contours 10/9/8 (see figure 8.10), whilst the other (right) corresponds to contours 
7/6.
Contours 5/4: Collagen is seen with sub-micron particles forming on the collagen 
bundles and in the interfibrillar spaces. These particles are characterised by a weak 
EDS spectrum containing some traces of silicon, phosphorus and calcium (see figure 
8.12). In association with these sub-micron particles, other particles of about 1-2 /xm 
and containing calcium, phosphorus and silicon traces are found partially embedded 
inside the collagen matrix, with a Ca/P ratio of 1.609 (see figure 8.13).
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Figure 8.12: ESEM secondary electron micrograph (left) corresponding to contours 
5/4, showing sub-microns particles on the collagen bundles and in the interfibrillar 
space (center of the micrograph) from the inside of a day 1 0 0  o f implantation 
sample. Corresponding EDS spectrum (right) showing the presence of calcium, 
phosphorus and silicon.
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Figure 8.13: ESEM secondary electron micrograph (left) corresponding to contours 
5/4, showing 1-2 /mi particles (center of the micrograph) embedded inside the 
collagen matrix from the inside of a day 100 of implantation sample. Corresponding 
EDS spectrum (right) showing the presence of calcium, phosphorus and silicon. The 
spectrum exhibits a Ca/P ratio of 1.609.
Contour 3: The secondary electron micrograph (see figure 8.14) shows a typical 
repartition of particles growing from the collagen matrix surface and along collagen 
bundles, with a Ca/P ratio ranging from 1.654 to 1.685. These crystals are rich in 
calcium and phosphate, whilst possibly incorporating silicon and magnesium (see 
figure 8.15). The morphology observed (see figure 8.16) is mostly of a tabular 
hexagonal or plate-like shape, along with some spherical-shaped aggregates o f a few
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microns. The plate-like morphology of the calcific crystals may be comparable to 
hydrolysed octacalcium phosphate (OCPH), and they can be seen in the 
neighbourhood of small-sized-crystals that are probably of apatitic structure 
(although the exact nature of the calcium phosphate crystals formed cannot be 
established by morphological examination alone). Furthermore, the abutting of small 
and large crystals tends to confirm the hypothesis that a hydrolytic process occurs 
during the calcification. Indeed, the calcification process is thought to involve 
various precursor phases such as OCP that has been previously proposed for calcium 
phosphate formation, although the formation of dicalcium phosphate dihydrate 
(DCPD) was not precluded25.
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Figure 8.14: ESEM secondary electron micrograph (left) corresponding to contour 3, 
showing a typical particles distribution growing from the collagen matrix along the 
collagen bundles from the inside of a day 1 0 0  of implantation sample. 
Corresponding EDS spectrum (right) showing a large presence of calcium and 
phosphorus with a Ca/P ratio of 1.680.
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Figure 8.15: ESEM secondary electron micrograph (left) corresponding to contour 3, 
showing crystals growing off collagen bundles from the inside of a day 1 0 0  of
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implantation sample. Corresponding EDS spectrum (right) showing the presence of 
calcium, phosphorus along with traces of magnesium and silicon with a Ca/P ratio of 
1.654.
Figure 8.16: ESEM secondary electron micrograph corresponding to contour 3, 
showing a typical morphology of tabular-hexagonal shape or plate-like shape (top 
left), along with some spherical-shaped aggregates o f a few microns in size (center 
of the picture) from the inside of a day 1 0 0  of implantation sample.
Contour 2: The calcific deposits growing along collagen tend to accumulate in the 
interfibrillar space, disrupting the collagen bundles (see figure 8.17 (left)). It also 
appears that the arrangement of the collagen bundles seems to partially control the 
formation of calcification (see figure 8.17 (right)). The morphology of the calcific 
deposits appeared to be homogeneous at low magnification, although at high 
magnification it is seen to be composed of a mixture of small spherical nodules and 
needle-like particles (see figure 8.18 (left)), the needle-like morphology being quite 
similar to the morphology of crystalline hydroxyapatite (see figure 8.18 (right)). 
EDS analyses of the various deposits demonstrates the presence of essentially 
calcium and phosphorus, while magnesium and silicon are not observed, however 
their presence is not precluded because of ICP-OES data obtained on these samples 
(see section8.3.3). Although the morphologies are different, the Ca/P ratios of the 
various deposits are quite similar and typically between 1.622 and 1.943. This high 
ratio, along with the morphology of the calcific deposits, may be explained by the 
incorporation of non-metallic and metallic impurities in the crystal lattice, similar to
331
that thought to occur in the calcific deposits found in explanted valves (see chapter
7).
Figure 8.17: ESEM secondary electron micrographs corresponding to contour 2, 
showing collagen bundles disrupted by the accumulation of calcific deposits in the 
interfibrillar spaces (left), and collagen bundles that seem to control the accumulation 
of calcific deposits that form parallel arrays by following the longitudinal orientation 
o f the collagen fibrils (right), from the inside of a day 1 0 0  of implantation sample.
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Figure 8.18: ESEM secondary electron micrographs corresponding to contour 2, 
showing calcific deposits (left) showing various morphologies (needle-like particles 
with a fluffy aspect and spherical nodules), and the morphology of highly crystalline 
hydroxyapatite standard (right) which appears essentially as a fluffy aspect 
composed of needle-like crystals, from the inside of a day 1 0 0  o f implantation 
sample.
Contour 1: The accumulating calcific deposits are filling gaps between the collagen 
bundles (see figure 8.19). They eventually aggregate to such an extent that they 
cover the collagen matrix by forming a sort of “crust” (see figure 8.20), with a Ca/P
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ratio of 1.692 (see figure 8.20), which is very close to that o f crystalline 
hydroxyapatite.
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Figure 8.19: ESEM secondary electron image corresponding to contour 1 from the 
inside of a day 1 0 0  of implantation sample (left), showing accumulating calcific 
deposits between collagen bundles. Corresponding EDS mapping (right) shows 
collagen bundle, identified by their rich content in carbon, while the inorganic 
calcific deposits are richer in calcium, phosphorus and oxygen.
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Figure 8.20: ESEM secondary electron micrograph (left) corresponding to contour 1, 
showing calcific deposits totally covering the collagen matrix from the inside of a 
day 100 of implantation sample. Corresponding EDS spectrum (right) shows the 
large presence of calcium and phosphorus with a Ca/P ratio of 1.692, which is very 
close to that of crystalline hydroxyapatite.
The observations from ESEM and EDS analyses (summary given in table 8.1) o f a 
calcified glutaraldehyde-treated pericardium sample after 1 0 0  days of subcutaneous 
implantation revealed that mineralisation is not so heterogeneous after all, as 
generally held, and a pattern could be drawn from the data. These observations
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specifically revealed the significant role of collagen in the orientation of calcific 
deposits, along with its potential role as being an important factor in the formation of 
early crystals. The presence of calcific deposits with various morphologies and 
different Ca/P ratios shows that calcification is a complex process involving many 
inorganic precursor phases that lead inevitably to a phase that resembles that of 
hydroxyapatite (similar morphology and Ca/P ratio).
8 .3.2.2 In-vitro samples:
Calcific deposits were only found on the surface of the pericardial tissue subjected to
9the in-vitro experiment. Mavrilas et al have previously studied in-vitro calcified 
porcine valve tissue (static in-vitro model) using SEM, reporting some evidence of 
calcific deposits on the surface and in the central region of the collagen tissue 
(mainly in fibrosa). The main difference in their static in-vitro set up was the fact 
that they used a computer-controlled pump to restore the consumed ions (potassium, 
sodium, calcium and phosphate) throughout the experiment, thus maintaining the 
initial physiological concentrations, which can have a great influence on the 
formation and propagation of Ca-rich deposits. The fact that in our study calcific 
crystals were essentially found on the external surface of the pericardial tissue leads 
to the conclusion that calcification in this type of static in-vitro model is essentially a 
deposition process and that calcification is intrinsic (i.e. it occurred selectively on the 
valve tissue, which is the same statement as Mavrilas et al from their in-vitro 
calcification study of porcine tissue valves).
No samples were analysed by ESEM prior to day 21 of the in-vitro experiment, 
except for the treated and untreated tissue samples (day 0 ) used as a reference.
8.3.2.2.1 Glutaraldehyde-treated pericardial tissue:
After incubation of the pericardial tissue with the calcifying solution for 21 days, 
ESEM-EDS analyses detected very thin accumulated crystals of a few microns (see 
figure 8 . 2 1  (left)) in association with collagen or aggregates of several microns in 
size (up to 5 pm) attached to collagen (see figure 8.21 (right) and figure 8.22). All 
were essentially rich in calcium with only weak traces of phosphorus from day 2 1  of 
implantation. This could lead to the hypothesis that the calcium is bound to some
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negatively-charged components of the collagenous matrix, such as phospholipids (as 
proposed by Irving et al in a study of the mineralisation of cartilage24.) 
Unfortunately, samples were not analysed prior to day 21 and hence one can only 
hypothesise that calcification started to occur before this time.
Figure 8.21: ESEM secondary electron micrographs, showing crystals of a few 
microns in size accumulating in association with collagen matrix (left) and calcific 
crystals clearly attached to the collagen matrix (right), from the analysis o f the 
outside surface of a calcified glutaraldehyde-treated pericardial tissue sample after 
2 1  days of incubation in-vitro.
Figure 8.22: ESEM secondary electron micrograph from the analysis o f the outside 
surface o f a calcified glutaraldehyde-treated pericardial tissue sample after 2 1  days 
of incubation in-vitro, showing calcific crystals associated with the collagen matrix 
(left) and corresponding EDS mapping (right) showing collagen matrix rich in 
carbon and oxygen while the calcific deposits is richer in calcium.
At day 100, plate-like (see figure 8.23 (left)) and needle-shaped (see figure 8.23 
(right)) aggregates were found on the tissue samples. These calcific deposits were
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larger in size ( 2 0  /mi) than those seen at day 2 1 , but they were still characterised by a 
very high calcium content and very low phosphorus content (see figure 8.24). In 
addition, the samples exhibited calcium phosphate-rich particles growing along 
collagen and elastin (see figure 8.25), ranging in size from less than 1 /mi up to 10 
/mi, and showing uptake of potassium (see figure 8.24), probably from the 
calcification medium. This could indicate the growth of various unrelated phases or 
the presence of some crystal growth phases which eventually form an ultimate 
crystal phase containing essentially calcium and phosphate (as yet undetermined). 
The range of morphologies seen includes needle-like and plate-like crystal growth, 
sometimes with a sort of tabular hexagonal shape or even a fluffy aspect. All this 
suggests gradual development of the crystals through precursors towards a final 
phase. During the experiments, the vials were not opened and thus the content of 
calcium and other constituents of the medium have not been replenished. This may 
have impeded the crystals’ growth and development. Nevertheless, the fact that after 
1 0 0  days of incubation the deposits are richer in calcium than they are in 
phosphorus, may lead to the hypothesis that calcium deposition firstly involve the 
negatively-charged components of the organic matrix, followed by the progressive 
accumulation of phosphorus. Phosphoproteins, for example, have already been 
reported as being implicated in the calcification of glutaraldehyde-treated cardiac
97bioprostheses and could possibly account for the observed phenomenon in this 
study.
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Figure 8.23: ESEM secondary electron micrographs, showing plate-like aggregated 
calcific crystals (aggregate of 2 0  /mi in size) (left), and needle-shaped-like 
aggregated crystals (aggregate of 2 0  /mi in size) (right), from the analysis of the 
outside surface of a calcified glutaraldehyde-treated pericardial tissue sample after 
1 0 0  days of incubation in-vitro.
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Figure 8.24: Typical EDS spectra from calcific crystals from the analysis o f the 
outside surface of a calcified glutaraldehyde-treated pericardial tissue sample after 
1 0 0  days of incubation in-vitro, showing the presence of various amounts of 
essentially Ca and P.
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Figure 8.25: ESEM secondary electron micrograph (left), showing particles (from 
sub-/xm up to 1 0  pm  in size) growing along collagen and larger fibrils (possibly 
elastin), from the analysis of the outside surface of a calcified glutaraldehyde-treated 
pericardial tissue sample after 100 days of incubation in-vitro. Corresponding EDS 
spectrum (right) shows the presence of calcium and phosphorus.
8.3.2.2.2 Untreated pericardial tissue:
Unexpectedly, untreated pericardial tissue incubated for 100 days in-vitro was found 
to calcify. This can be explained if one considers that the in-vitro calcification 
process involved here does not involve any host-immune response (see chapter 1 
section 1.8.1.5) that would part of the generally observed in-vivo tissue degradation. 
It has indeed been reported that untreated valve tissue does not undergo calcification 
in the rat subdermal (in-vivo) model, but undergoes necrosis28. Mineral growths of a 
micron in size were found all along collagen fibrils, sometimes forming large 
aggregates of 10 /mi in size (see figure 8.26 below). The elemental composition 
differed from one aggregate to another and the Ca/P ratio was not constant, probably 
reflecting the presence of amorphous calcium deposits. The EDS spectra did,
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however, show some consistency, as they were rich in calcium and phosphorus, with 
traces of potassium and chlorine (see figure 8.27 below). The morphology of the 
crystal aggregates was comparable to that found with treated pericardial tissue at day 
100. The larger crystals also exhibited morphology that had some similarities with 
that of some structures observed in the in-vivo model and explanted calcified valves 
(see chapter 7), although their elemental composition differed markedly. Calcium 
phosphate precipitation in-vitro is random in comparison to pathological 
calcification in-vivo and this may explain the observed differences between in-vitro 
calcification and the in-vivo calcification crystal phases.
Figure 8.26: ESEM secondary electron micrograph, showing mineral growth along 
collagen bundles forming large aggregates up to 1 0  jiim in size, from the analysis of 
the outside surface of a calcified untreated pericardial tissue sample after 1 0 0  days of 
incubation in-vitro.
5
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Figure 8.27: Typical EDS spectra from calcific crystals from the analysis of the 
outside surface of a calcified untreated pericardial tissue sample after 1 0 0  days of 
incubation in-vitro, showing the presence of various amounts of essentially Ca and 
P, along with traces of potassium and chlorine (the presence of C, O and S is 
attributed to the collagen matrix).
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8.3.2.2.3 Comparison between in-vitro and in-vivo calcification studies:
ESEM micrographs of in-vitro calcified tissue showed the existence of different 
sizes of crystal phases, ranging from less than 1 pm  up to 30 pm, in contact with 
collagen tissue fibres. The extent of calcification in-vitro was not comparable to that 
found in-vivo (rat subcutaneous model). Some studies17 already reported a poor 
correlation between the results of in-vitro and in-vivo calcification methods. Besides, 
whether mineral deposits obtained by in-vitro models are similar to the ones with in- 
vivo models is not particularly known. It should be emphasised also, that no in-vitro 
study up to now has reproduced the morphologies of both in-vivo and clinical 
explants.
However, with this in-vitro model, both untreated and glutaraldehyde-treated 
pericardial tissue were found to calcify. Although untreated pericardial tissue is 
reported not to calcify in-vivo but to be degraded by the host immune response, one 
can hypothesise that untreated collagen also has the capacity to calcify but that its 
degradation could be too fast in-vivo for calcification to be observed. All the above­
presented results indicate that pericardial tissue can calcify in-vitro (static in-vitro 
model) but it does not involve the same process of calcification as in-vivo, although 
similar products might be formed subsequently.
There are many limitations to this in-vitro calcification model when compared to in- 
vivo conditions. The calcification is mostly restricted to the surface (see ESEM data 
in section 8 .3.2.2 and histological results in section 8.3.4) and the available amount 
of calcium phosphate precipitated in the in-vitro system is limited. Furthermore 
calcification depends upon the initial working concentrations, while in contrast the 
body homeostasis generates unlimited amounts of calcium and phosphate. Although
29this static in-vitro system used in our study was reported to be highly reproducible , 
it does not seem to be of great value in mimicking the calcification behaviour of 
tissue bioprostheses since the morphology and composition of the calcific deposits 
was rather different from those in the in-vivo study. In previous studies, researchers 
who used a similar static in-vitro test methodology29’30, considered the tissue to be 
calcified as long as calcium was detected by atomic absorption spectroscopy, even in 
small quantities. However, they made no comment on the morphology observed nor 
reported the full elemental composition, along with the Ca/P ratio, of their calcific
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deposits. An alternative to the static in-vitro methodology used in this study would 
be to replace the calcification solution as often as possible so that the availability of 
calcium and phosphorus would be much higher than in our present study, although 
the outcome of such a procedure is unknown.
A possible advantage of in-vitro studies over in-vivo studies is the ability to study 
the early stages of the calcification process more easily. In-vivo studies generally 
quickly produce relatively heavily calcified material. However, in contrast to the in- 
vivo models, in-vitro models do not take into consideration the possible plasma 
insudation mechanism or the possible role of host immune response in calcification. 
Hence the early stages of calcification observed might not be representative of the 
true tissue calcification.
The validity of the static in-vitro model used in this study is therefore questioned, 
essentially because it does not produce a pathologic morphology of dystrophic 
calcification consistent with that seen in both circulatory models and clinical
C 1 1explants ’ . Although static in-vitro test systems can be used to study large numbers 
of small samples of materials relatively quickly, they cannot give information 
regarding the response of the material to mechanical stress, unlike dynamic in-vitro 
test systems (see chapter 1 section 1.7.5.2). An improvement on the model may be 
the use of dynamic in-vitro testing. It is postulated that ESEM might be useful in 
such a study, which has been reported to reproduce successfully the calcification
T9occurring in bioprostheses implanted in-vivo .
83.2.2.4 Collagen structure:
A detailed structural assessment of pericardial tissue in its native state using ESEM 
has not yet been reported. Our studies of pericardial tissue, which is essentially made 
of collagen, revealed the following structural features. The pericardial tissue was 
composed of bundles of parallel collagen fibres, with a certain definite periodicity of 
the bundles. This is similar to reported findings by SEM examination33 and to 
Normarski micrographs of wet collagenous tissue34. In cross-section (see figure 
8 .1 1 ), the pericardial tissue used in this study was found to have around twenty 
clearly stacked collagen bundles, which were very well organised without any 
located area of surface voids. The two surfaces of the pericardium were easily 
differentiated: the smooth pericardium was characterised by parallel collagen
340
bundles, whilst the rough surface showed a random collagen structure without a 
definite pattern. Furthermore, while micrographs of untreated pericardium showed a 
“loose” collagen structure with a well-defined crimp and thicker elastin fibres, 
micrographs of glutaraldehyde cross-linked pericardium revealed a tightened crimp 
structure and a greater compactness of the collagen bundles into a ribbon-like 
morphology.
8.3.3 ICP-OES analysis
The digestion of untreated pericardial tissue was readily achieved in acid, however 
the complete digestion of glutaraldehyde-treated pericardial tissue was much more 
difficult. Although the samples were left in acid for 5 hours at boiling temperature, 
digestion was not complete and the solid remnants of the samples were removed by 
filtration before analysis. Such a procedure has recently been mentioned to be 
necessary when digesting glutaraldehyde-treated tissues .
8.3.3.1 In-vivo study:
The results obtained from the in-vivo study can be found in table 8.2 below. The 
maximum calcium content determined was 642 /xg/g of dry tissue in the day 100 
sample. The calcium values found seem to be lower than the average reported by 
other authors . It is accepted, however, that calcification is affected by various host 
factors that can result in different values in each test. It is therefore important to 
compare results obtained using the same methodology and employing similar 
parameters (rat strain, age, sex, implantation place etc).
Implantation
time/elements
analysed
Silicon (/tg/g of tissue) Magnesium (/ig/g of tissue)
Calcium (/ig/g of 
tissue)
Day 0 29.67 6.16 68.63
Day 7 18.84 11.16 317.28
Day 14 141.01 23.99 252.74
Day 28 200.51 34.80 254.59
Day 35 209.65 29.09 272.73
Day 100 242.90 26.46 642.08
Table 8.2: Im plantation tim e in the rat m odel against elem enta data from  analyses
(silicon, magnesium and calcium) by ICP-OES of glutaraldehyde-treated pericardial
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tissue samples subdermally implanted in the rat model (number of samples that were 
averaged at each implantation time was n ^ ) .
The correlation of the elements analysed was calculated and a two-tailed statistical 
test carried out for each pair of elements to be correlated. The corresponding results 
can be found in table 8.3 below.
Pair of elements to be 
correlated
r value (estimator of 
the population 
correlation 
coefficient)
t value (statistic for 
the test of significance 
for the correlation 
coefficients)
Conclusion of the 
statistic under the 
null hypothesis
Ca/Mg 0.7185 2.0661
poor evidence for 
correlation only at 10% 
level o f significance
Ca/K 0.8641 3.4336
Poor evidence for 
correlation at 5% level 
o f significance
Ca/Si 0.9087 4.3551
evidence for 
correlation at 2% level 
o f significance
Mg/K 0.9295 5.0414
evidence for 
correlation at 1% level 
o f significance
Mg/Si 0.9178 4.6235
evidence for 
correlation at 1 % level 
o f significance
Si/K 0.9736 8.5365
strong evidence for 
correlation at the 0.2% 
level o f significance
Table 8.3: The correlation calculations of the elements analysed by ICP-OES from
analyses (silicon, magnesium and calcium) of glutaraldehyde-treated pericardial 
tissue samples subdermally implanted in the rat model.
From these results, it appears that potassium is somehow strongly correlated to 
silicon, as is magnesium with potassium and silicon. This is similar to the results 
obtained for calcified heart valves (see chapter 7), where the silicon appeared to be 
correlated with magnesium. The data however do not suggest significant correlation 
between magnesium and calcium, as might have been expected. As only a small 
number of samples were considered in this statistical analysis, the data cannot be 
said to preclude the involvement of magnesium in the calcific precursors o f tissue 
calcification. Further experiments, using many more samples, would have to be 
performed to obtain reliable statistical correlations.
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8.3.3.2 In-vitro study:
The determination of calcium in the day 100 sample gave the following results: 141 
/ig/g of dry tissue for the untreated pericardial tissue and 243 fig/g of dry tissue for 
the glutaraldehyde-treated pericardial tissue. It is extremely difficult to compare our 
data with those from other studies because chemical analysis from other static in-
9 Avitro experiments are generally excluded as the low mineral content of the tissues 
calcified in-vitro preclude accurate chemical analysis.
8.3.4 Light microscopy analysis
Histologic examination (Von Kossa staining) confirmed that all in-vitro test samples 
showed varying degrees of calcification, with intrinsic Von Kossa stain-positive 
deposits, and thus that the observed minerals formed in-vitro were calcium 
phosphate salts. This was in agreement with the ESEM-EDS data. The calcification 
was observed only on the outside/external surface of the in-vitro calcified pericardial 
tissue despite a long period of incubation. Because of the absence of any host 
immune response, no infiltration neither foreign body giant cells nor phagocytotic 
activity were observed with the in-vitro calcified tissue, as expected.
Although no histologic examination of in-vivo samples was carried out in this study, 
the presence of such infiltration, phagocytic activity and foreign body giant cells has 
been reported from the study of in-vivo calcified tissue26,37. Additionally, light 
microscopy examinations of in-vivo calcified samples reported in the literature
37indicated that mineral deposits were found located in the centre of the implants . 
This is particularly interesting because this is in agreement with our study by ESEM- 
EDS.
8.3.5 XRD analysis
The limited quantities of sample and the low mineral content formed by nucleation 
and crystal growth in-vitro and in-vivo, resulted in insufficient material to be reliably 
analysed by X-ray diffraction methods. Therefore results from the in-vivo and in- 
vitro experiments were excluded.
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8.4 Conclusion
In both in-vitro and in-vivo models, it was shown that calcification was intrinsic (i.e. 
it occurred selectively on the surface and inside of the in-vivo samples and on the 
surface of the tissue calcified in-vitro). This study also provided further evidence for 
the similarity of intrinsic calcific deposits in the rat models and in explanted valves 
(see chapter 7). However, the calcification obtained in the in-vitro model, although 
also observed as being intrinsic, is somehow different from in-vivo mineralisation 
(rat experiment or explants). Nevertheless, it is of interest that calcification can be 
induced in tissue even in the absence of cellular mechanisms and despite the lack of 
elements present in live biologic systems.
Overall, this study again demonstrated the broad ranging applicability of the ESEM 
technique, which allows investigation of wet, unstable biomaterials with minimal 
sample preparation.
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Chapter 9
9 General conclusion and suggested future work.
9.1 General Conclusion
Little is known of the mechanism of pathological calcification which leads to the 
failure of bioprosthetic heart valves and, until this is rectified, strategies for its 
prevention will remain elusive. Unfortunately, valve companies and research groups 
receiving commercial sponsorship are governed by strict codes of commercial 
confidentiality. These limit the release of information into the public domain. 
Without free access to the results of all relevant research, progress is greatly 
hindered. This is reflected in the fact that, to date, there have been no clear reports of 
the factors influencing the valves pathological calcification, no consensus on the 
chemistry behind the cross-linking process and no proven successful anticalcification 
treatments developed.
The deterioration of collagenous tissue used in clinical devices must be prevented 
and hence there is a need to stabilise it by glutaraldehyde cross-linking. However, 
glutaraldehyde (the chemical used to treat all commercially available bioprosthetic 
valves) has been cited as being likely to be implicated in the process of their failure 
and calcification. In addition, naturally occurring cross-links break down during 
implantation. Failures of bioprosthetic heart valves are thus mostly due either to 
structural and mechanical degeneration or to calcification.
In structural and mechanical degeneration, the chemical cross-linking might not be 
sufficient or chemical bonds, created through the cross-linking process, may break 
up with time in-vivo. Glutaraldehyde-treated bioprostheses are known to slowly 
release glutaraldehyde over time (see chapter 1 section 1.7.2), possibly by the partial 
hydrolytic degradation and reversibility of some cross-links (for example, Schiff
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bases possess a 
=CH group which represents a hydrolysis-sensitive site). The 
degradation of these cross-links can cause a lack of structural and mechanical 
integrity, which in turn can be responsible for failure of the valves. In the process of 
calcification, it is thought that free carbonyl groups of the molecules resulting from 
the cross-linking process can be oxidised in-vivo to carboxyl groups (see chapter 1 
and 6 ). These, may have the ability to bind host plasma calcium and contribute 
toward initiating calcification during implantation. Also, the hypothesis that the slow 
release of glutaraldehyde within tissue may be a potential initiator for calcification is 
supported by the fact that mineralisation is prevented by the use of binding agents 
that react with residual or free glutaraldehyde moieties. Additionally, many reports 
have suggested a role for aldehyde-induced cross-links in initiating tissue 
mineralisation (see chapter 1 and 6 ). For example, quaternary pyridinium-type cross­
links found in both elastin and collagen are thought to serve as a nucleation point for 
calcification, while cyclic cross-links (dipyridine structure) have been suggested to 
account for the high stability of the cross-links as well as being possibly involved in 
the calcification of glutaraldehyde-treated collagen.
Despite its wide use in many commercial applications, including manufacturing of 
bioprostheses, the chemistry of glutaraldehyde remains to be fully elucidated. An 
understanding of the interactions between glutaraldehyde and tissue is essential if we 
are to comprehend why bioprostheses calcify and ultimately fail. This represents the 
main aim of this thesis.
Many studies have investigated the reactions of glutaraldehyde with a range of 
model compounds, from the simplest amino acids to complex collagenous tissue (see 
chapter 2 section 2.2.4). A number of structures have been proposed for reactions 
products (see chapter 2 and appendices III and IV) but at present there is no 
definitive understanding of the processes that take place. Many contradictions can be 
found in the literature regarding the nature of glutaraldehyde in solution and also the 
nature of the products of the reactions between proteins and glutaraldehyde. An 
earlier study by colleagues within this research group, investigating the cross-linking 
of valve tissue by glutararaldehyde, showed promise. They subjected the reaction 
products of 6 -amino-n-caproic acid and glutaraldehyde to analysis by electrospray 
ionisation-mass spectrometry (ESI-MS) and successfully characterised ten molecular 
structures that had previously been reported by others using different techniques.
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This previous study was the starting point for the present thesis since the application 
of mass spectrometry along with other analytical techniques was expected to produce 
data that would lead to a better comprehension of the cross-linking process of valve 
tissue by glutaraldehyde.
Initially, methodology was developed to analyse glutaraldehyde solutions at various 
pH values by mass spectrometry, nuclear magnetic resonance, infrared and Raman 
spectroscopy (see chapter 4). This methodology was first used to determine the 
presence and nature of other molecular structures of glutaraldehyde than those 
already reported in the literature. Consideration of the theoretical chemistry that can 
take place under the conditions of analysis was used in the elucidation of possible 
structures. A summary of these findings can be found in appendix III.
The methodology was then used to determine the structures of species present in 
glutaraldehyde-treated tissue (see chapter 5). The reactions between glutaraldehyde 
and amines, peptides and proteins were investigated in order to determine possible 
molecular structures of the reaction products and to extrapolate these to those 
occuring during the glutaraldehyde-treatment of bioprosthetic valves. Twenty nine 
stable mono-bound structures along with twenty five stable multi-bound (cross- 
linking) entities, including anabilysine-like compounds (the only stable cross-linking 
entity reported so far in the literature) were determined. All these structures were in 
agreement with the theoretical chemistry that takes place under the conditions of 
analysis (Schiff base formation, aldol, aldol-type, Mannich-type, Michael and 
Michael-type additions). A summary of results can be found in appendix IV. In 
addition to the stable structures, other less-stable chemical entities were also 
characterised. It was hypothesised that these could play a role in the tissue failure of 
bioprostheses (probably via in-vivo degradation of cross-linked tissue). All the 
chemical structures determined may also have a potential role in the initiation of 
mineralisation due to the presence of many free pendant electronegative groups.
These hypotheses prompted an investigation of the potential of glutaraldehyde, along 
with its oxidised form (di-acid, glutaric acid), to initiate mineralisation by 
complexing ions such as calcium (see chapter 6 ). A similar investigation dealt with 
the possible uptake of calcium (calcification) by amino acids and other molecules 
that can mimic the behaviour of collagenous tissue (see chapter 6  and appendix I).
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Glutaraldehyde and glutaric acid have thus been shown to have the potential to 
induce mineralisation by attracting cations (potentially calcium) from a metastable 
calcifying solution, although the two compounds seemed to behave differently. 
Model compounds not reacted with glutaraldehyde were also shown to bind calcium, 
probably via the carbonyl oxygen atoms of their backbones.
It is ironic that the glutaraldehyde treatment itself, presently used in commercial 
valve processing, might be an initiator of calcification. Results from the analysis of 
glutaraldehyde and glutaric acid demonstrated a strong potential for their 
involvement in the mineralisation process of glutaraldehyde-treated tissues. The 
ability of glutaraldehyde to cross-link is thus unfortunately opposed to its potential to 
intrinsically facilitate tissue mineralisation, which was demonstrated in-vitro by this 
study. Overall, the data bring forward some new insights into the hypothetical 
primary processes of mineralisation of tissue. The data may also help to explain the 
involvement of glutaraldehyde and tissue factors in the calcification process o f valve 
bioprostheses.
In an attempt to gain a better understanding of the mineralisation process of 
bioprosthetic heart valves, the next step was to analyse calcified heart valve tissue. 
The objectives of the first part of this study were to develop methodology to 
investigate heart valve tissue and associated calcification in its natural state, using 
environmental scanning electron microscopy (ESEM) and to comment on future 
applications of ESEM in tissue bioprostheses research (see chapter 7). ESEM was 
found to allow the imaging of hydrated heart valve bioprostheses with minimal 
manipulation and without the need for conducting coatings. It is thought that ESEM 
will be useful in the study of new tissue-engineered heart valves. It may also play an 
important role in further developing our understanding of the calcification of heart 
valve bioprostheses.
Energy dispersive X-ray analysis (EDS coupled to the ESEM), X-ray diffraction 
(XRD), Fourier-transform infrared (FTIR) and Raman spectroscopy were used to 
characterise the various calcific deposits observed with ESEM, while the major 
elements present in calcified valves were analysed by inductively coupled plasma- 
optical emission spectroscopy (ICP-OES). The calcific crystals observed by ESEM 
were found attached to dense collagen bundles, following their orientation
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throughout the tissue and within the fibrils, and possibly also attached to elastin. The 
role of elastin in heart valves has been largely ignored in the past due to its low 
content. However, the importance of elastin (even when present as a minor 
component) in proper mechanical function indicates that any disruption of elastin 
through disease or other means could be the reason for mechanical failure o f a valve. 
Thus the potential mineralisation of elastin could play a significant role in the failure 
of these valves and it has already been demonstrated in the literature that elastin 
fibres might be the principal site of calcification of biological vascular grafts when 
implanted in animals. Additionally, these results suggest the potential role that 
collagen can play in valve mineralisation. Furthermore, although not reported, it is 
conceivable that similarly to collagen, the natural cross-linking of elastin may be 
strengthened by the glutaraldehyde cross-linking process and that the new cross- 
linking entities would be involved in the mineralisation process.
The likelihood of involvement of the tissue factor in the mineralisation of 
bioprosthetic heart valves is thus strongly believed by our group. However, no 
conclusive evidence for this was found in this work from a study of glutaraldehyde- 
treated model compounds by infrared (FTIR-ATR) spectroscopy. It has not been 
possible to identify interactions of the amino or carbonyl/carboxyl groups of the 
molecules backbones as binding sites for phosphate and calcium respectively. Yet, 
since the attraction of calcium by both glutaraldehyde and model compounds on their 
own was observed using infrared spectroscopy, it can be strongly hypothesised that 
glutaraldehyde-treated model compounds would behave similarly. After all, it has 
already been reported that collagen has potential calcium-binding sites and therefore 
may have a natural tendency to calcify, while elastin has been reported as a 
predominant site of calcification in aortic tissue (see chapters 1 and 6 , sections 1.7.2 
and 6 . 1  respectively).
From a study of human explanted calcified valve tissue by ESEM, two main patterns 
of organisation of calcific deposits were observed: spherical aggregates ( 1 - 1 0  /mi) 
found along collagen fibrils and in inter-fibrillar spaces, and needle-like crystal 
structures (sub-micron, micron scale). EDS microanalysis identified the crystals 
observed by ESEM as salts containing mainly calcium and phosphate with Ca/P 
ratios varying from 1.340 (possibly octacalcium phosphate (OCP), which has a Ca/P 
ratio of 1.336) to 2.045 (possibly hydroxyapatite (HAP) with incorporation of
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carbonate and metal ion contaminants, such as silicon and magnesium, in the crystal 
lattice). The presence of peaks attributable to silicon and magnesium in the EDS 
spectra confirmed this view and raised the possibility of the presence of precursor 
phases associated with the embryonic stages of calcification. The crystalline calcium 
phosphate salts found on heavily calcified valves had a mean Ca/P ratio of 1.676, 
which is very close to crystalline hydroxyapatite with a Ca/P ratio of 1.670. XRD 
patterns from these same calcium deposits showed a poorly crystalline 
hydroxyapatite-like pattern. Raman and FTIR spectroscopy also identified the 
presence of carbonate and the analyses showed spectral features very similar to a 
crystalline hydroxyapatite spectrum, thus refuting the presence of precursor phases 
such as /3-tricalcium phosphate (/3-TCP), OCP and dicalcium phosphate dihydrate 
(DCPD) at this stage in the calcification. However, it is still possible that these 
precursor mineral phases might have been formed but transformed too quickly into 
other phases to be detected by these techniques.
Other researchers have stated that there is no evidence for the presence of a precursor 
phase in calcific deposits with only apatite, as the single mineral component being 
observed. Additionally, the initiation site of valve mineralisation has not been 
established conclusively. Thus, the final section of this work (see chapter 8 ) 
investigated the calcification obtained in a static in-vitro model and compared it with 
that produced in-vivo (subcutaneous animal model) and with human explanted 
calcified valves, using the ESEM methodology previously developed. Explanted 
samples are generally extensively calcified and hence do not easily allow the 
determination of any possible precursor phases. Thus the use of in-vivo and in-vitro 
models was investigated to study the precursor phases of calcification.
A picture of the onset of tissue mineralisation in-vivo was hypothesised involving 
precursors containing various amounts of calcium and phosphate, along with silicon 
and magnesium. These evolved with the time of implantation, to a poorly crystalline 
form of hydroxyapatite (as found in late stage calcification of both in-vivo samples 
and explanted valves). Calcific deposits in the static in-vitro model were however 
mostly composed of calcium associated with low levels of phosphorus and often 
potassium. It therefore appears that in-vitro calcific deposits are not the same as 
those found in-vivo and from explants, bringing into question the reliability of the 
static in-vitro model.
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This work has advanced our understanding of relevant potential factors associated 
with mineralisation and failure of bioprosthetic implants. There are still many areas 
that require a thorough investigation and it is hoped that the work presented in this 
thesis will bring new insights for future studies of both the cross-linking and 
calcification of bioprosthetic heart valves.
9.2 Suggested Future Work
The following represents some general ideas for future work continuing from the 
present thesis. The investigations proposed are believed to either involve new 
applications of the techniques or to potentially bring new insights into aspects of this 
study.
9.2.1 High Performance Liquid Chromatography-Matrix Assisted Laser 
Desorption Ionisation Mass Spectrometry (HPLC-MALDI MS)
Another approach to the analysis of the reaction products formed between 
glutaraldehyde and various model compounds would be to separate the reaction 
products by reverse-phase HPLC, collect sample fractions and then analyse the latter 
by MALDI-TOF MS. The early phases of this work, including some analysis of 
fractions by MALDI-TOF MS, has been achieved1. The HPLC separation achieved 
was far from being optimal and much work is still required. It is thought that once a 
reproducible separation is achieved, the collected fractions could be concentrated by 
freeze-drying and then analysed by techniques such as FTIR and NMR spectroscopy, 
as well as mass spectrometry. Preliminary analyses of freeze-dried fractions using 
NMR proved unsuccessful due to the inherent insensitivity of the technique2. Hence 
further work would also be required to ensure samples of adequate concentration 
were available.
9.2.2 Atomic Force Microscopy (AFM)
■jSince its invention in 1986 , AFM has evolved as a valuable imaging technique with 
a spatial resolution in the micrometre to subnanometre region. This could be of great 
value when analysing collagen films and tissues. In AFM, a sharp probe is attached
353
to a cantilever spring, which is scanned in close proximity to a sample surface. 
During scanning (or imaging), the cantilever is deflected by forces acting between 
the surface and the probe. AFM employs probes with a tip to produce contact areas 
of ca. 10 nm . AFM can be also used to measure Van der Waals and electrostatic 
forces4. To produce an image, the deflections are monitored with respect to its lateral 
position on the sample5. However, care must be taken when analysing non-flat 
topographical samples (such as valve collagenous tissues), although some methods 
do exist to allow this type of analysis.
It is thought that AFM analysis could provide details about the surface topography 
and variations in chemical composition across glutaraldehyde-treated collagen 
surfaces. As an example, this would be particularly useful for mapping specific sites 
on a tissue surface, such as COO', that are thought to be involved in calcification 
(see chapter 6 ). The detection of such functional groups by AFM has been reported6. 
Carboxylic acid groups have also been covalently bound to the probe tip, which was 
scanned across a surface having various organic functional groups. The differences 
in frictional forces, between the acid groups on the tip and the surface of the sample, 
result in a map of the distribution of surface functional groups. The surface 
morphology of apatite film (calcific deposits found within calcified tissue are apatitic 
in nature) has also been reported using AFM7. It may be possible therefore to study 
valve calcification using AFM and it might also be particularly useful perhaps for the 
investigation of the very early stages of calcification or even initiation of 
mineralisation.
9.2.3 Scanning Tunnelling Microscopy (STM)
The use of STM to study the surface defects of heart valve bioprostheses has been 
reported8. It was used to prove the hypothesis that surface imperfections (such as 
surface defects or sub-surface voids) may serve as preferred sites for initiating the 
calcification process, as proposed for smooth polymer surfaces9' 11. Lee found that 
calcification in explanted valves was always associated with surface defects and 
proposed that calcification could be a result of the increased development of these 
surface defects, which would cause the subsequent insudation of plasma constituents 
and then the interaction of calcium. These constituents and the valve structure may
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aid the initiation of calcification. Only “first-generation” valves (those fixed at high 
pressure were more prone to mechanical surface damages, in comparison to the low- 
pressure fixation process of the “second-generation” cardiac bioprostheses actually 
on the market) have been previously analysed. No data have yet been reported for 
the analysis of “second-generation” valves or newly tissue-engineered cardiac valves 
that can be considered as “third generation” valves. It is thus thought that using STM 
to study “second generation” bioprostheses or tissue-engineered valves may increase 
our understanding of the calcification process. A major difficulty when using STM, 
however, is the requirement that the sample surface being examined must conduct 
electricity.
Scanning tunnelling microscopy has also been used in the investigation of a chemical 
reaction involving glutaraldehyde on a nanometre scale12. Heckl and Smith have 
studied the effect of a high electric field and a high current density between the STM 
tip and glutaraldehyde molecules covering a graphite surface, during a short voltage 
pulse. They reported that the resulting energy polymerised monomers of 
glutaraldehyde to oligomers ranging from about 5 to 15 monomeric glutaraldehyde 
units in size. It is thought that further work in this area might prove beneficial, since 
there are some doubts regarding their theory of polymerisation because commercial 
unbuffered glutaraldehyde solution has been shown to contain some (see chapters 2  
and 4). It is possible, however, that energy in the form of heat might have accelerated 
and increased polymerisation of the glutaraldehyde.
9.2.4 Circular Dichroism (CD)
The use of circular dichroism in the study of metal ion binding (aluminium and
1 Tcalcium) on a-elastin has been reported . However the application of this technique 
to collagen has not. It is thought that a similar study of the interaction of calcium 
ions and collagen could prove useful.
9.2.5 X-ray Photoelectron Spectroscopy
The study of hydroxyapatitie-collagen nanocomposites cross-linked with 
glutaraldehyde has been recently reported14. They confirmed the covalent bond
2_j_formation between Ca of hydroxyapatite and RCOO' of collagen molecule, along 
with the assessment for bridge formation between collagen fibers. It is believed that 
the use of XPS for investigating bond formation between Ca2+ and carbonyl groups 
of glutaraldehyde and or of glutaraldehyde treated proteins could be carried out in a 
similar manner.
9.2.6 Time of Flight Secondary Ion Mass Spectrometry (TOF-SIMS)
Static secondary ion mass spectrometry (SSIMS) employs very low intensity 
primary ion or fast atom beams to sputter the top monolayer o f a surface15. The 
secondary ions produced under static SIMS conditions are elemental or molecular in 
nature and are characteristic of the near-surface composition. Detection in the ppm- 
ppb region can be achieved with this technique. The advantage of such a method 
would be the direct analysis of solid surfaces (such as collagen or polylysine films, 
reacted or not with glutaraldehyde) with good sensitivity for high molecular weight 
species. This is thought to be possible since the study of a number of biomaterials, 
drugs and protein systems using this technique has been reported16. The data 
obtained might be correlated to the mass spectrometry results obtained from model 
compounds reacted with glutaraldehyde, as described in chapter 5. Furthermore, in 
the context of biological tissue imaging, SIMS has been used to map heterogeneous 
cation distribution and other secondary ions at the cellular level17. It would therefore 
be of interest to apply similar methodology to the study of calcified valve tissues. 
Samples might be analysed directly following freeze-drying, or they could be 
prepared in a solid organic matrix (2,5-dihydroxybenzoic acid) similar to the sample 
preparation used in MALDI (see chapters 4 and 5). Such a preparation technique was 
reported to provide a general enhancement of molecular secondary ions emitted from 
analyte/matrix mixtures when peptides, proteins and nucleic acids were analysed by 
TOF-SIMS18.
9.2.7 Surface Enhanced Raman Spectroscopy (SERS)
The Raman analysis of the reaction of glutaraldehyde and model compounds in 
solution was very difficult for two major reasons. Firstly, the low concentrations of
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the compounds used produced spectra that were not intense enough to allow proper 
spectral interpretation. Secondly, the level of fluorescence was too great.
A solution could be to mix the aqueous reacted solutions with silver colloids that 
would generate an interaction between the sample and the silver colloids electron 
waves (plasmon) thus increasing considerably the intensity of the Raman signal (this 
is essentially the SERS technique). Additionally, the fluorescent background 
associated with Raman spectroscopy is decreased in SERS. Additionally, the 
coupling of thin layer chromatography with spectroscopic techniques such as surface 
enhanced resonance Raman spectroscopy (SERRS) or even Fourier-transform 
infrared (FTIR) may provide useful information. The possibility of coupling such 
spectroscopic techniques with this form of chromatography has been previously 
reported19,20.
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Appendix I
A.l Investigation of the in-vitro calcification 
potential of type I collagen films by FTIR 
microscopy.
1.1 Introduction
It has been demonstrated that the formation of hydroxyapatite crystals from slightly 
undersaturated, metastable calcium phosphate solutions can be catalysed by 
reconstituted collagen fibres, tendons and skin1,2. Subsequently, it has also been 
shown that beef tendon matrix will catalyse the formation of a matrix-bound form of 
calcium phosphate from solutions of calcium and phosphate ions with a solubility
■j rproduct lower than that of normal serum ' . Moreover, collagen was later reported to 
be the most important site for the calcification of cardiac bioprostheses7. Study of the 
in-vitro calcification of glutaraldehyde, model compounds (mimicking the amino 
residues of collagenous tissue) and glutaraldehyde-treated model compounds by 
FTIR spectroscopy (see chapters 4 and 5) brought about the postulate that chemical 
groups of the amino-residues of the collagenous tissue are likely to be involved in an 
ion-complex formation. Such chemical groups (likely carbonyl and/or amino groups 
could act as a nidus for further calcification. Collagen is thought to have the potential 
to behave similarly. A preliminary study of collagen type I films and their 
subsequent in-vitro calcification was thus undertaken.
Infrared spectroscopy has been used in the past to study the secondary and tertiary
o nstructure of type I collagen " . FTIR spectroscopic studies of glutaraldehyde-treated 
type I collagen have already been reported in the solid state, showing two 
characteristic peaks (1658 and 1628 cm '1) in the convoluted amide I region14' 17. A
I
study of collagen extracted from bovine tendon (untreated and aldehyde-treated) by
1RFTIR can be also found in the literature .
The use of an attenuated total reflectance Fourier transform infrared (ATR-FTIR) 
microscope to enable us to see chemical differences on the surface of collagenous 
tissue was investigated. The infrared microscope can allow us to probe surface 
groupings. It can also indicate how calcium ions may interact with chemical groups 
on the surface of the collagen and hence how this may influence its in-vitro 
calcification.
1.2 Materials and Methods
1.2.1 Sample preparation
The preparation steps of collagen solutions can be found in the Sigma-Aldrich 
catalogue, or an alternative avoiding the laboratory preparation is to order a 0 .1% 
w/v collagen solution in 0.1 M acetic acid (Ref. C8919 SIGMA, UK). Collagen type I 
films were prepared as follows.
Spin-coating was first investigated. Five drops of 0.1% w/v collagen solution was 
placed on a quartz slide and spin at between 3400 and 4000 rpm for one minute. The 
film thickness achieved was less than the penetration depth of the infrared beam (a 
few /mi) and the resulting spectra were essentially from the quartz. Thus, in order to 
achieve a reasonable but uniform thickness, one would need to repeat, at least 1 0  
times, the previous procedure in order to achieve a thickness that would be of the 
order of the penetration depth of the ATR-FTIR beam (typically ca. 20 /mi).
Another method to prepare the collagen films was thus thought. Acid-cleaned quartz 
slides were coated with a few mL of the 0.1% w/v collagen solution. Gentle rocking 
ensured an even coating on the quartz slide surface. The collagen was then allowed 
to bind for several hours at room temperature. It was planned to study the in-vitro 
calcification potential of untreated and glutaraldehyde-treated collagen films. The 
films, on quartz slides, were placed in acid-cleaned glass petri dishes that allowed 
treatment with glutaraldehyde to take place. After glutaraldehyde treatment took 
place for a defined period, the glutaraldehyde solution was removed and the film was 
gently washed with distilled water. The glutaraldehyde-treated and untreated films
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were then subjected to an in-vitro calcification solution (see chapter 6  for details). 
The collagen films can be stored in sterile plastic tubes filled with this calcification 
solution or simply left in the glass petri dishes and the calcification solution added. 
Both methods can allow the calcification solution to be changed when felt necessary. 
After a determined period, the films can be removed from the calcification solution 
and gently washed with distilled water to remove any unbound inorganic ions. The 
films were left to air-dry and then analysed by ATR-FTIR microscopy.
Pericardium valve tissue was prepared as in chapter 8  section 8.2.2.
1.2.2 Instrument
The FTIR microscope used was a Nicolet continuum microscope with a silicon ATR 
objective (Spectra-Tech, UK). The data collection parameters were as follows: 1000 
scans, resolution of 4 cm '1, aperture of 100, MCT detector, KBr beamsplitter, 
spectral range of 4000-400 cm '1, Happ-Genzel apodisation and Mertz phase 
correction.
1.3 Results
1.3.1 Analysis of collagen films by FTIR microscopy
The first method of preparing thin films of collagen was the spin-coating technique. 
A typical FTIR spectrum obtained from a spin-coated film, can be found in figure 
A 1.1 below. It appears that the film thickness achieved was too thin and the 
spectrum represents the underlying quartz slide.
The second method for preparation of the collagen films involved evaporation. A 
typical FTIR spectrum, obtained from a film prepared by evaporation, can be found 
in figure A 1.1 below. The characteristic bands of collagen (from the second 
derivative) can be seen and are summarised in table A l.l .
Peak position 
(c m 1)
Assignment
-3200 cm’1 NH stretching of proteins (amide A)
-3311 cm’1 OH stretching of hydroxyl groups
2947 anti-symmetric stretching of the CH2 group
2872 symmetric stretching of the CH2 group
-1722 cm’1 protonated carboxyl and carbonyl groups
III
1695 cm"1 band resulting from amide 1 components
-1656 cm '1 amide I o f a-helical structures
-1630 cm"1 amide I o f p-pleated sheet structures
1553 cm"1 amide II band
1517 cm"1 tyrosine band
1469 cm '1 CH scissoring of methylene
1405 cm"1 symmetric CO stretching of carboxylate anion
Table A l.l:  FTIR peaks and their corresponding assignments, from the analysis of
collagen films (not incubated in calcification solution). See also figure A l.l .
1 Black: Spin coating techn ique
Blue: Evaporation  techn ique
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Figure Al . l :  FTIR-ATR spectra of collagen films formed using two different 
techniques (spin coating and evaporation).
The glutaraldehyde-treated films were not analysed.
1.3.2: Analysis of pericardium valve tissue by FTIR microscopy
The FTIR microscope can also be used to study valve tissue. Tissue samples have to 
be frozen in liquid nitrogen and sliced, as in sample preparation for light microscopy 
(histological technique). This allows the sample to be flat and of a known thickness. 
A typical FTIR spectrum of untreated pericardium tissue, can be found in figure 
A1.2 below. The infrared absorption pattern is quite similar to the one found above 
in figure Al . l  because the pericardium tissue consists essentially of type I collagen.
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Figure A1.2: FTIR-ATR spectrum of a histological section of untreated pericardium 
tissue.
1.4 Overall Discussion
Due to a lack of time on the FTIR microscope, the study was not completed and only 
the few first steps, indicating the success of the preparation method, were carried out. 
The mapping of collagen film surfaces (typically 100 x 100 /mi) using FTIR 
microscopy is nevertheless expected to give information regarding the calcification 
potential of collagen, especially through mapping of C =0 and COO' groups. Such 
findings have not been reported yet. Although not completed, a preliminary study of 
such maps has been successfully achieved with some untreated collagen films (data 
not shown here). A similar approach could be carried out with glutaraldehyde-treated 
collagen films, allowing the influence of cross-links, formed by the reaction between 
glutaraldehyde with protein, on collagen mineralisation to be studied. There are 
thirty-four amino groups in a collagen unit of molecular weight 1 0 0 , 0 0 0  and 
seventeen cross-links could be theoretically accommodated in this unit (assuming 
glutaraldehyde only to be a single dialdehyde molecule), while the maximum 
number reported, found by reaction with glutaraldehyde, was between thirteen19 and 
twenty five20. The resulting cross-links would therefore be complex and very 
difficult to determine solely by FTIR spectroscopy. However, the use of FTIR
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microscopy could still provide information on the role of collagen and cross-links in 
the mineralisation of tissue.
1.5 Conclusion
Successful methodologies for the preparation of collagen films and valve tissue 
sections have been carried out. Preliminary analyses by FTIR microscopy showed 
that such methodology could prove useful in increasing our understanding of the role 
of collagen and cross-links in the calcification of collagenous tissue.
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A.2 Investigation of the reaction products of 
glutaraldehyde-treated model compounds using 
TLC-MALDI-TOF MS.
1.1 Introduction
The use of Matrix Assisted Laser Desorption Ionisation Time-Of-Flight Mass 
Spectrometry (MALDI-TOF MS) has already been described in chapters 4 and 5 of 
this thesis, for the analysis of the reaction of glutaraldehyde with model compounds 
(amino acids, peptides and proteins) at various pH values. However, another 
application of MALDI-TOF MS was undertaken by analysing the same reaction 
products of glutaraldehyde and model compounds as the ones mentioned previously 
but this time directly from thin layer chromatography plates (TLC MALDI-TOF 
MS).
There are several methodologies for combining TLC with MALDI MS. The 
components of a reaction mixture are initially separated on a TLC plate. In the first 
method, the analyte spots are then scraped off the plate, extracted into a solvent and
1 9analysed by mass spectrometry ’ . This method requires an independent visualisation 
method to locate the analyte spots before extracting the samples. Another method 
involves the formation of a matrix layer on a stainless steel substrate while the TLC 
plate is sprayed with an extraction solvent. The matrix and the TLC plate are then 
placed face to face, transferring matrix to the plate and the stainless steel substrate 
discarded3.
Our approach was much simpler and did not require the sample to be scraped or 
extracted from the TLC plate, thus maintaining the integrity of the TLC plate.
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Additionally, an advantage of the TLC-MALDI-TOF MS technique is the high 
sensitivity of MALDI and its ability to ionise low and high molecular weight 
compounds without fragmentation.
1.2 Materials and Methods
Please refer back to chapter 5 (sections 5.2.1 and 5.2.2) for details of chemicals and 
consumables used (e.g. model compounds, glutaraldehyde, etc.).
1.2.1 Sample preparation
This methodology involved the direct analysis of the intact TLC plate mounted on a 
modified MALDI target. The samples (3 x 25 mL of model compound reacted with 
glutaraldehyde were freeze-dried and re-dissolved in 3 mL of methanol (same 
methodology as reported previously in chapter 5). With the help of a capillary tube, a 
very small volume (~4 /jL) of the sample in methanol was spotted on a TLC plate 
(TLC plates (10 x 3 cm) coated with 0.2 nm layers of silica gel ref.: 60F254 from 
Merck, UK), backed with an aluminium support material. To achieve the best 
separation, the sample spot was kept as small as possible.
1.2.2 Development
The separation of each sample, using various mobile phases, was first carried out. 
The TLC development jars were lined with filter paper and sealed tightly to ensure 
that no solvent vapour evaporated. The mobile phases were thus always left to 
saturate for 2 hours prior to use. The TLC plates were then placed in an upright 
position and developed on their own in a pre-prepared jar. After separation had 
occurred the plates were removed and the solvent front was marked by a pencil line, 
in order to allow calculation of the Rf value of each spot. The TLC plates were air- 
dried and then visualised under UV light at 254 nm. Each TLC separation was 
carried out several times, whilst maintaining the experiment conditions, in order to 
check the reproducibility of the methodology. The following tables summarise the 
samples analysed (including dissolving solvent), the mobile phases used and the 
success of the separations4,5.
1.2.2.1 Unreacted Glutaraldehyde:
IX
Solvent used and 
resulting pH
Mobile Phase Quality of separation (number of spots 
along with R f values)
Water (pH 3.97) methanol:water:acetic acid 
(80:15:5)
poor separation achieved with one clear 
spot with R f 0.87
Buffer pH 4 methanol:water:acetic acid 
(80:15:5)
poor separation achieved with one clear 
spot with R f 0.87
Buffer pH 7.4 methanol:water:acetic acid 
(80:15:5)
poor separation achieved with one clear 
spot with R f 0.80
Buffer pH 9.2 methanol:water:acetic acid 
(80:15:5)
poor separation achieved with two spots 
with R f of 0.42 and 0.78
Table A2.1: Mobi 
separation of aque 
4-9).
1.2.2.2 Glutaraldel
e phases and the corresponding retention factors4,5 from the TLC 
ous solutions of 0.6% v/v glutaraldehyde at various pH values (pH
wde-treated 6 -Amino-n-caproic acid:
Solvent used and 
resulting pH
Mobile Phase Quality of separation (number of spots 
along with R f values)
Water (pH 4.76) methanol:water:acetic acid 
(80:15:5)
very good separation achieved with 6 
spots with R f values of 0.034, 0.17, 0.26, 
0.43, 0.60 and 0.77
Buffer pH 4 methanol:water:acetic acid 
(80:15:5)
very good separation achieved with 7 
spots with R f values o f 0.017, 0.086, 
0.17, 0.29, 0.46, 0.65 and 0.76
Buffer pH 7.4 methanol: water: acetonitrile 
(80:15:5)
very good separation achieved with 6 
spots with R f values of 0.016, 0.083, 
0.16, 0.23, 0.42 and 0.75
Buffer pH 9.2 methanol: acetonitrile: cy clohexane 
(80:15:5)
very good separation achieved with 6 
spots with R f values of 0.017, 0.086, 
0.21,0.29, 0.60 and 0.72
Table A2.2: Mobi e phases and the corresponding retention factors4,5 from the TLC
separation of aqueous solutions of 0 .1 % w/v 6 -amino-n-caproic acid reacted with
0.6% v/v glutaraldehyde at various pH values (pH 4-9).
1.2.2.3 Glutaraldehyde-treated N-Acetyl-L-lysine:
Solvent used and 
resulting pH
Mobile Phase Quality of separation (number of spots 
along with R f values)
Water (pH 3.96) methanol:water:acetic acid 
(80:15:5)
very good separation achieved with 6 
spots with R f values o f 0.030, 0.028, 
0.25, 0.45, 0.62 and 0.79
Buffer pH 4 methanol:water:acetic acid 
(80:15:5)
very good separation achieved with 6 
spots with Rf values o f 0.016, 0.066, 
0.15, 0.33, 0.50 and 0.75
X
Buffer pH 7.4 methanol:water:acetonitrile
(80:15:5)
very good separation achieved with 6 
spots with Rf values of 0.015, 0.07, 0.15, 
0.31, 0.50 and 0.76
Buffer pH 9.2 methanol: acetonitrile: cyclohexane 
(80:15:5)
very good separation achieved with 5 
spots with Rf values o f 0.016, 0.10, 0.23, 
0.50 and 0.66
Table A2.3: Mobi 
separation of aqu( 
v/v glutaraldehyde
1.2.2.4 Glutaralde
e phases and the corresponding retention factors4,5 from the TLC 
^ous solutions of 0.1% w/v N-Acetyl-L-lysine reacted with 0.6% 
at various pH values (pH 4-9).
ivde-treated N-Acetvl Glvcine Lvsine Methvl Ester:
Solvent used and 
resulting pH
Mobile Phase Quality of separation (number of spots 
along with R f values)
Water (pH 4.38) Methanol:water:acetic acid 
(80:15:5)
Good separation achieved with 4 spots 
with R f values o f 0.06, 0.15, 0.33 and 
0.70
Buffer pH 4 methanol:water:acetic acid 
(80:15:5)
Good separation achieved with 3 spots 
with R f values o f 0.19, 0.34 and 0.70
Buffer pH 7.4 methanol:water:acetonitrile
(80:15:5)
Very good separation achieved with 5 
spots with R f values o f 0.10, 0.26, 0.40, 
0.50 and 0.75
Buffer pH 9.2 methanol: acetonitrile: cyclohexane 
(80:15:5)
Very good separation achieved with 5 
spots with R f values of 0.047, 0.20, 0.36 
and 0.68
Table A2.4: Mobi 
separation of aque 
with 0 .6 % v/v glut
1.2.2.5 Glutaraldel
e phases and the corresponding retention factors4,5 from the TLC 
ous solutions of 0.1% w/v N-acetyl Gly Lys Methyl Ester reacted 
araldehyde at various pH values (pH 4-9).
ivde-treated N-Acetvl Phenvlalanine Lvsine:
Solvent used and 
resulting pH
Mobile Phase Quality of separation (number of spots)
Water (pH 3.60) methanol:water:acetonitrile
(80:15:5)
Relatively good separation achieved with 
5 spots but the separation was faint and 
the spots were difficult to identify (no R f 
values available)
Buffer pH 4 methanol:water:acetonitrile
(80:15:5)
Very good separation achieved with 5 
spots (no R f values available)
Buffer pH 7.4 methanol: water:acetonitrile 
(80:15:5)
Very good separation achieved with 6 
spots (no Rf values available)
Buffer pH 9.2 methanol:water:acetonitrile
(80:15:5)
Poor separation achieved with only 2 
spots (no Rf values available)
Table A2.5: Mobile phases from the separation of aqueous solutions of 0.1% w/v N-
acetyl Phe Lys reacted with 0.6% v/v glutaraldehyde at various pH values (pH 4-9).
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1.2.2.6 Glutaraldehyde-treated Proteins (lysosyme and cytochrome c):
Separation of glutaraldehyde-treated proteins was not carried out because of time 
constraints, however work on the separation of drugs reacted with glutaraldehyde has 
already been reported6. The mobile phase used consisted of methanol, ethyl acetate 
and acetic acid in a ratio of 85:10:5. Although this mobile phase was not found to 
work efficiently in the separation of both amino acids and peptides (results showed 
only one clear spot without any streaks), it is believed that this mobile phase might 
be successful for the separation of the reaction products of proteins reacted with 
glutaraldehyde because the separated drugs contained similar pendant groups as 
reactions products of glutaraldehyde-treated model compounds.
1.2.3 Matrix application
In all experiments, a 600 x 2 mm strip of the developed TLC plate, containing the 
spots for analysis, was attached to a modified MALDI target with double-sided tape 
before the matrix (2,5-dihydroxycinnamic acid, DHB) was electrosprayed onto the 
silica gel surface. The matrix solution (7 mg DHB/mL of methanol) was 
electrosprayed onto the TLC plate using an in-house modified commercial robotic 
x,y,z axis motion system (PROBOT, BAI, Germany). The electrospray used in this 
study consisted of a syringe pump fitted with a 1 0 0  /rL syringe which was connected 
via PTFE tubing to a HPLC zero dead volume fitting to a capillary steel needle, to 
which a high voltage (ca 2.5 kV) was applied. The capillary needle was further 
threaded to a HPLC T-piece zero dead volume fitting through which dry nitrogen 
could be applied to the capillary tube. The TLC plate was earthed and held 
horizontally during electrospraying and set to a distance of ca. 4 mm from the spray 
needle7. The syringe was filled with the matrix solution, which was electrosprayed at 
a rate of 150 jiiL.h'1, whilst the TLC plate was moving at 0.6 cm.min*1. Once the TLC 
plate was electrosprayed, it was left to air dry for at least an hour, before placing the
oMALDI target into the spectrometer . Letting the solvent evaporate, allowed the 
matrix solution to co-crystallise with the sample to be analysed on the TLC plate.
1.2.4 Mass spectrometer
Mass spectra and mass chromatograms were recorded directly from the TLC plate 
with a modified linear Laser TOF 1500 (Scientific Analytical Instruments, 
Manchester, UK), equipped with a N2 laser (A=337 nm). The sample holder within
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this instrument has been modified to enable TLC strips of approximately 65 x 2 mm 
to be fitted into the recessed slot and the sample probe was adapted to allow free 
movement along the z (vertical) axis, while the software has also been modified to 
allow the construction of total ion and mass chromatograms. These modifications to 
the instrument and its software, for use in TLC-MALDI-MS mode, have been
opreviously further described elsewhere . Only the positive ion mode was used in 
these investigations.
1.3 Results
The TLC-MALDI-TOF MS method was used to identify low molecular weight 
compounds with masses within the matrix region (100 Da and above), a goal that is 
normally difficult to achieve. Low molecular weight compounds were successfully 
detected by almost complete suppression of the matrix peaks using a relatively low 
matrix concentration in comparison to the analyte. The data obtained from the TLC 
plates showed similarities with the same reaction mixtures analysed by simple 
MALDI-TOF MS (see chapter 5 of this thesis). Such correlation was expected and 
successfully achieved. A typical TLC-MALDI-TOF MS spectrum is shown in figure 
A2.1 below (glutaraldehyde-treated 6 -amino-n-caproic acid at pH 9.2).
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Figure A2.1: TLC-MALDI-TOF MS spectrum of a mixture of 0.1% w/v 6 -amino-n- 
caproic acid reacted with 0.6% v/v glutaraldehyde at pH 9.2 separated using a 
methanol:acetonitrile:cyclohexane mobile phase with a 80:15:5 ratio (spot position 
on the TLC: 31.33mm from the origin).
The peaks appear as M and [M+H]+ ions. In addition, many molecular structures also 
appear with the addition of a sodium (Mw 23) or potassium (Mw 39) cation such as 
[M+Na]+ or [M+K]+, and more rarely as [M+Na+H]+ and [M+K+H]+ adduct ions. A 
tentative assignment of the spectrum shown in figure A2.1 is given in table A2.6 
below (for the molecules of glutaraldehyde please refer to the appendix III, and for 
those of the reaction between glutaraldehyde and 6 -amino-n-caproic acid, please 
refer to appendix IV).
m/z (vs=very strong, s=strong, 
w -w eak signal)
Proposed assignment for 
glutaraldehyde molecules 
(Mw)
Proposed assignment for 
model compound + 
glutaraldehyde reaction 
products (Mw)
165s/168s/169w Mol XXIII (163)
183w Mol XV (182); Mol XXXI (182); Mol XXXII (182)
214w/217s/218w
Mol LX (213); Mol LXV 
(195+Na=218); Mol LXVI 
(194+Na=217)
250s/252vs/254vs/256w Mol XXV (228+Na=251); Mol V (218+K=257)
Mol LX (213+K=252); Mol 
LXII (231+Na=254); Mol 
LXVII (231+Na=254); Mol 
LXXII (231+Na=254)
296w/297w Mol XCII (295); Mol CIII (295); Mol CIV (295)
324w/327w/328w
Mol IX (301+Na=324); Mol 
XII (300+Na=323); Mol XVIb 
(300+Na=323); Mol 17b 
(300+Na=323)
Mol LXI (326)
395s/397s/399s Mol CXLI (395); Mol CXLVIII (395); Mol CLXIV (395)
Table A2.6: Tentative assignment of the mass spectrometric data from the spectrum 
of 6 -amino-n-caproic acid reacted with glutaraldehyde at pH 9.2 (see figure A2.1).
1.4 Overall Discussion
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The major problem encountered was to obtain a reasonable separation of the reaction 
products. The TLC separation of such products has been rarely attempted, only 
limited TLC separations of such products have been reported9,10. However, HPLC 
methodology has been reported for the separation of related species. For example, 
measurement of personal exposure to glutaraldehyde11, quantify glutaraldehyde
19 19traces on medical equipment after final rinsing ’ and after inactivation with sodium 
bisulphite14, detect glutaraldehyde into hydrolysed pericardial tissue15' 17, but also to
1 ftfollow the extent of protein (cottonseed) cross-linking with glutaraldehyde . 
Nevertheless, this study has shown that a relatively satisfactory TLC separation can 
be attained, however this was not a complete separation, as indicated by the number 
of different products found in the mass spectra.
The results summarised in table A2.6 obtained from the analysis of a TLC plate of a 
glutaraldehyde-treated model compound showed similarities with the same reaction 
mixtures analysed by simple MALDI-TOF MS (data shown in chapter 5). Most 
peaks can either be assigned for unreacted glutaraldehyde or reaction products.
The methodologies presented here offer a good basis for future experiments. It is 
thought that TLC-MALDI-TOF MS would be most successful once an optimum 
TLC separation is achieved. It was also noted that different concentrations of the 
matrix solution can affect the spectra. It is believed that better resolution may be 
achieved by altering the matrix solution or altering the ratio of sample:matrix. Also, 
the addition of trifluoroacetic acid (generally used to ionise the matrix) to the matrix 
might be beneficial. Additionally, from MALDI-TOF MS data, the analysis of 
glutaraldehyde-treated proteins seems to give relatively easier spectra to interpret 
than glutaraldehyde-treated model compounds spectra. Thus, it is postulated that if  a 
suitable TLC separation could be found the resulting spectra may help our 
understanding of the reaction between glutaraldehyde and proteins.
1.5 Conclusion
It has already been shown (see chapter 5) that the analysis of a model compound 
reacted with glutaraldehyde at various pH values (pH 4-9) by MALDI-TOF MS can 
be successfully achieved. Many peaks could be assigned to different chemical
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structures of varying complexity involving both reaction products and unreacted 
glutaraldehyde molecules. This preliminary study demonstrates that TLC-MALDI- 
TOF MS can also be successful in the separation and analysis of products of 
complex reactions involving small amino acids or peptides with glutaraldehyde.
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Appendix III
A.3 Hypothetical molecular structures present in 
glutaraldehyde solutions.
The table below summarises the possible molecular structures identified from the 
mass spectrometric data (see chapters 4 and 5) obtained from the analysis of 
glutaraldehyde and glutaraldehyde-treated compounds. The references found in 
association with some molecules in the table below refer to authors who reported 
proof of their likely presence in the literature.
Note that the molecular structures that are not cross-referenced have not previously 
been reported. Only 23 molecules out of the 73 found below have previously been 
proposed in the literature. These represent only 31% of all the hypothetical 
molecular structures present in glutaraldehyde solutions proposed in this thesis, 
emphasising the important contribution of this study to the elucidation o f the 
behaviour of glutaraldehyde in solution.
Molecule
number
(Molecular
weight)
Molecular structure
Molecule
number
(Molecular
weight)
Molecular structure
M o ll1'4 (100)
M onom eric glutaraldehyde/  Jo ' o '
Mol XXVI 
(328)
Aldol condensation product 
A x .  te tram er partially cyclised
0
Mol II1'4 
(118)
| I Glutaraldehyde monohydrate
J  Ao ' HO OH
Mol XXVII 
(310)
1 i Aldo1 j ! condensation 
n .  te tram e r  
1 f fully-cyclised
V acA J
XVII
Mol III1*4 
(136)
Clutaraldehyde dlhydrate
H O ^  ^ O H6 h 6 h
Mol XXVIII 
(410) U k
f^^^A ldo l condensation pentamer product pertlally cyclised
Mol IV1*3 
(118)
(2 isomers4: 
IVa and IVb)
” 7 ^
C lu ta ra ld c h y d e ? y c llc  h e m iac e ta l (els) IV a  OH OH
G lu ta ra ld e h y d e  cyclic  h e m iac eta l ( tr a n s )  IV b
Mol XXIX 
(392)
—' N s >^?r \  Aldol condensation | | j J pentamer product 
partially cyclised
0 ^  /
Mol V 1’3’5 
(218)
Clutaraldehyde hem iacetal dim er
Mol XXX  
(374)
1 Hr" 1 Al‘ll>,I l f ]  condensation 
ft pentamer | j? product fully I 1 cyclised
Mol VI1’5’5 
(318)
Clutaraldehyde hemiacetal t rlm er
Mol XXXI6 
(182)
Dimer produced by aldol 
condensation of two ® jf | monomeric[ 1 [glutaraldehyde molecules-- "”^ O H  ^ ^ 0
Mol VII1’3’5 
(418) Clutaraldehyde cyclic acetal tetramer
Mol XXXII7 
(182)
Cyclic «c .tal
0  | | form  of moleculeUsAr
Mol Vila8 
(202)
Oligomer of clutaraldehyde consisting of the a-oxyopyran ring
Mol XXXIII 
(282)
Aldol condensation/Michael addition trlmer product
Mol VIII5 
(202)
G lutaraldehyde hemlacetal-type d im er
Mol XXXIV 
(364)
Aldol condensation/Michael addition tetramer product
Mol IX5 
(301)
O ligom er o f  g lu taraldehyde conslslng o f  the  a-oxypy ran  ring
Mol XXXIVa 
(382)
Fully-hydrated aldol/MIchael addition te tram er product
Mol X (132) Clutarlc a d d  (dl-add form of monomeric glutaraldehyde)
/  K h Oh o
Mol XXXV  
(464)
Aldol condensation/Michael addition pentam er product
XVIII
Mol XI (116) |  | M ono -add  form  of 
1 monomeric
glutaraldehyde
C r X H
Mol XXXVI 
(464)
i
Isomer of XXXV. Aid
^ f a r \
X
1/MIchael addition pentam er product
Mol XII7 
(300)
| jX  | Trloxane-typeO  ^  J  " ,M< 
°
Mol XXXVII 
(364)
1
Isomer of XXXI V?Ald
0
ol/Mlchael addition te tram er product
Mol XIII8 
(500)
G lutaraldehyde trloxane-type pentam er
Mol
XXXVIIa
(382)
0
/ L t x
II Fully-hydrated aldol/Michael 
°  addition te tram er product
Mol XIV8 
(700) x / T p O ^ V ?
Glutaraldehyde trioxane-type heptam er
Mol
XXXVIII
(446) [  I S ----- Aldol condensation/Michael^  ^  addition pentamer product
Mol XV 
(182)
Aldol condensation product consisting of two 
monomeric glutaraldehyde molecules
Mol
XXXVIIIa
(464)
1 1
j 1 S\ ------Partially hydrated aldol
A  A  1 N . condensation/Michael addition 
q-x ^  1 pentamer product
Mol XVa 
(200)
Hydrated form of molecule XV 
(hydrated aldol condensation 
dimer product)
Mol
XXXVIIIb
(482)
j |
[ j \ _ _ X - q  Fully-hydrated aldol 
\  \  1 \  condensation/Michael 
y y  y y  L  | addition pentamer product 
0  0
Mol XVI1 
(264)
/ y  / /  Aldol condensation trlm er producto ' o '
Mol XXXIX 
(546)
° 0 o
A ldol condensation /M ichael add itio n  h e x am e r  p ro d u c t
Mol XVia8'11 
(282)
l l v d r s ^ ^ ^ ^  product
Mol XXXIXa 
(564)
Fully  hy d ra te d  aldo l condensation /M ichael 
add ition  hexam er p ro d u c t
XIX
X  X
Mol XVIb Mol XL
(300) (646)
Z ' / }  H ydrated form o f an aldol 
&  &  condensation trlm er nrodu
A ldol condensation /M ichael a ddition  bep tam er p ro d u ct
Mol XVII Mol XLI
(264) (528)
(hydrated aldol
Mol XVIIa Mol XLIa
(282) (546)
(hydrated aldol
trlm er product)
Partially hydrated aldol condensation/Michael addllle
Mol XVIIb Mol XLIb
(300) (564)
(hydrated trlm er
Mol XVIII Mol XLIc
(346) (582)
(y  Aldol condensadon te tram er product
Mol XVIIIa Mol XLII
(364) (628)
/ }  / }  Partially-hydrated aldol condensation te tram er product
Mol XVIIIb Mol XLIIa
(382) (646)
Partially-hydrated aldol condensation te tram er product
Mol XVIIIc Mol XLIII
(400) (728)
^  j ?  Fully-hydrated aldol condensation tetramer product
molecuJe represeats the largest aldol condensation/Michael 
addition product proposed according to the mass ipectrometric
XX
Mol XIX 
(428)
°  0  Aldol condensation pentamer product (this represents the 
largest "pure" aldol condensation product detected and 
proposed according to the mass spectrometrlc results 
obtained)
Mol XLIIIa 
(746)
Fully hydrated a Mot twMJcuadoa/MlduH addition aetaaMr prodad
Mol XlXa 
(446)
/ /  / /  Partially-hydrated aldol condensation pentamer product
o /  o /
Mol XLV 
(264)
1 Aldol 1 condesatlon/cyclisation/ 
Michael addition trlmer 
J J J  product partially
( l
X
Mol XlXb 
(464)
J J Partially-hydrated aldol condensation 
I ( pentamer product
/  /
Mol XL VI 
(364) 1 ' ' ' ' °  Aldolcondensation/cydisatlon/ | 1*^  j Michael addition 
I tetram er product 
^  partially cyclised
Mol XIXc 
(482)
[ j  ' '“OH ^ ^ 0  Partially-hydrated aldol 
A A  condensation pentamer product
c r  or
Mol XL VII 
(346) I. Aldol
0  fl 1 condensation/cydisatlon/
II 1 Michael addition te tram er 
1^ . 0  p roduct partially  cyclised
J
Mol XlXd 
(500)
j 1 '''Ss‘OH Fully-hydrated aldol 
A  A  condensation pentamer 
< /  product 0  0
Mol XLVIII 
(446)
_____
^  i \^^\Aldot0  condensation/cydlsation/
0  J Michael addition 
pentam er product 
0  ||  partially  cyclised 
0
Mol X X 12’13 
(264)
\  Hydrated enol form of an aldol 
h q /  ( y  condensation trlmer product
Mol XLIX 
(546)
/  Aldolcondensation/cydlsation/ 
j Michael addition 
| j  hexam er product
|^ ^ ^ ^ |^ p a r t i a l l y  cyclised
i
Mol XXI9’14 
(266)
^ /} Cannizzaro product of a trl-aldol 
O ' o  condensation oligomer
Mol L (328) <^ |------ >s. Aldol
^ ^ 0  eoodeasatloa/cycllsatloa/
JL a .  Michael addltloa f  *etrlm*r produd fully 
( I  cyclised
X  X
Mol XXII9 
(302)
C r ^ ^ O N a  
/ }  / }  Cannizzaro product of a 
q /  O ' tri-aldol condensation oligomer
Mol LI (428)
] X  Aldol 
JL .  condensation/cyclisadon/ 
Michael addition [ | j |  pentam er product 
1 I partially cyclised
J / X
i
XXI
Mol X X I I I  
(163)
(  Fully cyclised dimer 
produced by aldol 
- jX  X j .  condensation of two 
O monomeric 
glutaraldehyde 
molecules
Mol L I I  (528) < ^ S  < ~ X ,
JL J ?  JL Aldolf  X .  condensation/cyclisation/ 
1 Michael addition 
1 L  1 hexamer product 
^ X  X ^ ^ X ,  partially cyclised
O
Mol X X I V 5 ’6  
(246)
f  X s  Partially-cyclised trim er 
j 1 form ed by aldol condensation
X
X
Mol L I I I
(628)
X  <  X
I Aldol
condensation/cyclisation/ 
| | Michael addition 
pentam er product 
Is. ^  s. 0  partially cyclised° \ / _ 1 l _ X X °
o ' \
0 ^  X
Mol X X V 1 5 ’ 1 6  
(228)
s ' Fully-cyclised trim er of 
XXIV, formed by aldol 
1 ^ ^  condensation
X
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Appendix IV
A.4 Hypothetical molecular structures present in 
solutions of glutaraldehyde-treated model 
compounds.
The table below summarises the possible molecular structures identified from the 
mass spectrometric data (see chapters 4 and 5) obtained from the analysis of 
glutaraldehyde-treated model compounds. The references found in association with 
some molecules in the table below refer to authors who reported proof of their likely 
presence in the literature.
Note that the molecular structures that are not cross-referenced have not previously 
been reported. Only 23 molecules out of 84 have previously been proposed in the 
literature. These represent only ca. 27% of all the proposed molecular structures 
present in glutaraldehyde-treated model compounds identified in this thesis 
(excluding the glutaraldehyde molecules summarised in appendix III). This 
emphasises the complexity of the reaction of glutaraldehyde with proteins and the 
important contribution of this study to the elucidation of the cross-links between 
glutaraldehyde and lysino groups of tissue.
N. B. R stands for the radical: R=115 for 6 -amino-n-caproic acid (also called 6 - 
amino hexanoic acid); R=172 for N-acetyl-L-lysine; R=335 for N-acetyl 
phenylalanine lysine; R=243 for N-acetyl glycine lysine methyl ester.
Molecule Molecule
number numberMolecular structure Molecular structure(Molecular (Molecular
weight) weight)
XXIII
Mol LX1'3 
(98+R)
f  A s  Mono-SchifTbase * »■ addition on a \  Jl U monomeric 
0 ^  W 'r  HN glutaraldehyde ^ £ molecule
Mol CXIX 
(180+R)
Michael-type edition 
Y  J on a dialdol 
|  |  | condensation product
Mol LXI1*3 
(96+2R)
S '  s. Di-Schiff base 
r  jl jl addition on a J  J  J| | |  monomeric
HN' H N ^
l l l l
Mol CXX 
(196+2R)
/ R Aldol
condensation 
I dimer that
underwent two \  ] MIchaei-type 1 1 additions
Mol LXII4 
(116+R) sxMO HN-----R Mol CXXII5 (262+R) hn/ r
Michael-type addition on 
aa aldol condensation 
trimer
Mol LXIII6 
(102+2R) R R
Mol CXXIII7 
(260+2R)
R R
NH NH 
1 1 A cyclised aldol 
/ s .  condensation f  A A  A  trimer that| |  underwent two L L  J  MichaeMype 
additions
k ,  0 ^
Mol LXV3’7’8 
(80+R)
(l l) SchifTbase addition on a 
monomeric glutaraldehyde IL 1J followed by a cyclisation 
step (dihydropyridlne 
structure)
Mol CXXVI 
(258+3R)
N *
| 1 A cyclised aldol Jv >n. vL condensation f ;[ A  trlmer that 
| |  underwent three I JL 1%. J Michael-type 
additions
0 0
Mol
LXVI3’6’8
(79+R)
j j  O xidised fo rm  o f  molecule LXV I f| (q u a te rn a ry  p y rid in ium  com pound)
S ? /N
i
Mol
CXXVIII
(225+2R)
------------- D l-S th lrrb .it on inl l l l  aldol condensation
Mol
LXVII3,9
(116+R)
|  | N-alkyl-2,6-dIhydroplperidine 
1 I (cyclic amlnal)
R
Mol CXXIX 
(260+2R)
HN
| A Michael-type aad a Scbiff base addition 
on a cyclised trlaldol condensation product 
0  (aote that the aldlmlne bond b  In resonance 
with the ethykuk linkage)
Mol LXVIII 
3)10 (199+R) s/XXXScbiff base reaction on a hemlacetaMike glutaraldehyde dimer Mol CXXX (258+3R) hn/ R
k — «
| A MIcbaeMype and two SchlfTbase additions 
on a eydbed trlaldol condensation product^ •o
Mol LXIX3’9 
(299+R) ScUff base additioa m  a bemiacetal-llke gtutaraklefayde trimer
Mol
CXXXIV10
(198+R)
hA *1 Michael-type addition aa | « cycttaed UlakMAcc~"
Mol LXX 
(214+2R) Di-ScbifTbate additioa oa a bemketal glutaraldehyde dimer
Mol
CXXXV10
(198+R)
HNy '|  Hemiacetal form of 
I molecule CXXXIVm
XXIV
Mol LXXII 
(116+R) H
Mol
CXXXVI10
(196+2R)
X X -
Scbiff base addition on the hemiacetal farm of molecule CXXXIV
Mol LXXIII 
(114+2R) H H
Mol
CXXXVII
(180+R)
r mScbiff bate additioa on a eyeflted 
dialdol condematioa product
Mol LXXIV 
(216+R)
Mol
CXXXVIII
(178+2R)
r X C V
Df-SchlfTbase addition on a cyclised 
dialdol condensation product
Mol LXXV 
(316+R)
Mol
CXXXIX
(180+R)
O X X
Hemiacetal form of molecule CXXXVII
Mol LXXVI 
(299+R)
/ 1 / X A , Mol CXL (198+R)
Mkhaet-type additioa on a dialdol condeuMtioa product
Mol LXXX 
(298+R)
SchifTbase addition on 
1 la  trioxane-type 
0 > ^ J  o  glutaraldehyde trfmer
1
Mol CXLI 
(280+R) Trlaldol condensation product \  lx that underwent a Mkbad-type v /  additioa of tWamiae
Mol
LXXXIII
(498+R) SchlfT base additioa on a trioiane-type glutaraldehyde pentamer
Mol CXLII 
(278+2R)
Molecule CXLI that underwent a V  Scbiff base adtStioa (note that Ibc N 0 aldlmfne bond Is ia resonance \  with the ethytentc Unkace) "
Mol XCII 
(180+R)
^  Di-eldot condensation 
product that 
underwent a SchifT 
1 1 ^ 3  base addition
0/ I
Mol CXLV7 
(277+2R) 1 A SchlfT base and a Michael-type additioa 
on a trlaldol condensation product
Mol XCIII 
(178+2R) X  U Di-SchlfT base addition aa if % dlaldot condensation 
^  |  glutaraldehyde product
Mol CXLVI 
(278+2R)
dl-ScMffbase addition I | followed by a partial 1 J — j '  cyclHation step
I  O
Mol XCIV 
(176+3R)
Trl-Schlff bate1^ s r ~
condensationJ  \
V I
Mol CXLVII 
(260+2R)
0  Aldol trimer [1 1 that underwent
n n /  1 1 1 twov 1 j Mkhael-type 
R /  \  addition 
0  N \ followed by a 
\ _ _ _ /  cyclisation step
Mol XCV 
(196+2R)
t— A SchifTbase and a 
Michael-type 
L  L  addition on a dialdol 
^ •N H  ^ 0  condensation productJ  \  i
Mol
CXL VIII 
(280+R)
j Aldol dimer that 
/ S .  1 underwent a
f  ]-----  ^Ss. Mkhad addition>—  °andaScMfrbesey  y  |
XXV
Mol CXLIXMol XCVI Partially cyclised
(262+R)(178+2R)
MolMol XCVII Folly cyclised molecule XCV 
(dihydropyridlne structure)
(160+2R) CXLIXa
(261+R)
MolMol CL
(pyridinium structure, 
called anabilysine) (262+R)xcvnr
(159+2R)
Mol CLIMol
dialdol condensation product, 
followed by a cyclisation step 
(dihydropyridlne structure) (278+2R)(176+3R)
Mol CLIIMol
product that(pyridinium structure)
(242+2R)(175+3R)
Mol CLVMol CII
l^M khael-type addition
(198+R) (345+R)
Mol CL VIIMol CIII
(180+R) (442+2R)
Mol CLIXMol CIV
with a different cyclisation
(180+R) (344+R)
Mol CLXIII 
11)12 (198+R)
Mol CV Michael-type addition
(180+R)
XXVI
Mol CVI3’13 
(262+R) 0^ 0^ i
SchifTbase addition on a trlaldol condensation product
Mol CLXIV 
(280+R) ^  A dialdol condensation
\  | | i  Mannicb-type R I I reaction, forming a 
f f  ^ s ta b k  secondary' amine0 O
Mol CVII3’11 
(262+R)
Isomer of molecule CVI
Mol CLXV 
(278+2R) Mofecak CLXIV [  ]  tbat underwent a \ | 1 Scbiff base reactloa
\
Mol
CVIIa14’15
(262+R)
^  SchlfT ba*c addition eo * trlaldol 
0 \  (tideiiitiM  prodKl (rtw iiK t tlTMt between the aldlmfoe and ethyfcnk U>k)
Mol CLXVI 
(262+R) \  / \  Cyclised molecak N\  1 CLXIV
O O
Mol CVIII 
(260+2R) [ |= =  ^ N^ . DLSchlff bate additioa a I 1 n IrlaUd coadcasatka preduct 
/ r  ^  1 (resonance effect btlawa the 
Cf \  k aldimlae aad ethykak link)
I
Mol CLXVII 
(242+2R) S .  a  Molecule CLXIV H that anderwent a \ Scbiff base « (1 J) add irk a, followed 
N j /  by two cycttsatka\
Mol CIX 
(25 8+3R)
j | Trt-Scbiff bate addition___ 1 1 aa aa t rf aldol| j V eM dntabipnrfw l 1 | *  (aate tbat only two\ |--  V 1 aMlmlnelaksarela\  A resonance with ethyleaks  \  iI
Mol
CLXVIII
(260+2R)
Jv .  Mokrule CLXIV 'k  v / n .  that is l im U  s\  j 1 addition./ /  \  fellewsd bys q'  ^eycHsatloa step\
Mol CXI 
(262+R)
SchlfT bm  addition on a trlaldol ^  condensation product, followed 0 0 byacycllsatloa step
Mol CLXIX 
(362+R)
anderwent a Manakb-type additioa (Isomer of mokcak CLXX)
Mol CXII 
(260+2R)
Dl-Schlff base addition o n \  ^  W 
a trlaldol condensation ® ® 
product, with two 
subsequent cyclbation step
Mol CLXX 
(362+R)
A trlaldol coodematka product that anderwent a Maaakb-type additioa (isomer of molecule CLXIX)
Mol CXIV 
(344+R)
Scbiff base addition on aa 1 1 'fc aldol condensation 
jV  ^ tetramer (aote that the 
aldimlae Is la resonance 
wllb the ethylenk linkage)
Mol
CLXXIII16
(99+R)
HO N 
1
Mol CXV 
(162+R)
1 \ 1 dimer formed by^ 5 ^  aldol condensation,I Scbiff base additions, „
Mol
CLXXIV16
(263+R)
Mol CXVI 
(160+2R)
ClulMrtUrtydt 1 1 1 dimer formed by 1 J  L aldol condensation, 
tbat underwent two T |  SchifTbase nddltloat
N-----R
Mol
CLXXV16
(261+R)
o ^  J J  ^
J
XXVII
Mol CXVII Mol
(178+2R) CLXXVIII 
(344+2R)
Mol CXVIII Mol
CLXXIX
(342+2R)
(176+3R)
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